WorldWideScience

Sample records for arv drug patents

  1. Patent Pooling for Promoting Access to Antiretroviral Drugs (ARVs) - A Strategic Option for India.

    Science.gov (United States)

    Satyanarayana, Kanikaram; Srivastava, Sadhana

    2010-01-19

    The current HIV/AIDS scenario in India is quite grim with an estimated 2.4 million people living with HIV/AIDS (PLHA) in 2008, just behind South Africa and Nigeria. The anti-retroviral drugs (ARVs) remain the main stay of global HIV/AIDS treatment. Over 30 ARVs (single and FDCs) available under six categories viz., NRTIs (nucleoside reverse transcriptase inhibitors), NNRTIs (non-nucleoside reverse transcriptase inhibitors), Protease inhibitors, the new Fusion inhibitors, Entry inhibitors-CCR5 co-receptor antagonists and HIV integrase strand transfer inhibitors. The major originator companies for these ARVs are: Abbott, Boehringer Ingelheim (BI), Bristol-Myers Squibb (BMS), Gilead, GlaxoSmithKline (GSK), Merck, Pfizer, Roche, and Tibotec. Beginning with zidovidine in 1987, all the drugs are available in the developed countries. In India, about 30 ARVs are available as generics manufactured by Aurobindo, Hyderabad, Andhra Pradesh; Cipla Limited, Goa; Emcure Pharmaceuticals, Pune, Maharashtra; Hetero Drugs, Hyderabad, Andhra Pradesh; Macleods Pharmaceuticals, Daman; Matrix Laboratories, Nashik, Maharashtra; Ranbaxy, Sirmour, Himachal Pradesh; and Strides Arcolab, Bangalore, Karnataka. The National AIDS Control Organization (NACO) set up in 1992 by the Govt. of India provides free ARVs to HIV positive patients in India since 2004. The drugs available in India include both single drugs and FDCs covering both first line and second line ARVs. Even while there are claims of stabilization of the disease load, there is still huge gap of those who require ARVs as only about 150,000 PLHA receive the ARVs from the Govt. and other sources. Access to ARVs therefore is still a cause of serious concern ever since India became fully Trade Related Aspects of Intellectual Property Rights (TRIPS)-complaint in 2005. Therefore, the Indian pharmaceutical companies cannot make generics for those for drugs introduced post-2005 due to product patent regime. Other concerns include heat stable

  2. Price Reversal Pattern of ARV Drugs: A Transaction-Cost Approach Digression

    Directory of Open Access Journals (Sweden)

    Frank LORNE

    2015-05-01

    Full Text Available A price reversal pattern of ARV drugs was noted across lower and middle income countries in that the lower-income countries have higher prices relative to higher-income countries based on a 2008-2009 Summary Report by World Health Organization. The transaction costs affecting AVR drug pricing can be broadly classified into two kinds: One between the final users and the opinion/knowledge experts, and the other between the opinion/knowledge experts and the manufacturers. Economist’s version of price discrimination needs to be modified by including transaction costs. Transaction costs also point to institution creditability factors that will affect NGO procurement.

  3. Can drug patents be morally justified?

    Science.gov (United States)

    Sterckx, Sigrid

    2005-01-01

    This paper offers a few elements of an answer to the question to what extent drug patents can be morally justified. Justifications based on natural rights, distributive justice and utilitarian arguments are discussed and criticized. The author recognizes the potential of the patents to benefit society but argues that the system is currently evolving in the wrong direction, particularly in the field of drugs. More than a third of the world's population has no access to essential drugs. The working of the patent system is an important determinant of access to drugs. This paper argues that drug patents are not easily justified and that the 'architecture' of the patent system should be rethought in view of its mission of benefiting society.

  4. [The patents game. Generic and biosimilar drugs].

    Science.gov (United States)

    Villamañán, E; González, D; Armada, E; Ruano, M; Álvarez-Sala, R; Herrero, A

    2016-01-01

    The protection provided by patents on medicines has a limited duration. The expiry of patents expiration allows copies of the drugs to be released, competing with original. At first, they were identical to the original, known as generic drugs, but in recent years, due to the marketing of biological therapies and the expiry of many of their patents, biosimilar drugs have also emerged. These are not exact copies of the original, but, like generic drugs, biosimilar drugs have to demonstrate equivalence to the reference drugs in quality, safety and efficacy. Nevertheless, despite their importance and contribution to sustainability of health system, doctors are sometimes unaware of differences between them, and their impact in terms of clinical and economic effects. An attempt is made to review and clarify certain aspects often unknown by physicians, despite their involvement in their use.

  5. Drug repurposing and the prior art patents of competitors.

    Science.gov (United States)

    Sternitzke, Christian

    2014-12-01

    Drug repurposing (i.e., finding novel indications for established substances) has received increasing attention in industry recently. One challenge of repositioned drugs is obtaining effective patent protection, especially if the 'novel' indications have already been claimed by competitors within the same drug class. Here, I report the case of patents relating to phosphodiesterase type 5 (PDE5) inhibitors. Patentees of later-filed patents on novel indications (even when they could not observe prior patenting of their direct competitors) filed patents for which patent examiners did not see the prior-filed patents of the competitors as relevant prior art, whereas these follower patent applications often failed because of other reasons.

  6. Social arv

    DEFF Research Database (Denmark)

    Jensen, Bente

    Denne publikation er det første arbejdspapir/rapport i serien om forskningsprojektet "Handlekompetence i pædagogisk arbejde med socialt udsatte børn og unge - indsats og effekt (HPA-projektet). Social arv og det deraf afledte begreb om 'udsatte børn', som er det samfundsproblem, der danner rammen...... om HPA-projektets intervenstionsdel og -analyser er ikke et entydigt begreb. Formålet med papiret er derfor at indkredse diskussionen om social arv set som reproduktion af ulighed og på den baggrund belyse relevante indikatorer som kan tjene som baggrundvariable i studiet af effekter i relation til...... samfundets institutionelle mulighder for at skabe fornyelse på det sociale område gennem social intervention...

  7. Drug patents and intellectual property rights.

    Science.gov (United States)

    Raj, Gerard Marshall; Priyadarshini, Rekha; Mathaiyan, Jayanthi

    2015-04-01

    Inquisitive scientists are untiring and relentless in the hard work they perform day in and day out. In this pursuit, a researcher has to exercise their intellectual expertise in its entirety. Eventually, all credit of the invention is vested with the inventor who has the right of control over their intellectual creation. Likewise, pharmaceutical companies spend extravagantly in successfully introducing a novel drug from hundreds and thousands of lead compounds. Hence, it is a prerogative for every company to protect its innovative products from unauthorized duplication. Certainly, "patents" are the sole custodians of these products of medical intelligence - the drugs! This review focuses on the various intricacies of the drug patent system all over the world with special emphasis on India, Europe, and the United States. A note on other intellectual properties such as copyrights, trademarks, and designs is also added.

  8. The Pharmaceutical Patent Protection Impact on Indonesia Drugs Price

    Directory of Open Access Journals (Sweden)

    Tomi Suryo Utomo

    2012-02-01

    Full Text Available This paper examines the pharmaceutical patent protection impact on Indonesian drugs price. As patent owner, companies could set high price for their drugs. However, such condition limits the access of the poor from patented drugs. Therefore, balance between patent protection, public welfare, and compliance to TRIPs agreement must be ensured. Penelitian ini membahas dampak paten produk-produk farmasi terhadap harga obat di Indonesia. Sebagai pemegang hak paten, perusahaan farmasi dapat menetapkan harga yang tinggi. Namun, kondisi ini membatasi akses masyarakat miskin untuk memperoleh obat yang terpatenkan. Dengan demikian, harus ada keseimbangan antara perlindungan hak paten, kesejahteraan masyarakat, dan kepatuhan terhadap TRIPs.

  9. India: Court upholds patent law denying patents for slightly modified versions of existing drugs.

    Science.gov (United States)

    Swamy, Madhavi

    2007-12-01

    In August 2007, the Madras High Court struck down a petition by the Swiss pharmaceutical company Novartis to declare the anti-evergreening provision in Indian patent law invalid. Evergreening is the practice of effectively extending the patent on a drug by filing a new patent for a marginal modification to that drug, such as a change in its shape, dosing range or color. The Court's decision is critical for global access to essential medicines in the form of affordable generic drugs from India

  10. Compulsory license of antiretroviral (ARV) drugs for HIV/AIDS: review of international situation and analysis of its feasibility in China%艾滋病抗病毒药品强制许可国际现状与我国实施强制许可可行性分析

    Institute of Scientific and Technical Information of China (English)

    晋灿瑞; 马春涛; 刘霞; 王强; 赵燕; 刘中夫

    2012-01-01

    目的 分析国际国内艾滋病抗病毒(ARV)药品强制许可状况,为中国实施强制许可提供建议.方法 在回顾知识产权与公共健康的冲突及可能解决途径的基础上,分析中国对部分ARV药品实施强制许可的必要性及可行性,以及中国实施强制许可后需要重点考虑的问题.结果 中国ARV药品费用控制形势严峻,对部分费用高的药品实施强制许可有其必要性.目前国际国内法律环境为强制许可提供了有力支持,国内已具备仿制生产技术和能力,还有相关国际组织的支持以及其他国家的经验可借鉴,故中国对部分ARV药品实施强制许可具有可行性.结论 中国可对部分ARV药品实施强制许可.除需应对国际上的质疑和诉讼考验之外,同时还应注重确保强制许可药品的质量,发展国内药品研发生产能力,以及对包括ARV药品在内的基本药物统筹考虑降低费用,增加药品可及性的综合策略和可行措施.%Objective To analyze international and domestic compulsory licensing of ARV drugs for HIV/AIDS and give relevant policy suggestions. Methods On the basis of reviewing the conflicts between pharmaceutical patents and public health and possible solutions, the necessity and feasibility of enforcing compulsory license of several ARV drugs in China were analyzed, and some issues were taken into account if compulsory license is practiced in this country. Results Considering the importance of controlling cost of ARV drugs to make them available and accessible to the population in need, it is essential to enforce compulsory license of some expensive ARV drugs. Owing to international and domestic legal support, domestic capacity of producing generic drugs, assistance from related international organizations and learning experiences of other countries, China is in a position to implement compulsory licensing of ARV drugs. Conclusion China is capable to implement compulsory licensing of some ARV

  11. Competitive intelligence and patent analysis in drug discovery.

    Science.gov (United States)

    Grandjean, Nicolas; Charpiot, Brigitte; Pena, Carlos Andres; Peitsch, Manuel C

    2005-01-01

    Patents are a major source of information in drug discovery and, when properly processed and analyzed, can yield a wealth of information on competitors activities, R&D trends, emerging fields, collaborations, among others. This review discusses the current state-of-the-art in textual data analysis and exploration methods as applied to patent analysis.:

  12. Fair drug prices and the patent system.

    Science.gov (United States)

    Resnik, David B

    2004-06-01

    This paper uses John Rawls' theory of justice to defend the patent system against charges that it has an unfair effect on access to medications,from the perspective of national and international justice. The paper argues that the patent system is fair in a national context because it respects intellectual property rights and it benefits the least advantaged members of society by providing incentives for inventors, investors, and entrepreneurs. The paper also argues that the patent system is fair in an international context, provided that developed nations take steps to help disease-stricken countries secure internal justice. Fairness in a national or international context also requires that the patent system should include emergency exceptions to deal with short-term inequities.

  13. Liposomal drug delivery: recent patents and emerging opportunities.

    Science.gov (United States)

    Webb, Murray S; Rebstein, Patrick; Lamson, Wendy; Bally, Marcel B

    2007-01-01

    It is challenging to develop innovative, as well as commercially viable, lipid-based drug delivery systems for the treatment of cancer because of the breadth of existing intellectual property that limits freedom-to-operate. For example, novel compositions can be described in which a new chemical entity is associated with a lipid based carrier, but if the loading method or components of the lipid compositions are proprietary then the ability to develop novel compositions will require access to the appropriate intellectual property. We believe it is useful to present a review of the patent literature describing novel liposomal drug delivery systems given by parenteral administration to humans for the treatment of serious medical conditions such as cancer. This review is intended to: (i) identify and describe novel approaches that have recently been protected by US or international patents and patent applications, and; (ii) identify founding technology in the field which is recently off-patent, thus presenting emerging opportunities for the development of new therapeutic options for patients. Issued patents, and selected patent applications, having publication dates in 2005 or 2006 were retrieved from searches of the US, European, German, Japanese, INPADOC and WIPO PCT databases. Liposomal delivery systems patented for systemic administration in the treatment of human medical conditions were reviewed in detail.

  14. 'Government Patent Use': A Legal Approach To Reducing Drug Spending.

    Science.gov (United States)

    Kapczynski, Amy; Kesselheim, Aaron S

    2016-05-01

    The high cost of patent-protected brand-name drugs can strain budgets and curb the widespread use of new medicines. An example is the case of direct-acting antiviral drugs for the treatment of hepatitis C. While prices for these drugs have come down in recent months, they still create barriers to treatment. Additionally, prescribing restrictions imposed by insurers put patients at increased risk of medical complications and contribute to transmission of the hepatitis C virus. We propose that the federal government invoke its power under an existing "government patent use" law to reduce excessive prices for important patent-protected medicines. Using this law would permit the government to procure generic versions of patented drugs and in exchange pay the patent-holding companies reasonable royalties to compensate them for research and development. This would allow patients in federal programs, and perhaps beyond, to be treated with inexpensive generic medicines according to clinical need-meaning that many more patients could be reached for no more, and perhaps far less, money than is currently spent. Another benefit would be a reduction in the opportunity for companies to extract monopoly profits that far exceed their risk-adjusted costs of research and development.

  15. Herbal drugs for diabetic treatment: an updated review of patents.

    Science.gov (United States)

    Wais, Mohd; Nazish, Iram; Samad, Abdus; Beg, Sarwer; Abusufyan, S; Ajaj, S Ajaz; Aqil, Mohd

    2012-04-01

    Diabetes mellitus is the most common endocrine disorder, affecting 16 million individuals in the United States and 200 million worldwide. Despite the use of advanced synthetic drugs for the treatment, use of herbal remedies is gaining higher importance because of synthetic drugs have drawbacks and limitations. The herbal drugs with antidiabetic activity are extensively formulated commercially because of easy availability, affordability and less side effects as compared to the synthetic antidiabetic drugs. Antidiabetic herbal formulations (AHF) are considered to be more effective for the management of diabetes. There are around 600 herbal drug manufacturers in India of which almost all manufacturers are developing AHF in addition to others. Till date, no article is published to give detailed information of the patents on AHF. Thus, this review article undertake the attempt for providing updated information on the type of diabetes and patented AHF which will enhance the existing knowledge of the researchers.

  16. Preferred supplier contracts in post-patent prescription drug markets.

    Science.gov (United States)

    Blankart, Carl Rudolf; Stargardt, Tom

    2016-02-22

    In recent years, the expiration of patents for large drug classes has increased the importance of post-patent drug markets. However, previous research has focused solely on patent drug markets. In this study, the authors evaluate the influence of preferred supplier contracts, the German approach to tendering, in post-patent drug markets using a hierarchical market share attraction model. The authors find that preferred supplier contracts are a powerful strategic instrument for generic manufacturers in a highly competitive environment. They quantify the effects of signing a preferred supplier contract and show that brand-name manufacturers are vulnerable to tendering. Therefore, brand-name manufacturers should readjust their strategies and consider including preferred supplier contracts in their marketing mix. In addition, the authors employ a simulation to demonstrate that a first-mover advantage might be gained from signing a preferred supplier contract. Furthermore, their results can be used as a blueprint for decision makers in the pharmaceutical industry to assess the market share effects of different contracting strategies regarding preferred supplier contracts.

  17. Social opdrift - social arv

    DEFF Research Database (Denmark)

    Ejrnæs, Morten; Gabrielsen, G.; Nørrung, Per

    "Social opdrift - social arv" stiller på flere måder spørgsmål ved begrebet social arv. Bogen konkluderer blandt andet, at langt de fleste børn, der opvokser i en socialt belastet familie, bliver velfungerende voksne. Professionelle, der møder socialt belastede familier, har derfor et stort ansvar....... Naturligvis skal der tages hånd om udsatte børn, men det kræver samtidig stor opmærksomhed at sørge for, at fokuseringen på den sociale arv ikke tager overhånd, så det bliver en selvopfyldende profeti."Social opdrift - social" arv viser, hvordan forskningsresultater er blevet fremlagt på en måde, som har...... medvirket til at skabe en skæv opfattelse af, at forældrenes problemer er hovedårsag til børns sociale problemer. I selvstændige analyser vises, hvordan data, der normalt bruges som "bevis" for den sociale arvs betydning, tydeligt illustrerer, at det er en undtagelse, at børn får sociale problemer af samme...

  18. Drug delivery via porous silicon: a focused patent review.

    Science.gov (United States)

    Kulyavtsev, Paulina A; Spencer, Roxanne P

    2017-03-01

    Although silicon is more commonly associated with computer chips than with drug delivery, with the discovery that porous silicon is a viable biocompatible material, mesoporous silicon with pores between 2 and 50 nm has been loaded with small molecule and biomolecule therapeutics and safely implanted for controlled release. As porous silicon is readily oxidized, porous silica must also be considered for drug delivery applications. Since 2010, only a limited number of US patents have been granted, primarily for ophthalmologic and immunotherapy applications, in contrast to the growing body of technical literature in this area.

  19. 37 CFR 1.775 - Calculation of patent term extension for a human drug, antibiotic drug or human biological product.

    Science.gov (United States)

    2010-07-01

    ... extension for a human drug, antibiotic drug or human biological product. 1.775 Section 1.775 Patents... drug or human biological product is eligible for extension, the term shall be extended by the time as... term of the patent for a human drug, antibiotic drug or human biological product will be extended...

  20. Heideggers sorte arv

    DEFF Research Database (Denmark)

    Olesen, Søren Gosvig

    2015-01-01

    Martin Heidegger var antisemit, men er hans tænkning og intellektuelle arv det også? Søren Gosvig Olesen opsøger den store tyske tænkers arvinger og bindene fra 1938-48 i Heideggers efterladte ’Sorte hæfter’, hvor den lille mands meninger blander sig med en stor tænkers tanker......Martin Heidegger var antisemit, men er hans tænkning og intellektuelle arv det også? Søren Gosvig Olesen opsøger den store tyske tænkers arvinger og bindene fra 1938-48 i Heideggers efterladte ’Sorte hæfter’, hvor den lille mands meninger blander sig med en stor tænkers tanker...

  1. Scope of claim coverage in patents of fufang Chinese herbal drugs: Substitution of ingredients

    Directory of Open Access Journals (Sweden)

    Tian Jiaher

    2011-08-01

    Full Text Available Abstract Herbal ingredients in a Chinese fufang prescription are often replaced by one or several other herbal combinations. As there have been very few Chinese herbal patent infringement cases, it is still unclear how the Doctrine of Equivalents should be applied to determine the scope of 'equivalents' in Chinese fufang prescriptions. Case law principles from cases in other technical areas such as chemical patents and biological drug patents can be borrowed to ascertain a precise scope of a fufang patent. This article summarizes and discusses several chemical and biopharmaceutical patent cases. In cases where a certain herbal ingredient is substituted by another herb or a combination of herbs, accused infringers are likely to relate herbal drug patents to chemical drug patents with strict interpretation whereas patent owners may take advantage of the liberal application of Doctrine of Equivalence in biopharmaceutical patents by analogizing the complex nature of herbal drugs with biological drugs. Therefore, consideration should be given to the purpose of an ingredient in a patent, the qualities when combined with the other ingredients and the intended function. The scope of equivalents also depends on the stage of the prior art. Moreover, it is desirable to disclose any potential substitutes when drafting the application. Claims should be drafted in such a way that all foreseeable modifications are encompassed for the protection of the patent owner's intellectual property.

  2. The effect of pharmaceutical patent term length on research and development and drug expenditures in Canada.

    Science.gov (United States)

    Grootendorst, Paul; Matteo, Livio Di

    2007-02-01

    While pharmaceutical patent terms have increased in Canada, increases in patented drug spending have been mitigated by price controls and retrenchment of public prescription drug subsidy programs. We estimate the net effects of these offsetting policies on domestic pharmaceutical R&D expenditures and also provide an upper-bound estimate on the effects of these policies on Canadian pharmaceutical spending over the period 1988-2002. We estimate that R&D spending increased by $4.4 billion (1997 dollars). Drug spending increased by $3.9 billion at most and, quite likely, by much less. Cutbacks to public drug subsidies and the introduction of price controls likely mitigated drug spending growth. In cost-benefit terms, we suspect that the patent extension policies have been beneficial to Canada.

  3. A brief literature and patent review of nanosuspensions to a final drug product.

    Science.gov (United States)

    Chin, William Wei Lim; Parmentier, Johannes; Widzinski, Michael; Tan, En Hui; Gokhale, Rajeev

    2014-10-01

    Particle size reduction can be used for enhancing the dissolution of poorly water-soluble drugs in order to enhance bioavailability. In nanosuspensions, the particle size of the drug is reduced to nanometer size. Nanosuspensions after downstream processing into drug products have successfully shown its impact on formulation design, the augmentation of product life cycle, patent life, and therapeutic efficacy. Formulation considerations for the nanosuspension formulation, its processing into a solid form, and aspects of material characterization are discussed. Technology assessments and feasibility of upstream processes for nanoparticle creation, and subsequently transformation into a drug product via the downstream processes have been reviewed. This paper aims to bridge formulation and process considerations along with patent reviews and may provide further insight into understanding the science and the white space. An analysis of current patent outlook and future trends is described to fully understand the limitations and opportunities in intellectual property generation.

  4. Compulsory patent licensing and local drug manufacturing capacity in Africa.

    Science.gov (United States)

    Owoeye, Olasupo Ayodeji

    2014-03-01

    Africa has the highest disease burden in the world and continues to depend on pharmaceutical imports to meet public health needs. As Asian manufacturers of generic medicines begin to operate under a more protectionist intellectual property regime, their ability to manufacture medicines at prices that are affordable to poorer countries is becoming more circumscribed. The Doha Declaration on the TRIPS Agreement and Public Health gives member states of the World Trade Organization (WTO) the right to adopt legislation permitting the use of patented material without authorization by the patent holder, a provision known as "compulsory licensing". For African countries to take full advantage of compulsory licensing they must develop substantial local manufacturing capacity. Because building manufacturing capacity in each African country is daunting and almost illusory, an African free trade area should be developed to serve as a platform not only for the free movement of goods made pursuant to compulsory licences, but also for an economic or financial collaboration towards the development of strong pharmaceutical manufacturing capacity in the continent. Most countries in Africa are in the United Nations list of least developed countries, and this allows them, under WTO law, to refuse to grant patents for pharmaceuticals until 2021. Thus, there is a compelling need for African countries to collaborate to build strong pharmaceutical manufacturing capacity in the continent now, while the current flexibilities in international intellectual property law offer considerable benefits.

  5. Biomarkers and biometric measures of adherence to use of ARV-based vaginal rings

    Directory of Open Access Journals (Sweden)

    Randy M Stalter

    2016-05-01

    Full Text Available Introduction: Poor adherence to product use has been observed in recent trials of antiretroviral (ARV-based oral and vaginal gel HIV prevention products, resulting in an inability to determine product efficacy. The delivery of microbicides through vaginal rings is widely perceived as a way to achieve better adherence but vaginal rings do not eliminate the adherence challenges exhibited in clinical trials. Improved objective measures of adherence are needed as new ARV-based vaginal ring products enter the clinical trial stage. Methods: To identify technologies that have potential future application for vaginal ring adherence measurement, a comprehensive literature search was conducted that covered a number of biomedical and public health databases, including PubMed, Embase, POPLINE and the Web of Science. Published patents and patent applications were also searched. Technical experts were also consulted to gather more information and help evaluate identified technologies. Approaches were evaluated as to feasibility of development and clinical trial implementation, cost and technical strength. Results: Numerous approaches were identified through our landscape analysis and classified as either point measures or cumulative measures of vaginal ring adherence. Point measurements are those that give a measure of adherence at a particular point in time. Cumulative measures attempt to measure ring adherence over a period of time. Discussion: Approaches that require modifications to an existing ring product are at a significant disadvantage, as this will likely introduce additional regulatory barriers to the development process and increase manufacturing costs. From the point of view of clinical trial implementation, desirable attributes would be high acceptance by trial participants, and little or no additional time or training requirements on the part of participants or clinic staff. We have identified four promising approaches as being high priority

  6. Natural products against cancer: A comprehensive bibliometric study of the research projects, publications, patents and drugs

    Directory of Open Access Journals (Sweden)

    Jian Du

    2014-01-01

    Full Text Available Objectives: To analyze multi-source data including awards, publications, patents and drugs, and try to draw the whole landscape of the research and development community in the area of natural products (NPs against cancer. Materials and Methods: Awards, publications, patents and drugs data from National Institute of Health/Natural Science Foundation of China (NIH/NSFC, PubMed, Derwent Innovation Index and Cortellis were collected. Bibliometric methodologies and technology are used to investigate publications/patents/drugs, their contents and relationships. Results: NIH and NSFC respectively demonstrated a stable and sustained expenditure growth in this area. The number of publications is continuously increasing. Yet the annual patent applications worldwide and FDA drug approvals were little changed or not obviously fluctuated in 2003-2013. USA and several Asia-pacific countries/territories are important contributing powers. We described the evolution of major research topics by those MeSH Major Topics indexed in PubMed with the largest growth range in three intervals, and analyzed hot research topics in the recent 10 years which include NPs or NPs derivatives, cell line/animal model, laboratory technologies and activation mechanisms. Conclusions: China published the most publications and received the most patent applications, but drug discovery performance is no better than USA and Japan. Research on anti-neoplastic structures and compounds originated from Chinese traditional medicine (TCM, medicinal plants, herbal medicine and marine NPs are major research topics in the recent 10 years. There still exits translational gap between basic research and drug discovery. Translational research should be undertaken to strengthen the applicability of NPs.

  7. In vitro comparative evaluation of monolayered multipolymeric films embedded with didanosine-loaded solid lipid nanoparticles: a potential buccal drug delivery system for ARV therapy.

    Science.gov (United States)

    Jones, Elsabé; Ojewole, Elizabeth; Kalhapure, Rahul; Govender, Thirumala

    2014-05-01

    Drug delivery via the buccal route has emerged as a promising alternative to oral drug delivery. Didanosine (DDI) undergoes rapid degradation in the gastrointestinal tract, has a short half-life and low oral bioavailability, making DDI a suitable candidate for buccal delivery. Recent developments in buccal drug delivery show an increased interest toward nano-enabled delivery systems. The advantages of buccal drug delivery can be combined with that of nanoparticulate delivery systems to provide a superior delivery system. The aim of this study was to design and evaluate the preparation of novel nano-enabled films for buccal delivery of DDI. Solid lipid nanoparticles (SLNs) were prepared via hot homogenization followed by ultrasonication and were characterized before being incorporated into nano-enabled monolayered multipolymeric films (MMFs). Glyceryl tripalmitate with Poloxamer 188 was identified as most suitable for the preparation of DDI-loaded SLNs. SLNs with desired particle size (PS) (201 nm), polydispersity index (PDI) (0.168) and zeta potential (-18.8 mV) were incorporated into MMFs and characterized. Conventional and nano-enabled MMFs were prepared via solvent casting/evaporation using Eudragit RS100 and hydroxypropyl methylcellulose. Drug release from the nano-enabled films was found to be faster (56% versus 20% in first hour). Conventional MMFs exhibited higher mucoadhesion and mechanical strength than nano-enabled MMFs. SLNs did not adversely affect the steady state flux (71.63 ± 13.54 µg/cm(2) h versus 74.39 ± 15.95 µg/cm(2) h) thereby confirming the potential transbuccal delivery of DDI using nano-enabled MMFs. Nano-enabled buccal films for delivery of DDI can be successfully prepared, and these physico-mechanical studies serve as a platform for future formulation optimization work in this emerging field.

  8. Click chemistry patents and their impact on drug discovery and chemical biology.

    Science.gov (United States)

    Xu, Hua; Jones, Lyn H

    2015-01-01

    First introduced by K Barry Sharpless in 2001, the term 'click chemistry' soon became a widely used description of chemical reactions that proceed rapidly, cleanly and in a manner that is often compatible with aqueous solutions. Click chemistry is frequently employed throughout the process of drug discovery, and greatly helps advance research programs in the pharmaceutical industry. It facilitates library synthesis to support medicinal chemistry optimization, helps identify the targets and off-targets of drug candidates, and can facilitate the determination of drug efficacy in clinical trials. In the last decade, a large number of patent applications covering the various types and utilities of click chemistry have been filed. In this review, we provide the first analysis of click chemistry applications.

  9. A review of recent patents on the protozoan parasite HSP90 as a drug target.

    Science.gov (United States)

    Angel, Sergio O; Matrajt, Mariana; Echeverria, Pablo C

    2013-04-01

    Diseases caused by protozoan parasites are still an important health problem. These parasites can cause a wide spectrum of diseases, some of which are severe and have high morbidity or mortality if untreated. Since they are still uncontrolled, it is important to find novel drug targets and develop new therapies to decrease their remarkable social and economic impact on human societies. In the past years, human HSP90 has become an interesting drug target that has led to a large number of investigations both at state organizations and pharmaceutical companies, followed by clinical trials. The finding that HSP90 has important biological roles in some protozoan parasites like Plasmodium spp, Toxoplasma gondii and trypanosomatids has allowed the expansion of the results obtained in human cancer to these infections. This review summarizes the latest important findings showing protozoan HSP90 as a drug target and presents three patents targeting T. gondii, P. falciparum and trypanosomatids HSP90.

  10. Nanosuspension Technology For Poorly Soluble Drugs: Recent Researches, Advances and Patents.

    Science.gov (United States)

    Agarwal, Vijay; Bajpai, Meenakshi

    2015-01-01

    Nowadays, in pharmaceutical industries, the attention on nanosized materials is growing gradually due to their wide applications in drug delivery systems. Recently, out of different nanosize systems, nanosuspension system has undergone a lot of interest in such a way to rectify the solubility and bioavailability problem due to their technical simplicity and cost-effectiveness property compared to other colloidal systems. Nanosuspension technology has proven that it can be a superior substitute over alternative approaches, which are available for enhancing the bioavailability of different drugs having low solubility. Since today, nanosuspensions have been greatly evolved for a huge number of drugs and also investigated for their potential applications. The various unique features make the nanosuspension to enable their utilization in numerous dosage forms and given through different routes, including parenteral, oral, topical, peroral, ocular and pulmonary routes. A large number of products grounded in nanosuspension technology are present in the market, and some are on the way. In fact, the number of such types of products is much more in comparison of other nanotechnologies based products. Additionally, the different preparation methods used to prepare the nanosuspensions are also well- established and patented. This article reviews the recent research, advances in formulation and their approaches related to nanosuspensions with emphasis given on different patents related to nanosuspension methods.

  11. Patented drug extension strategies on healthcare spending: a cost-evaluation analysis.

    Directory of Open Access Journals (Sweden)

    Nathalie Vernaz

    Full Text Available BACKGROUND: Drug manufacturers have developed "evergreening" strategies to compete with generic medication after patent termination. These include marketing of slightly modified follow-on drugs. We aimed to estimate the financial impact of these drugs on overall healthcare costs and also to examine the impact of listing these drugs in hospital restrictive drug formularies (RDFs on the healthcare system as a whole ("spillover effect". METHODS AND FINDINGS: We used hospital and community pharmacy invoice office data in the Swiss canton of Geneva to calculate utilisation of eight follow-on drugs in defined daily doses between 2000 and 2008. "Extra costs" were calculated for three different scenarios assuming replacement with the corresponding generic equivalent for prescriptions of (1 all brand (i.e., initially patented drugs, (2 all follow-on drugs, or (3 brand and follow-on drugs. To examine the financial spillover effect we calculated a monthly follow-on drug market share in defined daily doses for medications prescribed by hospital physicians but dispensed in community pharmacies, in comparison to drugs prescribed by non-hospital physicians in the community. Estimated "extra costs" over the study period were €15.9 (95% CI 15.5; 16.2 million for scenario 1, €14.4 (95% CI 14.1; 14.7 million for scenario 2, and €30.3 (95% CI 29.8; 30.8 million for scenario 3. The impact of strictly switching all patients using proton-pump inhibitors to esomeprazole at admission resulted in a spillover "extra cost" of €330,300 (95% CI 276,100; 383,800, whereas strictly switching to generic cetirizine resulted in savings of €7,700 (95% CI 4,100; 11,100. Overall we estimated that the RDF resulted in "extra costs" of €503,600 (95% CI 444,500; 563,100. CONCLUSIONS: Evergreening strategies have been successful in maintaining market share in Geneva, offsetting competition by generics and cost containment policies. Hospitals may be contributing to increased

  12. Pharmaceutical Equivalence of Distributed Generic Antiretroviral (ARV in Asian Settings: The Cross-Sectional Surveillance Study - PEDA Study.

    Directory of Open Access Journals (Sweden)

    Vorapot Sapsirisavat

    Full Text Available Ensuring that medicines meet quality standards is mandatory for ensuring safety and efficacy. There have been occasional reports of substandard generic medicines, especially in resource-limiting settings where policies to control quality may be less rigorous. As HIV treatment in Thailand depends mostly on affordable generic antiretrovirals (ARV, we performed quality assurance testing of several generic ARV available from different sources in Thailand and a source from Vietnam.We sampled Tenofovir 300mg, Efavirenz 600mg and Lopinavir/ritonavir 200/50mg from 10 primary hospitals randomly selected from those participating in the National AIDS Program, 2 non-government organization ARV clinics, and 3 private drug stores. Quality of ARV was analyzed by blinded investigators at the Faculty of Pharmaceutical Science, Chulalongkorn University. The analysis included an identification test for drug molecules, a chemical composition assay to quantitate the active ingredients, a uniformity of mass test and a dissolution test to assess in-vitro drug release. Comparisons were made against the standards described in the WHO international pharmacopeia.A total of 42 batches of ARV from 15 sources were sampled from January-March 2015. Among those generics, 23, 17, 1, and 1 were Thai-made, Indian-made, Vietnamese-made and Chinese-made, respectively. All sampled products, regardless of manufacturers or sources, met the International Pharmacopeia standards for composition assay, mass uniformity and dissolution. Although local regulations restrict ARV supply to hospitals and clinics, samples of ARV could be bought from private drug stores even without formal prescription.Sampled generic ARVs distributed within Thailand and 1 Vietnamese pharmacy showed consistent quality. However some products were illegally supplied without prescription, highlighting the importance of dispensing ARV for treatment or prevention in facilities where continuity along the HIV treatment

  13. 专利组合价值评估探讨——以药品专利组合为例%Patent Portfolio Evaluation:an Empirical Study Based on Drug Patent

    Institute of Scientific and Technical Information of China (English)

    曹晨; 胡元佳

    2012-01-01

    The paper is to develop an evaluation model of drug patent portfolio based on Lanjouw - Schankerman model and Parchomovsky - Wagner patent portfolio theory by retrieving data of 610 patent from 82 drugs marketed in USA. The paper obtains drug patent portfolio value index by integrating composite index of patent value of single patent; validates by running correlation analysis between sales and PPVI. The result shows that arithmetic separate integration model of CPIV fits patent portfolio evaluation most.%目的:以药品专利组合为例,构建基于Lanjouw-Schankerman专利价值评估模型与Parchomovsky-Wagner专利组合理论的专利组合价值评估模型.方法:以在美国上市的82个药品的610项专利为样本,通过整合单项专利的综合专利价值指数(composite index of patent value,CIPV),进而构成专利组合价值指数(patent portfolio value index,PPVI),并与对应药品的销售额进行相关分析采检验其显著度水平.结果:CIPV值算术平均数分块加和模型最适用于专利组合价值的评估.

  14. Drugmakers struggle with Indian patents.

    Science.gov (United States)

    2012-12-01

    Pharmaceutical companies continue their legal battles for intellectual property protection for their drugs in India after the country's patent office revoked Pfizer's local patent for Sutent (sunitinib malate).

  15. Wnt Drug Discovery: Weaving Through the Screens, Patents and Clinical Trials.

    Science.gov (United States)

    Lu, Benjamin; Green, Brooke A; Farr, Jacqueline M; Lopes, Flávia C M; Van Raay, Terence J

    2016-09-01

    The Wnt signaling pathway is intricately involved in many aspects of development and is the root cause of an increasing number of diseases. For example, colorectal cancer is the second leading cause of death in the industrialized world and aberration of Wnt signaling within the colonic stem cell is the cause of more than 90% of these cancers. Despite our advances in successfully targeting other pathways, such as Human Epidermal Growth Factor Receptor 2 (HER2), there are no clinically relevant therapies available for Wnt-related diseases. Here, we investigated where research activities are focused with respect to Wnt signaling modulators by searching the United States Patent and Trade Office (USPTO) for patents and patent applications related to Wnt modulators and compared this to clinical trials focusing on Wnt modulation. We found that while the transition of intellectual property surrounding the Wnt ligand-receptor interface to clinical trials is robust, this is not true for specific inhibitors of β-catenin, which is constitutively active in many cancers. Considering the ubiquitous use of the synthetic T-cell Factor/Lymphoid Enhancer Factor (TCF/Lef) reporter system and its success in identifying novel modulators in vitro, we speculate that this model of drug discovery does not capture the complexity of in vivo Wnt signaling that may be required if we are to successfully target the Wnt pathway in the clinic. Notwithstanding, increasingly more complex models are being developed, which may not be high throughput, but more pragmatic in our pursuit to control Wnt signaling.

  16. Wnt Drug Discovery: Weaving Through the Screens, Patents and Clinical Trials

    Directory of Open Access Journals (Sweden)

    Benjamin Lu

    2016-09-01

    Full Text Available The Wnt signaling pathway is intricately involved in many aspects of development and is the root cause of an increasing number of diseases. For example, colorectal cancer is the second leading cause of death in the industrialized world and aberration of Wnt signaling within the colonic stem cell is the cause of more than 90% of these cancers. Despite our advances in successfully targeting other pathways, such as Human Epidermal Growth Factor Receptor 2 (HER2, there are no clinically relevant therapies available for Wnt-related diseases. Here, we investigated where research activities are focused with respect to Wnt signaling modulators by searching the United States Patent and Trade Office (USPTO for patents and patent applications related to Wnt modulators and compared this to clinical trials focusing on Wnt modulation. We found that while the transition of intellectual property surrounding the Wnt ligand-receptor interface to clinical trials is robust, this is not true for specific inhibitors of β-catenin, which is constitutively active in many cancers. Considering the ubiquitous use of the synthetic T-cell Factor/Lymphoid Enhancer Factor (TCF/Lef reporter system and its success in identifying novel modulators in vitro, we speculate that this model of drug discovery does not capture the complexity of in vivo Wnt signaling that may be required if we are to successfully target the Wnt pathway in the clinic. Notwithstanding, increasingly more complex models are being developed, which may not be high throughput, but more pragmatic in our pursuit to control Wnt signaling.

  17. Vi kan bryde den negative kulturelle arv

    DEFF Research Database (Denmark)

    Pecseli, Benedicta

    2014-01-01

    Den ny bekendtgørelse for pædagoguddannelsen fokuserer på brydning af den negative sociale arv, men det som inklusionspædagogikken skal inkludere til, eller den horisont inden for hvilken alle børn skal gives lige livschance/mulighed, er der næsten ingen redegørelse for. Begreber som Kultur og...

  18. Comprehensive Quantitative Analysis of 32 Chemical Ingredients of a Chinese Patented Drug Sanhuang Tablet

    Directory of Open Access Journals (Sweden)

    Hau-Yee Fung

    2017-01-01

    Full Text Available Sanhuang Tablet (SHT is a Chinese patented drug commonly used for the treatment of inflammations of the respiratory tract, gastrointestinal tract, and skin. It contains a special medicinal composition including the single compound berberine hydrochloride, extracts of Scutellariae Radix and Rhei Radix et Rhizoma, as well as the powder of Rhei Radix et Rhizoma. Despite advances in analytical techniques, quantitative evaluation of a Chinese patented drug like SHT remains a challenge due to the complexity of its chemical profile. In this study, ultra-high performance liquid chromatography coupled with quadrupole-time-of-flight mass spectrometry (UHPLC-Q-TOF-MS was used to simultaneously quantify 29 non-sugar small molecule components of SHT (11 flavonoids, two isoflavonoids, one flavanone, five anthraquinones, two dianthranones, five alkaloids, two organic acids and one stilbene. Three major saccharide components, namely fructose, glucose, and sucrose, were also quantitatively determined using high performance liquid chromatography-charged aerosol detector (HPLC-CAD on an Asahipak NH2P-50 4E amino column. The established methods were validated in terms of linearity, sensitivity, precision, accuracy, and stability, and then successfully applied to analyze 27 batches of commercial SHT products. A total of up to 57.61% (w/w of SHT could be quantified, in which the contents of the determined non-saccharide small molecules varied from 5.91% to 16.83% (w/w and three saccharides accounted for 4.41% to 48.05% (w/w. The results showed that the quality of the commercial products was inconsistent, and only four of those met Chinese Pharmacopoeia criteria.

  19. HIV/AIDS drugs for Sub-Saharan Africa: how do brand and generic supply compare?

    Directory of Open Access Journals (Sweden)

    Colleen V Chien

    Full Text Available BACKGROUND: Significant quantities of antiretroviral drugs (ARVs to treat HIV/AIDS have been procured for Sub-Saharan Africa for the first time in their 20-year history. This presents a novel opportunity to empirically study the roles of brand and generic suppliers in providing access to ARVs. METHODOLOGY/PRINCIPAL FINDINGS: An observational study of brand and generic supply based on a dataset of 2,162 orders of AIDS drugs for Sub-Saharan Africa reported to the Global Price Reporting Mechanism at the World Health Organization from January 2004-March 2006 was performed. Generic companies supplied 63% of the drugs studied, at prices that were on average about a third of the prices charged by brand companies. 96% of the procurement was of first line drugs, which were provided mostly by generic firms, while the remaining 4%, of second line drugs, was sourced primarily from brand companies. 85% of the generic drugs in the sample were manufactured in India, where the majority of the drugs procured were ineligible for patent protection. The remaining 15% was manufactured in South Africa, mostly under voluntary licenses provided by brand companies to a single generic company. In Sub-Saharan African countries, four first line drugs in the dataset were widely patented, however no general deterrent to generic purchasing based on a patent was detected. CONCLUSIONS/SIGNIFICANCE: Generic and brand companies have played distinct roles in increasing the availability of ARVs in Sub-Saharan Africa. Generic companies provided most of the drugs studied, at prices below those charged by brand companies, and until now, almost exclusively supplied several fixed-dose combination drugs. Brand companies have supplied almost all second line drugs, signed voluntary licenses with generic companies, and are not strictly enforcing patents in certain countries. Further investigation into how price reductions in second line drugs can be achieved and the cheapest drugs can

  20. Research and Development of Hepatitis B Drugs: An Analysis Based on Technology Flows Measured by Patent Citations

    Science.gov (United States)

    Wan, Jian-bo; He, Chengwei; Hu, Yuanjia

    2016-01-01

    Despite the existence of available therapies, the Hepatitis B virus infection continues to be one of the most serious threats to human health, especially in developing countries such as China and India. To shed light on the improvement of current therapies and development of novel anti-HBV drugs, we thoroughly investigated 212 US patents of anti-HBV drugs and analyzed the technology flow in research and development of anti-HBV drugs based on data from IMS LifeCycle databases. Moreover, utilizing the patent citation method, which is an effective indicator of technology flow, we constructed patent citation network models and performed network analysis in order to reveal the features of different technology clusters. As a result, we identified the stagnant status of anti-HBV drug development and pointed the way for development of domestic pharmaceuticals in developing countries. We also discussed about therapeutic vaccines as the potential next generation therapy for HBV infection. Lastly, we depicted the cooperation between entities and found that novel forms of cooperation added diversity to the conventional form of cooperation within the pharmaceutical industry. In summary, our study provides inspiring insights for investors, policy makers, researchers, and other readers interested in anti-HBV drug development. PMID:27727319

  1. Scaling-up the use of generic antiretrovirals in resource-limited countries: generic drugs for health.

    Science.gov (United States)

    Beck, Eduard J; Passarelli, Carlos; Lui, Iris; Guichard, Anne-Claire; Simao, Mariangela; De Lay, Paul; Loures, Luiz

    2014-01-01

    The number of people living with HIV (PLHIV) continues to increase around the world because of the increasing number on antiretroviral therapy (ART) and their associated increase of life expectancy, in addition to the number of people newly infected with HIV each year. Unless a 'cure' can be found for HIV infection, PLHIV can anticipate the need to take antiretroviral drugs (ARVs) for the rest of their lives. Because ARVs are now being used for HIV prevention, as well as for therapeutic purposes, the need for effective, affordable ARVs with few adverse effects will continue to rise. It is important to note that the dramatic growth in treatment coverage of PLHIV seen during the past decade has been primarily due to the increased use of generic ARVs. Thus, there will be a need to scale-up the research and development, production, distribution and access to generic ARVs and ART regimens. However, these processes must occur within national and international regulated free-market economic systems and must deal with increasingly multifaceted patent issues affecting the price while ensuring the quality of the ARVs. National and international regulatory mechanisms will have to evolve, which will affect broader national and international economic and trade issues. Because of the complexity of these issues, the Editors of this Supplement conceived of asking experts in their fields to describe the various steps from relevant research and development, to production of generic ARVs, their delivery to countries and subsequently to PLHIV in low- and middle-income countries. A main objective was to highlight how these steps are interrelated, how the production and delivery of these drugs to PLHIV in resource-limited countries can be made more effective and efficient, and what the lessons are for the production and delivery of a broader set of drugs to people in low- and middle-income countries.

  2. Influence of foreign drug patent policy on pharmaceutical industry%国外药品专利政策对制药业的影响分析

    Institute of Scientific and Technical Information of China (English)

    倪娜; 刁天喜; 王磊; 赵晓宇

    2011-01-01

    通过研究美国、日本和印度三个具有代表性的国家的药品专利政策,分析了药品专利政策对制药业的影响,分别阐述了近期美国的专利法改革及其他药品相关法案中药品专利政策对制药业的影响,对运用专利战略非常成功的日本专利制度改革进行了分析,比较了印度旧专利法和新专利法中药品相关专利政策对印度生物制药业的影响.最后分析了典型国家专利政策对我国的启示.%The contents of this paper included drug patent policy of the developed countries such as USA and Japan and developing countries like India, and analysis of the foreign experiences. The first part introduced the influence of the reform of USA patent law on pharmaceutical industries. The cases of most important drug patents were analyzed. The second part analyzed the drug patent policy reform of Japan, in which the patent strategy is very successful. According to the four stages of development in pharmaceutical industry, this part examined the Japanese drug patent policy reform and the influences on industry. The third part introduced the Indian drug patent policy and the influences of patent laws, and also presented the strategies of some Indian medicine companies. Finally the last part gave recommendations on strategies of drug patent policy to improve the protection of patent.

  3. Software Patents.

    Science.gov (United States)

    Burke, Edmund B.

    1994-01-01

    Outlines basic patent law information that pertains to computer software programs. Topics addressed include protection in other countries; how to obtain patents; kinds of patents; duration; classes of patentable subject matter, including machines and processes; patentability searches; experimental use prior to obtaining a patent; and patent…

  4. Off-patent generic medicines vs. off-patent brand medicines for six reference drugs: a retrospective claims data study from five local healthcare units in the Lombardy Region of Italy.

    Directory of Open Access Journals (Sweden)

    Giorgio L Colombo

    Full Text Available The scientific documentation supporting the potential clinical and economic benefits of a growing use of off-patent generic drugs in clinical practice seems to be limited in Italy as yet.We compared differences in outcomes between off-patent generic drugs and off-patent brand drugs in real clinical practice. The outcomes were: persistence and compliance with therapy, mortality, and other health resources consumption (hospitalizations, specialist examinations, other drugs and total costs. Retrospective analysis was carried out by using the administrative databases of five Local Healthcare Units (ASLs - Aziende Sanitarie Locali in the Lombardy Region of Italy. Data from the five ASLs were aggregated through a meta-analysis, which produced an estimate indicator of the mean or percentage difference between the two groups (branded vs. generic and their respective significance tests. The therapeutic areas and studied drugs were: diabetes: metformin - A10BA02; hypertension: amlodipine - C08CA01; dyslipidemia: simvastatin - C10AA01; psychiatry: sertraline - N06AB06; cardiology: propafenone - C01BC03; osteoporosis: alendronate - M05BA04.The 5 Local Healthcare Units (ASL represent a population of 3,847,004 inhabitants. The selected sample included 347,073 patients, or 9.02% of the total ASL population; 67% of the patients were treated with off-patent brand drugs. The average age was 68 years, with no difference between the two groups. After 34 months of observation, compliance and persistence were in favor to generic drugs in all therapeutic areas and statistically significant in the metformin, amlodipine, simvastatin, and sertraline groups. The clinical outcomes (hospitalizations, mortality, and other health costs show no statistically significant differences between off-patent generic vs. off-patent brand medicines.Off-patent generic drugs appear to be a therapy option of choice in Italy as well, based on clinical outcomes and economic consequences

  5. ION EXCHANGE RESINS: AN APPROACH TOWARDS TASTE MASKING OF BITTER DRUGS AND SUSTAINED RELEASE FORMULATIONS WITH THEIR PATENTS

    Directory of Open Access Journals (Sweden)

    Ajay Bilandi

    2013-08-01

    Full Text Available The purpose of this review is to cover various aspects related with the use of ion exchange resins for taste masking of bitter drugs and for formulating sustained release dosage form. Ion exchange resins are water insoluble cross-linked polymers containing a salt-forming group at repeating positions on the polymer chain and have the ability to exchange counter-ions within aqueous solutions surrounding them. The bitterness of pharmaceutical medicines plays a critical role in patient compliance, as the oral administration of bitter drugs is often hampered by their unpleasant taste which leads to non-compliance and further worsening of diseased condition. One of the popular approaches in the taste masking of bitter drugs is based on IER. For taste masking purpose weak cation exchange or weak anion exchange resins are used, depending on the nature of drug. The drug resin complex is absolutely tasteless with no after taste, and at the same time, its bioavailability is not affected. Sustained release dosage forms are designed to release a drug at a pre determined rate in order to maintain a constant drug concentration for a specific period of time with minimum side effects. The usage of IER during the development of sustained release formulations plays a significant role because of their drug retarding properties. In this review also incorporates various patents related to taste masking and sustained release formulations using IER.

  6. Patente gera patente?

    OpenAIRE

    Joana Coeli Ribeiro Garcia

    2006-01-01

    A patente, fonte de informação e geradora de nova patente em condições e contexto favoráveis, constitui objeto desta pesquisa. Esta é respaldada em quadro teórico da Ciência da Informação e identifica os fatores intervenientes no fluxo das relações desde a patente-fonte até o registro de nova patente. Da amostra da pesquisa constam instituições privadas e públicas representadas por unidades situadas em Brasília, Belo Horizonte e Rio de Janeiro. A entrevista é a técnica usada para a coleta de ...

  7. AUSTRALIAN COMPETITION AND CONSUMER COMMISSION v PFIZER: EVERGREENING AND MARKET POWER AS A BLOCKBUSTER DRUG GOES OFF PATENT.

    Science.gov (United States)

    Faunce, Thomas

    2015-06-01

    In Australian Competition and Consumer Commission v Pfizer Australia Pty Ltd [2015] FCA 113, the ACCC alleged that Pfizer's "Project LEAP" involved a scheme to lock pharmacists into substituting its generic version of the high sales volume anti-cholesterol drug, patent-expired atorvastatin (Lipitor), which took advantage of a substantial degree of market power for a purpose proscribed by s 46(1)(c) of the Competition and Consumer Act 2010 (Cth). The ACCC also claimed that Pfizer's actions constituted a course of exclusive dealing pursuant to s 47(1)(d) and (e) for the proscribed purpose of lessening competition. Flick J in the Federal Court of Australia, in a judgment heavy with quotations but sparse in reasoning, dismissed the ACCC's Amended Originating Application alleging abuse of market power and ordered the ACCC to pay Pfizer's costs. The ACCC has now appealed the decision. This column explores this case in the context of Pfizer's broader strategies to preserve its income globally from this high sales volume drug in the period following its patent expiration.

  8. Antiretroviral Drug Use in a Cohort of HIV-Uninfected Women in the United States: HIV Prevention Trials Network 064

    Science.gov (United States)

    Chen, Iris; Clarke, William; Ou, San-San; Marzinke, Mark A.; Breaud, Autumn; Emel, Lynda M.; Wang, Jing; Hughes, James P.; Richardson, Paul; Haley, Danielle F.; Lucas, Jonathan; Rompalo, Anne; Justman, Jessica E.; Hodder, Sally L.; Eshleman, Susan H.

    2015-01-01

    Antiretroviral (ARV) drug use was analyzed in HIV-uninfected women in an observational cohort study conducted in 10 urban and periurban communities in the United States with high rates of poverty and HIV infection. Plasma samples collected in 2009–2010 were tested for the presence of 16 ARV drugs. ARV drugs were detected in samples from 39 (2%) of 1,806 participants: 27/181 (15%) in Baltimore, MD and 12/179 (7%) in Bronx, NY. The ARV drugs detected included different combinations of non-nucleoside reverse transcriptase inhibitors and protease inhibitors (1–4 drugs/sample). These data were analyzed in the context of self-reported data on ARV drug use. None of the 39 women who had ARV drugs detected reported ARV drug use at any study visit. Further research is needed to evaluate ARV drug use by HIV-uninfected individuals. PMID:26445283

  9. Antiretroviral Drug Use in a Cohort of HIV-Uninfected Women in the United States: HIV Prevention Trials Network 064.

    Directory of Open Access Journals (Sweden)

    Iris Chen

    Full Text Available Antiretroviral (ARV drug use was analyzed in HIV-uninfected women in an observational cohort study conducted in 10 urban and periurban communities in the United States with high rates of poverty and HIV infection. Plasma samples collected in 2009-2010 were tested for the presence of 16 ARV drugs. ARV drugs were detected in samples from 39 (2% of 1,806 participants: 27/181 (15% in Baltimore, MD and 12/179 (7% in Bronx, NY. The ARV drugs detected included different combinations of non-nucleoside reverse transcriptase inhibitors and protease inhibitors (1-4 drugs/sample. These data were analyzed in the context of self-reported data on ARV drug use. None of the 39 women who had ARV drugs detected reported ARV drug use at any study visit. Further research is needed to evaluate ARV drug use by HIV-uninfected individuals.

  10. Making tenofovir accessible in the brazilian public health system: patent conflicts and generic production.

    Science.gov (United States)

    Veras, Juliana

    2014-08-01

    In May 2011, the Brazilian Ministry of Health announced the distribution of the first batch of locally produced generic tenofovir disoproxil fumarate (TDF) to support its program of universal and free access for the treatment of HIV/AIDS. The inclusion of TDF in the public health program illustrates what has been considered the 'Brazilian model' of HIV/AIDS response, as it illustrates the current phase of the Brazilian pharmaceutical economy. Brazil is known for having managed to control the expansion of HIV/AIDS through a unique initiative combining the public health and the industrial production of generics. But, if at first local manufacturers could freely copy ARVs and produce cheaper generic versions that were delivered to the Ministry of Health, since the country started to grant patents on drugs in 1996, the sustainability of this policy has been challenged by the high cost of patented second-line HIV/AIDS treatments. In order to assure continuity of the local production of ARVs, and keep the program of public health alive, Brazilians are now forced to deal with conflicts of drugs' intellectual property rights in order to open the path to generic production. This article aims to describe the experiences surrounding TDF in Brazil and the unprecedented conflicts and challenges it has brought for our different interviewees. Blurring the frontier between the public and the private, the TDF case was driven at the same time by an ethic of drug access and regulation of drug quality, which has inspired Brazilians to intervene and transform the world they live in.

  11. MORBILI PADA ANAK DALAM PENGOBATAN ANTI RETRO VIRAL (ARV

    Directory of Open Access Journals (Sweden)

    Surya Dipta Nugraha

    2016-03-01

    Full Text Available MEASLES IN CHILDREN WITH ANTI RETRO VIRAL (ARV ON TREATMENT ABSTRACT Introduction: Morbili is an acute viral infectious disease caused by a virus transmitted morbili. Morbili is a contagious acute viral infectious disease that is characterized by three stages: catarrhal stage, eruption stage and convalence stage. Another name morbili is measles, measles, or rubeola. Morbili caused by a virus that is classified as Family paramyxovirus, the virus genus morbili contained in nasopharyngeal secretions and blood during the prodromal period until 24 hours after the onset of spots. Case: Patient male, 6 years old, Hindu, Balinese tribe, came with complaints of febris since 5 days ago. Febris is not measured with a thermometer. The heat is felt up and down, getting better with medicine. Complaints red spots felt since 1 day ago. Originally discovered red spots appear in the neck area and then to the face and chest. The incidence of rash accompanied by itching and heat. This complaint is accompanied with nosebleeds 1 day ago, cough with sputum since 5 days ago and the red eye from one day ago. Patients feel the first time such complaints. Having a history of antiretroviral use regularly since 1.5 years old. Keywords: rash, morbili, HIV, antiretroviral drugs.

  12. Thoughts on drug patent strategies in foreign countries%国外药品专利战略及其启示

    Institute of Scientific and Technical Information of China (English)

    贾启燕; 徐亮; 房彤宇

    2012-01-01

    目前,美国、日本、德国作为国际医药专利申请数量全世界排名前3位的国家,其在实施药品专利战略方面的相关做法为我们提供了很好的参考.以介绍它们的药品专利战略为出发点,探讨其对我国制订和实施药品专利战略的启示.%To provide references for implementing drug patent strategy in China,we introduced the drug patent strategies of America,Japan and Germany,which rank the first three in the amount of patent in the world,and analyzed their successful experiences.

  13. Google Patents: The global patent search engine

    OpenAIRE

    Alireza Noruzi; Mohammadhiwa Abdekhoda

    2014-01-01

    Google Patents (www.google.com/patents) includes over 8 million full-text patents. Google Patents works in the same way as the Google search engine. Google Patents is the global patent search engine that lets users search through patents from the USPTO (United States Patent and Trademark Office), EPO (European Patent Office), etc. This study begins with an overview of how to use Google Patent and identifies advanced search techniques not well-documented by Google Patent. It makes several sug...

  14. Patent protection strategies

    Directory of Open Access Journals (Sweden)

    Himanshu Gupta

    2010-01-01

    Full Text Available It is widely recognized that the pharmaceutical industry faces serious financial challenges. Large numbers of blockbuster drugs are losing patent protection and going generic. The pipeline of new drugs is too sparse to fill the gap and generate a platform for future growth. Moreover, many of the new products are biologics with much narrower target patient populations and comparatively higher prices relative to traditional pharmaceuticals. So now the time has come for pharmaceutical scientists to have a better understanding of patent fundamentals. This need is illustrated by analyses of key scientific and legal issues that arose during recent patent infringement cases involving Prozac, Prilosec, and Buspar. Facing this scenario, the pharmaceutical industry has moved to accelerate drug development process and to adopt at the same time different strategies to extend the life time of the patent monopoly to provide the economic incentives and utilizing it for drug discovery and development. This review covers the need of patent protection and various strategies to extend the patent.

  15. Abortide arv kahaneb Eestis iga aastaga / Rebekka Lotman

    Index Scriptorium Estoniae

    Lotman, Rebekka, 1978-

    2005-01-01

    Vt. ka Zdorovje dlja Vsehh 2005 märts, lk. 6. Kuigi abortide arv väheneb Eestis iga aastaga, tuleb naistearstide hinnangul oodata veel kümmekond aastat, et see langeks sama madalale tasemele nagu Põhjamaades. Lisaks diagramm abortide arvu kohta 1991-2004

  16. Tallinlaste arv kukkus alla 400 000 / Dagne Hanschmidt

    Index Scriptorium Estoniae

    Hanschmidt, Dagne

    2006-01-01

    Ilmunud ka: Postimees : na russkom jazõke 6. märts lk. 8. Rahvastikuregister kõrvaldas elanike nimekirjast kehtiva elamisloata isikud, mille tõttu kahanes Tallinna elanike arv 4766 inimese võrra. 1. märtsi seisuga on pealinlasi kokku 398 753 inimest

  17. 21 CFR 314.53 - Submission of patent information.

    Science.gov (United States)

    2010-04-01

    ... 21 Food and Drugs 5 2010-04-01 2010-04-01 false Submission of patent information. 314.53 Section... of patent information. (a) Who must submit patent information. This section applies to any applicant...)(2) of this section. (b) Patents for which information must be submitted and patents for...

  18. Google Patents: The global patent search engine

    Directory of Open Access Journals (Sweden)

    Alireza Noruzi

    2014-06-01

    Full Text Available Google Patents (www.google.com/patents includes over 8 million full-text patents. Google Patents works in the same way as the Google search engine. Google Patents is the global patent search engine that lets users search through patents from the USPTO (United States Patent and Trademark Office, EPO (European Patent Office, etc. This study begins with an overview of how to use Google Patent and identifies advanced search techniques not well-documented by Google Patent. It makes several suggestions for improving Google Patents. This study also compares the citation counts provided by Google Patents for journals in the field of library and information science (LIS. Finally, it concludes that Google Patents provides a free alternative or complement to other patent databases. It also addressed the advantages of Google Patents, for example, easy-use search interface and fast search engine; convenient access to patent images in PDF format; and fast downloads of PDF patent documents.

  19. Production of antiretroviral drugs in middle- and low-income countries.

    Science.gov (United States)

    Pinheiro, Eloan dos Santos; Brüning, Karin; Macedo, M Fernanda; Siani, Antonio C

    2014-01-01

    This review outlines the main issues concerning the production of antiretroviral (ARV) drugs in middle- and low-income countries and the relevant political, legal and technical requirements for supporting such production. The requirements for efficient local production, including the manufacture of generic and branded products and public demand, have been considered from economic, market and socio-political perspectives. A steady and consistent government policy is crucial to success. Additional crucial factors in establishing local production are adequate infrastructure, qualified human resources in technical and managerial areas, and production-distribution logistics systems. The creation or strengthening of a national drug regulatory agency is a basic requirement. Production of ARVs relies on the structure of the international market for active pharmaceutical ingredients (APIs), which are highly monopolized for inclusion in branded or patented drugs, or are concentrated in a few Asian generic companies. Countries seeking to begin local production must develop strategies to overcome the various barriers. For instance, sub-Saharan African countries may benefit from developing multilateral health agreements with neighbouring countries. Such agreements are recommended and should be complemented by technology transfers, especially for the manufacture of APIs. Achieving a production level that is sustainable in the long term is crucial to maintaining patients' access to ARVs.

  20. Lapsetoetuse saajate arv tõuseb / Eli Lilles

    Index Scriptorium Estoniae

    Lilles, Eli

    2007-01-01

    1. septembrist saavad lapsetoetust ja teisi peretoetusi ka 16-19-aastased noored, kes õpivad õhtuses õppevormis või kaugõppes. Ilmunud ka Türi Rahvaleht 7. september 2007, lk. 4, pealkiri kujul : lapsetoetuse saajate arv suurenes; Vooremaa 11. september 2007, lk. 5, pealkiri kujul: lapsetoetust saavad ka õhtukoolis õppijad; Lõuna-Mulgimaa 8. september 2007, lk. 6, pealkiri kujul: lapse- ja peretoetused

  1. MORBILI PADA ANAK DALAM PENGOBATAN ANTI RETRO VIRAL (ARV)

    OpenAIRE

    Surya Dipta Nugraha

    2016-01-01

    MEASLES IN CHILDREN WITH ANTI RETRO VIRAL (ARV) ON TREATMENT ABSTRACT Introduction: Morbili is an acute viral infectious disease caused by a virus transmitted morbili. Morbili is a contagious acute viral infectious disease that is characterized by three stages: catarrhal stage, eruption stage and convalence stage. Another name morbili is measles, measles, or rubeola. Morbili caused by a virus that is classified as Family paramyxovirus, the virus genus morbili contained in nasopharyngea...

  2. Canada's Patented Medicines (Notice of Compliance) Proceedings and Intellectual Property.

    Science.gov (United States)

    Bian, Henry; McCourt, Conor

    2015-01-08

    Canada's Patent Register is a tool created by the Patented Medicines (Notice of Compliance) Regulations to help innovators protect their inventions relating to pharmaceuticals. This tool exists at the intersection between the intellectual property and drug approval regimes. By listing a patent on the Patent Register, an innovator can prevent a generic manufacturer from entering the marketplace rather than having to wait for his or her patent to be infringed. This article provides information on the requirements for listing a patent on the Patent Register and an overview of how the Patent Medicines (Notice of Compliance) Regulations affect the drug approval process.

  3. 75 FR 34749 - Determination of Regulatory Review Period for Purposes of Patent Extension; BYSTOLIC; U.S. Patent...

    Science.gov (United States)

    2010-06-18

    ... Patent Extension; BYSTOLIC; U.S. Patent Nos. 5,759,580 and 6,545,040 AGENCY: Food and Drug Administration... has made the determination because of the submission of applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug...

  4. Tööpuudus hiilib kikivarvul Võrumaale / Arved Breidaks

    Index Scriptorium Estoniae

    Breidaks, Arved, 1975-

    2008-01-01

    Võrumaal on töötute arv eelmise aastaga võrreldes tõusma hakanud: mullu suvel maakonnas registreeritud 3,9%-line töötuse määr asendus tänavu juuli lõpus 5,4%-lise töötusega. Lisa: Töötus Võrumaal. Vt. samas: Kuidas iseloomustate olukorda Võrumaa tööjõuturul? Vastavad Martin Arula (AS Toftan), Kaido Mäesalu (AS Suwem), Meelis Munski (AS Semuehitus), Indrek Klampe (OÜ Selista Ehitus), Andres Visanpuu (Võru TÜ)

  5. Measuring performance in off-patent drug markets: a methodological framework and empirical evidence from twelve EU Member States.

    Science.gov (United States)

    Kanavos, Panos

    2014-11-01

    This paper develops a methodological framework to help evaluate the performance of generic pharmaceutical policies post-patent expiry or after loss of exclusivity in non-tendering settings, comprising five indicators (generic availability, time delay to and speed of generic entry, number of generic competitors, price developments, and generic volume share evolution) and proposes a series of metrics to evaluate performance. The paper subsequently tests this framework across twelve EU Member States (MS) by using IMS data on 101 patent expired molecules over the 1998-2010 period. Results indicate that significant variation exists in generic market entry, price competition and generic penetration across the study countries. Size of a geographical market is not a predictor of generic market entry intensity or price decline. Regardless of geographic or product market size, many off patent molecules lack generic competitors two years after loss of exclusivity. The ranges in each of the five proposed indicators suggest, first, that there are numerous factors--including institutional ones--contributing to the success of generic entry, price decline and market penetration and, second, MS should seek a combination of supply and demand-side policies in order to maximise cost-savings from generics. Overall, there seems to be considerable potential for faster generic entry, uptake and greater generic competition, particularly for molecules at the lower end of the market.

  6. 专利的公共政策--以印度首个专利强制许可案为例%Public Policy in Patent Regime:Citing the First Compulsory Licensing Case on Patented Drug in India

    Institute of Scientific and Technical Information of China (English)

    易继明

    2014-01-01

    2013年德国拜耳公司诉印度拿特科公司一案中,印度知识产权上诉委员会维持了授权拿特科公司的药品强制许可。这是印度首个专利强制许可案,对发展中国家有导向性作用,也将对欧美大型药剂企业的知识产权战略产生巨大影响。本世纪初建立在《多哈健康宣言》《总理事会决议》以及《修订TRIPS协议议定书》基础上的药品强制许可机制,让发展中国家和最不发达国家的民众能够负担起必要的基础药品,一定程度上缓解了这些国家某些公共健康危机。不过,机制建立至今,实际案例还是屈指可数。中国专利法上虽有这一制度,但却从未利用这一公共政策工具颁发过一例强制许可。在财产性权利和生命健康权利发生根本性冲突时,作为一种公共政策工具,专利强制许可可以在医药市场上加以运用。%The pharmaceutical case Natco v .Bayer in early 2013 , has ended with a first-time compulsory license of a patented drug being granted by the Indian Intellectual Property Appellate Board .As the very first compulsory license ever to be granted , this particular decision will exert its guiding effects on other developing nations, whilst substantially influencing the IP strategies of Euro-American pharmaceutical giants .The com-pulsory licensing mechanism of patented drugs based on the Doha Declaration , the Decision by the WTO Gen-eral Council on the Implementation of Paragraph 6 of The Doha Declaration in 2003 and Amendment of the TRIPS Agreement , has enabled developing nations and least developed nations to afford essential drugs , which in turn has alleviated certain public health crisis in these areas .However , actual cases of compulsory licenses have been rare since the establishment of the said mechanism .Such dilemma also troubles Chinese patent re-gime as the public policy doctrine has not been practically maneuvered despite its existence

  7. Begreber og indfaldsvinkler i forskningsprogrammet om social arv

    DEFF Research Database (Denmark)

    Ploug, Niels

    opvækstvilkår og livschancer. Tværtimod ser denne sammenhæng ud til at være relativt stabil jf Erikson & Goldthorpe (1992), Hansen (1995). Den hidtidige forskning har således bidraget til at slå fast, at udbygningen af velfærdsstaten – mod forventning - ikke har elimineret den negative sociale arv. Den......Forskningsprogrammet om social arv er igangsat ud fra en politisk målsætning om at opnå ny forskningsbaseret viden som et input til politiske bestræbelser på at bekæmpe ’den negative sociale arv’. Politisk er det således en klar målsætning med programmet at opnå viden om forhold, der bidrager til...... forskningsmæssige udfordring bliver derfor at finde forhold, der kan forklare hvorfor en bevidst satsning på lighed gennem afskaffelse af fattigdom og satsning på uddannelse, ikke har ført til et samfund med lige chancer for alle. I den forbindelse er det relevant at overveje på, hvad begrebet ’social arv’ kan...

  8. Begreber og indfaldsvinkler i forskningsprogrammet. Forskningsprogrammet om social arv

    DEFF Research Database (Denmark)

    Ploug, Niels

    opvækstvilkår og livschancer. Tværtimod ser denne sammenhæng ud til at være relativt stabil jf Erikson & Goldthorpe (1992), Hansen (1995). Den hidtidige forskning har således bidraget til at slå fast, at udbygningen af velfærdsstaten – mod forventning - ikke har elimineret den negative sociale arv. Den......Forskningsprogrammet om social arv er igangsat ud fra en politisk målsætning om at opnå ny forskningsbaseret viden som et input til politiske bestræbelser på at bekæmpe ’den negative sociale arv’. Politisk er det således en klar målsætning med programmet at opnå viden om forhold, der bidrager til...... forskningsmæssige udfordring bliver derfor at finde forhold, der kan forklare hvorfor en bevidst satsning på lighed gennem afskaffelse af fattigdom og satsning på uddannelse, ikke har ført til et samfund med lige chancer for alle. I den forbindelse er det relevant at overveje på, hvad begrebet ’social arv’ kan...

  9. Suvehooajal Saare maakonnas ööbinud turistide arv kahanes / Urmas Kiil

    Index Scriptorium Estoniae

    Kiil, Urmas

    2008-01-01

    Saare maakonna majutusasutustes suvel viibinud turistide arv vähenes mullusega võrreldes 7 %. Diagrammid: Eesti maakondades peatunud välisturistid; Ööbimiste arv Saare maakonna majutuskohtades; Ööpäeva keskmine maksumus suviti

  10. Drug discovery using very large numbers of patents. General strategy with extensive use of match and edit operations

    Science.gov (United States)

    Robson, Barry; Li, Jin; Dettinger, Richard; Peters, Amanda; Boyer, Stephen K.

    2011-05-01

    A patent data base of 6.7 million compounds generated by a very high performance computer (Blue Gene) requires new techniques for exploitation when extensive use of chemical similarity is involved. Such exploitation includes the taxonomic classification of chemical themes, and data mining to assess mutual information between themes and companies. Importantly, we also launch candidates that evolve by "natural selection" as failure of partial match against the patent data base and their ability to bind to the protein target appropriately, by simulation on Blue Gene. An unusual feature of our method is that algorithms and workflows rely on dynamic interaction between match-and-edit instructions, which in practice are regular expressions. Similarity testing by these uses SMILES strings and, less frequently, graph or connectivity representations. Examining how this performs in high throughput, we note that chemical similarity and novelty are human concepts that largely have meaning by utility in specific contexts. For some purposes, mutual information involving chemical themes might be a better concept.

  11. Drug-drug interactions: antiretroviral drugs and recreational drugs.

    Science.gov (United States)

    Staltari, Orietta; Leporini, Christian; Caroleo, Benedetto; Russo, Emilio; Siniscalchi, Antonio; De Sarro, Giovambattista; Gallelli, Luca

    2014-01-01

    With the advances in antiretroviral (ARV) therapy, patients with Human Immunodeficiency Virus (HIV) infection are living longer, however, some patients encounter co- morbidities which sometimes require treatment. Therefore, during the treatment with ARV drugs these patients could take several recreational drugs (e.g. amphetamines, hallucinogenes, opiates, or alcohol) with a possible development of drug-drug interactions (DDIs). In particular, Nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs/NtRTIs) are mainly excreted through the kidney and are not substrates of the cytochrome P450 or P-glycoprotein, therefore the DDIs during this treatment are minimal. In contrast, the other ARV drugs (i.e. non-nucleoside reversetranscriptase inhibitors, Protease inhibitors, Integrase inhibitors, chemokine receptor 5 antagonists and HIV-fusion inhibitors) are an important class of antiretroviral medications that are frequent components of HAART regimens but show several DDIs related to interaction with the cytochrome P450 or P-glycoprotein. In this paper we will review data concerning the possibility of DDI in HIV patients treated with ARV and taking recreational drugs.

  12. Aurora A regulates expression of AR-V7 in models of castrate resistant prostate cancer

    Science.gov (United States)

    Jones, Dominic; Noble, Martin; Wedge, Steve R.; Robson, Craig N.; Gaughan, Luke

    2017-01-01

    Androgen receptor variants (AR-Vs) provide a mechanism of therapy evasion in castrate-resistant prostate cancer (CRPC), yet mechanisms of regulation remain largely unknown. Here we investigate the role of Aurora A kinase on AR-Vs in models of CRPC and show depletion of Aurora A reduces AR-V target gene expression. Importantly, knockdown of Aurora A reconfigures splicing of AR pre-mRNA to discriminately down-regulate synthesis of AR-V transcripts, including AR-V7, without effecting full-length AR mRNA; and as a consequence, AR-V-driven proliferation and survival of CRPC cells is markedly reduced. Critically, these effects are reproduced by Aurora A inhibition. We show that Aurora A levels increase in advanced disease and AURKA is an AR-V target gene demonstrating a positive feedback mechanism of androgenic signalling in CRPC. In all, our data suggests that Aurora A plays a pivotal role in regulation of AR-V7 expression and represents a new therapeutic target in CRPC. PMID:28205582

  13. Chinese Invention Patent about Anti-parasitic Drug Albendazale%与抗寄生虫药物阿苯达唑相关的中国发明专利

    Institute of Scientific and Technical Information of China (English)

    赵军; 高惠静; 王建华

    2012-01-01

    This paper summarizes authorized Chinese invention patents about albendazole and shows research status of albendazole from patents. It can provide data for persons involved in the relevant research activities on the drug.%本文对在中国已授权的阿苯达唑药物发明专利进行综述,从专利角度反映抗寄生虫药物阿苯达唑的研究现状,为从事阿苯达唑药物研究或申请有关发明专利的研究人员提供资料.

  14. Long-term efficacy and toxicity of abacavir/lamivudine/nevirapine compared to the most prescribed ARV regimens before 2013 in a French Nationwide Cohort Study.

    Science.gov (United States)

    de Boissieu, Paul; Dramé, Moustapha; Raffi, François; Cabie, André; Poizot-Martin, Isabelle; Cotte, Laurent; Garraffo, Rodolphe; Delobel, Pierre; Huleux, Thomas; Rey, David; Bani-Sadr, Firouzé

    2016-09-01

    Data on the long-term efficacy and safety of abacavir/lamivudine (ABC/3TC) and nevirapine (NVP) are scarce. This combination has the advantage of simplifying treatment and improving long-term tolerance. The aim of this study was to compare the rate of any discontinuation of antiretroviral (ARV) regimen because of virologic failure (VF), and/or adverse drug reaction (ADR) among patients receiving stable ARV regimens for at least 6 months.ABC/3TC/NVP was compared to ABC/3TC with either ritonavir-boosted darunavir (DRV/r) or ritonavir-boosted atazanavir (ATV/r), unboosted ATV, or tenofovir/emtricitabine (TDF/FTC) with either one of the following: ATV/r, unboosted ATV, DRV/r, efavirenz (EFV), or NVP, in the French prospective multicenter Dat'AIDS cohort.The study enrolled 16,511 patients treated with following ARV regimens: ABC/3TC/NVP (n = 1089), TDF/FTC/NVP (n = 1542), ABC/3TC/DRV/r (n = 1065), ABC/3TC/ATV/r (n = 1847), ABC/3TC/ATV (n = 563), TDF/FTC/ATV/r (n = 3519), TDF/FTC/DRV/r (n = 2767), TDF/FTC/ATV (n = 419), and TDF/FTC/EFV (n = 3700). Mean follow-up was 36 ± 24 months. Patients treated with ABC/3TC/NVP received this regimen as a switch regimen in 97% of cases. By multivariable analysis, the risk of treatment discontinuation due to VF was similar between ABC/3TC/NVP and other ARV regimens, except for TDF/FTC/ATV and ABC/3TC/ATV, which were associated with a higher risk of treatment interruption due to VF (hazard ratio [HR] 1.99; 95% confidence interval [CI] 1.29-3.06 and HR 2.19; 95% CI 1.51-3.18, respectively). Treatment discontinuation due to ADR was lowest with the ABC/3TC/NVP regimen. Other ARV regimens were associated with a 1.80- to 3.19-fold increase in the risk of treatment discontinuation due to ADR (P < 0.0001 for all comparisons).ABC/3TC/NVP as a simplification regimen is a long-term effective regimen with lower discontinuation due to long-term toxicity compared with other standard ARV regimens.

  15. Paying for On-Patent Pharmaceuticals

    OpenAIRE

    Fuller, Richard L.; Goldfield, Norbert

    2016-01-01

    In this article we propose a new approach to pricing for patent-protected (on-patent) pharmaceuticals. We describe and define limit pricing as a method for drug companies to maximize revenue for their investment by offering budget-neutral pricing to encourage early adoption by payers. Under this approach, payers are incentivized to adopt innovative but expensive drugs more quickly if drug companies provide detailed analyses of the net impact of the new pharmaceutical upon total health budgets...

  16. 谈中药技术在国际专利分类法中的分布%Distribution of Traditional Chinese Drug Technology in the International Patent Classification

    Institute of Scientific and Technical Information of China (English)

    张洋; 施毅

    2012-01-01

    International Patent Classification (IPC) is a management and classification method of patent documents used internationally. The IPC is consisted of 8 sections, including inventions about knowledge in all areas. The classification system is arranged in a descending hierarchical structure. Traditional Chinese drug patents should be classified by the source of drugs, therapeutic activity, chemical composition, pharmaceutical technology, usage, and etc. There are many IPC sections, among which the traditional Chinese drug patents are distributed. The technology subject is about medicine, health care, chemistry, food, drink, food additives, and etc. The "Sec- tion A-Human Necessities" - "Health; life-Saving; Amusement" - "A61 -Medical or Veterinary Science; Hygiene" and "Section C - Chemistry; Metallurgy" are main classifications, which contain large number of patents on traditional Chinese drug.%国际专利分类法(IPC)是目前国际通用的一种管理和分类专利文献的方法.内容设置包括与发明创造有关的全部知识领域,共分8个部,分类体系是由高至低依次排列的等级式结构.中药相关专利主要可依据药物的来源、治疗活性、化学成分、制剂工艺和用途等进行分类,主要分布于IPC分类的“A部:人类生活必需”中的医学、保健部分和“C部:化学;冶金”中的化学部分,以及食品、饮料和食品添加剂等相关的IPC类下.

  17. How patent experts create patent breadth

    DEFF Research Database (Denmark)

    Beukel, Karin

    2014-01-01

    Science as an input to patented inventions is a fundamental of economic growth. However, our understanding of how science is transformed into patents is limited. In the present paper I seek to fill this gap by examining the micro-foundations of science-patent transformations. Using an inductive......, grounded theory approach to study the transformation of 12 scientific discoveries into patents I recast the relationship between science and patents: I show it as a particular process that affects patent breadth. Exploiting surplus patent breadth depends on the processes of abstraction and cognitive...... variety, which can be mobilized by patenting experts. The theory is tested using a recently published algebraic interpretive method for examining causal relationships in small-N studies....

  18. How patent experts create patent breadth

    DEFF Research Database (Denmark)

    Beukel, Karin

    Science as an input to patented inventions is a fundamental of economic growth. However, our understanding of how science is transformed into patents is limited. In the present paper I seek to fill this gap by examining the micro-foundations of science-patent transformations. Using an inductive......, grounded theory approach to study the transformation of 12 scientific discoveries into patents I recast the relationship between science and patents: I show it as a particular process that affects patent breadth. Exploiting surplus patent breadth depends on the processes of abstraction and cognitive...... variety, which can be mobilized by patenting experts. The theory is tested using a recently published algebraic interpretive method for examining causal relationships in small-N studies....

  19. Utilization Analysis of Traditional Patent Chinese Drugs in 116 Cases of Chronic Osteomyelitis%116例慢性骨髓炎患者中成药应用情况分析

    Institute of Scientific and Technical Information of China (English)

    雷凯君

    2011-01-01

    Objective To evaluate the utilization status of traditional patent Chinese drugs in chronic osteomyelitis patients in our hospital.Methods The orthopedic use status of traditional patent Chinese drugs with chronic osteomyelitis in our hospital during January to December 2009 was analyzed retrospectively and statistically. Results Among all patients in this study, the use rale of traditional patent Chinese drugs was 100%.Conclusion The utilization of traditional Chinese drugs in our hospital as TCM hospital is reasonable. But some problems such as inappropriate us and too long duration of administration exist, which should be further standardized.%目的 评价医院骨科慢性骨髓炎患者中成药应用情况.方法 回顾性调查2009年1月至2009年12月骨科慢性骨髓炎患者中成药应用资料.结果 中成药使用率为100%.结论 中成药使用情况较合理,但仍存在用药不当、用药时间长等问题,需进一步规范.

  20. Trends in nanotechnology patents

    Science.gov (United States)

    Chen, Hsinchun; Roco, Mihail C.; Li, Xin; Lin, Yiling

    2008-03-01

    An analysis of 30 years of data on patent publications from the US Patent and Trademark Office, the European Patent Office and the Japan Patent Office confirms the dominance of companies and selected academic institutions from the US, Europe and Japan in the commercialization of nanotechnology.

  1. Are There Enduring Patents?

    Science.gov (United States)

    Noma, Elliot; Olivastro, Dominic

    1985-01-01

    A study comparing citations received by patents in given year to number received in subsequent years found that, even though influential patents remain influential, both highly and infrequently cited patents age at same rate. Distribution of patents by number of citations received is stable over time. (17 references) (EJS)

  2. Patent Assessment Quality

    DEFF Research Database (Denmark)

    Burke, Paul F.; Reitzig, Markus

    2006-01-01

    The increasing number of patent applications worldwide and the extension of patenting to the areas of software and business methods have triggered a debate on "patent quality". While patent quality may have various dimensions, this paper argues that consistency in the decision making on the side...... of the patent office is one important dimension, particularly in new patenting areas (emerging technologies). In order to understand whether patent offices appear capable of providing consistent assessments of a patent's technological quality in such novel industries from the beginning, we study the concordance...... of the European Patent Office's (EPO's) granting and opoposition decisions for individual patents. We use the historical example of biotech patens filed between 1978 until 1986, the early stage of the industry. Our results indicate that the EPO shows systematically different assessments of technological quality...

  3. Analysis of in vitro bioactivity data extracted from drug discovery literature and patents: Ranking 1654 human protein targets by assayed compounds and molecular scaffolds

    Directory of Open Access Journals (Sweden)

    Southan Christopher

    2011-05-01

    Full Text Available Abstract Background Since the classic Hopkins and Groom druggable genome review in 2002, there have been a number of publications updating both the hypothetical and successful human drug target statistics. However, listings of research targets that define the area between these two extremes are sparse because of the challenges of collating published information at the necessary scale. We have addressed this by interrogating databases, populated by expert curation, of bioactivity data extracted from patents and journal papers over the last 30 years. Results From a subset of just over 27,000 documents we have extracted a set of compound-to-target relationships for biochemical in vitro binding-type assay data for 1,736 human proteins and 1,654 gene identifiers. These are linked to 1,671,951 compound records derived from 823,179 unique chemical structures. The distribution showed a compounds-per-target average of 964 with a maximum of 42,869 (Factor Xa. The list includes non-targets, failed targets and cross-screening targets. The top-278 most actively pursued targets cover 90% of the compounds. We further investigated target ranking by determining the number of molecular frameworks and scaffolds. These were compared to the compound counts as alternative measures of chemical diversity on a per-target basis. Conclusions The compounds-per-protein listing generated in this work (provided as a supplementary file represents the major proportion of the human drug target landscape defined by published data. We supplemented the simple ranking by the number of compounds assayed with additional rankings by molecular topology. These showed significant differences and provide complementary assessments of chemical tractability.

  4. Recent survey on nanosuspension: a patent overview.

    Science.gov (United States)

    Jethara, Sahilhusen I; Patel, Alpesh D; Patel, Mukesh R; Patel, Mukesh S; Patel, Kanu R

    2015-01-01

    The major goals of designing nanosuspension of nanosize materials are increasing due to their tremendous potential as a drug delivery system with the wide range of applications. Nanosuspension is a unique tool for improving the bioavailability of poorly soluble drugs. Nanosuspension drug delivery has wide range of application like oral, injectable, transdermal, inhalation, peroral, ocular, pulmonary and topical etc. by improviing the bioavailability, reducing the dose, gastric irritation, decreasing intra subject variability and increasing adhesivness with intestinal membrane. Recently, nanosuspension has been received much interest as a way to resolve solubility and stability problem because of their cost-effectiveness and technical simplicity compare to other liposome and colloidal drug carriers. Nanosuspensions are engaged to control particle size, surface properties and release of pharmacologically active agents in order to achieve the site-specific action of the drug at the therapeutically optimal rate, improve the bioavaibility of drug with poor solubility and dose regimen. Application and preparation method of nanosuspension has been reported by research articles and patented in different countries. Most of the marketed nanosuspensions are in preclinical and clinical based study for its application. More than 100 patents have been published on nanosuspensions by the recent days. This patent reviews covers different methods of pharmaceutical preparation and applications in drug delivery as well as the recent marketed published or granted patent surveys. This patent review is useful in enhance the knowledge of controlled drug delivery and applications.

  5. Comprehensive quantitative analysis of Chinese patent drug YinHuang drop pill by ultra high-performance liquid chromatography quadrupole time of flight mass spectrometry.

    Science.gov (United States)

    Wong, Tin-Long; An, Ya-Qi; Yan, Bing-Chao; Yue, Rui-Qi; Zhang, Tian-Bo; Ho, Hing-Man; Ren, Tian-Jing; Fung, Hau-Yee; Ma, Dik-Lung; Leung, Chung-Hang; Liu, Zhong-Liang; Pu, Jian-Xin; Han, Quan-Bin; Sun, Han-Dong

    2016-06-01

    YinHuang drop pill (YHDP) is a new preparation, derived from the traditional YinHuang (YH) decoction. Since drop pills are one of the newly developed forms of Chinese patent drugs, not much research has been done regarding the quality and efficacy. This study aims to establish a comprehensive quantitative analysis of the chemical profile of YHDP. ultra high-performance liquid chromatography quadrupole time of flight mass spectrometry (UHPLC-Q-TOF-MS/MS) was used to identify 34 non-sugar small molecules including 15 flavonoids, 9 phenolic acids, 5 saponins, 1 iridoid, and 4 iridoid glycosides in YHDP samples, and 26 of them were quantitatively determined. Sugar composition of YHDP in terms of fructose, glucose and sucrose was examined via a high performance liquid chromatography-evaporative light scattering detector on an amide column (HPLC-NH2P-ELSD). Macromolecules were examined by high performance gel permeation chromatography coupled with ELSD (HPGPC-ELSD). The content of the drop pill's skeleton component PEG-4000 was also quantified via ultra-high performance liquid chromatography coupled with charged aerosol detector (UHPLC-CAD). The results showed that up to 73% (w/w) of YHDP could be quantitatively determined. Small molecules accounted for approximately 5%, PEG-4000 represented 68%, while no sugars or macromolecules were found. Furthermore, YHDP showed no significant differences in terms of daily dosage, compared to YinHuang granules and YinHuang oral liquid; however, it has a higher small molecules content compared to YinHuang lozenge.

  6. Modern evaluation of patents

    Science.gov (United States)

    Ignat, V.

    2016-08-01

    The number of patents is not so important as the market value. The market value is especially important for licensing of patents, make-or-buy decisions for technology procurement, corporate finance. Patents can be used as collateral for financing. Patents and credit approvals: without patents only 46% and with patents 54%. The value share of knowledge-based components to industrial products already reached 50% and it is still rising. OECD called these developments under the slogan "knowledge economy”. German Norm-DIN 77100 provides a working method for monetary evaluation of a patent. The value of a patent arises from its use. A patent can be used to protect or to earn licensing revenues. An evaluation expertise is required in areas, such as marketing, finance, R & D and strategic planning. As an indicator of the value of a patent is often used the number of citations. The number of a patent citation refers to its meaning and value. Other indicators would be: size of the patent family, validity of the patent, result of objections against patent application, number and quality of claims. The analysis of 9.000 patents resulted that only 7.2% worth over 10 million euro and 68% below 1 million euro. The cost method: it is considered the cost that would be incurred for the development and patenting of a similar invention. The market method: are used the prices that have been achieved in comparable with recently transactions. The Income method: the potential reward is measured, which can arise from a patent. The evaluation will be in the following areas: legal status, technology, market conditions, finance and strategy. Each question relates to a different parameter of a value.

  7. Mentaliseringsbegrebet og dets arv fra Freuds begreb om binding

    DEFF Research Database (Denmark)

    Pedersen, Signe Holm

    2011-01-01

    Artiklen undersøger og diskuterer forskelle og ligheder mellem mentaliseringsbegrebet og Freuds bindingsbegreb. Begrebet mentalisering, som betegner en evne til at forholde sig refleksivt til egne og andres mentale tilstande, har indenfor de sidste fem- ti år vundet en central placering i klinisk...... psykologiske teoridannelser. Dets ophavsmænd Fonagy et al. forsøger imidlertid ikke at tage patent på begrebet, men peger på, at en række teoretikere har understreget betydningen af en refleksiv funktion. Alle disse begreber kan ifølge Fonagygruppen føres tilbage til Freuds begreb om binding. På baggrund af en...... udlægning af det oprindelige bindingsbegreb hos Freud, ønskes det i denne artikel at tydeliggøre den grundlæggende forskel på Freuds – og Fonagys subjektopfattelse....

  8. Patent ductus arteriosus

    Science.gov (United States)

    ... this page: //medlineplus.gov/ency/article/001560.htm Patent ductus arteriosus To use the sharing features on this page, please enable JavaScript. Patent ductus arteriosus (PDA) is a condition in which the ductus ...

  9. Püsiühenduste arv kasvas aastaga poole võrra / Tõnu Vare

    Index Scriptorium Estoniae

    Vare, Tõnu, 1947-

    2005-01-01

    Uuringufirma Point Topic andmetel oli 30. septembri 2004. a. seisuga Interneti püsiühenduste arv maailmas 136,4 miljonit. Diagrammid: Püsiühendustega leibkondade osakaal (%) Euroopas; 512 Kb/s allalaadimiskiirusega püsiühenduse kuutasu (eurodes)

  10. A novel rudivirus, ARV1, of the hyperthermophilic archaeal genus Acidianus

    DEFF Research Database (Denmark)

    Vestergaard, Gisle Alberg; Häring, Monika; Peng, Xu;

    2005-01-01

    Virus ARV1, the first member of the family Rudiviridae infecting hyperthermophilic archaea of the genus Acidianus, was isolated from a hot spring in Pozzuoli, Italy. The rod-shaped virions, 610 +/- 50 nm long and 22 +/- 3 nm wide, are non-enveloped and carry a helical nucleoprotein core, with three...

  11. Adherence to ARV medication in Romanian young adults: self-reported behaviour and psychological barriers

    NARCIS (Netherlands)

    Dima, A.L.; Schweitzer, A.M.; Diaconita, R.; Remor, E.; Wanless, R.

    2013-01-01

    Adherence to antiretroviral (ARV) treatment during adolescence and young adulthood is a significant clinical issue for the current management of the HIV/AIDS epidemic in Romania. Understanding patients' own perceptions of their adherence behaviours and related psychological barriers is instrumental

  12. Tööõnnetuste arv Ida-Virus väheneb / Erika Prave

    Index Scriptorium Estoniae

    Prave, Erika, 1970-

    2004-01-01

    Ilmunud ka: Severnoje Poberezhje, 7. dets. 2004, lk. 3. Tööinspektsiooni viimase üheksa aasta statistikast järeldub, et tööõnnetuste arv on Ida-Virumaal aastatega vähenenud peaaegu poole võrra

  13. 37 CFR 1.5 - Identification of patent, patent application, or patent-related proceeding.

    Science.gov (United States)

    2010-07-01

    ... 37 Patents, Trademarks, and Copyrights 1 2010-07-01 2010-07-01 false Identification of patent, patent application, or patent-related proceeding. 1.5 Section 1.5 Patents, Trademarks, and Copyrights UNITED STATES PATENT AND TRADEMARK OFFICE, DEPARTMENT OF COMMERCE GENERAL RULES OF PRACTICE IN...

  14. Patenting Nanomedicine in Europe:

    DEFF Research Database (Denmark)

    Nordberg, Ana

    Patenting Nanomedicine in Europe: Applying the ‘medical methods exception’ to emerging technologies is based on the authors PhD dissertation, defended in March 2014, at the University of Copenhagen. The book debates restrictions on the patentability of medical methods in European Patent Law....... The main question addressed is whether it is viable and advisable the reinterpretation, reformulation or replacement of Article 53 (c) EPC – a provision restricting the patenting of medical methods. The subject is approached by reference to emerging technologies, and using nanomedicine innovation...... as example and point of departure. Nanotechnology inventions blur the lines between patentable subject matter and what may fall under the exception from patentability. It is a good example of how in recent years, emerging technologies have been challenging the patent system and exposing the need for re...

  15. The Indian Drug Patent Compulsory Licensing System:An Inspiration to China%印度药品专利强制许可制度的启示

    Institute of Scientific and Technical Information of China (English)

    杨燕琳

    2016-01-01

    Drug patent compulsory licensing system is an effective measure to restrict the abuse of intellectual property rights. Though there are relevant provisions in China,the system was rarely implemented.Though sharing a similar situation with China, India has practiced compulsory licensing system for many times in the patent-protection-oriented inter-national environment.By introducing the case of India,the inadequacies in Chinese“Patent Law” is analyzed with the purpose of using the Indian example to provide certain advice to Chinese law-making.%药品专利强制许可制度作为一种限制知识产权滥用的有效措施,我国对此虽然有相关规定,但是却实施的较少。而相较与我国国情相类似的印度却在注重专利保护的国际环境下已经实施过多次的强制许可制度。为此,文章将通过介绍印度药品专利强制许可制度,分析我国《专利法》关于该制度的不足,以期借鉴印度的相关制度完善我国药品专利强制许可的立法。

  16. Droplet Digital PCR Based Androgen Receptor Variant 7 (AR-V7 Detection from Prostate Cancer Patient Blood Biopsies

    Directory of Open Access Journals (Sweden)

    Yafeng Ma

    2016-08-01

    Full Text Available Androgen receptor splice variant V7 (AR-V7 was recently identified as a valuable predictive biomarker in metastatic castrate-resistant prostate cancer. Here, we report a new, sensitive and accurate screen for AR-V7 mRNA expression directly from circulating tumor cells (CTCs: We combined EpCAM-based immunomagnetic CTC isolation using the IsoFlux microfluidic platform with droplet digital polymerase chain reaction (ddPCR to analyze total AR and AR-V7 expression from prostate cancer patients CTCs. We demonstrate that AR-V7 is reliably detectable in enriched CTC samples with as little as five CTCs, even considering tumor heterogeneity, and confirm detection of AR-V7 in CTC samples from advanced prostate cancer (PCa patients with AR-V7 detection limited to castrate resistant disease status in our sample set. Sensitive molecular analyses of circulating tumor cells (CTCs or circulating tumor nucleic acids present exciting strategies to detect biomarkers, such as AR-V7 from non-invasive blood samples, so-called blood biopsies.

  17. 75 FR 17415 - Determination of Regulatory Review Period for Purposes of Patent Extension; FANAPT

    Science.gov (United States)

    2010-04-06

    ... human drug product FANAPT (iloperidone). FANAPT is indicated for the acute treatment of schizophrenia in adults. Subsequent to this approval, the Patent and Trademark Office received a patent term...

  18. Patent indicators: a window to pharmaceutical market success.

    Science.gov (United States)

    Guo, Yang; Hu, Yuanjia; Zheng, Mingli; Wang, Yitao

    2013-07-01

    Pharmaceutical success in the market is the best reward for pharmaceutical investors undergoing the lengthy, costly and risky process of pharmaceutical Research and Development (R&D). Drugs with high market revenues trigger fierce competition between pharmaceutical enterprises, as is demonstrated by the increasing Mergers & Acquisitions (M&A) cases focusing on seizing the best-selling products. On the other hand, patents, as the best shield for innovative drugs against generic drugs, become a powerful weapon for pharmaceutical enterprises to win the substantial returns generated by market exclusivity. Patents seem to be directly responsible for the commercial success of new medicines. In this context, it is of great significance to find out the empirical associations between pharmaceutical commercial success and patents. By comprehensively analysing 127 drugs marketed in the USA and their 621 American patents, this article identifies the evidence to link various patent indicators with pharmaceutical sales in actual market.

  19. Regulation and the circulation of knowledge: penicillin patents in Spain.

    Science.gov (United States)

    Romero de Pablos, Ana

    2011-01-01

    This paper tells the early history of penicillin patenting in Spain. Patents turn out to be useful instruments for analysing the management of knowledge and its circulation in different professional and geographical domains. They protected knowledge while contributing to standardisation. Patents also ensured quality and guaranteed reliability in manufacturing, delivering and prescribing new drugs. They gained special prominence by allowing the creation of a network in which political, economic and business, industrial power, public health and international cooperation fields came together. The main source of information used for this purpose has been the earliest patent applications for penicillin in Spain between 1948 and 1950, which are kept in the Historical Archives of the Oficina Española de Patentes y Marcas. The study of these patents for penicillin shows their role as agents in introducing this drug in Spain.

  20. Performance of Patenting Firms

    DEFF Research Database (Denmark)

    Madsen, Erik Strøjer; Smith, Valdemar; Nielsen, Anders Østergaard

    2000-01-01

    -patenting firms within the manufacturing sector in Denmark. Performance is measured both by growth in employment as well as in the return on equity and profit share in turnover. The results suggest that differences in performance of patenting and non-patenting firms are very small, which questions the political......Most countries focus on industries with high technology and the governments grant subsidies to innovating firms. However, there has been remarkable few studies of the performance of innovative firms or industries. This study examines the performance of patent active firms compared to the non...

  1. AR-V7 and prostate cancer: The watershed for treatment selection?

    Science.gov (United States)

    Ciccarese, Chiara; Santoni, Matteo; Brunelli, Matteo; Buti, Sebastiano; Modena, Alessandra; Nabissi, Massimo; Artibani, Walter; Martignoni, Guido; Montironi, Rodolfo; Tortora, Giampaolo; Massari, Francesco

    2016-02-01

    The androgen receptor (AR) plays a key role in progression to metastatic castration-resistant prostate cancer (mCRPC). Despite the recent progress in targeting persistent AR activity with the next-generation hormonal therapies (abiraterone acetate and enzalutamide), resistance to these agents limits therapeutic efficacy for many patients. Several explanations for response and/or resistance to abiraterone acetate and enzalutamide are emerging, but growing interest is focusing on importance of AR splice variants (AR-Vs) and in particular of AR-V7. Increasing evidences highlight the concept that variant expression could be used as a potential predictive biomarker and a therapeutic target in advanced prostate cancer. Therefore, understanding the mechanisms of treatment resistance or sensitivity can help to achieve a more effective management of mCRPC, increasing clinical outcomes and representing a promising and engaging area of prostate cancer research.

  2. What Is Patent Ductus Arteriosus?

    Science.gov (United States)

    ... page from the NHLBI on Twitter. What Is Patent Ductus Arteriosus? Patent ductus arteriosus (PDA) is a heart problem ... the lung arteries. Normal Heart and Heart With Patent Ductus Arteriosus Figure A shows the interior of a normal ...

  3. A Patent Dilemma

    Science.gov (United States)

    Downes, Stephen

    2007-01-01

    When Blackboard unveiled its U.S. patent for 44 features of learning management systems and then filed a patent infringement suit against Design2Learn, the response of the educational technology community was negative and swift. Stephen Downes discusses why many educators oppose Blackboard's proprietary claims to technologies long considered in…

  4. Environmentally conscious patent histories

    Science.gov (United States)

    Crouch, Dennis D.; Crouch, Henry L.

    2004-02-01

    There is a need for investigators, legislators, and business leaders to understand the magnitude of innovation and discovery in the field of environmentally conscious technologies (ECTs). Knowledge of the "big picture" is important to providing a national and global account of actual environmental stewardship over the last twenty-five years. A recitation of the Environmental Protection Agency (EPA) supported Acts which have been enacted into law reveals one facet of the multifaceted dynamic of environmental consciousness. The popular discussion and debate, as well as partisan lobbying, which created the political forces leading to environmentally conscious legislation is another facet. A third facet is the corporate response to the threats and opportunities predicted by CEO"s and others through environmental scanning. This paper examines changes in environmentally conscious inventive effort by comparing data from United States Patents issued from 1976 through 2003. Patents are useful tool for measuring technological innovation because they are publicly available records of innovative activity. Although not all inventions result in patent applications, the monopoly rights granted on the invention give the inventor a strong incentive to obtain patents on any viable product or process. Among the results, we found a significant increase in patents relating to environmentally conscious products and processes during the period in question. Specifically, a dramatic increase in patent activity was seen for the decade of the 1990"s. Surprisingly, the patenting rate from 2000 to 2003 seems to have stabilized. Additionally public discussion of ECTs appears to have a positive impact on patent filings.

  5. Patenting Nanomedicine in Europe

    DEFF Research Database (Denmark)

    Nordberg, Ana

    chosen a different approach to integrate in patent law similar policy considerations. Observing how this issue was debated and solved differently is in itself important, but it also allows questioning whether in future patent reforms serious consideration should not be given to alternative solutions....

  6. Detection and characterization of two co-infection variant strains of avian orthoreovirus (ARV) in young layer chickens using next-generation sequencing (NGS).

    Science.gov (United States)

    Tang, Yi; Lin, Lin; Sebastian, Aswathy; Lu, Huaguang

    2016-04-19

    Using next-generation sequencing (NGS) for full genomic characterization studies of the newly emerging avian orthoreovirus (ARV) field strains isolated in Pennsylvania poultry, we identified two co-infection ARV variant strains from one ARV isolate obtained from ARV-affected young layer chickens. The de novo assembly of the ARV reads generated 19 contigs of two different ARV variant strains according to 10 genome segments of each ARV strain. The two variants had the same M2 segment. The complete genomes of each of the two variant strains were 23,493 bp in length, and 10 dsRNA segments ranged from 1192 bp (S4) to 3958 bp (L1), encoding 12 viral proteins. Sequence comparison of nucleotide (nt) and amino acid (aa) sequences of all 10 genome segments revealed 58.1-100% and 51.4-100% aa identity between the two variant strains, and 54.3-89.4% and 49.5-98.1% aa identity between the two variants and classic vaccine strains. Phylogenetic analysis revealed a moderate to significant nt sequence divergence between the two variant and ARV reference strains. These findings have demonstrated the first naturally occurring co-infection of two ARV variants in commercial young layer chickens, providing scientific evidence that multiple ARV strains can be simultaneously present in one host species of chickens.

  7. Is Patent "Evergreening" Restricting Access to Medicine/Device Combination Products?

    Directory of Open Access Journals (Sweden)

    Reed F Beall

    Full Text Available Not all new drug products are truly new. Some are the result of marginal innovation and incremental patenting of existing products, but in such a way that confers no major therapeutic improvement. This phenomenon, pejoratively known as "evergreening", can allow manufacturers to preserve market exclusivity, but without significantly bettering the standard of care. Other studies speculate that evergreening is especially problematic for medicine/device combination products, because patents on the device component may outlast expired patents on the medicine component, and thereby keep competing, possibly less-expensive generic products off the market.We focused on four common conditions that are often treated by medicine/device product combinations: asthma and chronic obstructive pulmonary disease (COPD, diabetes, and severe allergic reactions. The patent data for a sample of such products (n = 49 for treating these conditions was extracted from the United States Food and Drug Administration's Orange Book. Additional patent-related data (abstracts, claims, etc were retrieved using LexisNexis TotalPatent. Comparisons were then made between each product's device patents and medicine patents.Unexpired device patents exist for 90 percent of the 49 medicine/device product combinations studied, and were the only sort of unexpired patent for 14 products. Overall, 55 percent of the 235 patents found by our study were device patents. Comparing the last-to-expire device patent to that of the last-to-expire active ingredient patent, the median additional years of patent protection afforded by device patents was 4.7 years (range: 1.3-15.2 years.Incremental, patentable innovation in devices to extend the overall patent protection of medicine/device product combinations is very common. Whether this constitutes "evergreening" depends on whether these incremental innovations and the years of extra patent protection they confer are proportionately matched by

  8. An empirical analysis of primary and secondary pharmaceutical patents in Chile.

    Science.gov (United States)

    Abud, María José; Hall, Bronwyn; Helmers, Christian

    2015-01-01

    We analyze the patent filing strategies of foreign pharmaceutical companies in Chile distinguishing between "primary" (active ingredient) and "secondary" patents (patents on modified compounds, formulations, dosages, particular medical uses, etc.). There is prior evidence that secondary patents are used by pharmaceutical originator companies in the U.S. and Europe to extend patent protection on drugs in length and breadth. Using a novel dataset that comprises all drugs registered in Chile between 1991 and 2010 as well as the corresponding patents and trademarks, we find evidence that foreign originator companies pursue similar strategies in Chile. We find a primary to secondary patents ratio of 1:4 at the drug-level, which is comparable to the available evidence for Europe; most secondary patents are filed over several years following the original primary patent and after the protected active ingredient has obtained market approval in Chile. This points toward effective patent term extensions through secondary patents. Secondary patents dominate "older" therapeutic classes like anti-ulcer and anti-depressants. In contrast, newer areas like anti-virals and anti-neoplastics (anti-cancer) have a much larger share of primary patents.

  9. Discuss relationship between public heath crisis and drug patent protection——from the system of drug patent term extension perspective%论药品专利保护与公共健康平衡——从药品专利期限延长制度的视角

    Institute of Scientific and Technical Information of China (English)

    邱俊晨

    2012-01-01

      各国传染病暴发和公共健康危机的产生,引发了有关药品专利和公共健康直之间冲突的思考。本文从药品专利保护和公共健康危机之间的关系入手,分析药品专利期限延长制度。%  Public health crisis and the infectious diseases break out in different countyries,which bring us the thinking about medical patent and public health.This article analyzes the promotion of medical patent institution by analyze the relationship between medical patent and public health crisis.

  10. Paradoxes in antiretroviral treatment for injecting drug users: access, adherence and structural barriers in Asia and the former Soviet Union.

    Science.gov (United States)

    Wolfe, Daniel

    2007-08-01

    Offered proper support, injection drug users (IDUs) can achieve the same levels of adherence to and clinical benefit from antiretroviral treatment (ARV) as other patients with HIV. Nonetheless, in countries of Asia and the former Soviet Union where IDUs represent the largest share of HIV cases, IDUs have been disproportionately less likely to receive ARV. While analysis of adherence amongst IDUs has focused on individual patient ability to adhere to medical regimens, HIV treatment systems themselves are in need of examination. Structural impediments to provision of ARV for IDUs include competing, vertical systems of care; compulsory drug treatment and rehabilitation services that often offer neither ARV nor effective treatment for chemical dependence; lack of opiate substitution treatments demonstrated to increase adherence to ARV; and policies that explicitly or implicitly discourage ARV delivery to active IDUs. Labeling active drug users as socially untrustworthy or unproductive, health systems can create a series of paradoxes that ensure confirmation of these stereotypes. Needed reforms include professional education and public campaigns that emphasize IDU capacity for health protection and responsible choice; recognition that the chronic nature of injecting drug use and its links to HIV infection require development of ARV treatment delivery that includes active drug users; and integrated treatment that strengthens links between health providers and builds on, rather than seeks to bypass, IDU social networks and organizations.

  11. How Important are Noncorporate Patents?

    DEFF Research Database (Denmark)

    Schneider, Cédric

    2011-01-01

    This article analyses the innovative performances of noncorporate inventors using patent citations data from the European Patent Office. The results show that inventions patented outside an established corporate framework are on average less ‘important’ than corporate patents, but with large...... variations across technology classes. Patents applied for by independent inventors, start-ups and corporate firms are of comparable ‘quality’ in emerging technologies. The results also highlight that in these fields noncorporate patents are more ‘radical’ than corporate patents....

  12. Patents - An Information Resource.

    Science.gov (United States)

    1980-09-01

    cacher, ii existe dana certaines entreprises des sortes de concurrence entre lea services de propri~t6 industrielle at ceux de documentation h...spizialistea A telle ou telle entreprise . -Lea statiatiques: dont on commence b saisir l’intir~t, at qui sont devenues plus fiables avec lea ddlais...you to look at your patent office as a public organisation which in general is financed fully or to a large extend by those who file patent

  13. [Specificities of patent protection in the pharmaceutical industry: modalities and traits of intellectual property].

    Science.gov (United States)

    Jannuzzi, Anna Haydée Lanzillotti; Vasconcellos, Alexandre Guimarães; de Souza, Cristina Gomes

    2008-06-01

    Different forms of protection for inventions in the pharmaceutical industry point to strategies for the perpetuation of patent protection. Based on a literature review showing the specificities of patenting in the industry, the article provides a brief history of drug patents in Brazil, a discussion of patentable and non-patentable inventions, and the modalities and traits of patent protection that aim to extend the temporary monopoly granted under the patent. Such strategies include patents targeting polimorphs and optical isomers of drugs and drug combinations and specific clinical preparations, increasingly present in the drug patent claims filed by pharmaceutical companies. The study's objective is to discuss the specificities of drug patent claims in order to help develop expertise in the area and discuss the impact of expanding the scope of patent protection. In conclusion, while the tendency to expand towards more a permissive protective scope could produce opportunities for Brazilian national inventors, it could also be harmful to a policy for access to medicines.

  14. 多国植物药专利申请状况比较研究及我国企业应对%Comparative Study of Patent Application Situation for Herbal Drugs in Different Countries and its Revelation of Enterprises in China

    Institute of Scientific and Technical Information of China (English)

    张晓东; 徐嘉慧

    2014-01-01

    Patent protection system has a profound impact on the sustainable development and internationalization of herbal drugs based on the traditional medicine.However,the ability of Chinese enterprises in applying the current system of patent protection is still weak.In this article,the patent application situation for herbal drugs is analyzed and compared,by using the data of China,Japan,Republic of Korea,the United States,European Union and India,based on their domestic patent applications,Chinese patent applications and the foreign patent applications.In the meantime,combined with patent port-folio of key Chinese medicine enterprises in Europe and US,this article also gives some suggestions for strengthening the awareness of intellectual property protection of traditional Chinese medicine and the global layout.%现代专利保护对以传统药物为基础的植物药产业的可持续发展和国际化有着深刻的影响。我国中药大部分可归为植物药范畴,但目前中药企业应用专利保护制度的能力还较为薄弱。分析中国、日本、韩国、美国、欧盟、印度等国家和地区针对植物药专利在其母国的申请情况、在中国的申请情况以及向外申请情况。同时,结合我国重点中药企业在欧美的专利布局提出建议,以期加强企业对于中药知识产权的保护意识,重视全球布局。

  15. Essential Patents and Coordination Mechanisms

    OpenAIRE

    Justus Baron; Tim Pohlmann

    2010-01-01

    This article investigates the interplay between formal standards, essential patents and informal industry alliances such as consortia and patent pools. Building upon more than 6.200 declarations of essential patents to major international Standard Development Organizations (SDO), we investigate how informal standardization consortia and patent pools influence the number and timing of patent declarations to formal SDOs. This is the first thorough empirical investigation of the effectiveness of...

  16. Confocal fluorescence microscopy: An ultra-sensitive tool used to evaluate intracellular antiretroviral nano-drug delivery in HeLa cells

    Directory of Open Access Journals (Sweden)

    Subhra Mandal

    2015-08-01

    Full Text Available In the last decade, confocal fluorescence microscopy has emerged as an ultra-sensitive tool for real-time study of nanoparticles (NPs fate at the cellular-level. According to WHO 2007 report, Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome (HIV/AIDS is still one of the world’s major health threats by claiming approximately 7,000 new infections daily worldwide. Although combination antiretroviral drugs (cARV therapy has improved the life-expectancy of HIV-infected patients, routine use of high doses of cARV has serious health consequences and requires complete adherence to the regimen for success. Thus, our research goal is to fabricate long-acting novel cARV loaded poly(lactide-co-glycolic acid (PLGA nanoparticles (cARV-NPs as drug delivery system. However, important aspects of cARV-NPs that require special emphasis are their cellular-uptake, potency, and sustained drug release efficiency over-time. In this article, ultra-sensitive confocal microscopy is been used to evaluate the uptake and sustained drug release kinetics of cARV-NPs in HeLa cells. To evaluate with the above goal, instead of cARV-drug, Rhodamine6G dye (fluorescent dye loaded NPs (Rho6G NPs have been formulated. To correlate the Rhodamin6G release kinetics with the ARV release from NPs, a parallel HPLC study was also performed. The results obtained indicate that Rho6G NPs were efficiently taken up at low concentration (<500 ng/ml and that release was sustained for a minimum of 4 days of treatment. Therefore, high drug assimilation and sustained release properties of PLGA-NPs make them an attractive vehicle for cARV nano-drug delivery with the potential to reduce drug dosage as well as the number of drug administrations per month.

  17. Confocal fluorescence microscopy: An ultra-sensitive tool used to evaluate intracellular antiretroviral nano-drug delivery in HeLa cells

    Science.gov (United States)

    Mandal, Subhra; Zhou, You; Shibata, Annemarie; Destache, Christopher J.

    2015-08-01

    In the last decade, confocal fluorescence microscopy has emerged as an ultra-sensitive tool for real-time study of nanoparticles (NPs) fate at the cellular-level. According to WHO 2007 report, Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome (HIV/AIDS) is still one of the world's major health threats by claiming approximately 7,000 new infections daily worldwide. Although combination antiretroviral drugs (cARV) therapy has improved the life-expectancy of HIV-infected patients, routine use of high doses of cARV has serious health consequences and requires complete adherence to the regimen for success. Thus, our research goal is to fabricate long-acting novel cARV loaded poly(lactide-co-glycolic acid) (PLGA) nanoparticles (cARV-NPs) as drug delivery system. However, important aspects of cARV-NPs that require special emphasis are their cellular-uptake, potency, and sustained drug release efficiency over-time. In this article, ultra-sensitive confocal microscopy is been used to evaluate the uptake and sustained drug release kinetics of cARV-NPs in HeLa cells. To evaluate with the above goal, instead of cARV-drug, Rhodamine6G dye (fluorescent dye) loaded NPs (Rho6G NPs) have been formulated. To correlate the Rhodamin6G release kinetics with the ARV release from NPs, a parallel HPLC study was also performed. The results obtained indicate that Rho6G NPs were efficiently taken up at low concentration (<500 ng/ml) and that release was sustained for a minimum of 4 days of treatment. Therefore, high drug assimilation and sustained release properties of PLGA-NPs make them an attractive vehicle for cARV nano-drug delivery with the potential to reduce drug dosage as well as the number of drug administrations per month.

  18. Social arv

    DEFF Research Database (Denmark)

    Jensen, Bente

    Arbejdspapir som er udarbejdet i forbindelse med HPA-projektet og brugt i en anden udgivelse fra 2007. Nu genudgivet med nyt forord og ISBN nummer, samt udgive via DPU's forlag som e-bog......Arbejdspapir som er udarbejdet i forbindelse med HPA-projektet og brugt i en anden udgivelse fra 2007. Nu genudgivet med nyt forord og ISBN nummer, samt udgive via DPU's forlag som e-bog...

  19. Drug therapy of patent foramen ovale with cryptogenic stroke%卵圆孔未闭合并不明原因脑卒中的药物治疗

    Institute of Scientific and Technical Information of China (English)

    何璐; 张玉顺

    2013-01-01

    卵圆孔未闭(patent foramen ovale,PFO)是一种先天性心脏病变,超过25%的成人均存在PFO.PFO可能与多种病理情况有关,包括不明原因脑卒中(cryptogenic stroke,CS)、斜卧呼吸-直立型低氧血症、减压病、偏头痛等,其诊断、评估和治疗已经越来越引起人们的重视.但是,有关其治疗方法的选择目前仍在争议中,虽然尚未得到美国食品和药物管理局(FDA)的批准,经导管封堵PFO的方法在继续.其潜在的并发症包括封堵器表面血栓形成,术后房颤、残余分流,封堵器侵蚀或穿孔等.鉴于PFO封堵术与任何心脏干预一样可能引起极严重的并发症,药物治疗似乎是安全、有效的选择.本文主要综述了PFO并发CS的药物治疗,旨在为临床医生对PFO并发CS的药物选择提供理论依据.%Patent foramen ovale (PFO) is a congenital cardiac lesion present in > 25% of the adult population.Diagnosis,evaluation and treatment of PFO have attracted increasing interest as it has been suggested that PFO may be associated with various pathological conditions such as cryptogenic stroke,platypnea-orthodeoxia syndrome,decompression sickness and migraine.Management of PFO remains controversial and,although not yet approved by the U.S.Food and Drug Administration,transcatheter approach to PFO closure continues to develop.However,its potential complications include device embolization,thrombus formation,atrial arrhythmias,residual shunting and device erosion or perforation.As with any cardiac intervention,transcatheter closure may cause serious complications and drug therapy thus seems to be a safe and effective option.This paper reviews the drug therapy of PFO with cryptogenic stroke to provide a theoretical basis of its drug treatment for clinicians.

  20. Patent Statistics and IPR Laws Update Online

    Institute of Scientific and Technical Information of China (English)

    2006-01-01

    Patent Statistics Beginning from No.2 of 2005 of China Patents & Trademarks, the Statistics on Patent Applications & Grants in China, previously published under the column of Statistics, will be updated online, including the monthly Statistics on Patent Applications by Patent Category, the Patent Grants by Patent Category, the Domestic Patent Applications by Province, and the Overseas Patent Applications by Country, and their yearly statistics at www.cpt.cn or www.cpahkltd.com/cn/ Publications/staten.htm...

  1. Text mining patents for biomedical knowledge.

    Science.gov (United States)

    Rodriguez-Esteban, Raul; Bundschus, Markus

    2016-06-01

    Biomedical text mining of scientific knowledge bases, such as Medline, has received much attention in recent years. Given that text mining is able to automatically extract biomedical facts that revolve around entities such as genes, proteins, and drugs, from unstructured text sources, it is seen as a major enabler to foster biomedical research and drug discovery. In contrast to the biomedical literature, research into the mining of biomedical patents has not reached the same level of maturity. Here, we review existing work and highlight the associated technical challenges that emerge from automatically extracting facts from patents. We conclude by outlining potential future directions in this domain that could help drive biomedical research and drug discovery.

  2. CHALLENGES CONFRONTING HEALTH CARE WORKERS IN GOVERNMENT'S ARV ROLLOUT: RIGHTS AND RESPONSIBILITIES

    Directory of Open Access Journals (Sweden)

    Yousuf A Vawda

    2012-08-01

    Full Text Available South Africa is renowned for having a progressive Constitution with strong protection of human rights, including protection for persons using the public health system. While significant recent discourse and jurisprudence have focused on the rights of patients, the situation and rights of providers of health care services have not been adequately ventilated. This paper attempts to foreground the position of the human resources personnel located at the centre of the roll-out of the government's ambitious programme of anti-retroviral (ARV therapy.The HIV/AIDS epidemic represents a major public health crisis in our country and, inasmuch as various critical policies and programmes have been devised in response, the key to a successful outcome lies in the hands of the health care professionals tasked with implementing such strategies. Often pilloried by the public, our health care workers (HCWs face an almost Herculean task of turning the tide on the epidemic. Unless the rights of HCWs are recognised and their needs adequately addressed, the best laid plans of government will be at risk.This contribution attempts to identify and analyse the critical challenges confronting HCWs at the coalface of the HIV/AIDS treatment programme, in particular the extent to which their own rights are under threat, and offers recommendations to remedy the situation in order to ensure the successful realisation of the ARV rollout.

  3. Meta Analysis on Chinese Patent Medicine in Prevention and Cure of Hepatic Lesion Caused by Anti-tuberculosis Drugs%中医成方防治抗结核药物致肝损害的Meta分析

    Institute of Scientific and Technical Information of China (English)

    魏华

    2012-01-01

    目的:系统评价中医成方防治抗结核药致肝损害的疗效和安全性.方法:电子检索2000年1月到2011年7月的Medline、Embase、Cochrane library、中国生物医学光盘数据库,万方、维普数据库,并手工检索相关文献,纳入治疗组为中医成方,对照组为常规保肝治疗,逐个对其进行质量评价和资料提取,用RevMan 4.2软件进行Meta分析.结果:最终纳入6个半随机对照试验,共372例患者,纳入研究质量均为C级.中医成方组肝功正常率优于常规l保肝治疗(P<0.01,OR-13.50,95%CI 6.89~26.46);未发现严重不良反应.结论:中医成方防治肝损害效果优于常规保肝治疗,且无明显不良反应.但由于纳入研究的方法学质量较低、观察时间较短,且存在中西医结合诊断不标准、中药使用不规范等问题,可能影响评价结果,尚需更多高质量、长周期、中西医结合规范化研究以系统评价其疗效.%Objective: To evaluate systemically the efficacy and safety of Chinese patent medicine in prevention and cure hepatic lesion caused by anti-tuberculosis drugs. Method :Medline, Embase, Cochrane Library, CBM, VIP and WanFang data from 2000 to May, 2011 were searched online and the literatures published or not were manually retrieved. The papers on Chinese patent medicine were divided into treatment group while routine treatment were in control group, all were undergoing the quality analysis and information extraction. RevMan 4.2 was used for data analysis. Finally six Quasi-randomized control trials involving 372 patients were recruited. Methodological qualities were all graded C. Result: After 1-6 months' treatment, normal rate of liver function in Chinese patent medicine group were higher than in routine treatment (P <0.01, OR=13.50, 95% CI 6.89-26.46) without serious side effects. Conclusion: Chinese patent medicine is better than routine treatment in prevention and cure hepatic lesion caused by anti-tuberculosis drugs

  4. Prediction of phenotypic susceptibility to antiretroviral drugs using physiochemical properties of the primary enzymatic structure combined with artificial neural networks

    DEFF Research Database (Denmark)

    Kjaer, J; Høj, L; Fox, Z

    2008-01-01

    OBJECTIVES: Genotypic interpretation systems extrapolate observed associations in datasets to predict viral susceptibility to antiretroviral drugs (ARVs) for given isolates. We aimed to develop and validate an approach using artificial neural networks (ANNs) that employ descriptors...

  5. The new patent regime and disease priorities in India.

    Science.gov (United States)

    Gupta, Indrani; Guin, Pradeep; Trivedi, Mayur

    2013-01-01

    The World Trade Organization (WTO) and Trade-Related Aspects of Intellectual Property Rights (TRIPS), which made product patents compulsory for countries to follow, meant that the entire market for generic drugs was out of bounds for manufacturing till the time the products went off-patent. The TRIPS has generated widespread discussions and debates around the costs and benefits of new patent regimes on countries such as India. This article analyses whether the post-WTO system was consistent with, and conducive to, improved public health in India. It is a first-of-its-kind effort in which the data on pharmaceutical patents applications were collected, collated, cleaned and classified according to IPC codes, to enable preliminary understanding of the nature and type of the applications. The patent applications that are filed in India are not found to be consistent with the disease burden of the country.

  6. The Introduction of Pharmaceutical Product Patents in India: "Heartless Exploitation of the Poor and Suffering"?

    OpenAIRE

    Lanjouw, Jean O.

    1998-01-01

    The decision to require that countries grant product patents for pharmaceutical innovations as a condition of membership in the World Trade Organization was very contentious. Almost 50 developing countries were not granting patent monopolies for drugs during the period the Uruguay round of GATT was being debated and these countries fiercely resisted the inclusion of this requirement, claiming that vastly higher drug prices would be associated with such patents. On the other side, business int...

  7. Title: The Introduction of Pharmaceutical Product Patents in India: Heartless Exploitation of the Poor and Suffering

    OpenAIRE

    Lanjouw, Jean O.

    1997-01-01

    The decision to require that countries grant product patents for pharmaceutical innovations as a condition of membership in the World Trade Organization was very contentious. Almost fifty developing countries were not granting patent monopolies for drugs during the period the Uruguay round of GATT was being debated and these countries fiercely resisted the inclusion of this requirement, claiming that vastly higher drug prices would be associated with such patents. On the other side, business ...

  8. Patent Races and Market Value

    DEFF Research Database (Denmark)

    Czarnitzki, Dirk; Hussinger, Katrin; Leten, Bart;

    Patent races are models of strategic interactions between firms competing to develop an invention. The winning firm secures a patent, protecting the invention from imitation. This paper tests the assumption made about the reward structure in patent races, both in discrete and complex industries. We...... identify patent race winners using detailed information from the patent examination reports at the European Patent Office (EPO). Estimates of a market value equation featuring large, R&D-intensive U.S., European and Japanese firms, show that if firms win patent races, their market value increases...... significantly. We further show that the gain in market value is significantly larger for patent race winners in discrete industries than for firms in complex industries....

  9. Androgen receptor and its splice variant, AR-V7, differentially regulate FOXA1 sensitive genes in LNCaP prostate cancer cells.

    Science.gov (United States)

    Krause, William C; Shafi, Ayesha A; Nakka, Manjula; Weigel, Nancy L

    2014-09-01

    Prostate cancer (PCa) is an androgen-dependent disease, and tumors that are resistant to androgen ablation therapy often remain androgen receptor (AR) dependent. Among the contributors to castration-resistant PCa are AR splice variants that lack the ligand-binding domain (LBD). Instead, they have small amounts of unique sequence derived from cryptic exons or from out of frame translation. The AR-V7 (or AR3) variant is constitutively active and is expressed under conditions consistent with CRPC. AR-V7 is reported to regulate a transcriptional program that is similar but not identical to that of AR. However, it is unknown whether these differences are due to the unique sequence in AR-V7, or simply to loss of the LBD. To examine transcriptional regulation by AR-V7, we have used lentiviruses encoding AR-V7 (amino acids 1-627 of AR with the 16 amino acids unique to the variant) to prepare a derivative of the androgen-dependent LNCaP cells with inducible expression of AR-V7. An additional cell line was generated with regulated expression of AR-NTD (amino acids 1-660 of AR); this mutant lacks the LBD but does not have the AR-V7 specific sequence. We find that AR and AR-V7 have distinct activities on target genes that are co-regulated by FOXA1. Transcripts regulated by AR-V7 were similarly regulated by AR-NTD, indicating that loss of the LBD is sufficient for the observed differences. Differential regulation of target genes correlates with preferential recruitment of AR or AR-V7 to specific cis-regulatory DNA sequences providing an explanation for some of the observed differences in target gene regulation.

  10. Patent litigation in India continues to throw up new challenges.

    Science.gov (United States)

    Reddy Thikkavarapu, Prashant

    2016-07-01

    For several years after the reinstitution of a pharmaceutical patent regime in India, most innovator pharmaceutical companies have faced a string of high-profile defeats during litigation in India. In the last 2 years, however, the fortunes of pharmaceutical patentees have changed dramatically. Not only have Indian courts enforced pharmaceutical patents and issued injunctions restraining Indian generic companies from infringing valid patents, but they have also refused to invoke 'public interest' arguments to delay the enforcement of patents. This string of victories for pharmaceutical patents indicates a new era for the innovator industry in India. These victories for the innovator industry demonstrate the objectivity of the Indian judiciary. Even on the issue of compulsory licensing, the Patent Office, which functions as a part of the central government, has been restrained - granting only one compulsory license for a drug owned by Bayer but declining two other similar requests. Similarly, even the Indian judiciary while enforcing patents has also remained sensitive to the flexibilities in the Patents Act, such as the 'Bolar-type' provisions and compulsory licensing provisions.

  11. Patents for Soldiers

    Science.gov (United States)

    2016-06-10

    while certainly critical to the commercialization of patentable innovations, is not explored herein. Fifth, this research only considers laws and...conclusions and recommendations. 33 Lieutenant General Robert Brown, “The Human Dimension” ( Speech ...must be likely that an Army activity will use the invention, as evaluated by the Army activity, or the invention has commercial potential as judged

  12. Used, Blocking and Sleeping Patents

    DEFF Research Database (Denmark)

    Torrisi, Salvatore; Gambardella, Alfonso; Giuri, Paola

    2016-01-01

    and sleeping patents. We also examine the association between used and unused patents and their characteristics such as family size, scope, generality and overlapping claims, technology area, type of applicant, and the competitive environment from where these patents originate. We discuss our results...

  13. Framing the patent troll debate.

    Science.gov (United States)

    Risch, Michael

    2014-02-01

    The patent troll debate has reached a fevered pitch in the USA. This editorial seeks to frame the debate by pointing out the lack of clarity in defining patent trolls and their allegedly harmful actions. It then frames the debate by asking currently unanswered questions: Where do troll patents come from? What are the effects of troll assertions? Will policy changes improve the system?

  14. Patent pools: Intellectual property rights and competition

    NARCIS (Netherlands)

    Rodriguez, V.

    2010-01-01

    Patent pools do not correct all problems associated with patent thickets. In this respect, patent pools might not stop the outsider problem from striking pools. Moreover, patent pools can be expensive to negotiate, can exclude patent holders with smaller numbers of patents or enable a group of major

  15. Patented herbal formulations and their therapeutic applications.

    Science.gov (United States)

    Musthaba, Mohamed; Baboota, Sanjula; Athar, Tanwir M D; Thajudeen, Kamal Y; Ahmed, Sayeed; Ali, Javed

    2010-11-01

    Recently, there is a greater global interest in non synthetic, natural medicines derived from plant sources due to better tolerance and minimum adverse drug reactions as compared to synthetic medicines. Herbal products are also commonly used by the patients with certain chronic medical conditions, including breast cancer, liver disease, human immunodeficiency, asthma and rheumatological disorders. WHO estimates that about three-quarters of the world's population currently uses herbs and other forms of traditional medicines for the treatment of various diseases. The herbs are formulated in different modern dosage forms, such as Tablets, Capsules, Topical cream, Gel, Ointment and even some novel drug delivery forms, like extended release, sustained release, and microencapsules dosage forms. Patenting of herbal formulations has increased over the past few years and scientific evidence of therapeutic activity has been reported by performing various in vitro and in vivo experiments. This manuscript deals with various patented herbal formulations with their therapeutic application against various diseases.

  16. 基于在研药物相关专利判别指标分析药物开发的基础研究状况%Analysis for Basic Research of Drugs Using Reifned Indicators for Patents Linked with Marketed Drugs and Pipelines

    Institute of Scientific and Technical Information of China (English)

    治部真里; 李颖

    2015-01-01

    For the sake of providing evidences that contribute to policy making or strategy planning in a Japanese version of the NIH and pharmaceutical companies, we tried to give an overview and future prospects of pharmaceutical industry based on new indicators. Here we show the trends of very basic research of small molecule drug and bio-medicine by country, patents assignees, using new indicators for identifying patents related with pharmaceutical entities' marketed drugs and pipeline%日本版NIH及其制药企业,政策制定·战略规划需要佐证.为此,本研究尝试基于新的指标体系进行制药行业的现状俯瞰与未来预测.本篇基于连载第四篇导出的用于辨识制药企业在研药物及药物密切相关专利的新指标,按照国别和专利申请人,揭示低分子药物、不同技术类别的生物药的基础研究能力.

  17. Prevention of mother-to-child transmission of HIV in Zambia: implementing efficacious ARV regimens in primary health centers

    Directory of Open Access Journals (Sweden)

    Mandala Justin

    2009-08-01

    Full Text Available Abstract Background Safety and effectiveness of efficacious antiretroviral (ARV regimens beyond single-dose nevirapine (sdNVP for prevention of mother-to-child transmission (PMTCT have been demonstrated in well-controlled clinical studies or in secondary- and tertiary-level facilities in developing countries. This paper reports on implementation of and factors associated with efficacious ARV regimens among HIV-positive pregnant women attending antenatal clinics in primary health centers (PHCs in Zambia. Methods Blood sample taken for CD4 cell count, availability of CD4 count results, type of ARV prophylaxis for mothers, and additional PMTCT service data were collected for HIV-positive pregnant women and newborns who attended 60 PHCs between April 2007 and March 2008. Results Of 14,815 HIV-positive pregnant women registered in the 60 PHCs, 2,528 (17.1% had their CD4 cells counted; of those, 1,680 (66.5% had CD4 count results available at PHCs; of those, 796 (47.4% had CD4 count ≤ 350 cells/mm3 and thus were eligible for combination antiretroviral treatment (cART; and of those, 581 (73.0% were initiated on cART. The proportion of HIV-positive pregnant women whose blood sample was collected for CD4 cell count was positively associated with (1 blood-draw for CD4 count occurring on the same day as determination of HIV-positive status; (2 CD4 results sent back to the health facilities within seven days; (3 facilities without providers trained to offer ART; and (4 urban location of PHC. Initiation of cART among HIV-positive pregnant women was associated with the PHC's capacity to provide care and antiretroviral treatment services. Overall, of the 14,815 HIV-positive pregnant women registered, 10,015 were initiated on any type of ARV regimen: 581 on cART, 3,041 on short course double ARV regimen, and 6,393 on sdNVP. Conclusion Efficacious ARV regimens beyond sdNVP can be implemented in resource-constrained PHCs. The majority (73.0% of women identified

  18. Patenting Nanomedicines Legal Aspects, Intellectual Property and Grant Opportunities

    CERN Document Server

    Souto, Eliana B

    2012-01-01

    "Patenting Nanomedicines: Legal Aspects, Intellectual Property and Grant Opportunities" focuses on the fundamental aspects of Patenting Nanomedicines applied in different "Drug Delivery and Targeting Systems". The promoters of new findings in this field of research are numerous and spread worldwide; therefore, managing intellectual property portfolios, and the acquisition and exploitation of new knowledge face several contingency factors. Today, the scientific community is discussing issues of economic outcomes in the field of Nanomedicines. Major concerns include questions

  19. Antiretroviral drug supply challenges in the era of scaling up ART in Malawi

    OpenAIRE

    2011-01-01

    Abstract The number of people receiving antiretroviral treatment (ART) has increased considerably in recent years and is expected to continue to grow in the coming years. A major challenge is to maintain uninterrupted supplies of antiretroviral (ARV) drugs and prevent stock outs. This article discusses issues around the management of ARVs and prevention of stock outs in Malawi, a low-income country with a high HIV/AIDS burden, and a weak procurement and supply chain management system. This sy...

  20. Patent monopoly : protecting your ideas

    Energy Technology Data Exchange (ETDEWEB)

    Caldwell, R.B. [Bennett Jones LLB, Calgary, AB (Canada)

    2002-06-01

    A form of intellectual property, patents can be bought and sold, thereby having a lot of financial value. The petroleum industry is a sector very involved with patent protection. At some time, it is expected that most technical companies will be involved in obtaining patent protection or busy defending themselves against a patent suit. In this paper, the author focussed on the procedure to obtain patent protection. Progressing from the basic facts concerning patents, the author then briefly described the necessary steps in the procedure. The author began by distinguishing the three major intellectual properties of use in the petroleum industry, namely patents, trademarks, and copyrights. Words, symbols or designs, including the various combinations of those, which distinguish the services of one company from those of another, are considered trademarks. Creative works, on the other hand, are protected under copyrights from being copied without permission. Inventions are protected by patents. What should be known about inventions was the focus of the next section in the presentation, followed by a section entitled: seeking patent protection: the first steps. The filing of the formal patent applications was discussed, then the emphasis was placed on after filing: the examination. The issued patent, which can be enforced against competitors, was the very last section in the presentation.

  1. 37 CFR 3.21 - Identification of patents and patent applications.

    Science.gov (United States)

    2010-07-01

    ... 37 Patents, Trademarks, and Copyrights 1 2010-07-01 2010-07-01 false Identification of patents and patent applications. 3.21 Section 3.21 Patents, Trademarks, and Copyrights UNITED STATES PATENT AND... for Recording § 3.21 Identification of patents and patent applications. An assignment relating to...

  2. Traditional Knowledge and Patent Protection: Conflicting Views On International Patent Standards

    Directory of Open Access Journals (Sweden)

    A Andrzejewski

    2010-12-01

    Full Text Available As diseases continue to spread around the globe, pharmaceutical and biotech companies continue to search for new and better drugs to treat them. Most of these companies have realised that useful compounds for these purposes may be found in the natural resources that indigenous and local communities use. And yet, even though the importance of these biological resources to global health and economic livelihood is well recognised, the legal ownership and control of this traditional knowledge is still very controversial. This article undertakes a comparative analysis of American and European, as well as international legal regulations on patent law and traditional knowledge. Key questions include: What is traditional knowledge? How have the national patent laws of these countries treated the protection of plant variety and plant genetic resources? What are the existing international standards for patents, and what implications do they have for protecting traditional knowledge? And finally, what protection systems are emerging for the future?

  3. Labor Mobility and Patenting Activity

    DEFF Research Database (Denmark)

    Kaiser, Ulrich; Kongsted, Hans Christian; Rønde, Thomas

    We measure the quantitative importance of labor mobility as a vehicle for the transmission of knowledge and skills across firms. For this purpose we create a unique data set that matches all applications of Danish firms at the European Patent Office to linked employer-employee register data...... for the years 1999-2002. The Danish workforce is split into "R&D workers", who hold a bachelor's or a master's degree in a technical field, and "non{R&D workers". We find that mobile R&D workers ("R&D joiners"') contribute more to patenting activity than immobile R&D workers. Furthermore, R&D workers who have...... previously been employed by a patenting firm ("patent exposed workers") have a larger effect on patenting activity than R&D workers without this experience. Patent exposed R&D joiners constitute the most productive group of workers: for firms that patented prior to 1999, one additional worker of this type...

  4. IL-21 and probiotic therapy improve Th17 frequencies, microbial translocation, and microbiome in ARV-treated, SIV-infected macaques.

    Science.gov (United States)

    Ortiz, A M; Klase, Z A; DiNapoli, S R; Vujkovic-Cvijin, I; Carmack, K; Perkins, M R; Calantone, N; Vinton, C L; Riddick, N E; Gallagher, J; Klatt, N R; McCune, J M; Estes, J D; Paiardini, M; Brenchley, J M

    2016-03-01

    Increased mortality in antiretroviral (ARV)-treated, HIV-infected individuals has been attributed to persistent immune dysfunction, in part due to abnormalities at the gastrointestinal barrier. In particular, the poor reconstitution of gastrointestinal Th17 cells correlates with residual translocation of dysbiotic, immunostimulatory microflora across a compromised intestinal epithelial barrier. We have previously demonstrated that oral probiotics promote increased intestinal CD4(+) T-cell reconstitution during ARV treatment in a non-human primate model of HIV infection; however, essential mucosal T-cell subsets, such as Th17 cells, had limited recovery. Here, we sought to promote Th17 cell recovery by administering interleukin (IL)-21 to a limited number of ARV-treated, probiotic-supplemented, Simian Immunodeficiency Virus (SIV)-infected pigtailed macaques. We demonstrate that probiotic and IL-21 supplementation of ARVs are associated with enhanced polyfunctional Th17 expansion and reduced markers of microbial translocation and dysbiosis as compared with infected controls receiving ARVs alone. Importantly, treatment resulted in fewer morbidities compared with controls, and was independent of increased immune activation or loss of viral suppression. We propose that combining ARVs with therapeutics aimed at restoring intestinal stasis may significantly improve disease prognosis of ARV-treated, HIV-infected individuals.

  5. Antiretroviral drug supply challenges in the era of scaling up ART in Malawi.

    Science.gov (United States)

    Schouten, Erik J; Jahn, Andreas; Ben-Smith, Anne; Makombe, Simon D; Harries, Anthony D; Aboagye-Nyame, Francis; Chimbwandira, Frank

    2011-07-06

    The number of people receiving antiretroviral treatment (ART) has increased considerably in recent years and is expected to continue to grow in the coming years. A major challenge is to maintain uninterrupted supplies of antiretroviral (ARV) drugs and prevent stock outs. This article discusses issues around the management of ARVs and prevention of stock outs in Malawi, a low-income country with a high HIV/AIDS burden, and a weak procurement and supply chain management system. This system for ARVs, paid for by the Global Fund to Fight AIDS, Tuberculosis and Malaria, and bypassing the government Central Medical Stores, is in place, using the United Nations Children's Fund's (UNICEF's) procurement services. The system, managed by a handful of people who spend limited time on supply management, is characterized by a centrally coordinated quantification based on verified data from all national ART clinics, parallel procurement through UNICEF, and direct distribution to ART clinics. The model worked well in the first years of the ART programme with a single first-line ARV regimen, but with more regimens becoming available (e.g., alternative first-line, second-line and paediatric regimens), it has become more difficult to administer. Managing supplies through a parallel system has the advantage that weaknesses in the national system have limited influence on the ARV procurement and supply chain management system. However, as the current system operates without a central warehouse and national buffer stock capacity, it diminishes the ability to prevent ARV stock outs. The process of ordering ARVs, from the time that estimates are made to the arrival of supplies in health facilities, takes approximately one year. Addressing the challenges involved in maintaining ARVs through an efficient procurement and supply chain management system that prevents ARV stock outs through the establishment of a dedicated procurement team, a central warehouse and/or national buffer stock is a

  6. Antiretroviral drug supply challenges in the era of scaling up ART in Malawi

    Directory of Open Access Journals (Sweden)

    Schouten Erik J

    2011-07-01

    Full Text Available Abstract The number of people receiving antiretroviral treatment (ART has increased considerably in recent years and is expected to continue to grow in the coming years. A major challenge is to maintain uninterrupted supplies of antiretroviral (ARV drugs and prevent stock outs. This article discusses issues around the management of ARVs and prevention of stock outs in Malawi, a low-income country with a high HIV/AIDS burden, and a weak procurement and supply chain management system. This system for ARVs, paid for by the Global Fund to Fight AIDS, Tuberculosis and Malaria, and bypassing the government Central Medical Stores, is in place, using the United Nations Children’s Fund’s (UNICEF’s procurement services. The system, managed by a handful of people who spend limited time on supply management, is characterized by a centrally coordinated quantification based on verified data from all national ART clinics, parallel procurement through UNICEF, and direct distribution to ART clinics. The model worked well in the first years of the ART programme with a single first-line ARV regimen, but with more regimens becoming available (e.g., alternative first-line, second-line and paediatric regimens, it has become more difficult to administer. Managing supplies through a parallel system has the advantage that weaknesses in the national system have limited influence on the ARV procurement and supply chain management system. However, as the current system operates without a central warehouse and national buffer stock capacity, it diminishes the ability to prevent ARV stock outs. The process of ordering ARVs, from the time that estimates are made to the arrival of supplies in health facilities, takes approximately one year. Addressing the challenges involved in maintaining ARVs through an efficient procurement and supply chain management system that prevents ARV stock outs through the establishment of a dedicated procurement team, a central warehouse and

  7. An overview of recent patents on nanosuspension.

    Science.gov (United States)

    Modh, Nirav; Mehta, Dharmik; Parejiya, Punit; Popat, Amirali; Barot, Bhavesh

    2014-01-01

    Pharmaceutical scientists involved in drug discovery and drug development are facing serious problems with newer poorly water soluble drugs with respect to their dissolution and bioavailability. Reducing the particle size of active pharmaceutical ingredient has been an efficient and reliable method for improving the bioavailability of insoluble drugs. Nanosuspension has emerged as an efficient and promising strategy for delivery of insoluble drugs due to its unique advantages such as ease of modification, process flexibility, targeting capabilities, altered pharmacokinetic profile leading to safety and efficacy. These unique features of nanosuspension have enabled its use in various dosage forms, including specialized delivery systems such as oral, parenteral, peroral, ocular and pulmonary routes. Currently, efforts are being directed to extend their applications in site-specific drug delivery. Large numbers of products based on nanosuspension are in the market and few are under clinical trials. The commercialization potential of nanosuspension based formulation for oral route is well established and products for other routes will enter the market within short span. Among the various techniques available, only wet milling technique has been successfully used for commercial production of nanosuspension. Nanosuspension based patents have extensive potential of reaching faster in the market as compared to other nanotechnology based formulations. This review covers various aspects of techniques of preparation, route of administration and commercialization of nanosuspension with main focus on the recent patents granted in the field.

  8. Patent activity in biotechnology

    OpenAIRE

    Ekaterina, Streltsova

    2014-01-01

    Biotechnologies are a priority area of development due to the scope of global challenges and social problems they help to resolve. There is demand for updated information about the the current state of research and challenges faced. This paper discusses the potential of patent analysis and surveys the Russian biotechnological market with both quantitative and qualitative methods. It reviews key statistical and analytical findings of empirical research. The main finding is that the Russian bio...

  9. 2种中药制剂微生物限度与控制菌方法验证%Method verification of microbial limit and control bacteria for two kinds of Chinese patent drugs

    Institute of Scientific and Technical Information of China (English)

    闵红; 唐娜; 尹良君

    2013-01-01

    目的 建立六味地黄胶囊与杞菊地黄胶囊微生物限度与控制菌的检查方法.方法 采用常规法与培养基稀释法对2种中药制剂进行微生物限度方法验证,采用直接接种法进行控制菌方法验证.结果 建立了2种中药制剂的微生物限度与控制菌检查方法.结论 六味地黄胶囊采用培养基稀释法(0.5 mL/皿)测定细菌数,常规法测定霉菌及酵母菌数;杞菊地黄胶囊采用培养基稀释法(0.2 mL/皿)测定细菌数,培养基稀释法(0.5 mL/皿)测定霉菌及酵母菌数.采用直接接种法对2种中药制剂进行控制菌(大肠埃希菌与大肠菌群)检测.%Objective To estabilish methods of the microbial limit and control bacteria tests for Liuweidihuang Capsules and Qijudi-huang Capsules. Methods Routine method and medium diluting method were adopted for the verification of microbial methodology, direct inoculation method for control bacteria. Results The methods of the microbial limit and control bacteria tests for two kinds of Chinese patent drugs were estabilished. Conclusion Bacterial count of Liuweidihuang Capsules could adopt the medium diluting method (0. 5 mL/plant) , while yeast and mold count could adopt the routine method. Bacterial count of Qijudihuang Capsules could adopt the medium diluting method (0. 2 mL/plant) , while yeast and mold count could adopt the medium diluting method (0. 5 mL/plant). Direct inoculation method could be adopted for detecting the control bacteria for the two kinds of Chinese patent preparations.

  10. How Patent Function Integration with R&D Influence the Value of Patents

    DEFF Research Database (Denmark)

    Beukel, Karin; Valentin, Finn

    Patent strategies are endogenous to firm appropriability. However, to what extent does firm’s R&D teams’ engagement with patent experts influence the value of patents? We estimate the relationship between firm’s R&D use of patent functions on patent value in Biotech firms. Controlling...... for characteristics of scientific team, firm effects, and other patent value indicators, we find that having a firm specific (in-house) internal patent function is a driver of patent value. In addition, we find that the way in which patent functions create patent value differs dependent on whether the firm has...... internal patent function or not. In-house patent functions create value through narrow patents, whereas, firms with no in-house patent function create valuable patents by the use of broader scoped patents. Our results point to a strong effect of firm specific patent functions, but also explain how firms...

  11. Patent production is a prerequisite for successful exit of a biopharmaceutical company.

    Science.gov (United States)

    Saotome, Chikako; Nakaya, Yurie; Abe, Seiji

    2016-03-01

    Patents are especially important for the business of drug discovery; however, their importance for biopharmaceutical companies has not been revealed quantitatively yet. To examine the correlation between patents and long-term business outcome of biopharmaceutical companies we analyze annual number of patent families and business conditions of 123 public-listed biopharmaceutical companies established from 1990 to 1995 in the USA. Our results show the number of patent families per year correlates well with the business condition: average of the bankruptcy group is significantly smaller than those of the continuing and the merger and acquisitions (M&A) groups. In the M&A by big pharma group, the acquisition cost correlates with the number of annual patent families. However, patentability and strategy of foreign patent application are not different among the groups. Therefore, the productivity of invention is the key factor for success of biopharmaceutical companies.

  12. Observational epidemiological study to identify the clinical profile of naïve patients starting antiretroviral (ARV therapy in Spain

    Directory of Open Access Journals (Sweden)

    A Ocampo

    2012-11-01

    Full Text Available Purpose of the study: To identify the proportion of patients starting ARV treatment with NNRTIs or with a PI/r and to explore and compare their clinical profile establishing different factors whereby physicians select the initial ARV treatment in a Spanish clinical setting. Methods: An observational study was conducted in two different phases. In Phase I a cross-sectional registration was conducted for patients who initiated ARV treatment in a 6-month period in 65 Spanish hospitals. In Phase II clinical and social-demographic features were collected retrospectively of patients who visited HIV clinics between August and November 2010 who had started ARV treatment containing an NNRTIs or a PI/r in Phase I. Summary of results: In Phase I, 1,687 subjects who initiated ARV treatment were registered, of which 53% started with an NNRTI-based regimen whereas 42% started with a PI/r-based regimen. Two percent of the treatment initiations occurred in a clinical trial. In Phase II, 642 patients were paired consecutively and retrospectively. The group of patients was composed of predominantly male subjects (81% vs 19%. The median time between diagnosis and the start of ARV treatment was 3.6±5.3 years. At the initiation of treatment, 72% of patients had a CD4 count below 350 cells/µl. Although treatment based on NNRTIs in naïve patients is the most frequent option in Spain, the analysis of clinical profiles shows that PI/r-based therapy is more often used than NNRTIs with statistical significance in patients with high viral load, Fig. A (≥100.000 copies/ml (58% vs 42%; OR:1,75; 95% CI: 1,26–2,43; p<0,01, with CD4 cell counts <200 cells/µl, Fig. B (68% vs 31%; OR: 2,92; 95% CI: 1,99–4,27; p<0,01, and in patients at CDC stage C (65% vs 35%; OR: 2,05; CI: 1,27–3,31; p<0,01. Conclusions: In Spain, HIV is still diagnosed late (as measured by CD4 count<350 cells/µl. Treatment based on NNRTIs are more frequently used in naïve patients, although PIs

  13. HIV Drug Resistance-Associated Mutations in Antiretroviral Naïve HIV-1-Infected Latin American Children

    Directory of Open Access Journals (Sweden)

    Luis E. Soto-Ramirez

    2010-01-01

    Full Text Available Our goal was to describe the presence of HIV drug resistance among HIV-1-infected, antiretroviral (ARV naïve children and adolescents in Latin America and to examine resistance in these children in relation to drug exposure in the mother. Genotyping was performed on plasma samples obtained at baseline from HIV-1-infected participants in a prospective cohort study in Brazil, Argentina, and Mexico (NISDI Pediatric Study. Of 713 HIV-infected children enrolled, 69 were ARV naïve and eligible for the analysis. At enrollment, mean age was 7.3 years; 81.2% were infected with HIV perinatally. Drug resistance mutations (DRMs were detected in 6 (8.7%; 95% confidence interval 3.1–18.2% ARV-naïve subjects; none of the mothers of these 6 received ARVs during their pregnancies and none of the children received ARV prophylaxis. Reverse transcriptase mutations K70R and K70E were detected in 3 and 2 subjects, respectively; protease mutation I50 V was detected in 1 subject. Three of the 6 children with DRMs initiated ARV therapy during followup, with a good response in 2. The overall rate of primary drug resistance in this pediatric HIV-infected population was low, and no subjects had more than 1 DRM. Mutations associated with resistance to nucleoside reverse transcriptase inhibitors were the most prevalent.

  14. Effectiveness and tolerability of abacavir-lamivudine-nevirapine (ABC/3TC/NVP in a multicenter cohort of HIV-infected ARV-experienced patients

    Directory of Open Access Journals (Sweden)

    D Podzamczer

    2012-11-01

    Full Text Available Purpose of the study: Very scarce information has been published to date with the combination of ABC/3TC/NVP but it is currently being used in clinical practice in many centers in Spain. Our aim was to present the clinical experience with this regimen in a cohort of adult HIV-infected pts. Methods: Retrospective, multicenter, cohort study. Consecutive adult HIV-infected ARV-experienced pts, HLA-B*5701-negative, who started ABC/3TC/NVP between 2005–2010, with at least one follow-up visit, were included. Demographic, clinical and laboratory variables were assessed at baseline, month 1, and every 3–4 months thereafter. The primary end point was HIV-1 viral load (VL <40 c/mL at 48 weeks. Data were analyzed by intent-to-treat (ITT (non-completer=failure and on treatment (OT. Summary of results: 227 pts were included and followed up for a median of 30 (0.5–76 months. 75% male, 47 (24–83 years, 21% AIDS, 13% HCV+, baseline CD4 570 (32–1404 cells/µL and VL undetectable in 90% with a median of <1.59 (<1.59–5.1 log. Most pts were receiving NVP (63%, ABC (25% or both (4% in the previous regimen. ABC/3TC/NVP was initiated due to toxicity (42%, simplification (35% or other reasons (22% including to reduce drug cost. After 48 weeks, VL was <40 c/mL in 82% (ITT and 94% (OT, and in 94% (OT after 96 weeks. CD4 increased +63 (p<0.001 and +77 (p<0.001 cells/µL after 48 and 96 weeks, respectively. One or more drugs of the regimen were discontinued in 18% of pts during follow up: toxicity (7%, virologic failure (3%, lost to follow-up (3%, unrelated death (0.4% or other reasons (4%. No significant differences were observed in ALT, AST, or triglyceride changes during follow up. A significant increase of 7%, 10% and 14% was observed in total cholesterol, LDLc and HDLc, and a significant decrease in TC/HDL ratio (−5%, p=0.004 after 96 weeks, respectively. Conclusions: In this particular cohort of ARV-experienced pts previously receiving NVP or ABC, a

  15. Assessment of analytical techniques for characterization of crystalline clopidogrel forms in patent applications

    Directory of Open Access Journals (Sweden)

    Luiz Marcelo Lira

    2014-04-01

    Full Text Available The aim of this study was to evaluate two important aspects of patent applications of crystalline forms of drugs: (i the physicochemical characterization of the crystalline forms; and (ii the procedure for preparing crystals of the blockbuster drug clopidogrel. To this end, searches were conducted using online patent databases. The results showed that: (i the majority of patent applications for clopidogrel crystalline forms failed to comply with proposed Brazilian Patent Office guidelines. This was primarily due to insufficient number of analytical techniques evaluating the crystalline phase. In addition, some patent applications lacked assessment of chemical/crystallography purity; (ii use of more than two analytical techniques is important; and (iii the crystallization procedure for clopidogrel bisulfate form II were irreproducible based on the procedure given in the patent application.

  16. Analysis of the Utilization of National Essential Drugs (Chinese Patent Medicines) in 18 Second-grade Hospitals%六省区18家二级医院国家基本药物(中成药)使用情况调研

    Institute of Scientific and Technical Information of China (English)

    李晓玲; 王香平; 王育琴; 王晓燕; 彭迎春; 白向荣; 元华龙

    2013-01-01

    目的:为《国家基本药物目录·基层医疗卫生机构配备使用部分》(2009版)(以下简称“2009年版国家基本药物目录”)中中成药部分的调整提供参考.方法:按照经济发达程度,选取广东省、江苏省、山东省、湖北省、四川省和宁夏回族自治区六省(区)的18家二级医院的中成药药品目录,分别与2009年版国家基本药物目录(中成药)和所在省(区)的基本药物增补目录(以下简称“省中成药增补目录”)进行比较,分析国家中成药基本药物、各省中成药增补目录和各医院2009年版国家基本药物目录外(以下简称“目录外”)中成药品种的使用情况.结果:国家中成药基本药物在18家医院的使用率平均为45%,六省(区)增补中成药目录的使用率为14%~41%,各医院目录外中成药品种使用比例平均为73%.结论:2009年版国家基本药物目录中成药部分的遴选与临床需求存在一定差距,该目录尚无法满足我国二级医院的医疗需求,特别是经济较发达地区.%OBJECTIVE: To provide reference for the adjustment of Chinese patent medicines in 2009 edition of Primary Medical Institutions Equipped Part · National Essential Drug List (called 2009 edition of National Essential Drug List for short). METHODS: Chinese patent medicine list of 18 second-grade hospitals were selected from 6 provinces such as Guangdong province, Jiang-su province, Shandong province, Hubei province, Sichuan province and Ningxia Hui autonomous region. 18 lists were compared to 2009 edition of National Essential Drug List (Chinese patent medicine) and supplementary lists of 6 provinces. The utilization of national essential drugs (Chinese patent medicines), Chinese patent medicines supplementary lists of 6 provinces and Chinese patent medicines out of the list were analyzed. RESULTS: 45% national essential Chinese patent medicines were used in 18 hospitals, and the percentages of supplementary lists

  17. Exploiting structural information in patent specifications for key compound prediction.

    Science.gov (United States)

    Tyrchan, Christian; Boström, Jonas; Giordanetto, Fabrizio; Winter, Jon; Muresan, Sorel

    2012-06-25

    Patent specifications are one of many information sources needed to progress drug discovery projects. Understanding compound prior art and novelty checking, validation of biological assays, and identification of new starting points for chemical explorations are a few areas where patent analysis is an important component. Cheminformatics methods can be used to facilitate the identification of so-called key compounds in patent specifications. Such methods, relying on structural information extracted from documents by expert curation or text mining, can complement or in some cases replace the traditional manual approach of searching for clues in the text. This paper describes and compares three different methods for the automatic prediction of key compounds in patent specifications using structural information alone. For this data set, the cluster seed analysis described by Hattori et al. (Hattori, K.; Wakabayashi, H.; Tamaki, K. Predicting key example compounds in competitors' patent applications using structural information alone. J. Chem. Inf. Model.2008, 48, 135-142) is superior in terms of prediction accuracy with 26 out of 48 drugs (54%) correctly predicted from their corresponding patents. Nevertheless, the two new methods, based on frequency of R-groups (FOG) and maximum common substructure (MCS) similarity measures, show significant advantages due to their inherent ability to visualize relevant structural features. The results of the FOG method can be enhanced by manual selection of the scaffolds used in the analysis. Finally, a successful example of applying FOG analysis for designing potent ATP-competitive AXL kinase inhibitors with improved properties is described.

  18. Subscribe to China Patents & Trademarks

    Institute of Scientific and Technical Information of China (English)

    1995-01-01

    The Chinese/English bilingual quarterly China Patents & Trademarks is a professional publicationsponsored by China Patent Agent (H.K.) Ltd.The journal commenced publication in April 1985 and hasbeen edited and published in Hong Kong for distribution in China and abroad.The main contents carried by China Patents & Trademarks are:guidelines,policies,laws and regula-tions relevant to intellectual property,economy and trade in China;matters related to the practical work

  19. Subscribe to China Patents & Trademarks

    Institute of Scientific and Technical Information of China (English)

    1995-01-01

    The Chinese/English bilingual quarterly China Patents & Trademarks is a professional publicationsponsored by China Patent Agent(H.K.)Ltd.The journal commenced publication in April 1985 and hasbeen edited and published in Hong Kong for distribution in China and abroad.The main contents carried by China Patents & Trademarks are:guidelines,policies,laws and regula-tions relevant to intellectual property,economy and trade in China;matters related to the practical work

  20. Monitoring and modeling the snowpack dynamics in the Arve upper catchment for hydrological purposes

    Science.gov (United States)

    Revuelto, Jesús; Lecourt, Grégoire; Charrois, Luc; Lafaysse, Matthieu; Condom, Thomas; Dumont, Marie; Morin, Samuel; Rabatel, Antoine; Six, Delphine; Vionnet, Vincent; Zin, Isabella

    2016-04-01

    Snow accumulation and its evolution over space and time have major importance for the hydrological cycle, especially at high elevations. The characteristics of mountain valley, such as a wide altitudinal range, large glaciated areas, snow presence all along the year; when combined with specific meteorological conditions like heat waves or extreme rain events, may originate dramatic flash floods, potentially affecting populated areas. Thus, improving snowpack monitoring and forecasting tools are needed to strength the reliability of warning systems. Nowadays, accurately characterising and simulating snowpack evolution over large areas still represents a challenge, and uncertainties arise. The study presented here is focused in analysing two different types of simulation of the snowpack dynamics, performed with different discretization approaches, distributed or semi-distributed, and how these could move forward assimilating remote sensing data from satellites. The considered study area is the Arve catchment at Chamonix, in the French Northern Alps. This valley has the previously mentioned characteristics: it comprises a large elevation range (between 1000 to 4800m asl, with large areas above 2000m asl) and about 32% of its extension (200km2) is glaciated. Thus, the hydrological cycle of this area is highly dependent on the snowpack and the glacier melt dynamics. The snowpack of the Arve catchment has been simulated from 1990 to 2014 with the Crocus model integrated within the SURFEX modelling platform. The input fields are provided by the SAFRAN reanalysis system and the simulations have been performed with both a semi-distributed (classifying terrain by aspect, elevation, slope and land use/land cover) and a distributed (250m spatial resolution grid cells over the study area) approaches. The use of these two approaches using the same snowpack model and same meteorological forcing, enables their comparison in terms of river discharges at several outlets; showing the

  1. Subscribe to China Patents & Trademarks

    Institute of Scientific and Technical Information of China (English)

    1996-01-01

    The Chinese/English bilingual quarterly China Patents & Trademarks is a professional publicationsponsored by China Patent Agent (H.K.) Ltd.The journal commenced publication in April 1985 and hasbeen edited and published in Hong Kong for distribution in China and abroad.The main contents carried by China Patents & Trademarks are:guidelines,policies,laws and regula-tions relevant to intellectual property,economy and trade in China;matters related to the practical workof patent application,trademark registration and copyright protection in China;concrete examples of

  2. 43 CFR 6.52 - Patents.

    Science.gov (United States)

    2010-10-01

    ... 43 Public Lands: Interior 1 2010-10-01 2010-10-01 false Patents. 6.52 Section 6.52 Public Lands: Interior Office of the Secretary of the Interior PATENT REGULATIONS Licenses § 6.52 Patents. Patents in... sublicenses, are classified as follows: (a) Class A. Patents, other than those referred to in paragraph (c)...

  3. 37 CFR 501.9 - Patent protection.

    Science.gov (United States)

    2010-07-01

    ... 37 Patents, Trademarks, and Copyrights 1 2010-07-01 2010-07-01 false Patent protection. 501.9 Section 501.9 Patents, Trademarks, and Copyrights UNDER SECRETARY FOR TECHNOLOGY, DEPARTMENT OF COMMERCE UNIFORM PATENT POLICY FOR RIGHTS IN INVENTIONS MADE BY GOVERNMENT EMPLOYEES § 501.9 Patent protection....

  4. Chemical named entity recognition in patents by domain knowledge and unsupervised feature learning

    OpenAIRE

    Zhang, Yaoyun; Xu, Jun; Chen, Hui; Wang, Jingqi; Wu, Yonghui; Prakasam, Manu; Xu, Hua

    2016-01-01

    Medicinal chemistry patents contain rich information about chemical compounds. Although much effort has been devoted to extracting chemical entities from scientific literature, limited numbers of patent mining systems are publically available, probably due to the lack of large manually annotated corpora. To accelerate the development of information extraction systems for medicinal chemistry patents, the 2015 BioCreative V challenge organized a track on Chemical and Drug Named Entity Recogniti...

  5. Comparative analysis on price negotiation models of patented drugs in Korea and Germany and its implications for China%韩国和德国专利药价格谈判模式比较研究及启示

    Institute of Scientific and Technical Information of China (English)

    伍琳; 陈永法

    2015-01-01

    为完善我国专利药价格谈判制度,本文从目标、程序及效果三方面,比较分析韩国和德国专利药价格谈判模式的共性与特点,从而为中国提供借鉴。结果发现,韩国和德国专利药价格谈判均以提高国家医保基金使用效率为关键目标,并通过科学的职责分工确保谈判的公平与效率,但技术评估标准的选择因国情差异而存在较大不同。建议我国加强专利药价格谈判与医保报销政策的衔接,建立以专利药创新程度为核心的评估标准体系,同时应制定科学合理的谈判程序与职责分工。%Objective: To provide policy recommendations for improving price negotiation system of patented drugs in China. Methods: This paper comparatively analyzes the commonalities and characteristics between Korea’ and Germany’s price negotiation models for patented drugs from three aspects of their goals, procedures and effects. Results:The key objective of both Korea’ and Germany’s price negotiation systems for patented drugs is to efficiently improve the utilization of national health insurance services, and responsibilities are properly assigned among differ-ent institutions to ensure the equity and efficiency of negotiations. However, due to the differences in national cir-cumstances, there is a big difference in the selection of technical assessment criteria. Conclusion: This paper sug-gests China to strengthen the convergence between price negotiations for patented drugs and medical insurance reim-bursement policy, to establish a technical assessment system with the innovation extent for patented drugs as its core, and to develop scientific and rational negotiation procedures and division of responsibilities as well.

  6. Patent and product piracy

    Science.gov (United States)

    Ignat, V.

    2016-08-01

    Advanced industrial countries are affected by technology theft. German industry annually loses more than 50 billion euros. The main causes are industrial espionage and fraudulent copying patents and industrial products. Many Asian countries are profiteering saving up to 65% of production costs. Most affected are small medium enterprises, who do not have sufficient economic power to assert themselves against some powerful countries. International organizations, such as Interpol and World Customs Organization - WCO - work together to combat international economic crime. Several methods of protection can be achieved by registering patents or specific technical methods for recognition of product originality. They have developed more suitable protection, like Hologram, magnetic stripe, barcode, CE marking, digital watermarks, DNA or Nano-technologies, security labels, radio frequency identification, micro color codes, matrix code, cryptographic encodings. The automotive industry has developed the method “Manufactures against Product Piracy”. A sticker on the package features original products and it uses a Data Matrix verifiable barcode. The code can be recorded with a smartphone camera. The smartphone is connected via Internet to a database, where the identification numbers of the original parts are stored.

  7. Patenting of Pharmaceuticals: An Indian Perspective

    Directory of Open Access Journals (Sweden)

    Vipin Mathur

    2012-09-01

    Full Text Available Patent is one of the major forms of Intellectual Property Rights (IPRs used in the pharmaceutical industry. Trade mark, industrial design, geographical indication and copyright are other forms of IPRs available in India. Grant of patent in India is governed under the Patents Act, 1970. Significant changes like provision of product patents and increase in the term of patent to 20 years were introduced in the Indian patent law, after India signed TRIPS (Trade Related Aspects of Intellectual Property Rights agreement in 1995. This review provides a brief overview of development of patent law in India as a consequence of TRIPS agreement. Criteria of patentability and different types of pharmaceutical patents currently being granted in India are described with the aim to provide the fundamental knowledge of pharmaceutical patenting to the researchers. Other relevant provisions related with patenting of pharmaceuticals like section 3(d, transfer of the patent rights, compulsory licensing etc. are explained with suitable example.

  8. Patent Overlay Mapping: Visualizing Technological Distance

    CERN Document Server

    Kay, Luciano; Youtie, Jan; Porter, Alan L; Rafols, Ismael

    2012-01-01

    The purpose of this paper is to present a new global patent map that represents all technological categories, and a method to locate patent data of individual organizations and technological fields on the global map. This second patent overlay map technique is shown to be of potential interest to support competitive intelligence and policy decision-making. The global patent map is based on similarities in citing-to-cited relationships between categories of the International Patent Classification (IPC) of European Patent Office (EPO) patents from 2000 to 2006. This patent dataset, extracted from PatStat database, represents more than 760,000 patent records in more than 400 IPC categories. To illustrate the kind of analytical support offered by this approach, the paper shows the overlay of nanotechnology-related patenting activities of two companies and two different nanotechnology subfields on to the global patent map. The exercise shows the potential of patent overlay maps to visualize technological areas and...

  9. Subscribe to China Patents & Trademarks

    Institute of Scientific and Technical Information of China (English)

    1996-01-01

    The Chinese/English bilingual quarterly China Patents & Trademarks is a professional publication sponsored by ChinaPatent Agent(H.K.)Ltd. The journal commenced publication in April 1985 and has been edited and published in HongKong for distribution in China and abroad.

  10. Wacky Patents Meet Economic Indicators

    DEFF Research Database (Denmark)

    Czarnitzki, Dirk; Hussinger, Katrin; Schneider, Cédric

    2011-01-01

    We investigate whether standard indicators can distinguish between “wacky” patents and a control group. Forward citations are good predictors of importance. However, “wacky” patents have higher originality, generality and citation lags, suggesting that these indicators should be interpreted...

  11. Optimal patent policies: A survey

    DEFF Research Database (Denmark)

    Poulsen, Odile

    2002-01-01

    , the government uses two policy tools, the optimal breadth and length. We show that theoretical models give very different answers to what is the optimal patent policy. In particular, we show that the optimal patent policy depends among othet things on the price elasticity of demand, the intersectoral elasticity...

  12. Recent patents on molecular cytogenetics.

    Science.gov (United States)

    Iourov, Ivan Y; Vorsanova, Svetlana G; Yurov, Yuri B

    2008-01-01

    The questions surrounding patenting of DNA sequences encoding specific proteins are relatively well reviewed in the available literature. However, neither applications nor molecular cytogenetic techniques, which use these sequences as a probe, have been reviewed in the light of the patenting. Furthermore, the patenting of the use of numerous probes, which are produced on different types of repetitive genome elements (i.e. satellite DNA or telomeric DNA sequences) and those generated by chromosome microdissection has not been reviewed. Molecular cytogenetic techniques are one of the most applied in current bioscience (as to June 2007, over 40,000 papers in browseable scientific databases mention one or several molecular cytogenetic techniques). Therefore, reviewing recent patents in this field is of general interest for numerous researchers in different areas of biology and medicine. Here, we address world-wide patents on DNA sequences used as molecular cytogenetic probes and molecular cytogenetic techniques to define current state and perspectives of this biomedical direction.

  13. Patent foramen ovale and cryptogenic stroke: the hole story.

    Science.gov (United States)

    Furlan, Anthony J; Jauss, Marek

    2013-09-01

    Despite 3 recent randomized clinical trials, the management of patients with cryptogenic stroke and patent foramen ovale remains unsettled. The primary results of Evaluation of the STARFlex Septal Closure System in Patients with a Stroke and/or Transient Ischemic Attack due to Presumed Paradoxical Embolism Through a Patent Foramen Ovale (CLOSURE), Percutaneous Closure of Patent Foramen Ovale in Cryptogenic Stroke (PC), and Randomized Evaluation of Recurrent Stroke Comparing PFO Closure to Established Current Standard of Care Treatment (RESPECT) were the same; the intent to treat analysis for the primary end point in all 3 trials failed to demonstrate superiority of device closure compared with medical therapy. CLOSURE put the brakes on indiscriminate device closure of patent foramen ovales in patients with cryptogenic stroke or transient ischemic attack. RESPECT suggested, but did not prove, that highly selected patients without vascular risk factors, with a cortical infarct on baseline magnetic resonance imaging and a substantial patent foramen ovale shunt may benefit from the Amplatzer device during a multiple-year period. In the absence of definitive clinical trial results, the precise definition of which patient subgroups should be considered for patent foramen ovale device closure should be agreed to by the stakeholder societies and the Food and Drug Administration.

  14. Modification de la biodisponibilité orale des médicaments : interactions « Herb-Drugs » « Drugs- Drugs».

    OpenAIRE

    Dossou-Yovo, Flore

    2014-01-01

    Oral dosing is still seen as the silver bullet of drug administration, as it is cheaper andbetter adapted to patient comfort. However, oral route is still inaccessible to many drugssuch as biologics and biosimilars respectively certain anticancer drugs and antiretrovirals(ARV).The aim of this present study was to find new drugs enhancers that improve the oralbioavailability of drugs and xenobiotics. All the studies were realized in vitro using Ussingchambers technic. To achieve the set object...

  15. ARV robotic technologies (ART): a risk reduction effort for future unmanned systems

    Science.gov (United States)

    Jaster, Jeffrey F.

    2006-05-01

    The Army's ARV (Armed Robotic Vehicle) Robotic Technologies (ART) program is working on the development of various technological thrusts for use in the robotic forces of the future. The ART program will develop, integrate and demonstrate the technology required to advance the maneuver technologies (i.e., perception, mobility, tactical behaviors) and increase the survivability of unmanned platforms for the future force while focusing on reducing the soldiers' burden by providing an increase in vehicle autonomy coinciding with a decrease in the total number user interventions required to control the unmanned assets. This program will advance the state of the art in perception technologies to provide the unmanned platform an increasingly accurate view of the terrain that surrounds it; while developing tactical/mission behavior technologies to provide the Unmanned Ground Vehicle (UGV) the capability to maneuver tactically, in conjunction with the manned systems in an autonomous mode. The ART testbed will be integrated with the advanced technology software and associated hardware developed under this effort, and incorporate appropriate mission modules (e.g. RSTA sensors, MILES, etc.) to support Warfighter experiments and evaluations (virtual and field) in a military significant environment (open/rolling and complex/urban terrain). The outcome of these experiments as well as other lessons learned through out the program life cycle will be used to reduce the current risks that are identified for the future UGV systems that will be developed under the Future Combat Systems (FCS) program, including the early integration of an FCS-like autonomous navigation system onto a tracked skid steer platform.

  16. Analysis on Composition Rules of Chinese Patent Drugs with Tonifying Spleen Based on Association Rules and Clustering Algorithm%基于关联规则与熵聚类的健脾类中成药组方规律研究

    Institute of Scientific and Technical Information of China (English)

    金燕萍; 吴嘉瑞; 张冰; 杨冰; 周唯; 张晓朦

    2015-01-01

    目的:探讨常用健脾类中成药组方规律。方法:收录《新编国家中成药》中的健脾类中成药处方,采用关联规则Apriori 算法和复杂系统熵聚类等方法,确定处方中药物的使用频次及药物之间的关联规则等。结果:高频次药物包括茯苓、白术、甘草、党参、陈皮等;高频次药物组合包括“白术、茯苓”“甘草、茯苓”“甘草、白术”等;置信度较高的关联规则包括“陈皮->白扁豆”“陈皮->半夏”等。结论:处方用药中除常见的健脾类中药外,尚包括具有健脾作用的部分理气药、消食药及其他类药物。%Objective:To investigate composition rules of Chinese patent drugs with tonifying spleen.Methods:The prescriptions of Chinese patent drugs with tonifying spleen in “The New National Medicine”were collected to build a database.The methods of association rules with apriori algorithm and complex system entropy cluster were used to achieve the frequency of medicines and as-sociation rules between drugs.Results:The data-mining results indicated that in the prescriptions of Chinese patent drugs with ton-ifying spleen,the most frequency used drugs were Poria Cocos Wolff,Rhizoma Atractylodis Macrocephalae,Radix Glycyrrhizae, Radix Codonopsitis,Pericarpium Citri Reticulatae.The most common drug combinations were”Rhizoma Atractylodis Macrocepha-lae,Poria Cocos Wolff”,”Radix Glycyrrhizae,Poria Cocos Wolff”,”Radix Glycyrrhizae,Rhizoma Atractylodis Macrocephalae”. The drugs with a high degree confidence coefficient of association rules include “Pericarpium Citri Reticulatae->Semen Dolicho-ris”,“Pericarpium Citri Reticulatae->Pinellia ternata”.Conclusion:There are not only the common drugs tonifying spleen,but also drugs regulating the flow of vital energy,removing obstruction toit,and helping digest.

  17. Technology Clusters Exploration for Patent Portfolio through Patent Abstract Analysis

    Directory of Open Access Journals (Sweden)

    Gabjo Kim

    2016-12-01

    Full Text Available This study explores technology clusters through patent analysis. The aim of exploring technology clusters is to grasp competitors’ levels of sustainable research and development (R&D and establish a sustainable strategy for entering an industry. To achieve this, we first grouped the patent documents with similar technologies by applying affinity propagation (AP clustering, which is effective while grouping large amounts of data. Next, in order to define the technology clusters, we adopted the term frequency-inverse document frequency (TF-IDF weight, which lists the terms in order of importance. We collected the patent data of Korean electric car companies from the United States Patent and Trademark Office (USPTO to verify our proposed methodology. As a result, our proposed methodology presents more detailed information on the Korean electric car industry than previous studies.

  18. 中成药宁泌泰应用后健康相关生活质量的评估%Assessment of health related quality of life in bladder cancer patients treated by Chinese patent drug Ningmitai

    Institute of Scientific and Technical Information of China (English)

    杨晓峰; 王倩倩

    2016-01-01

    life (HRQOL) in bladder patients after the treatment of pirarubicin bladder perfusion by using specific HRQOL questionnaire FACT-BL and compare the difference of patients HRQOL after applying Chinese patent drug Ningmitai, with a prospect of providing references for the clinical treatment of cancer. Methods: A prospective randomized controlled clinical trial was carried out. A total of 120 patients with bladder transitional cell carcinoma(TNM I-II), treated from June 2010 to June 2014 and underwent partial cystectomy or transurethral resection of bladder tumor, were randomly divided into pirarubicin bladder perfusion combined with Chinese patent drug Ningmitai group (61 cases) and pirarubicin bladder perfusion (59 cases). HRQOL was assessed using FACT-BL. The following scores were calculated from the FACT-BL questionnaire and list: physical well-being, social/family well-being, emotional well-being, and functional well being; total FACT-G, overall bladder-specific subscale and total FACT-BL were analyzed statistically.Results: A total of 115 patients answered questionnaires, 59 patients were in the combined medication group and 56 patients were in single medication group. The comparison between two groups revealed no significant differences in the percent of males, age, education, family monthly income, payment modes of medical expense, follow-up years and pathological stage(P>0.05), but there was significant difference in recurrence rates [8.2%(5/61)vs 22.0%(13/59)] and incidence of adverse reaction [6.5%(4/61)vs 47.6%(28/59)] between the two groups(P<0.05). Patients in combined medication group got significantly higher scores in physical well-being[(30.3±2.3)points vs(20.3±2.1)points], social/family well-being[(22.4±2.7)points vs(15.1±4.3)points] and total FACT-BL [(92.3±16.7)points vs(83.6±17.0)points] than those in single medication group (P<0.05). Conclusions: The HRQOL of patients treated by pirarubicin bladder perfusion combined with Chinese patent drug

  19. Negotiation Strategies for Antiretroviral Drug Purchasers in the United States.

    Science.gov (United States)

    Linnemayr, Sebastian; Ryan, Gery W; Karir, Veena; Liu, Jenny; Palar, Kartika

    2012-01-01

    Antiretroviral treatment has transformed HIV from a death sentence to a chronic condition, allowing people with HIV to live longer and healthier lives. However, they face significant barriers to accessing and affording life-saving-but expensive-antiretroviral (ARV) medications. These barriers are particularly severe for low-income patients, and they disproportionately affect racial and ethnic minorities. High ARV prices create pressure for government insurers to contain costs either by rationing care or by restricting eligibility for public programs. Limited funding, coupled with a growing demand for HIV care and treatment, is likely to make programmatic decisions about who is covered become more difficult over time. Therefore, it is important to identify options for reducing the cost of providing ARVs to allow more people to receive treatment. This study examines a variety of options for negotiating lower ARV procurement costs in U.S. markets. A case-study approach is used to assess options that different stakeholders could use in negotiating ARV price discounts with drug manufacturers given the regulatory and market constraints that exist in the United States.

  20. Patent classifications as indicators of intellectual organization

    NARCIS (Netherlands)

    L. Leydesdorff

    2008-01-01

    Using the 138,751 patents filed in 2006 under the Patent Cooperation Treaty, co-classification analysis is pursued on the basis of three- and four-digit codes in the International Patent Classification (IPC, 8th ed.). The co-classifications among the patents enable us to analyze and visualize the re

  1. 78 FR 67339 - Initial Patent Applications

    Science.gov (United States)

    2013-11-12

    ... Patent and Trademark Office Initial Patent Applications ACTION: Proposed collection; Extension of Comment Period. SUMMARY: The United States Patent and Trademark Office (USPTO), as part of its continuing efforts... Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. Federal Rulemaking Portal:...

  2. 14 CFR 1260.28 - Patent rights.

    Science.gov (United States)

    2010-01-01

    ... 14 Aeronautics and Space 5 2010-01-01 2010-01-01 false Patent rights. 1260.28 Section 1260.28... Provisions § 1260.28 Patent rights. Patent Rights May 2006 As stated at § 1260.136, this award is subject to... “Patent Rights (Small Business Firms and Nonprofit Organizations)” and the following: (a) Where the...

  3. 76 FR 72000 - Patent, Trademark & Copyright Acts

    Science.gov (United States)

    2011-11-21

    ... Geological Survey Patent, Trademark & Copyright Acts AGENCY: U.S. Geological Survey, Interior. ACTION: Notice...., Suite 200, Kennesaw, GA 30144, on U.S. Patent Application Serial No. 12/133,666, and a divisional patent application to be filed shortly at the Patent and Trademark Office, both entitled ``Anaerobic...

  4. 75 FR 20561 - Patent Term Extension

    Science.gov (United States)

    2010-04-20

    ... Patent and Trademark Office Patent Term Extension ACTION: Proposed collection; comment request. SUMMARY: The United States Patent and Trademark Office (USPTO), as part of its continuing effort to reduce... the Chief Information Officer, United States Patent and Trademark Office, P.O. Box 1450,...

  5. 77 FR 4887 - DOE Patent Licensing Regulations

    Science.gov (United States)

    2012-02-01

    ... Part 781 RIN 1990-AA41 DOE Patent Licensing Regulations AGENCY: Office of the General Counsel, Department of Energy. ACTION: Final rule. SUMMARY: The Department of Energy (DOE) is amending its patent... patents or patent applications vested in the United States of America, as represented by or in the...

  6. 78 FR 31885 - Patent Term Extension

    Science.gov (United States)

    2013-05-28

    ... Patent and Trademark Office Patent Term Extension ACTION: Proposed collection; comment request. SUMMARY: The United States Patent and Trademark Office (USPTO), as part of its continuing effort to reduce...: Susan K. Fawcett, Records Officer, Office of the Chief Information Officer, United States Patent...

  7. 75 FR 23227 - Initial Patent Applications

    Science.gov (United States)

    2010-05-03

    ... Patent and Trademark Office Initial Patent Applications ACTION: Proposed collection; comment request. SUMMARY: The United States Patent and Trademark Office (USPTO), as part of its continuing efforts to..., Records Officer, Office of the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box...

  8. "Patent Activity and Technical Change"

    OpenAIRE

    Robert L. Basmann; Michael, McAleer; Daniel, Slottje

    2003-01-01

    As creations of the mind, intellectual property includes industrial property and copyrights. This paper presents an aggregate production function of the generalized Fechner-Thurstone (GFT) form to analyze the impact of an important component of intellectual industrial property, namely patent activity, on technical change in the USA for the period 1947-1981. Patents should alter isoquant maps, and measuring their elasticities is both intuitively and empirically appealing. We define a technolog...

  9. Universities and Patent Demands.

    Science.gov (United States)

    Cordova, Andrew K; Feldman, Robin

    2015-11-01

    Research universities have made enormous contributions to the field of medicine and the treatment of human disease. Alone or in collaboration with pharmaceutical companies, academic researchers have added to the store of knowledge that has led to numerous life science breakthroughs. A new chapter may be opening for academic researchers, however, that could lead to a darker tale. 'The mouse that trolled: the long and tortuous history of a gene mutation patent that became an expensive impediment to Alzheimer's research, by Bubela et al., chronicles one such tale.' The authors do an excellent job of bringing to life the twisting saga that engulfed numerous academic and non-profit Alzheimer's researchers over many years. The authors note that the story is an outlier, but sadly, that may not be the case. There are increasing signs that academic researchers and their institutions are being caught up in the rush for gold that is accompanying the proliferation of the non-practicing entity business model. As I have noted before, academic institutions have a dual role, as keepers of the academic flame and guardians of the public monies entrusted to them through state and federal research funding. The specter of taxpayer money being used, not to advance research and for the betterment of society, but as part of schemes to extract money from productive companies may not sit well with voters, and ultimately, with legislators. In that case, researchers and institutions themselves may have much to lose.

  10. Disclosing in utero HIV/ARV exposure to the HIV-exposed uninfected adolescent: is it necessary?

    Science.gov (United States)

    Jao, Jennifer; Hazra, Rohan; Mellins, Claude A; Remien, Robert H; Abrams, Elaine J

    2016-01-01

    Introduction The tremendous success of antiretroviral therapy has resulted in a diminishing population of perinatally HIV-infected children on the one hand and a mounting number of HIV-exposed uninfected (HEU) children on the other. As the oldest of these HEU children are reaching adolescence, questions have emerged surrounding the implications of HEU status disclosure to these adolescents. This article outlines the arguments for and against disclosure of a child's HEU status. Discussion Disclosure of a child's HEU status, by definition, requires disclosure of maternal HIV status. It is necessary to weigh the benefits and harms which could occur with disclosure in each of the following domains: psychosocial impact, long-term physical health of the HEU individual and the public health impact. Does disclosure improve or worsen the psychological health of the HEU individual and extended family unit? Do present data on the long-term safety of in utero HIV/ARV exposure reveal potential health risks which merit disclosure to the HEU adolescent? What research and public health programmes or systems need to be in place to afford monitoring of HEU individuals and which, if any, of these require disclosure? Conclusions At present, it is not clear that there is sufficient evidence on whether long-term adverse effects are associated with in utero HIV/ARV exposures, making it difficult to mandate universal disclosure. However, as more countries adopt electronic medical record systems, the HEU status of an individual should be an important piece of the health record which follows the infant not only through childhood and adolescence but also adulthood. Clinicians and researchers should continue to approach the dialogue around mother–child disclosure with sensitivity and a cogent consideration of the evolving risks and benefits as new information becomes available while also working to maintain documentation of an individual's perinatal HIV/ARV exposures as a vital part of his

  11. Disclosing in utero HIV/ARV exposure to the HIV-exposed uninfected adolescent: is it necessary?

    Directory of Open Access Journals (Sweden)

    Jennifer Jao

    2016-10-01

    Full Text Available Introduction: The tremendous success of antiretroviral therapy has resulted in a diminishing population of perinatally HIV-infected children on the one hand and a mounting number of HIV-exposed uninfected (HEU children on the other. As the oldest of these HEU children are reaching adolescence, questions have emerged surrounding the implications of HEU status disclosure to these adolescents. This article outlines the arguments for and against disclosure of a child's HEU status. Discussion: Disclosure of a child's HEU status, by definition, requires disclosure of maternal HIV status. It is necessary to weigh the benefits and harms which could occur with disclosure in each of the following domains: psychosocial impact, long-term physical health of the HEU individual and the public health impact. Does disclosure improve or worsen the psychological health of the HEU individual and extended family unit? Do present data on the long-term safety of in utero HIV/ARV exposure reveal potential health risks which merit disclosure to the HEU adolescent? What research and public health programmes or systems need to be in place to afford monitoring of HEU individuals and which, if any, of these require disclosure? Conclusions: At present, it is not clear that there is sufficient evidence on whether long-term adverse effects are associated with in utero HIV/ARV exposures, making it difficult to mandate universal disclosure. However, as more countries adopt electronic medical record systems, the HEU status of an individual should be an important piece of the health record which follows the infant not only through childhood and adolescence but also adulthood. Clinicians and researchers should continue to approach the dialogue around mother–child disclosure with sensitivity and a cogent consideration of the evolving risks and benefits as new information becomes available while also working to maintain documentation of an individual's perinatal HIV/ARV exposures

  12. Patent Law for Computer Scientists

    Science.gov (United States)

    Closa, Daniel; Gardiner, Alex; Giemsa, Falk; Machek, Jörg

    More than five centuries ago the first patent statute was passed by the Venetian senate. It already had most of the features of modern patent law, recognizing the public interest in innovation and granting exclusive right in exchange for a full disclosure. Some 350 years later the industrial revolution led to globalisation. The wish to protect intellectual property on a more international level evolved and supranational treaties were negotiated. Patent laws are still different in many countries, however, and inventors are sometimes at a loss to understand which basic requirements should be satisfied if an invention is to be granted a patent. This is particularly true for inventions implemented on a computer. While roughly a third of all applications (and granted patents) relate, in one way or another, to a computer, applications where the innovation mainly resides in software or in a business method are treated differently by the major patent offices. The procedures at the USPTO, JPO and EPO and, in particular, the differences in the treatment of applications centring on software are briefly explained. In later sections of this book, a wealth of examples will be presented. The methodology behind the treatment of these examples is explained.

  13. 2010-2013年天津市第二人民医院肝病治疗口服中成药的使用情况分析%Analysis on use of oral Chinese patent drugs for liver disease treatment in The Second People’s Hospital of Tianjin during 2010-2013

    Institute of Scientific and Technical Information of China (English)

    满姗姗; 王立新; 王俊华

    2014-01-01

    目的:分析天津市第二人民医院2010—2013年肝病治疗口服中成药的临床用药情况,探讨用药90%(DU 90%)在肝病治疗口服中成药利用评价中应用的可行性和实用性,为临床用药的合理性和科学性提供参考。方法收集、整理2010—2013年医院肝病治疗口服中成药用药频度(DDDs)和限定日费用(DDDc)进行统计,分析DU 90%部分药物的使用情况。结果肝病治疗口服中成药的销售金额呈逐年上升趋势,增幅分别为21.70%、9.15%、26.43%;肝病治疗口服中成药的销售金额排名靠前的药物品种相对稳定,大多为清热解毒类、活血化瘀类和补益类药物;DU 90%部分药物的DDDs相对稳定,销售金额和DDDs的同步性较好。大部分药品的DDDc较低,构成比在2013年有所增加。结论2010—2013年天津市第二人民医院肝病治疗口服中成药使用情况基本合理,DU 90%可以作为一种有效的工具,应用到处方的评价过程中。%Objective To analyze use of oral Chinese patent drugs for liver disease treatment in The Second People’s Hospital of Tianjin during 2010—2013, and to discuss the feasibility and practicability of DU 90%in the evaluation of clinical drug utilization, so as to provide scientific evidence for the rational usage. Methods The utilization data including consumption sum, DDDs, and DDDc of oral Chinese patent drugs for liver disease treatments in The Second People’s Hospital of Tianjin during 2010—2013 were analyzed statistically, and the use of DU 90% was analyzed. Results The consumption sum of oral Chinese patent drugs for liver disease treatment increased by 21.70%, 9.15%, and 26.43%from 2010 to 2013, and there was an upward trend. Drug varieties high ranking in the consumption sum were relatively stable, including antipyretic and antidote drugs, blood-activating, stasis-eliminating drugs and Qi-restoring drugs. DDDs of DU 90%drugs were relatively stable

  14. Patent cliff mitigation strategies: giving new life to blockbusters.

    Science.gov (United States)

    Kakkar, Ashish Kumar

    2015-01-01

    With several blockbuster drugs on the brink of another significant patent expiry cliff, innovator pharmaceutical firms are at risk of losing billions of dollars in sales to generic competition. With issues such as staggering R&D costs, reduced productivity and increasing governmental emphasis on pharmacoeconomics, timely planning and implementation of product lifecycle management strategies is becoming indispensable. A variety of strategies designed to mitigate the post-patent expiry revenue loss exist. These approaches range from fairly straightforward measures, such as strategic price cuts and launching own or authorized generics, to complex and lengthy ones, such as new formulations and indications that require companies to reinvent their pharmaceuticals. As patent expiries loom and product pipelines continue to remain thin, proactive planning for generic entry will be critical for pharma companies to drive growth and earnings in a sustainable manner.

  15. Patent Literature Analysis of α - Glucosidase Inhibitor and Development Progress on Its Chinese Medicinal New Drug%α-葡萄糖苷酶抑制剂专利文献分析及其中药源新药开发进展

    Institute of Scientific and Technical Information of China (English)

    姚虹

    2012-01-01

    α-葡萄糖苷酶抑制剂是20世纪70年代后期研究开发的一类新型口服降血糖药物,具有作用温和持久、毒副作用小甚至无毒的优点,是近年来药物治疗糖尿病的研究热点之一.中药是我国特色的药物资源,从中药资源中寻找α-葡萄糖苷酶抑制剂的研究则是我国新药研究的特色.专利是新药开发产品化过程中标志性的知识产权和技术文献.通过相关中国专利及相关文献分析,综述中药源α-葡萄糖苷酶抑制剂新药开发的现状.%α-glucosidase inhibitor is a new oral hypoglycemic drug researched and developed in the late 1970s,with mild and persistent effect, little side - effect, even non - toxicity, which is one of the hot points of diabetic pharmacotherapy in recent years. The Chinese herbal medicine as the Chinese characteristics drug resource is becoming the new drug research way,it is our characteristics research to find a - glucosidase inhibitor from Chinese medicine. Patent is the key intellectual property and technical literature in the process of new drug development. By analyzing the relevant Chinese patents and literature, the development status quo of Chinese medicinal new drug of α - glucosidase is reviewed.

  16. Trends in Decline of Antiretroviral Resistance among ARV-Experienced Patients in the HIV Outpatient Study: 1999–2008

    Directory of Open Access Journals (Sweden)

    Kate Buchacz

    2012-01-01

    Full Text Available Background. Little is known about temporal trends in frequencies of clinically relevant ARV resistance mutations in HIV strains from U.S. patients undergoing genotypic testing (GT in routine HIV care. Methods. We analyzed cumulative frequency of HIV resistance among patients in the HIV Outpatient Study (HOPS who, during 1999–2008 and while prescribed antiretrovirals, underwent GT with plasma HIV RNA >1,000 copies/mL. Exposure ≥4 months to each of three major antiretroviral classes (NRTI, NNRTI and PI was defined as triple-class exposure (TCE. Results. 906 patients contributed 1,570 GT results. The annual frequency of any major resistance mutations decreased during 1999–2008 (88% to 79%, P=0.05. Resistance to PIs decreased among PI-exposed patients (71% to 46%, P=0.010 as exposure to ritonavir-boosted PIs increased (6% to 81%, P<0.001. Non-significant declines were observed in resistance to NRTIs among NRTI-exposed (82% to 67%, and triple-class-resistance among TCE patients (66% to 41%, but not to NNRTIs among NNRTI-exposed. Conclusions. HIV resistance was common but declined in HIV isolates from subgroups of ARV-experienced HOPS patients during 1999–2008. Resistance to PIs among PI-exposed patients decreased, possibly due to increased representation of patients whose only PI exposures were to boosted PIs.

  17. Patents, Inducement Prizes, and Contestant Strategy

    DEFF Research Database (Denmark)

    Davis, Jerome; Davis, Lee N.

    2006-01-01

    Debate over the merits of patents versus inducement prizes has tended to ignore the signaling roles of patents, and totally ignores the impact of patent signaling on prize contests. This paper asks: How does patent signaling affect the strategic choices of firms considering entering prize contests......? First, we consider contests that do not allow patenting, then contests that do. If patenting is not allowed, we argue, patent-holders, both internal and external to the contest, can adversely impact prize contests by claiming prize winner violation of their patents, and suing for damages. The likelihood...... of such challenges being made can deter entry, particularly in contests requiring large sunk costs. Furthermore, the firm's decisionmaking process will discriminate against entering prize contests and favor R&D projects with patentable outcomes. Together, these problems may circumscribe any future wider role...

  18. Reasons for Patent Protection and Cost-effective Patent Filing Options for SMEs

    Directory of Open Access Journals (Sweden)

    Art Brion

    2011-12-01

    Full Text Available Many innovative small and medium enterprises (SMEs do not seek patent protection for their innovations, either because they are skeptical about the perceived benefits or wary of the perceived costs. However, by failing to protect their intellectual property with patents, they leave themselves exposed to attack by other patent holders. This article explores arguments for patent protection as well as filing options that can protract the patenting process while simultaneously reducing patenting costs. By choosing their patent application filings wisely, SMEs can keep their patenting options open for as long as possible while delaying costs.

  19. HIV-1 Antiretroviral Drug Resistance Mutations in Treatment Naïve and Experienced Panamanian Subjects: Impact on National Use of EFV-Based Schemes

    Science.gov (United States)

    Mendoza, Yaxelis; Castillo Mewa, Juan; Martínez, Alexander A.; Zaldívar, Yamitzel; Sosa, Néstor; Arteaga, Griselda; Armién, Blas; Bautista, Christian T.; García-Morales, Claudia; Tapia-Trejo, Daniela; Ávila-Ríos, Santiago; Reyes-Terán, Gustavo; Bello, Gonzalo; Pascale, Juan M.

    2016-01-01

    The use of antiretroviral therapy in HIV infected subjects prevents AIDS-related illness and delayed occurrence of death. In Panama, rollout of ART started in 1999 and national coverage has reached 62.8% since then. The objective of this study was to determine the level and patterns of acquired drug resistance mutations of clinical relevance (ADR-CRM) and surveillance drug resistance mutations (SDRMs) from 717 HIV-1 pol gene sequences obtained from 467 ARV drug-experienced and 250 ARV drug-naïve HIV-1 subtypes B infected subjects during 2007–2013, respectively. The overall prevalence of SDRM and of ADR-CRM during the study period was 9.2% and 87.6%, respectively. The majority of subjects with ADR-CRM had a pattern of mutations that confer resistance to at least two classes of ARV inhibitors. The non-nucleoside reverse transcriptase inhibitor (NNRTI) mutations K103N and P225H were more prevalent in both ARV drug-naïve and ARV drug-experienced subjects. The nucleoside reverse transcriptase inhibitor (NRTI) mutation M184V was more frequent in ARV drug-experienced individuals, while T215YFrev and M41L were more frequent in ARV drug-naïve subjects. Prevalence of mutations associated to protease inhibitors (PI) was lower than 4.1% in both types of subjects. Therefore, there is a high level of resistance (>73%) to Efavirenz/Nevirapine, Lamivudine and Azidothymidine in ARV drug-experienced subjects, and an intermediate to high level of resistance (5–10%) to Efavirenz/Nevirapine in ARV drug-naïve subjects. During the study period, we observed an increasing trend in the prevalence of ADR-CRM in subjects under first-line schemes, but not significant changes in the prevalence of SDRM. These results reinforce the paramount importance of a national surveillance system of ADR-CRM and SDRM for national management policies of subjects living with HIV. PMID:27119150

  20. HIV-1 Antiretroviral Drug Resistance Mutations in Treatment Naive and Experienced Panamanian Subjects: Impact on National Use of EFV-Based Schemes.

    Directory of Open Access Journals (Sweden)

    Yaxelis Mendoza

    Full Text Available The use of antiretroviral therapy in HIV infected subjects prevents AIDS-related illness and delayed occurrence of death. In Panama, rollout of ART started in 1999 and national coverage has reached 62.8% since then. The objective of this study was to determine the level and patterns of acquired drug resistance mutations of clinical relevance (ADR-CRM and surveillance drug resistance mutations (SDRMs from 717 HIV-1 pol gene sequences obtained from 467 ARV drug-experienced and 250 ARV drug-naïve HIV-1 subtypes B infected subjects during 2007-2013, respectively. The overall prevalence of SDRM and of ADR-CRM during the study period was 9.2% and 87.6%, respectively. The majority of subjects with ADR-CRM had a pattern of mutations that confer resistance to at least two classes of ARV inhibitors. The non-nucleoside reverse transcriptase inhibitor (NNRTI mutations K103N and P225H were more prevalent in both ARV drug-naïve and ARV drug-experienced subjects. The nucleoside reverse transcriptase inhibitor (NRTI mutation M184V was more frequent in ARV drug-experienced individuals, while T215YFrev and M41L were more frequent in ARV drug-naïve subjects. Prevalence of mutations associated to protease inhibitors (PI was lower than 4.1% in both types of subjects. Therefore, there is a high level of resistance (>73% to Efavirenz/Nevirapine, Lamivudine and Azidothymidine in ARV drug-experienced subjects, and an intermediate to high level of resistance (5-10% to Efavirenz/Nevirapine in ARV drug-naïve subjects. During the study period, we observed an increasing trend in the prevalence of ADR-CRM in subjects under first-line schemes, but not significant changes in the prevalence of SDRM. These results reinforce the paramount importance of a national surveillance system of ADR-CRM and SDRM for national management policies of subjects living with HIV.

  1. HIV-1 Antiretroviral Drug Resistance Mutations in Treatment Naïve and Experienced Panamanian Subjects: Impact on National Use of EFV-Based Schemes.

    Science.gov (United States)

    Mendoza, Yaxelis; Castillo Mewa, Juan; Martínez, Alexander A; Zaldívar, Yamitzel; Sosa, Néstor; Arteaga, Griselda; Armién, Blas; Bautista, Christian T; García-Morales, Claudia; Tapia-Trejo, Daniela; Ávila-Ríos, Santiago; Reyes-Terán, Gustavo; Bello, Gonzalo; Pascale, Juan M

    2016-01-01

    The use of antiretroviral therapy in HIV infected subjects prevents AIDS-related illness and delayed occurrence of death. In Panama, rollout of ART started in 1999 and national coverage has reached 62.8% since then. The objective of this study was to determine the level and patterns of acquired drug resistance mutations of clinical relevance (ADR-CRM) and surveillance drug resistance mutations (SDRMs) from 717 HIV-1 pol gene sequences obtained from 467 ARV drug-experienced and 250 ARV drug-naïve HIV-1 subtypes B infected subjects during 2007-2013, respectively. The overall prevalence of SDRM and of ADR-CRM during the study period was 9.2% and 87.6%, respectively. The majority of subjects with ADR-CRM had a pattern of mutations that confer resistance to at least two classes of ARV inhibitors. The non-nucleoside reverse transcriptase inhibitor (NNRTI) mutations K103N and P225H were more prevalent in both ARV drug-naïve and ARV drug-experienced subjects. The nucleoside reverse transcriptase inhibitor (NRTI) mutation M184V was more frequent in ARV drug-experienced individuals, while T215YFrev and M41L were more frequent in ARV drug-naïve subjects. Prevalence of mutations associated to protease inhibitors (PI) was lower than 4.1% in both types of subjects. Therefore, there is a high level of resistance (>73%) to Efavirenz/Nevirapine, Lamivudine and Azidothymidine in ARV drug-experienced subjects, and an intermediate to high level of resistance (5-10%) to Efavirenz/Nevirapine in ARV drug-naïve subjects. During the study period, we observed an increasing trend in the prevalence of ADR-CRM in subjects under first-line schemes, but not significant changes in the prevalence of SDRM. These results reinforce the paramount importance of a national surveillance system of ADR-CRM and SDRM for national management policies of subjects living with HIV.

  2. 77 FR 26556 - Determination of Regulatory Review Period for Purposes of Patent Extension; EQUIDONE GEL

    Science.gov (United States)

    2012-05-04

    ... Patent Extension; EQUIDONE GEL AGENCY: Food and Drug Administration, HHS. ACTION: Notice. SUMMARY: The Food and Drug Administration (FDA) has determined the regulatory review period for EQUIDONE GEL and is....S.C. 156(g)(4)(B). FDA approved for marketing the animal drug product EQUIDONE GEL...

  3. Should ANVISA be permitted to reject pharmaceutical patent applications in Brazil?

    Science.gov (United States)

    Mueller, Lisa L; Taketsuma Costa, Silvia Moreira

    2014-01-01

    Pharmaceutical manufacturers who seek new markets for expansion are particularly attracted to Brazil given its potential for growth and the expectation that it will be the fifth largest drug market by 2015. Given the significance of Brazil in the marketplace, strong patent protection for pharmaceutical products and processes is critical. In April 2013, a new workflow came into effect in Brazil which allows the National Sanitary Vigilance Agency (ANVISA), a government agency whose function is to protect public health, to examine and reject any patent application that claims a pharmaceutical product or process before any examination of the application by the Brazilian Patent Office. If a patent application is rejected by ANVISA, the application is returned to the Brazilian Patent Office and filed away, without any further examination, for an unknown period of time. Therefore, the examination of pharmaceutical product and process applications under this new workflow is problematic for local and global pharmaceutical manufacturers for multiple reasons.

  4. Patents and the supply of therapeutic products.

    Science.gov (United States)

    Hayhurst, W L

    1992-01-01

    In some countries protests against the grant of exclusive rights in developments that benefit humanity have caused limits to be placed on the scope of patent rights. A characteristic of all modern patent systems is that the invention that one seeks to patent must have some practical utility and be new. The US is making patent protection available even for methods of medical treatment and for non human living things. A patent will expire in most developed countries 20 years from the filing of the application except in the US which grants patents from 17 years. India, China, and Brazil grant patents for shorter terms. In Australia and New Zealand, the term of a patent may be extended. In France and the US; extensions of term are possible only for medically related inventions. A patent grants to the owner of the patent the right, during its term, to exclude others from making, using, or selling the patented inventions. A patent grants to the owner of the patent the rights, during its term, to exclude others from making, using, or selling the patented invention. A patent owner who attempts to enforce a patent may be faced with a challenge that the patentee has misbehaved. In the US an alleged infringer may argue that the patentee misled the Patent Office when applying for the patent. The Patent laws of many countries enable the government to use patented inventions but compensate patent owners. Under sections 37 and 38 of the French patent legislation the government may decree that licenses are available in the interests of public health. In connection with Roussel-Uclaf's mifepristone, RU-486 it has been reported that such a decree cannot be made for a medicine that has not been approved by the government for distribution. The Canadian government has announced its intention to cancel the provisions in the Canadian Patent Act relating to compulsory licensing of medicines. Negotiations are continuing under the General Agreement on Tariffs and Trade that may lead to an

  5. An updated patent therapeutic agents targeting MMPs.

    Science.gov (United States)

    Shi, Zheng-gao; Li, Jin-pei; Shi, Lei-lei; Li, Xun

    2012-01-01

    The traditional consensus that matrix metalloproteinases (MMPs) has correlation with various pathological and physiological processes led to the exploitation of a vast number of natural or synthetic broad-spectrum MMP inhibitors (MMPIs) for the prophylaxis or treatment of various MMP-related disorders, such as autoimmune, inflammatory, cardiovascular, neurodegenerative, respiratory diseases, and malignant cancer as well. Yet the unsatisfactory preclinical and/or clinical results motivated further investigation of the physiological roles of certain MMP subtypes. Despite the intricate and complicated MMP functions in normal physiology and disease pathology, the effort of designing specific inhibitors that can selectively target certain MMP family members for individualized therapy is ongoing and remains an arduous task. Success will rely on continued insight into the biological roles of these multifaced proteases. In our previous effort, we summarized various MMPIs that have entered preclinical or clinical trials as well as the patents in regard to MMPIs (Recent Pat Anticancer Drug Discov. 2010; 5(2): 109-41). In our on-going review, to illustrate the major challenges in MMP validation as druggable targets, we highlighted the physiological and pathological roles of representative MMPs, with an emphasis on description of the newly emerging MMPI-based patents, in particular, the inhibitors containing sulfonamide or sulfone motif. By analyzing the structural characteristics and selectivity profiles of these supplementary inhibitors, we hereby described their pharmaceutical application, and also expanded the strategies for potent MMPI design.

  6. RRLC-Q-TOF-NS法测定安神类中成药、保健食品中14种非法添加的催眠类药物%Study on the analysis of illegally added 14 hypnotic drugs in Chinese traditional patent medicine and healthy foods by RRLC-Q-TOF-MS

    Institute of Scientific and Technical Information of China (English)

    王自; 严小红; 张玉英

    2014-01-01

    Objective To establish a qualitative and quantitative analysis method of illegally added 14 hypnotic drugs in Chinese traditional patent medicine and healthy foods. Methods RRLC-Q-TOF-NS was as the detection method. The qualitative analysis was based on the retention time,ms spectrometer and ms/ms spectrometer. The quantitative analysis was based on the quasi-molecular ion peak areas of 14 hypnotic drugs. Results The related coefficients of 14 components were all above 0. 99,the recover factors were between 80% ~120%. The qualitative and quantitative analysis method of illegally added 14 hypnotic drugs in Chinese traditional patent medicine and healthy foods was established. Conclusion This method is accu-rate and less interference,the liner relationships and the recover factors of the quantitative results are all well,which is suitable for the analysis of illegally added 14 hypnotic drugs in Chinese traditional patent medicine and healthy foods.%目的:建立安神类中成药、保健食品中非法添加14种催眠类药物的定性和定量测定方法。方法使用RRLC-Q-TOF-NS作为检测方法,化合物准分子离子峰的保留时间、一级质谱和二级质谱作为定性依据;一级质谱准分子离子峰面积作为定量依据。结果建立安神类中成药、保健食品中非法添加14种催眠类药物的定性和定量检验测定方法,14种成分线性相关系数( r)均>0.99,回收率80%~120%。结论 RRLC-Q-TOF-NS法定性准确,干扰少,定量线性及回收率良好,适用于安神类中成药、保健食品非法添加催眠类药品的定性和定量检验。

  7. Formulation Patents and Dermatology and Obviousness

    Directory of Open Access Journals (Sweden)

    Josephine Liu

    2011-11-01

    Full Text Available Most patents covering dermatologic products contain patent claims directed to the pharmaceutical formulation of the product. Such patents, known as formulation patents, are vulnerable to attacks based on the legal argument that the formulations covered are obvious over formulations already known prior to the filing of the patent application. Because obviousness is an important concept in patent law, recent court cases concerning obviousness and formulation patents were examined and discussed below. Courts have ruled that patent claims are obvious when features of the claimed formulation are found in the prior art, even if the features or characteristics of the formulation are not explicitly disclosed in the prior art. However, patentees have successfully overcome obviousness challenges where there were unexpected results or properties and/or the prior art taught away from the claimed invention.

  8. On the Nature of Standards and Patents

    Institute of Scientific and Technical Information of China (English)

    Bing WANG; Xu LI; Lanxi XIONG

    2008-01-01

    @@ Introduction 'Standard' and 'patent' are the buzz words in China's information and communication technology (ICT) industry. While the government has expressed its intention to promote standardization and patent protec-tion, what direction should enterprises especially domestic ICT companies take?

  9. Patent Eligibility of Business Methods in Canada

    Institute of Scientific and Technical Information of China (English)

    Zheng Li; Brian Lee

    2011-01-01

    @@ While the same fundamental principles underlining patent law are generally accepted in every major jurisdiction in the world, the patent eligibility of computer-implemented business method inventions ("business methods") has received different treatment between jurisdictions.

  10. Effect of firm variables on patent price

    Directory of Open Access Journals (Sweden)

    Shyam Sreekumaran Nair

    2012-03-01

    Full Text Available In this study, using singleton patent auction price data from Ocean Tomo, LLC, we analyse the effect of firm variables on patent price. Patents owned by small firms attract higher price than patents owned by large firms, if they engage in multi-country filings. The patents owned by small firms get cited more than the patents owned by large firms. The patents owned by individual inventors attract a higher price than the patents owned by organisations when multi-country filings are not included. We believe that the lack of resources is preventing individual inventors from engaging in multi-country filings and maximising the revenue from their invention. A larger representative data should be used to replicate the results before generalising it.

  11. The Transformation of Science Into Patented Inventions

    DEFF Research Database (Denmark)

    Beukel, Karin

    . The findings recast the relationship between science and patents as a process in which the way the transformation of the scientific invention is handled has an effect on the breadth of the patent scope. Unleashing patent scope surplus is dependent on processes related to abstraction and cognitive variety......, which can be mobilized by patent experts with both an in-depth understanding of the scientific discovery, due to their educational background in the life sciences, and capabilities within the legal framework for patenting. More specifically, the findings reveal previously unreported aspects...... of the transformation of academic science into patents, particularly how university scientists take a fragmented approach to the patenting process, while scientists employed in private companies can reap the benefits of close interaction with patenting experts ? experts who potentially can assume responsibility...

  12. 48 CFR 1427.201 - Patent and copyright infringement liability.

    Science.gov (United States)

    2010-10-01

    ... 48 Federal Acquisition Regulations System 5 2010-10-01 2010-10-01 false Patent and copyright... INTERIOR GENERAL CONTRACTING REQUIREMENTS PATENTS, DATA, AND COPYRIGHTS Patents and Copyrights 1427.201 Patent and copyright infringement liability....

  13. 48 CFR 1227.305 - Administration of patent rights clauses.

    Science.gov (United States)

    2010-10-01

    ... 48 Federal Acquisition Regulations System 5 2010-10-01 2010-10-01 false Administration of patent... TRANSPORTATION GENERAL CONTRACTING REQUIREMENTS PATENTS, DATA, AND COPYRIGHTS Patent Rights Under Government Contracts 1227.305 Administration of patent rights clauses....

  14. 48 CFR 1327.305 - Administration of patent rights clauses.

    Science.gov (United States)

    2010-10-01

    ... 48 Federal Acquisition Regulations System 5 2010-10-01 2010-10-01 false Administration of patent... GENERAL CONTRACTING REQUIREMENTS PATENTS, DATA, AND COPYRIGHTS Patent Rights Under Government Contracts 1327.305 Administration of patent rights clauses....

  15. 48 CFR 2427.305 - Administration of patent rights clauses.

    Science.gov (United States)

    2010-10-01

    ... 48 Federal Acquisition Regulations System 6 2010-10-01 2010-10-01 true Administration of patent... AND URBAN DEVELOPMENT SOCIOECONOMIC PROGRAMS PATENTS, DATA, AND COPYRIGHTS Patent Rights Under Government Contracts 2427.305 Administration of patent rights clauses....

  16. 48 CFR 27.305 - Administration of patent rights clauses.

    Science.gov (United States)

    2010-10-01

    ... 48 Federal Acquisition Regulations System 1 2010-10-01 2010-10-01 false Administration of patent... REGULATION GENERAL CONTRACTING REQUIREMENTS PATENTS, DATA, AND COPYRIGHTS Patent Rights under Government Contracts 27.305 Administration of patent rights clauses....

  17. 7 CFR 1210.367 - Patents, copyrights, inventions, and publications.

    Science.gov (United States)

    2010-01-01

    ... 7 Agriculture 10 2010-01-01 2010-01-01 false Patents, copyrights, inventions, and publications....367 Patents, copyrights, inventions, and publications. Any patents, copyrights, inventions, product... such patents, copyrights, inventions, product formulations, or publications shall be considered...

  18. 48 CFR 27.201 - Patent and copyright infringement liability.

    Science.gov (United States)

    2010-10-01

    ... 48 Federal Acquisition Regulations System 1 2010-10-01 2010-10-01 false Patent and copyright... REGULATION GENERAL CONTRACTING REQUIREMENTS PATENTS, DATA, AND COPYRIGHTS Patents and Copyrights 27.201 Patent and copyright infringement liability....

  19. Prevalence and type of drug-drug interactions involving antiretrovirals in patients attending a specialist outpatient clinic in Kampala, Uganda

    Directory of Open Access Journals (Sweden)

    K Seden

    2012-11-01

    Full Text Available Scale-up of HIV services in countries such as Uganda has resulted in a rapid increase in facilities offering antiretrovirals (ARVs and an increase in healthcare workers trained to deliver care. Consequently, evaluating medication safety is increasingly important in these settings. Data from developed countries suggest that drug-drug interactions (DDIs involving ARVs are common, occurring at rates of 14–58%. Few data are available from low resource settings, however a study of 996 Kenyan patients found that 33.5% were at risk of clinically significant DDIs. We evaluated the prevalence and type of ARV DDIs and the patients most at risk in an African outpatient setting. A random sample of patients taking current ARVs and accessing care at the Infectious Diseases Institute, Makerere University, Kampala was selected from the clinic database. The most recent prescription for each patient was screened for DDIs using www.hiv-druginteractions.org. Clinical significance of DDIs was assessed by two of us using a previously developed technique evaluating: likelihood of interaction, therapeutic index of affected drug and severity of potential adverse effect. From 1000 consecutive patients 99.6% were taking≥1 co-medication alongside their ARV regimen (mean 1.89. 24.5% had≥1 potential DDI, with a total of 335 DDIs observed. Of these, 255 DDIs were considered clinically significant, affecting 18.8% of patients. Only 0.3% of DDIs involved a contraindicated combination. There was a higher rate of potential DDIs observed in patients taking TB treatment (p=0.0047, who were WHO stage 3 or 4 (p=0.001, or patients taking ≥2 co-medications alongside ARVs (p<0.0001 (Fishers exact test. Patient age, gender, CD4 count and weight did not affect risk for DDIs. Co-medications commonly associated with potential DDIs were antibiotics (6.2% of 1000 patients, anthelminthics (4.6% and antifungals (3.5%. Potential DDIs involving ARVs occur at similar rates in resource

  20. Research use of patented inventions: opening remarks

    OpenAIRE

    Fernández de Labastida, José M.

    2006-01-01

    Opening remarks for the 2006 conference in Madrid on the research use of patented inventions. The conference, which was held at CSIC on 18-19 May 2006, was jointly organised by the Spanish National Research Council (CSIC), the Spanish Patent and Trademark Office (OEPM) and the OECD, with support from the European Patent Office (EPO) through its European Patent Academy. The conference brochure is also included as an attachment to the Opening remarks file.

  1. PCT Reforms Its Patent Filing System

    Institute of Scientific and Technical Information of China (English)

    2004-01-01

    As of January 1,2004,the first critical steps in seekingpatent protection in multiple countries will be easier as aresult of reforms to the international patent filing system.Aseries of reforms to the World Intellectual PropertyOrganisation's(WIPO)Patent Cooperation Treaty(PCT),ranging from a new simplified system of designatingcountries in which patent protection is sought to an enhancedsearch and preliminary examination system,will simplify thecomplex procedure of obtaining patent protection in severa...

  2. 22 CFR 92.72 - Services in connection with patents and patent applications.

    Science.gov (United States)

    2010-04-01

    ... 22 Foreign Relations 1 2010-04-01 2010-04-01 false Services in connection with patents and patent... RELATED SERVICES Miscellaneous Notarial Services § 92.72 Services in connection with patents and patent applications. (a) Affidavit of applicant. The form of the affidavit of an applicant for a United States...

  3. 76 FR 18194 - Notice of Patent Application Deadline for Advanced Battery Technology Related Patents for...

    Science.gov (United States)

    2011-04-01

    ... Department of the Army Notice of Patent Application Deadline for Advanced Battery Technology Related Patents for Exclusive, Partially Exclusive, or Non- Exclusive Licenses; Battery Day Patent Licensing Meeting... patent licensing meeting was subsequently held February 16, 2011 at the SAIC Enterprise Bldg...

  4. Patents in the pharmaceutical industry

    Directory of Open Access Journals (Sweden)

    Jovanović Slobodanka

    2003-01-01

    Full Text Available The pharmaceutical industry is characterized by dynamic development, the existence of big multinational companies and a global market. Such development of the pharmaceutical industry was highly influenced by the introduction of patent protection and compliance with intellectual property regulations. One of the most important international obligations is the TRIPS Agreement.

  5. Patentering af det humane genom

    DEFF Research Database (Denmark)

    Sommer, Tine

    2004-01-01

    Direktiv 98/44/EF om retlig beskyttelse af bioteknologiske opfindelser blev gennemført i dansk ret med ikrafttrædelse den 30. juli 2000. Direktivet indeholder i artikel 5 en central bestemmelse som giver adgang til patent på humane gener. I artikel 5, stk. 3, er indføjet et skærpet krav til...

  6. Labor Mobility and Patenting Activity

    DEFF Research Database (Denmark)

    Kaiser, Ulrich; Kongsted, Hans Christian; Rønde, Thomas

    We measure the quantitative importance of labor mobility as a vehicle for the transmission of knowledge and skills across firms. For this purpose we create a unique data set that matches all applications of Danish firms at the European Patent Office to linked employer-employee register data......, confirming the importance of labor mobility for innovation in the economy....

  7. 48 CFR 970.2703 - Patent rights.

    Science.gov (United States)

    2010-10-01

    ... 48 Federal Acquisition Regulations System 5 2010-10-01 2010-10-01 false Patent rights. 970.2703 Section 970.2703 Federal Acquisition Regulations System DEPARTMENT OF ENERGY AGENCY SUPPLEMENTARY REGULATIONS DOE MANAGEMENT AND OPERATING CONTRACTS Patents, Data, and Copyrights 970.2703 Patent rights....

  8. 15 CFR 734.10 - Patent applications.

    Science.gov (United States)

    2010-01-01

    ... 15 Commerce and Foreign Trade 2 2010-01-01 2010-01-01 false Patent applications. 734.10 Section... EXPORT ADMINISTRATION REGULATIONS § 734.10 Patent applications. The information referred to in § 734.3(b)(3)(iv) of this part is: (a) Information contained in a patent application prepared wholly...

  9. 43 CFR 402.10 - Patent.

    Science.gov (United States)

    2010-10-01

    ... 43 Public Lands: Interior 1 2010-10-01 2010-10-01 false Patent. 402.10 Section 402.10 Public Lands... LANDS IN FEDERAL RECLAMATION PROJECTS Public Lands § 402.10 Patent. When a purchaser has complied fully... and patent and shall state the statutory authority for such liens. The receipt shall be submitted...

  10. 77 FR 4885 - Patent Compensation Board Regulations

    Science.gov (United States)

    2012-02-01

    ... Part 780 RIN 1990-AA33 Patent Compensation Board Regulations AGENCY: Office of the General Counsel... Patent ] Compensation Board regulations to provide that the Secretary of Energy, or a person acting in that position, shall appoint, as needed, a three member panel to serve as the Patent Compensation...

  11. 48 CFR 35.012 - Patent rights.

    Science.gov (United States)

    2010-10-01

    ... 48 Federal Acquisition Regulations System 1 2010-10-01 2010-10-01 false Patent rights. 35.012 Section 35.012 Federal Acquisition Regulations System FEDERAL ACQUISITION REGULATION SPECIAL CATEGORIES OF CONTRACTING RESEARCH AND DEVELOPMENT CONTRACTING 35.012 Patent rights. For a discussion of patent rights,...

  12. 37 CFR 1.705 - Patent term adjustment determination.

    Science.gov (United States)

    2010-07-01

    ... 37 Patents, Trademarks, and Copyrights 1 2010-07-01 2010-07-01 false Patent term adjustment determination. 1.705 Section 1.705 Patents, Trademarks, and Copyrights UNITED STATES PATENT AND TRADEMARK OFFICE, DEPARTMENT OF COMMERCE GENERAL RULES OF PRACTICE IN PATENT CASES Adjustment and Extension of Patent...

  13. The importance of patents to innovation: updated cross-industry comparisons with biopharmaceuticals.

    Science.gov (United States)

    Cockburn, Iain; Long, Genia

    2015-07-01

    Patents have long been considered essential incentives to foster innovation, particularly the development of new prescription drugs, due to the lengthy, costly, and risky nature of the research and development (R&D) process as compared to the lower levels of investment and risk associated with generic drug entry. Compared with other forms of intellectual property protection (such as trade secrets, trademarks, and copyrights) and strategic complementary assets (such as lead time, sales and service, and manufacturing advantages), researchers focused on the US since the 1980s consistently have found patents to be relatively more important to R&D in pharmaceuticals than in other industries. Despite many changes in the market and patent landscape, the most recent data from government surveys and annual surveys of licensing professionals continue to find differential and high importance of patents to biopharmaceutical innovation.

  14. A comprehensive review of patented antileishmanial agents.

    Science.gov (United States)

    Rama, Murugappan; Kumar, Nanjangud Venkatesh Anil; Balaji, Seetharaman

    2015-01-01

    On 14 October 2010, the WHO reported that more than 1 billion people worldwide who live in remote rural areas are affected by neglected tropical diseases. Leishmaniasis is caused by protozoa of more than 20 different species in humans. The three major forms of disease are cutaneous, mucocutaneous and visceral leishmaniasis (VL). Cutaneous leishmaniasis causes an ulcer on exposed parts of the body and it was estimated that 0.7-1.3 million cases occur worldwide annually. Mucocutaneous leishmaniasis leads to destruction of mucous membranes in various parts of the body and it was reported that it occurs widely in South America. VL is a deadly disease and it is characterized by various symptoms, such as anemia, fever, fatigue and weight loss. The WHO estimated that 200,000-400,000 cases per annum of VL occur worldwide. Although different drugs and drug combinations are used for leishmaniasis, US FDA-approved drugs are limited. Miltefosine is the only drug approved for all forms of leishmaniasis and AmBisome(®) is approved for VL. Moreover, the drugs used for leishmaniasis have severe side effects. The article summarizes the patents filed between January 2010 and June 2013 for antileishmanial activity. The article covers only the chemical agents and excludes the vaccines and the peptides. A large number of compounds are filed for antileishmanial activity annually, but only a few are more potent than reference drugs such as miltefosine, pentamidine and metronidazole. In addition, most of the compounds are not as efficient as amphotericin B. Therefore, there is a need for novel compounds that are not only potent than the FDA-approved AmBisome and miltefosine, but are also less toxic and more cost effective in humans. This article provides an eclectic compilation of different classes of compounds that are active against amastigotes (the protozoa form found in humans) for the treatment of leishmaniasis.

  15. New drug applications and abbreviated new drug applications; technical amendment. Final rule; technical amendment.

    Science.gov (United States)

    2009-03-06

    The Food and Drug Administration (FDA) is amending its new drug application (NDA) and abbreviated new drug application (ANDA) regulations to update agency contacts for patent information and patent notifications and to correct an inaccurate cross-reference. This action is being taken to ensure accuracy and clarity in the agency's regulations.

  16. Economic valuation of patents methods and applications

    CERN Document Server

    Munari, F

    2011-01-01

    The Economic Valuation of Patents provides an original and essential analysis of patent valuation, presenting the main methodologies to value patents in different contexts. Starting with an analysis of the relevance of patent valuation from a strategic, economic and legal perspective, the book undertakes a thorough review of the existing financial and qualitative valuation methodologies. The contributing authors, IP experts from academia and business, discuss the application of valuation issues in various contexts such as patent portfolio management, licensing agreements, IP litigation, IP-bac

  17. Patentability of methods of human enhancement

    DEFF Research Database (Denmark)

    Nordberg, Ana

    2015-01-01

    This article explores how to apply patentability rules to human enhancement, particularly focusing on Article 53(c) of the European Patent Convention (EPC). The global size and value of the cosmetic and wellness market and industry allow for the prediction of considerable market potential for human......, and subsequently developed through European Patent Office (EPO) case law, by reference to the dichotomy between therapeutic and cosmetic methods. Subsuming enhancement methods under this patentability rule may be challenging. Ultimately, patentability of human enhancement will depend on the concept of health, its...

  18. US photovoltaic patents: 1991--1993

    Energy Technology Data Exchange (ETDEWEB)

    Pohle, L

    1995-03-01

    This document contains US patents on terrestrial photovoltaic (PV) power applications, including systems, components, and materials as well as manufacturing and support functions. The patent entries in this document were issued from 1991 to 1993. The entries were located by searching USPA, the database of the US Patent Office. The final search retrieved all patents under the class ``Batteries, Thermoelectric and Photoelectric`` and the subclasses ``Photoelectric,`` ``Testing,`` and ``Applications.`` The search also located patents that contained the words ``photovoltaic(s)`` or ``solar cell(s)`` and their derivatives. After the initial list was compiled, most of the patents on the following subjects were excluded: space photovoltaic technology, use of the photovoltaic effect for detectors, and subjects only peripherally concerned with photovoltaic. Some patents on these three subjects were included when ft appeared that those inventions might be of use in terrestrial PV power technologies.

  19. A Case Study of Pharmaceutical Pricing in China: Setting the Price for Off-Patent Originators.

    Science.gov (United States)

    Hu, Shanlian; Zhang, Yabing; He, Jiangjiang; Du, Lixia; Xu, Mingfei; Xie, Chunyan; Peng, Ying; Wang, Linan

    2015-08-01

    This article aims to define a value-based approach to pricing and reimbursement for off-patent originators using a multiple criteria decision analysis (MCDA) approach centered on a systematic analysis of current pricing and reimbursement policies in China. A drug price policy review was combined with a quantitative analysis of China's drug purchasing database. Policy preferences were identified through a MCDA performed by interviewing well-known academic experts and industry stakeholders. The study findings indicate that the current Chinese price policy includes cost-based pricing and the establishment of maximum retail prices and premiums for off-patent originators, whereas reference pricing may be adopted in the future. The literature review revealed significant differences in the dissolution profiles between originators and generics; therefore, dissolution profiles need to be improved. Market data analysis showed that the overall price ratio of generics and off-patent originators was around 0.54-0.59 in 2002-2011, with a 40% price difference, on average. Ten differentiating value attributes were identified and MCDA was applied to test the impact of three pricing policy scenarios. With the condition of implementing quality consistency regulations and controls, a reduction in the price gap between high-quality off-patent products (including originator and generics) seemed to be the preferred policy. Patents of many drugs will expire within the next 10 years; thus, pricing will be an issue of importance for off-patent originators and generic alternatives.

  20. Idea on patent ; It is high time to stress quality

    Energy Technology Data Exchange (ETDEWEB)

    NONE

    2012-03-15

    This book deals with patent stressing on the quality, which includes from idea to technical business, It's simple to register the computer program, why do patent lawyer appoint the patent attorney's office? construction of patent right range, a good patent and a bad patent, strong patent and weak patent. It doesn't allow for Dus to use as we like, each patent has different value, Let's write technical specifications, advice on talking for invention with a patent attorney's office and what kind of task do intellectual property division do?.

  1. Information Extraction From Chemical Patents

    Directory of Open Access Journals (Sweden)

    Sandra Bergmann

    2012-01-01

    Full Text Available The development of new chemicals or pharmaceuticals is preceded by an indepth analysis of published patents in this field. This information retrieval is a costly and time inefficient step when done by a human reader, yet it is mandatory for potential success of an investment. The goal of the research project UIMA-HPC is to automate and hence speed-up the process of knowledge mining about patents. Multi-threaded analysis engines, developed according to UIMA (Unstructured Information Management Architecture standards, process texts and images in thousands of documents in parallel. UNICORE (UNiform Interface to COmputing Resources workflow control structures make it possible to dynamically allocate resources for every given task to gain best cpu-time/realtime ratios in an HPC environment.

  2. Patent Abstract Digest. Volume IV.

    Science.gov (United States)

    1982-11-01

    WITH END 3.8=2410 7/1974 Moay ............... 331/94S PE TAPERED WIGGLER STENT OTHER PUBLICATIONS [75] In ventors: John M. J. Malley, Palo Alto; Lo R...34, Oct. 7, 1966, pp. 267-284. 9 Claims, 3 Drawing Figares to: U.S. eettn fteArI=A19 MO.Hdf Stmet S.W. Wah.. 11C I02 Mpies of this patent are satilable W

  3. Vietnamese Women's Struggle to Access Antiretroviral Drugs in a Context of Free Treatment

    DEFF Research Database (Denmark)

    Nguyen, Nam Thi Thu; Rasch, Vibeke; Bygbjerg, Ib Christian

    2013-01-01

    provided, they were not always accessible for women in need. A variety of factors at the population and health system level interacted in ways that often made access to ARV drugs a complicated and time-consuming process. We have suggested changes that could be made at the health system level that may help...... facilitate women's ability to access treatment....

  4. Potential drug–drug interactions in HIV-perinatally infected adolescents on antiretroviral therapy in Buenos Aires, Argentina

    Directory of Open Access Journals (Sweden)

    Ezequiel Cordova

    2014-11-01

    Full Text Available Introduction: An increasing number of treatment-experienced perinatally HIV-infected adolescents (PHA are being transitioned from paediatric centres to adult HIV-care [1]. Most of them had been heavily exposed to antiretroviral drugs (ARVs, harbour drug-resistant viruses and require non-antiretroviral medication due to comorbidities [2]. This may predispose for clinically significant drug–drug interactions (CSDDIs [3]. There are no studies concerning CSDDIs in PHA. We aimed to evaluate the prevalence of concomitant medications and CSDDIs in PHA who were transitioned for adult HIV-care to the Infectious Diseases Unit, Cosme Argerich Hospital, Buenos Aires City, Argentina. Materials and Methods: Descriptive pilot cross-sectional study (March to June 2014. PHA under ARVs at the time of the study were assessed for concomitant medication. CSDDIs were screened and categorized using the University of Liverpool Drug Interactions Program (www.hiv-druginteractions.org [4]. Results: Forty-five patients were included. Female sex: 53%. Median (IQR age: 20 years (18–22. CDC-stage C was observed in 27 (79%; 50% had ≥1 comorbidities including 3 with HCV co-infection. Drug abuse was observed in 6 (13%. The median of prior ARV regimens was 3 (3–5. Current ARV regimen included: PI: 87%, NNRTI: 27%, INSTI: 20%, enfuvirtide: 7% and CCR5 inhibitor: 4%. Median CD4 T-cell count: 568 cells/mL (279–771. Viral load <50 copies/mL: 80%. Sixty percent (27/45 had ≥1 co-medications (median 1. The most frequent co-medications were NSAIDs (40%, hormonal therapy (19% and antimicrobials (19%. Use of herbal supplements was observed in 10 (22%. Overall, 23 (51% had ≥ 1 CSDDIs: 19/27 (70% with co-medication (orange flag=18 and red flag=1; and 2/10 (20% with herbal supplements. ARV–ARV interactions were observed in 4/45 (9%: unboosted atazanavir+tenofovir (n=2, unboosted atazanavir+efavirenz (n=1 and lopinavir/ritonavir+efavirenz (n=1 (all orange flag. Considering

  5. Nikola Tesla’s Patent Applications for Which Patents Were Not Granted

    Directory of Open Access Journals (Sweden)

    S. Šarboh

    2013-06-01

    Full Text Available In this paper are presented the results of an investigation directed to discovering and identifying Nikola Tesla’s patent applications filed with the United States Patent Office, but for which appropriate patents were not granted to him. The investigation showed that Tesla had at least 33 American patent applications for which patents were not granted, that shed a new light on his inventive activities in the United States of America. The subject matter of these patent applications are different Tesla’s inventions in the fields of electrical engineering, mechanical engineering and processing technology, more precisely metallurgy.

  6. The Tiger Awakens: The Tumultuous Transformation of India’s Patent System and the Rise of Indian Pharmaceutical Innovation

    OpenAIRE

    Janice M. Mueller

    2007-01-01

    The first day of January 2005 marked a dramatic turning point in the history of India. By deliberately excluding pharmaceutical products from patent protection for the previous 34 years, India became a world leader in high-quality generic drug manufacturing. But India’s entry into the global economy at the end of the 20th century, as evidenced by membership in the World Trade Organization (WTO), compelled the nation to once again award patents on drugs. Moreover, India henceforth would ...

  7. Antibody-drug conjugates: Intellectual property considerations.

    Science.gov (United States)

    Storz, Ulrich

    2015-01-01

    Antibody-drug conjugates are highly complex entities that combine an antibody, a linker and a toxin. This complexity makes them demanding both technically and from a regulatory point of view, and difficult to deal with in their patent aspects. This article discusses different issues of patent protection and freedom to operate with regard to this promising new class of drugs.

  8. Imatinib Case: Technical and Legal Analysis of Patent Prosecution in Colombia

    Directory of Open Access Journals (Sweden)

    Luisa Fernanda Díaz Pinilla

    2016-12-01

    Full Text Available Imatinib –marketed as Gleevec™ or Glivec™– is a drug mainly used to treat a condition called Acute myeloid leukemia (AML. Its patent protection in Colombia, as a polymorphic entity of mesylate salt –called Beta polymorphous–, exhibits a divergent procedure due to differences between Colombian Patent Office (SIC and State Council judgment given in order to deny patent right in 2003 and then revoking such denial and ordering patent grant in 2012, respectively. This paper evaluates technical regards associated with each institution arguments and legal topics considered to conclude the instance. Findings show that studies carried out in relation to testimonial evidence and expert advice –that were submitted by two experts –one of them– directly related to the patent application– guided Colombian State Council in order to grant the polymorphous patent, even when there was no clear evidence of inventive step, especially referred as a compound surprising technical effect. Furthermore, the paper includes some comparisons related to legal instances that are in charge of studying patent office decisions in other jurisdictions and protection given –or not– to polymorphous entities in other countries.

  9. An interdisciplinary framework for measuring and supporting adherence in HIV prevention trials of ARV-based vaginal rings

    Directory of Open Access Journals (Sweden)

    Kathleen M MacQueen

    2014-09-01

    Full Text Available Introduction: Product adherence and its measurement have emerged as a critical challenge in the evaluation of new HIV prevention technologies. Long-acting ARV-based vaginal rings may simplify use instructions and require less user behaviour, thereby facilitating adherence. One ARV-based ring is in efficacy trials and others, including multipurpose rings, are in the pipeline. Participant motivations, counselling support and measurement challenges during ring trials must still be addressed. In previous HIV prevention trials, this has been done largely using descriptive and post-hoc methods that are highly variable and minimally evaluated. We outline an interdisciplinary framework for systematically investigating promising strategies to support product uptake and adherence, and to measure adherence in the context of randomized, blinded clinical trials. Discussion: The interdisciplinary framework highlights the dual use of adherence measurement (i.e. to provide feedback during trial implementation and to inform interpretation of trial findings and underscores the complex pathways that connect measurement, adherence support and enacted adherence behaviour. Three inter-related approaches are highlighted: 1 adherence support – sequential efforts to define motivators of study product adherence and to develop, test, refine and evaluate adherence support messages; 2 self-reported psychometric measures – creation of valid and generalizable measures based in easily administered scales that capture vaginal ring use with improved predictive ability at screening, baseline and follow-up that better engage participants in reporting adherence; and 3 more objective measurement of adherence – real-time adherence monitoring and cumulative measurement to correlate adherence with overall product effectiveness through innovative designs, models and prototypes using electronic and biometric technologies to detect ring insertion and/or removal or expulsion

  10. Inventions and patents: a practical tutorial.

    Science.gov (United States)

    Tidwell, J Lille; Liotta, Lance A

    2012-01-01

    Patents are designed to protect and encourage creativity and innovation. Patenting a biomedical discovery can be a requirement before a pharmaceutical company or biotech entity will invest in the lengthy and costly clinical testing necessary to achieve patient benefit. Although scientists and clinicians are well versed in research publication requirements, patent descriptions and claims are formatted in a manner quite different from a research paper. Patents require (a) a series of logical statements clearly delineating the boundaries of the novel aspects of the invention and (b) sufficient disclosure of the invention so that it can be reproduced by others. Patents are granted only for inventions that meet three conditions: novelty, nonobviousness, and usefulness. This chapter provides basic guidelines and definitions of technology transfer: inventions, inventorship, and patent filing, which are summarized using a question and answer format.

  11. HIV-1 antiretroviral drug resistance in recently infected patients in Abidjan, Côte d'Ivoire: A 4-year survey, 2002-2006.

    Science.gov (United States)

    Toni, Thomas d'Aquin; Masquelier, Bernard; Minga, Albert; Anglaret, Xavier; Danel, Christine; Coulibaly, Ali; Chenal, Henri; Dabis, François; Salamon, Roger; Fleury, Hervé J

    2007-09-01

    We performed HIV-1 drug resistance genotypic analysis of viral isolates from 100 antiretroviral (ARV)-naive, recently HIV-1-infected (between 2002 and 2006) individuals from Abidjan (Côte d'Ivoire). The overall prevalence of HIV-1 variants with resistance mutations to reverse transcriptase, protease, or fusion inhibitors was 6%. The majority of isolates were CRF02_AG. Compared with a previous study carried out by our group in 2001-2002 in a similar population in Abidjan, our findings confirm the circulation and transmission of HIV-1 carrying key ARV drug resistance mutation.

  12. Expression of Genes for Drug Transporters in the Human Female Genital Tract and Modulatory Effect of Antiretroviral Drugs.

    Directory of Open Access Journals (Sweden)

    Karolin Hijazi

    Full Text Available Anti-retroviral (ARV -based microbicides are one of the strategies pursued to prevent HIV-1 transmission. Delivery of ARV drugs to subepithelial CD4+ T cells at concentrations for protection is likely determined by drug transporters expressed in the cervicovaginal epithelium. To define the role of drug transporters in mucosal disposition of topically applied ARV-based microbicides, these must be tested in epithelial cell line-based biopharmaceutical assays factoring the effect of relevant drug transporters. We have characterised gene expression of influx and efflux drug transporters in a panel of cervicovaginal cell lines and compared this to expression in cervicovaginal tissue. We also investigated the effect of dapivirine, darunavir and tenofovir, currently at advanced stages of microbicides development, on expression of drug transporters in cell lines. Expression of efflux ABC transporters in cervical tissue was best represented in HeLa, Ect1/E6E7 and End1/E6E7 cell lines. Expression of influx OCT and ENT transporters in ectocervix matched expression in Hela while expression of influx SLCO transporters in vagina was best reflected in VK2/E6E7 cell line. Stimulation with darunavir and dapivirine upregulated MRP transporters, including MRP5 involved in transport of tenofovir. Dapivirine also significantly downregulated tenofovir substrate MRP4 in cervical cell lines. Treatment with darunavir and dapivirine showed no significant effect on expression of BCRP, MRP2 and P-glycoprotein implicated in efflux of different ARV drugs. Darunavir strongly induced expression in most cell lines of CNT3 involved in cell uptake of nucleotide/nucleoside analogue reverse transcriptase inhibitors and SLCO drug transporters involved in cell uptake of protease inhibitors. This study provides insight into the suitability of cervicovaginal cell lines for assessment of ARV drugs in transport kinetics studies. The modulatory effect of darunavir and dapivirine on

  13. Writing reports to facilitate patent applications.

    Energy Technology Data Exchange (ETDEWEB)

    Libman, George H.; Doerry, Armin Walter

    2004-06-01

    Brief disclosures may often be sufficient for the filing of a Technical Advance with Sandia's Intellectual Property Center, but still be inadequate to facilitate an optimum patent application where more detail and explanation are required. Consequently, the crafting of a patent application may require considerably more additional interaction between the application preparer and the inventors. This inefficiency can be considerably mitigated if the inventors address some critical aspects of a patent application when they write a technical report.

  14. Knowledge transfer and university patents in Mexico

    OpenAIRE

    María Guadalupe Calderón-Martínez; José García-Quevedo

    2013-01-01

    Purpose The aim of this paper is to examine the factors that influence the ability of Mexican public universities to generate patents. Academic patents are deserving of increasing interest as channels for the transfer of knowledge from universities to firms. Design/methodology/approach A review of the international literature on the main factors that explain the production of patents was undertaken. On the basis of this information, a database for 80 Mexican universities was built and a mod...

  15. Persistent Confusion and Controversy Surrounding Gene Patents

    Science.gov (United States)

    Guerrini, Christi J.; Majumder, Mary A.; McGuire, Amy L.

    2016-01-01

    There is persistent confusion and controversy surrounding basic issues of patent law relevant to the genomics industry. Uncertainty and conflict can lead to the adoption of inefficient practices and exposure to liability. The development of patent-specific educational resources for industry members, as well as the prompt resolution of patentability rules unsettled by recent U.S. Supreme Court decisions, are therefore urgently needed. PMID:26849516

  16. The Coordination of Independently-Owned Vacuum Tube Patents in the Alleged Early Radio Patent Thicket

    DEFF Research Database (Denmark)

    Howells, John; Ron D, Katznelson

    present in radio development, 1905-1920, with numerous allegations of an impasse in bargaining the necessary patent rights for legal development. This paper seeks to determine with new precision how entrepreneurs and managers actually managed patent rights in this scenario. Accordingly, this paper re......-examines the legal trajectories and entrepreneurial exploitation of these patents with a focus on vacuum tube technology where Fleming’s diode patent ‘overlapped’ with earlier prior art and, dependent on court decisions, with later commercial implementations of De Forest’s triode patents. We show, by means...... of the relevant historical record, patent claims, litigation records and other relevant law, how the ‘overlapping’ patent rights were resolved by the courts and by the immunity of suppliers to the Government from patent infringement liability. We trace the cross-licensing agreements between the different radio...

  17. US Photovoltaic Patents, 1988--1990

    Energy Technology Data Exchange (ETDEWEB)

    1991-12-01

    This document contains US patents on terrestrial photovoltaic (PV) power applications, including systems, components, and materials, as well as manufacturing and support functions. The patent entries in this document were issued from 1988 through 1990. The entries were located by searching USPA, the data base of the US Patent Office. The final search retrieved all patents under the class Batteries, Thermoelectric and Photoelectric'' and the subclasses Photoelectric,'' Testing,'' and Applications.'' The search also located patents that contained the words photovoltaic(s)'' or solar cell(s)'' and their derivatives. A manual search of the patents in the Solar Energy Research Institute (SERI) patent file augmented the data base search. After the initial list was compiled, most of the patents on the following subjects were excluded: space photovoltaic technology, use of the photovoltaic effect for detectors and subjects only peripherally concerned with photovoltaics. Some patents on these three subjects were included when it appeared that those inventions might be of use in terrestrial PV power technologies.

  18. Performance of Patenting Firms in Danish Manufacturing

    DEFF Research Database (Denmark)

    Madsen, Erik Strøjer; Smith, Valdemar; Nielsen, Anders Østergaard

    2000-01-01

    -patenting firms within the manufacturing sector in Denmark. Performance is measured both by growth in employment as well as in the return on equity and profit share in turnover. The results suggest that differences in performance of patenting and non-patenting firms are very small, which questions the political......Most countries focus on industries with high technology and the governments grant subsidies to innovating firms. However, there has been remarkable few studies of the performance of innovative firms or industries. This study examines the performance of patent active firms compared to the non...

  19. US Photovoltaic Patents, 1988--1990

    Energy Technology Data Exchange (ETDEWEB)

    1991-12-01

    This document contains US patents on terrestrial photovoltaic (PV) power applications, including systems, components, and materials, as well as manufacturing and support functions. The patent entries in this document were issued from 1988 through 1990. The entries were located by searching USPA, the data base of the US Patent Office. The final search retrieved all patents under the class ``Batteries, Thermoelectric and Photoelectric`` and the subclasses ``Photoelectric,`` ``Testing,`` and ``Applications.`` The search also located patents that contained the words ``photovoltaic(s)`` or ``solar cell(s)`` and their derivatives. A manual search of the patents in the Solar Energy Research Institute (SERI) patent file augmented the data base search. After the initial list was compiled, most of the patents on the following subjects were excluded: space photovoltaic technology, use of the photovoltaic effect for detectors and subjects only peripherally concerned with photovoltaics. Some patents on these three subjects were included when it appeared that those inventions might be of use in terrestrial PV power technologies.

  20. 37 CFR 1.177 - Issuance of multiple reissue patents.

    Science.gov (United States)

    2010-07-01

    ... 37 Patents, Trademarks, and Copyrights 1 2010-07-01 2010-07-01 false Issuance of multiple reissue patents. 1.177 Section 1.177 Patents, Trademarks, and Copyrights UNITED STATES PATENT AND TRADEMARK OFFICE, DEPARTMENT OF COMMERCE GENERAL RULES OF PRACTICE IN PATENT CASES National Processing Provisions Reissues §...

  1. 37 CFR 1.81 - Drawings required in patent application.

    Science.gov (United States)

    2010-07-01

    ... 37 Patents, Trademarks, and Copyrights 1 2010-07-01 2010-07-01 false Drawings required in patent application. 1.81 Section 1.81 Patents, Trademarks, and Copyrights UNITED STATES PATENT AND TRADEMARK OFFICE, DEPARTMENT OF COMMERCE GENERAL RULES OF PRACTICE IN PATENT CASES National Processing Provisions The...

  2. 37 CFR 1.41 - Applicant for patent.

    Science.gov (United States)

    2010-07-01

    ... 37 Patents, Trademarks, and Copyrights 1 2010-07-01 2010-07-01 false Applicant for patent. 1.41 Section 1.41 Patents, Trademarks, and Copyrights UNITED STATES PATENT AND TRADEMARK OFFICE, DEPARTMENT OF COMMERCE GENERAL RULES OF PRACTICE IN PATENT CASES National Processing Provisions Who May Apply for...

  3. 37 CFR 1.315 - Delivery of patent.

    Science.gov (United States)

    2010-07-01

    ... 37 Patents, Trademarks, and Copyrights 1 2010-07-01 2010-07-01 false Delivery of patent. 1.315 Section 1.315 Patents, Trademarks, and Copyrights UNITED STATES PATENT AND TRADEMARK OFFICE, DEPARTMENT OF COMMERCE GENERAL RULES OF PRACTICE IN PATENT CASES National Processing Provisions Allowance and Issue...

  4. 77 FR 37879 - Cooperative Patent Classification External User Day

    Science.gov (United States)

    2012-06-25

    ... Patent and Trademark Office Cooperative Patent Classification External User Day AGENCY: United States Patent and Trademark Office, Commerce. ACTION: Notice. SUMMARY: The United States Patent and Trademark Office (USPTO) is hosting a Cooperative Patent Classification (CPC) External User Day event at...

  5. 37 CFR 1.314 - Issuance of patent.

    Science.gov (United States)

    2010-07-01

    ... 37 Patents, Trademarks, and Copyrights 1 2010-07-01 2010-07-01 false Issuance of patent. 1.314 Section 1.314 Patents, Trademarks, and Copyrights UNITED STATES PATENT AND TRADEMARK OFFICE, DEPARTMENT OF COMMERCE GENERAL RULES OF PRACTICE IN PATENT CASES National Processing Provisions Allowance and Issue...

  6. 37 CFR 11.9 - Limited recognition in patent matters.

    Science.gov (United States)

    2010-07-01

    ... 37 Patents, Trademarks, and Copyrights 1 2010-07-01 2010-07-01 false Limited recognition in patent matters. 11.9 Section 11.9 Patents, Trademarks, and Copyrights UNITED STATES PATENT AND TRADEMARK OFFICE, DEPARTMENT OF COMMERCE REPRESENTATION OF OTHERS BEFORE THE UNITED STATES PATENT AND TRADEMARK...

  7. 37 CFR 1.46 - Assigned inventions and patents.

    Science.gov (United States)

    2010-07-01

    ... 37 Patents, Trademarks, and Copyrights 1 2010-07-01 2010-07-01 false Assigned inventions and patents. 1.46 Section 1.46 Patents, Trademarks, and Copyrights UNITED STATES PATENT AND TRADEMARK OFFICE, DEPARTMENT OF COMMERCE GENERAL RULES OF PRACTICE IN PATENT CASES National Processing Provisions Who May...

  8. 37 CFR 1.215 - Patent application publication.

    Science.gov (United States)

    2010-07-01

    ... 37 Patents, Trademarks, and Copyrights 1 2010-07-01 2010-07-01 false Patent application publication. 1.215 Section 1.215 Patents, Trademarks, and Copyrights UNITED STATES PATENT AND TRADEMARK OFFICE, DEPARTMENT OF COMMERCE GENERAL RULES OF PRACTICE IN PATENT CASES National Processing Provisions...

  9. 37 CFR 3.81 - Issue of patent to assignee.

    Science.gov (United States)

    2010-07-01

    ... 37 Patents, Trademarks, and Copyrights 1 2010-07-01 2010-07-01 false Issue of patent to assignee. 3.81 Section 3.81 Patents, Trademarks, and Copyrights UNITED STATES PATENT AND TRADEMARK OFFICE... of patent to assignee. (a) With payment of the issue fee: An application may issue in the name of...

  10. Patent Abstract Digest. Volume I.

    Science.gov (United States)

    1979-04-30

    MPOSITIONS3.340.233 9/1967 Leavilt................260/590 D) [75] Inventors: Fred E. Arnold, Centerville; 3.458.548 7/,969 Carlson ...... .. . ....... 260/590 D...l1969 Colt tiu 356/112 x 1,564,257 2/i971 9-rrye tl1 250,.211 1731 Inventor: Theodor E. Wlrtsa, Chelmsford, ’.116.00D 6/1474 Fiedler . 356/12 Man...1561 References Cited HETEROCYCLIC POLYMERS U.S. PATENT DOCUMENTS Inventors: Fred E. Arold, Centerville. Ohio; 3,376,257 4/1968 Nakanishi el at

  11. Interactive overlay maps for US Patent (USPTO) data based on International Patent Classifications (IPC)

    NARCIS (Netherlands)

    L. Leydesdorff; D. Kushnir; I. Rafols

    2014-01-01

    We report on the development of an interface to the US Patent and Trademark Office (USPTO) that allows for the mapping of patent portfolios as overlays to basemaps constructed from citation relations among all patents contained in this database during the period 1976-2011. Both the interface and the

  12. Pre-empted Patents, Infringed Patents and Firms’ Participation in Markets for Technology

    DEFF Research Database (Denmark)

    Grimpe, Christoph; Hussinger, Katrin

    2014-01-01

    In recent years, firms have increasingly contributed to and been confronted with a patent landscape characterized by numerous but marginal inventions, overlapping claims and patent fences. As a result, firms risk their patent applications to be pre-empted or to be infringed upon by rivals. While...

  13. Using Patent Classification to Discover Chemical Information in a Free Patent Database: Challenges and Opportunities

    Science.gov (United States)

    Ha¨rtinger, Stefan; Clarke, Nigel

    2016-01-01

    Developing skills for searching the patent literature is an essential element of chemical information literacy programs at the university level. The present article creates awareness of patents as a rich source of chemical information. Patent classification is introduced as a key-component in comprehensive search strategies. The free Espacenet…

  14. 78 FR 72872 - Notice of Intent To Grant Partially Exclusive Patent License; ICAP Patent Brokerage, LLC

    Science.gov (United States)

    2013-12-04

    ... Department of the Navy Notice of Intent To Grant Partially Exclusive Patent License; ICAP Patent Brokerage... gives notice of its intent to grant to ICAP Patent Brokerage, LLC, a revocable, nonassignable, partially exclusive license in the United States to practice the Government-Owned inventions described in U.S....

  15. 37 CFR 3.24 - Requirements for documents and cover sheets relating to patents and patent applications.

    Science.gov (United States)

    2010-07-01

    ... 37 Patents, Trademarks, and Copyrights 1 2010-07-01 2010-07-01 false Requirements for documents and cover sheets relating to patents and patent applications. 3.24 Section 3.24 Patents, Trademarks, and Copyrights UNITED STATES PATENT AND TRADEMARK OFFICE, DEPARTMENT OF COMMERCE GENERAL...

  16. 37 CFR 1.378 - Acceptance of delayed payment of maintenance fee in expired patent to reinstate patent.

    Science.gov (United States)

    2010-07-01

    ... 37 Patents, Trademarks, and Copyrights 1 2010-07-01 2010-07-01 false Acceptance of delayed payment of maintenance fee in expired patent to reinstate patent. 1.378 Section 1.378 Patents, Trademarks, and Copyrights UNITED STATES PATENT AND TRADEMARK OFFICE, DEPARTMENT OF COMMERCE GENERAL RULES...

  17. Valuable Patents for U.S. Businesses: A Catalog of DTRC Patents Available for Licensing by the Private Sector

    Science.gov (United States)

    1991-10-01

    Veazey PATENT NO: 4,553,037 DATE OF PATENT Nov. 12, 1985 TITLE: Transverse Waterjet Propulsion with Auxiliary Inlets and Impellers INVENTOR(S): John G...Lee PATENT NO: 4,398,687 DATE OF PATENT: Aug. 16, 1983 DTRC-91 /CT07 19 Valuable Patents, A Catalog TITLE: Mono-Element Combined Supercritical High

  18. Patent foramen ovale: Unanswered questions.

    Science.gov (United States)

    Mojadidi, Mohammad Khalid; Christia, Panagiota; Salamon, Jason; Liebelt, Jared; Zaman, Tarique; Gevorgyan, Rubine; Nezami, Nariman; Mojaddedi, Sanaullah; Elgendy, Islam Y; Tobis, Jonathan M; Faillace, Robert

    2015-12-01

    The foramen ovale is a remnant of the fetal circulation that remains patent in 20-25% of the adult population. Although long overlooked as a potential pathway that could produce pathologic conditions, the presence of a patent foramen ovale (PFO) has been associated with a higher than expected frequency in a variety of clinical syndromes including cryptogenic stroke, migraines, sleep apnea, platypnea-orthodeoxia, deep sea diving associated decompression illness, and high altitude pulmonary edema. A unifying hypothesis is that a chemical or particulate matter from the venous circulation crosses the PFO conduit between the right and left atria to produce a variety of clinical syndromes. Although observational studies suggest a therapeutic benefit of PFO closure compared to medical therapy alone in patients with cryptogenic stroke, 3 randomized controlled trials (RCTs) did not confirm the superiority of PFO closure for the secondary prevention of stroke. However, meta-analyses of these RCTs demonstrate a significant benefit of PFO closure over medical therapy alone. Similarly, observational studies provide support for PFO closure for symptomatic relief of migraines. But one controversial randomized study failed to replicate the results of the observational studies while another two demonstrated a partial benefit. The goal of this review is to discuss the clinical conditions associated with PFO and provide internists and primary care physicians with current data on PFO trials, and clinical insight to help guide their patients who are found to have a PFO on echocardiographic testing.

  19. Recent patents in flavor microencapsulation.

    Science.gov (United States)

    Feng, Tao; Xiao, Zuobing; Tian, Huaixiang

    2009-11-01

    Many aroma compounds, used to flavor food products, are used in a solid state, after encapsulation. Synthetic or natural polymers are the common matrices used to entrap these volatiles. This paper reviews the recent patents of versatile matrices and methods used in flavor microencapsulation. The encapsulation ratio depends on both the carriers' physicochemical properties and the characteristics of the aroma compound. The patents about flavor encapsulation methods are spray drying, fluidized bed coating, melt extrusion, complex coacervation, aqueous diffusion and novel fat-coating etc. All these methods have both advantages and disadvantages. In brief, spray drying is very convenient but unsuitable for heat sensitive flavor and stored with moisture instability. Fluidized bed coating is costly but having better storage stability. Melt extrusion is suitable for large-scale production but having bad particle size distribution. Complex coacervation has good capsule size uniformity but controversial safety. Aqueous diffusion has excellent safety but low efficient encapsulation. Novel fat-coating has good encapsulation efficiency but uncontrollable size distribution.

  20. The revival of Phage Therapy to fight Antimicrobial Resistance – Part II: What about patent protection and alternative incentives?

    DEFF Research Database (Denmark)

    Minssen, Timo

    2014-01-01

    eligibility, i.e. Bilski v. Kappos (2010), Mayo v. Prometheus (2012) , AMP v. Myriad (2013) and Alice v. CLS (2014). Most relevant in this context are the decisions in Prometheus and Myriad. In its unanimous Prometheus opinion, the Supreme Court held that a claim to a “natural law” is not patentable unless...... into patentable subject matter. That the claims were directed to a specific regime optimizing the dosage for each patient to reduce side-effects of a particular drug (i.e. a typical claim in personalized medicine) did not rescue the patent. Then, in Myriad, the Court unanimously held that patent claims directed...... occurring viruses, such as phages, and the processes in which these are used. Myriad and Prometheus could thus have a fundamental impact on many patent portfolios relating to phage therapy and thus business involvement. In that context, it is important to realize that an important component of proper use...

  1. The Patent Literature As A Shortcut To Identify Knowledge Suppliers

    DEFF Research Database (Denmark)

    Søberg, Peder Veng

    The present paper explores characteristics of valuable patents that have been subject to litigation which resulted in some of the largest fines to patent infringers reported in history. The valuable patents are compared with less valuable patents in order to identify new methods of evaluating pat...... patents which decreases the time span between a patent is filed and its value can be evaluated when searching the patent literature. A potential benefit thereof could be that the patent literature could become relevant in order to identify potential knowledge suppliers.......The present paper explores characteristics of valuable patents that have been subject to litigation which resulted in some of the largest fines to patent infringers reported in history. The valuable patents are compared with less valuable patents in order to identify new methods of evaluating...

  2. 78 FR 30304 - Federal Acquisition Regulation; Information Collection; Patents

    Science.gov (United States)

    2013-05-22

    ... Regulation; Information Collection; Patents AGENCY: Department of Defense (DOD), General Services... requirement concerning patents. DATES: Submit comments on or before July 22, 2013. ADDRESSES: Submit comments identified by Information Collection 9000- 0096, Patents, by any of the following methods:...

  3. Pre-empted Patents, Infringed Patents and Firms’ Participation in Markets for Technology

    DEFF Research Database (Denmark)

    Grimpe, Christoph; Hussinger, Katrin

    2014-01-01

    In recent years, firms have increasingly contributed to and been confronted with a patent landscape characterized by numerous but marginal inventions, overlapping claims and patent fences. As a result, firms risk their patent applications to be pre-empted or to be infringed upon by rivals. While...... patents on firms’ engagement in in- and cross-licensing. Based on a sample of more than 1100 German manufacturing firms our results show that firms engage in in-licensing as a reaction to pre-empted patents and in cross-licensing if their protected IP was infringed upon. However, these effects vary...

  4. Behavioral Economics Matters for HIV Research: The Impact of Behavioral Biases on Adherence to Antiretrovirals (ARVs).

    Science.gov (United States)

    Linnemayr, Sebastian; Stecher, Chad

    2015-11-01

    Behavioral economics (BE) has been used to study a number of health behaviors such as smoking and drug use, but there is little knowledge of how these insights relate to HIV prevention and care. We present novel evidence on the prevalence of the common behavioral decision-making errors of present-bias, overoptimism, and information salience among 155 Ugandan HIV patients, and analyze their association with subsequent medication adherence. 36 % of study participants are classified as present-biased, 21 % as overoptimistic, and 34 % as having salient HIV information. Patients displaying present-bias were 13 % points (p = 0.006) less likely to have adherence rates above 90 %, overoptimistic clients were 9 % points (p = 0.04) less likely, and those not having salient HIV information were 17 % points (p < 0.001) less likely. These findings indicate that BE may be used to screen for future adherence problems and to better design and target interventions addressing these behavioral biases and the associated suboptimal adherence.

  5. Chinese Patent Medicine Liu Wei Di Huang Wan Combined with Antihypertensive Drugs, a New Integrative Medicine Therapy, for the Treatment of Essential Hypertension: A Systematic Review of Randomized Controlled Trials

    Directory of Open Access Journals (Sweden)

    Jie Wang

    2012-01-01

    Full Text Available Objectives. To assess the beneficial and adverse effects of Liu Wei Di Huang Wan (LWDHW, combined with antihypertensive drugs, for essential hypertension. Methods. Five major electronic databases were searched up to August 2012 to retrieve any potential randomized controlled trials designed to evaluate the clinical effectiveness of LWDHW combined with antihypertensive drugs for essential hypertension reported in any language, with main outcome measures as blood pressure. The quality of the included studies was assessed with the Jadad scale and a customized standard quality assessment scale. Results. 6 randomized trials were included. The methodological quality of the trials was evaluated as generally low. The pooled results showed that LWDHW combined with antihypertensive drugs was more effective in blood pressure and the scale for TCM syndrome and symptom differentiation scores compared with antihypertensive drugs alone. Most of the trials did not report adverse events, and the safety is still uncertain. Conclusions. LWDHW combined with antihypertensive drugs appears to be effective in improving blood pressure and symptoms in patients with essential hypertension. However, the evidence remains weak due to the poor methodological quality of the included studies.

  6. Patenting life forms and preserving human values.

    Science.gov (United States)

    Lisson, E L

    1981-01-01

    Utilitarian, pragmatic, and legal considerations, while valid, must not overshadow Catholic moral theology's concern about patenting life in view of natural law. The fundamental issues remain: Does technology diminish human values? Does the patent system's own monopolistic power pose its own risk?

  7. 75 FR 17380 - Patents Ombudsman Pilot Program

    Science.gov (United States)

    2010-04-06

    ... contact the various help desks for assistance (e.g., the Patents Electronic Business Center (EBC) for any assistance on electronic filings), rather than contacting the ombudsman. See Manual of Patent Examining... complaints to ensure each is handled within ten business days; (3) to provide feedback and early...

  8. The Unified Patent Court (UPC) in Action

    DEFF Research Database (Denmark)

    Petersen, Clement Salung; Schovsbo, Jens Hemmingsen; Riis, Thomas

    2015-01-01

    The new common judiciary for European patents (UPC) will play a crucial role in the future European patent system. The UPC will be a very specialised court that i.a. recruits judges from specialists’ circles and has as part of its mission to develop a coherent and autonomous body of case law...

  9. Revising the Complex Economics of Patent Scope

    DEFF Research Database (Denmark)

    Howells, John

    Merges and Nelson claim to have provided an empirically grounded argument that pioneer patents of 'broad' scope are used to block technological development. It is widely understood in both law and economics that they have, as they claim, faulted Kitch's 'prospect theory' of patents, a theory that...... of development. This interpretation restores the credibility of Kitch's prospect theory of patent function and emphasises that the administration of the patent institution should be designed to support the prospect function of patents.......Merges and Nelson claim to have provided an empirically grounded argument that pioneer patents of 'broad' scope are used to block technological development. It is widely understood in both law and economics that they have, as they claim, faulted Kitch's 'prospect theory' of patents, a theory...... that a function of patents is to enable the coordinated development of novel technical ideas. This article is a critical review of Merges and Nelson's historical empirical evidence. I find that, first, 'broad' scope is only implicated in one of the examples cited by Merges and Nelson as supportive evidence...

  10. The Cross-Referenced Patent Cooperation Treaty

    NARCIS (Netherlands)

    Mulder, Cees

    2016-01-01

    The Cross-Referenced Patent Cooperation Treaty covers the Patent Cooperation Treaty (PCT) and the Regulations under the PCT. The large number of references in the articles and rules makes the PCT difficult to read. The idea behind the book is to add cross-references to the articles and rules,

  11. Nanotechnology and patents in agriculture, food technology, nutrition and medicine - advantages and risks: worldwide patented nano- and absorber particles in food nutrition and agriculture.

    Science.gov (United States)

    Benckiser, Gero

    2012-12-01

    The keywords nanotechnology, super absorber, agriculture, nutrition, and food technology exhibited 28,149 positive matches under more than 68 million patents worldwide. A closer look at the first 500 nanotechnology, agriculture, nutrition and biotechnology related patents, published during 2011-2012, unveiled that 64% are parts of machines and control devices while about 36% comprise metal oxides, fertilizers, pesticides and drugs, which are compounds and often applied in combination with inorganic or organic super absorbing polymeric structures. The latter compounds are in the focus of this special issue.

  12. Are Patents used to Suppress Useful Technology?

    DEFF Research Database (Denmark)

    Howells, John

    2006-01-01

    This article examines the evidence behind claims that innovation is hindered or blocked (termed technology suppression) by corporations' use of patents. In other words, are there ways in which the exploitation of the exclusive development right of the patent can be shown to retard the process...... of innovation, other than in the trivial sense of excluding third parties from the right to develop the technology covered by the patent? There are many references to this possibility in the management, economic and legal literatures, but two highly-cited papers stand out for grounding their claims of corporate...... and the difference between economic monopoly and an exclusive right. It is argued here that what is at issue in this work is the proper function of the patent institution. It is shown early in this paper that the understanding of the patent institution as a system of development prospects makes better sense...

  13. Clean coal and patent policy in Romania

    Energy Technology Data Exchange (ETDEWEB)

    Florin Popa [State Office for Inventions and Trademarks (Romania)

    2003-07-01

    The talk explained the importance of intellectual property protection to both industry and business. Applications for patents and utility models (for inventions), trademarks and industrial designs are filed with the State Office for Inventions and Trademarks (OSIM) in Romania; Trade secrets and how they can be kept, are discussed. The routes to follow before filing a patent application are outlined. An example is given of how to search for patents on 'clean coal' on the European Patents Office's database. The abstract of one patent is presented. This is entitled: 'Clean combustion of coal, utility of the concomitant products of the clean combustion and the product by using the concomitant products'. 23 PowerPoint slides are also available in the proceedings. 1 fig.

  14. Patent for Invention of Guilin Rubber Machinery Transla- tional Vulcanizer Awarded the Honorary Title of China Excel- lent Patent

    Institute of Scientific and Technical Information of China (English)

    Yang Wenguang; Li Li

    2011-01-01

    Recently, the results of the 13th China Patent Awards were publicized. The patent for invention of "translational vulcanizer" applied by Guilin Rubber Machinery Factory was appraised as China Excellent Patent.

  15. A Database of EPO-Patenting Firms in Denmark

    DEFF Research Database (Denmark)

    Nielsen, Anders Østergaard

    1998-01-01

    The first section gives a brief introduction of the basic stages to be observed by the patent applicant from idea to the patent is granted. Section two presents three examples of how patents are registered in the online patent database INPADOC. Section three accounts for the initial analysis...... of the existing patent stock issued to firms with domicile in Denmark. Sections four and five report the basic characteristics of the EPO-patent sample and the procedures for linking the patent statistics to accounting data at the firm level, and finally they present the basic properties of the resulting database...... containing 421 EPO-patenting firms in Denmark....

  16. Pharmacologic management of patent ductus arteriosus.

    Science.gov (United States)

    Bhatt, V; Nahata, M C

    1989-01-01

    The incidence, pathophysiology, and clinical findings of symptomatic patent ductus arteriosus (PDA) are reviewed, and the pharmacologic management of symptomatic PDA is discussed. Spontaneous closure of the ductus arteriosus (DA) usually occurs within four days after birth in most premature and full-term infants. The incidence of PDA is related to birth weight in premature infants and has been shown to decrease with an increase in birth weight. Clinical findings are reviewed. Prophylactic treatment in the first few hours after birth may not be needed in most premature infants. Treatment should be considered only if the ductus becomes symptomatic. Medical management consists of respiratory support, fluid restriction, diuretics, digoxin, and indomethacin. Respiratory support, fluid restriction, and diuretics are used as first-line treatment of symptomatic PDA. Digoxin cannot be recommended as part of first-line therapy, since its risks seem to outweigh the benefits in preterm infants. Indomethacin should be used only if other standard measures including fluid restriction and diuretic treatment fail. The mechanism of action, pharmacokinetics, adverse effects, and drug interactions of indomethacin are discussed. Symptomatic PDA can increase morbidity and mortality, especially in very low birth weight infants. Treatment of symptomatic PDA may decrease the morbidity associated with this condition.

  17. 液质联用法检测中成药和保健食品中的6种肾上腺皮质激素%Determination of 6 adrenal corticosteroids in Chinese patent drugs or functional foods by HPLC-MS

    Institute of Scientific and Technical Information of China (English)

    关日晴; 刘敏敏; 李晨辉

    2011-01-01

    Objective To establish a method for determining 6 adrenal corticosteroids which may be added illegally to Chinese patent drugs or functional foods. Methods HPLC-MS was used after a serial extraction and separation procedure. HPLC conditions:C18-column at 30 ℃, eluting with acetonitrile-water(40: 60)at a flow rate of 1.0 mL/min,detecting at 240 nm wavelength, 10 μL injection volume;ESI-MS data was obtained in positive ion mode. Results 6 adrenal corticosteroids (dexamethasone acetate, prednisolone acetate, hydrocortisone acetate, prednisone acetate, cortisone acetate, betamethasone ) were accurately identified simultaneously. Conclusion The method was accurate and suitable for determining 6 adrenal corticosteroids which may be added illegally to Chinese patent drugs or functional foods.%目的 建立中成药或保健食品中非法添加的6种肾上腺皮质激素的检验方法.方法 样品经溶剂提取分离后,采用高效液相色谱-串联质谱法测定.色谱条件:色谱柱为C18柱,流动相为乙腈-水(体积比40∶60),检测波长240 nm,柱温30℃,流速1.0 mL/min,进样量10μL;质谱条件:以ESI电喷雾电离源正离子模式进行质谱数据采集.结果 可同时对中国药典收载的醋酸地塞米松、醋酸可的松、醋酸氢化可的松、醋酸泼尼松、醋酸泼尼松龙和倍他米松6种常用口服肾上腺皮质激素进行检查,准确率达到100%.结论 该方法准确性、专属性强,可作为中成药或保健食品中非法添加的6种肾上腺皮质激素的检验方法.

  18. Essential Patents and Coordination Mechanisms : The effects of patent pools and industry consortia on the interplay between patents and technological standards

    OpenAIRE

    Baron, Justus; Pohlmann, Tim

    2010-01-01

    CERNA WORKING PAPER SERIES 2010-13; This article investigates the interplay between formal standards, essential patents and informal industry alliances such as consortia and patent pools. Building upon more than 6.200 declarations of essential patents to major international Standard Development Organizations (SDO), we investigate how informal standardization consortia and patent pools influence the number and timing of patent declarations to formal SDOs. This is the first thorough empirical i...

  19. Herbal nanoparticles: A patent review

    Directory of Open Access Journals (Sweden)

    Namdeo R Jadhav

    2014-01-01

    Full Text Available Design and development of herbal nanoparticles has become a frontier research in the nanoformulation arena. To update researchers, an attempt has been made to review nanoformulation-based herbal patents. This article mainly covers herbal medicines are used for the treatment of cardiovascular diseases, Parkinsonism, pulmonary diseases, proliferative diseases, Alzheimer′s disease, diabetes, cancer therapy, anti-osteoporosis, and the like. It has been revealed that nanoparticles of Curcumin have been widely designed to increase its bioavailability and for treatment of cancers like breast cancer, lung cancer, pancreatic cancer, and so on. The common nanoformulated herbal medicines are Panax ginseng, Curcuma longa, Silybum marianum, Withania somnifera, Gymnema sylvestre, Salvia miltiorrhiza, and the like, having a profound future potential.

  20. 辨明Patent Troll

    Institute of Scientific and Technical Information of China (English)

    柳建朋

    2012-01-01

    它,究竟是凶恶的巨怪,还是可爱的精灵? 它,竟究是正当的手段,还是无赖的工具? 长久以来,patent troll便是国外学术圈、实务界探讨的焦点话题之一,如今其又转到了国内,而近来表现的越发激烈。各派对其是否应当存在、存在合法与否等等进行了持续不休的讨论与争吵,

  1. Need for improving quality of operating structures and processes for better ARV adherence for patients with HIV/AIDS in Tanzania and other African countries:an experi-ence from Tanzania

    Institute of Scientific and Technical Information of China (English)

    Irunde H; Nsimba SED; Comoro CJ

    2009-01-01

    Objective:The study was carried out in order to determine the following objectives:(1)To determine the pro-portion of patients who state achieving or not achieving optimal adherence to antiretroviral therapy (ART)in selected Care and Treatment Sites in Arusha and Dares Salaam regions in Tanzania.(2)To identify factors such as structural,cultural or disease related contributing to sub-optimal adherence to antiretroviral (ARVs). (3)To assess quality of operating structures and processes for provision of antiretroviral (ARVs)in the select-ed healthcare facilities.(4)To document suggestions and proposals for improving ART adherence among ARV users.Methods:Data from 7 studied facilities (3 public and 4 private /or faith based)includes 207 interviews from ARV users,28 staff interview staff,26 observations during consultations,8 focus group discussions,10 key informant interviews,and stock checks in 6 facilities.The study design was a cross-sectional using both qualitative and quantitative data collection techniques.Quantitative data were collected by using an adherence tool check list,while qualitative data were obtained using a consultation observation checklist,semi-structured interviews,focus group discussions (FGDs)and key informant interviews.Results:There were slight varia-tions in the quality of operating structures and processes in the two studied regions.However results indicate that ARV adherence in Arusha region was comparatively similar to that of Dares Salaam.The composite adher-ence for one month in seven facilities was 90 % and only 21 % of ARV users achieved optimal adherence. Conclusion:The overall mean composite adherence rate of 90 % in the two areas surveyed is encouraging. More efforts to improve the quality and processes of operating structures in our study facilities and others in Tanzania are needed to ensure optimal adherence among the larger group (79 %)of ARV users who are cur-rently taking less than the critical 95 % of their medications.

  2. Patenting bioactive molecules from biodiversity: the Brazilian experience.

    Science.gov (United States)

    Nogueira, Renata Campos; de Cerqueira, Harley Ferreira; Soares, Milena Botelho Pereira

    2010-02-01

    The use of natural compounds from biodiversity, as well as ethnobotanical knowledge, for the development of new drugs is the gate leading to support the conservation of natural resources in developing countries. Recent technological advances and the development of new methods are revolutionizing the screening of natural products and offer a unique opportunity to replace natural products as major source of drug leads. Over the past decades, the Brazilian government established a legislation aiming to grant patent protection in all technological fields. The Convention on Biological Diversity, an international agreement that recognizes the sovereign rights of States over their natural resources, and the Brazilian legislation (Decreto n degree 2186-12/01) set for legislative, administrative or policy measures regarding the share of research and product development benefits could be the key for progress in issues related to rational employment of the Brazilian biodiversity and economy, but are far from being effective. Based on literature review, this article provides a brief description of the Brazilian legislation policy regarding intellectual property and biodiversity access, places natural drug discovery in context, analyzes patent cases and highlights critical key issues responsible for the drawback of the whole process that has a direct impact on industrial and research development, nature protection and benefit share with our society.

  3. Simultaneous determination of 17 aphrodisiac chemical drugs illegally added in health products and Chinese patent medicines by high performance liquid chromatography-tandem mass spectrometry%高效液相色谱-串联质谱法同时测定保健品及中成药中非法添加的17种壮阳类化学药

    Institute of Scientific and Technical Information of China (English)

    黄芳; 吴惠勤; 黄晓兰; 罗辉泰; 朱志鑫; 林晓珊; 马立果; 蒋娅兰

    2016-01-01

    A method was proposed for the simultaneous determination of seventeen aphrodisiac chemical drugs which were illegally mixed into the health products and Chinese patent medi-cines by high performance liquid chromatography-mass spectrometry ( HPLC-MS/MS ). The extraction,chromatographic conditions and mass spectrometry parameters were optimized in order to separate three groups of isomers. The drugs were extracted with methanol under ultra-sonic condition,separated on an Agilent Extend C18 chromatographic column( 100 mm × 2. 1 mm,3. 5 μm ) with acetonitrile and water ( additional 10 mmol/L ammonium acetate ) as mobile phases under gradient elution at a flow rate of 0. 25 mL/min. The determination was conducted by tandem mass spectrometry in positive ESI mode under multiple reaction monito-ring( MRM)mode. The method made seventeen aphrodisiac chemical drugs as well as the three groups of isomers to get the ideal separation and accurate quantitative. The method was proved to be rapid,selective,sensitive and stable,and it has been applied to the screening and detec-tion of aphrodisiac chemical drugs illegally added in health products and Chinese patent medi-cines. All the tested samples show that the aphrodisiac chemical drugs have a high detection rate in the recent three years. The relevant regulatory authorities should pay more attention to it.%建立了高效液相色谱-串联质谱( LC-MS/MS)同时测定补肾壮阳类保健品及中成药中非法添加的17种壮阳化学药的定性、定量分析方法。实验优化了前处理方法,并针对几对同分异构体成分优化了分离条件和质谱参数。样品经甲醇超声萃取,提取液经 Aglient Extend C18色谱柱(100 mm×2.1 mm,3.5μm)分离,流动相为乙腈和水(含有10 mmol/L乙酸铵),梯度洗脱,流速为0.25 mL/min,以电喷雾离子源正离子多反应监测( MRM)模式进行MS/MS检测。该方法能很好地分离并定量17种壮

  4. A new model for gene patents

    Energy Technology Data Exchange (ETDEWEB)

    1993-04-02

    When the National Institutes of Health (NIH) filed for patents on thousands of gene fragments in 1991, it created a furor because it was attempting to assert broad rights to sequences whose functions were unknown. The cDNA fragments NIH researchers had discovered were simply short stretches of presumably expressed genes, yet the patent the agency was seeking would give it rights both to the full genes themselves and to all their possible future uses. If NIH prevailed, researchers argued, it would potentially discourage further work on those genes. Now the head of the genome project at the Department of Energy (DOE) - NIH's partner in the program - has proposed an alternative approach to gene patenting. At a meeting last week of a congressional Office of Technology Assessment panel that is preparing a report on this issue, DOE's David Galas revealed that University of Washington genome researcher Leroy Hood is preparing to file a patent application that could serve as a model for such patents in the future. Hood's team has been sequencing the genes encoding the beta chain of the human T cell receptor. Mutations in the T cell receptor genes may lead to any of a number of autoimmune diseases, including rheumatoid arthritis and multiple sclerosis. A broad patent on the genes could therefore conceivably cover not only techniques for diagnosing autoimmune diseases but also of therapies for the conditions, and indeed anything involving T cell activity. But Hood's patent application won't make such broad claims. Instead, Hood, with DOE's support, will not seek to patent the genes but will claim only the specific uses of developing the diagnostic and therapeutic tools for dealing with specific autoimmune diseases. By restricting patents just to known uses the problems of gene ownership are neatly avoided.

  5. Gentamicin pharmacokinetics in preterm infants with a patent and a closed ductus arteriosus

    NARCIS (Netherlands)

    Touw, D J; Proost, J H; Stevens, R; Lafeber, H N; van Weissenbruch, M M

    2001-01-01

    BACKGROUND AND AIM: A patent ductus arteriosus (PDA) may influence renal and hepatic blood flow and hence pharmacokinetics of drugs in neonates compared to neonates with a closed ductus arteriosus (CDA). A 10-percent difference of gentamicin pharmacokinetic parameters between PDA and CDA has been re

  6. Modeling HIV vaccines in Brazil: assessing the impact of a future HIV vaccine on reducing new infections, mortality and number of people receiving ARV.

    Directory of Open Access Journals (Sweden)

    Maria Goretti P Fonseca

    Full Text Available BACKGROUND: The AIDS epidemic in Brazil remains concentrated in populations with high vulnerability to HIV infection, and the development of an HIV vaccine could make an important contribution to prevention. This study modeled the HIV epidemic and estimated the potential impact of an HIV vaccine on the number of new infections, deaths due to AIDS and the number of people receiving ARV treatment, under various scenarios. METHODS AND FINDINGS: The historical HIV prevalence was modeled using Spectrum and projections were made from 2010 to 2050 to study the impact of an HIV vaccine with 40% to 70% efficacy, and 80% coverage of adult population, specific groups such as MSM, IDU, commercial sex workers and their partners, and 15 year olds. The possibility of disinhibition after vaccination, neglecting medium- and high-risk groups, and a disease-modifying vaccine were also considered. The number of new infections and deaths were reduced by 73% and 30%, respectively, by 2050, when 80% of adult population aged 15-49 was vaccinated with a 40% efficacy vaccine. Vaccinating medium- and high-risk groups reduced new infections by 52% and deaths by 21%. A vaccine with 70% efficacy produced a great decline in new infections and deaths. Neglecting medium- and high-risk population groups as well as disinhibition of vaccinated population reduced the impact or even increased the number of new infections. Disease-modifying vaccine also contributed to reducing AIDS deaths, the need for ART and new HIV infections. CONCLUSIONS: Even in a country with a concentrated epidemic and high levels of ARV coverage, such as Brazil, moderate efficacy vaccines as part of a comprehensive package of treatment and prevention could have a major impact on preventing new HIV infections and AIDS deaths, as well as reducing the number of people on ARV. Targeted vaccination strategies may be highly effective and cost-beneficial.

  7. The Coordination of Independently-Owned Vacuum Tube Patents in the Alleged Early Radio Patent Thicket

    DEFF Research Database (Denmark)

    Howells, John; Ron D, Katznelson

    of the relevant historical record, patent claims, litigation records and other relevant law, how the ‘overlapping’ patent rights were resolved by the courts and by the immunity of suppliers to the Government from patent infringement liability. We trace the cross-licensing agreements between the different radio......It has been proposed that when multiple, independently-owned and ‘over-lapping’ patents must be licensed for legal technology development the difficulty of negotiating cross-licenses may lead entrepreneurs to hold-up or deter that development. Our literature review finds these features allegedly...... present in radio development, 1905-1920, with numerous allegations of an impasse in bargaining the necessary patent rights for legal development. This paper seeks to determine with new precision how entrepreneurs and managers actually managed patent rights in this scenario. Accordingly, this paper re...

  8. Patenting in Europe: The Jurisdiction of the CJEU over European Patent Law

    Directory of Open Access Journals (Sweden)

    Minn Mari

    2015-11-01

    Full Text Available This paper will deal with EU competence over patent law, especially in the context of the TRIPS Agreement with reference to the ruling of CJEU in the Daiichi Sankyo case (CJEU case C-414/11 Daiichi Sankyo v DEMO Anonimos. The first part will explain the process of claiming patents at the national as well as the European level in order to understand the complexity of patent law, the second part will deal with the implications of jurisdiction and developments in EU patent regulations, the third part will deal with the effects of EU competence over the TRIPS patent provisions and the forth part will deal with the interpretation of substantive patent law in the light of the Daiichi Sankyo case.

  9. Preliminary analysis of patent trends for magnetic fusion technology

    Energy Technology Data Exchange (ETDEWEB)

    Levine, L.O.; Ashton, W.B.; Campbell, R.S.

    1984-02-01

    This study presents a preliminary analysis of development trends in magnetic fusion technology based on data from US patents. The research is limited to identification and description of general patent activity and ownership characteristics for 373 patents. The results suggest that more detailed studies of fusion patents could provide useful R and D planning information.

  10. 37 CFR 1.14 - Patent applications preserved in confidence.

    Science.gov (United States)

    2010-07-01

    ... in confidence. 1.14 Section 1.14 Patents, Trademarks, and Copyrights UNITED STATES PATENT AND... Records and Files of the Patent and Trademark Office § 1.14 Patent applications preserved in confidence... published under 35 U.S.C. 122(b) are generally preserved in confidence pursuant to 35 U.S.C....

  11. 37 CFR 401.13 - Administration of patent rights clauses.

    Science.gov (United States)

    2010-07-01

    ... 37 Patents, Trademarks, and Copyrights 1 2010-07-01 2010-07-01 false Administration of patent rights clauses. 401.13 Section 401.13 Patents, Trademarks, and Copyrights ASSISTANT SECRETARY FOR... patent rights clauses. (a) In the event a subject invention is made under funding agreements of more...

  12. 48 CFR 1327.201 - Patent and copyright infringement liability.

    Science.gov (United States)

    2010-10-01

    ... 48 Federal Acquisition Regulations System 5 2010-10-01 2010-10-01 false Patent and copyright infringement liability. 1327.201 Section 1327.201 Federal Acquisition Regulations System DEPARTMENT OF COMMERCE GENERAL CONTRACTING REQUIREMENTS PATENTS, DATA, AND COPYRIGHTS Patents and Copyrights 1327.201 Patent...

  13. 76 FR 53885 - Patent and Trademark Resource Centers Metrics

    Science.gov (United States)

    2011-08-30

    ... United States Patent and Trademark Office Patent and Trademark Resource Centers Metrics ACTION: Proposed collection; comment request. SUMMARY: The United States Patent and Trademark Office (USPTO), as part of its... following methods: E-mail: InformationCollection@uspto.gov . Include ``Patent and Trademark Resource...

  14. 48 CFR 31.205-30 - Patent costs.

    Science.gov (United States)

    2010-10-01

    ... 48 Federal Acquisition Regulations System 1 2010-10-01 2010-10-01 false Patent costs. 31.205-30....205-30 Patent costs. (a) The following patent costs are allowable to the extent that they are incurred... patent application where title or royalty-free license is to be conveyed to the Government. (b)...

  15. 50 CFR 401.21 - Patents and inventions.

    Science.gov (United States)

    2010-10-01

    ... 50 Wildlife and Fisheries 7 2010-10-01 2010-10-01 false Patents and inventions. 401.21 Section 401... CONSERVATION, DEVELOPMENT AND ENHANCEMENT § 401.21 Patents and inventions. Determination of the patent rights... to the Act shall be consistent with the “Government Patent Policy” (President's memorandum for...

  16. 45 CFR 650.2 - National Science Foundation patent policy.

    Science.gov (United States)

    2010-10-01

    ... 45 Public Welfare 3 2010-10-01 2010-10-01 false National Science Foundation patent policy. 650.2... FOUNDATION PATENTS § 650.2 National Science Foundation patent policy. As authorized by the National Science... adopted the following statement of NSF patent policy. (a) In accordance with the Bayh-Dole Act and...

  17. 78 FR 17102 - Setting and Adjusting Patent Fees; Correction

    Science.gov (United States)

    2013-03-20

    ... United States Patent and Trademark Office 37 CFR Parts 1 and 41 RIN 0651-AC86 Setting and Adjusting Patent Fees; Correction AGENCY: United States Patent and Trademark Office, Department of Commerce. ACTION: Interim rule. SUMMARY: The United States Patent and Trademark Office (Office) is correcting...

  18. 77 FR 14766 - Patents for Humanity Program (Formerly Humanitarian Program)

    Science.gov (United States)

    2012-03-13

    ... United States Patent and Trademark Office Patents for Humanity Program (Formerly Humanitarian Program) ACTION: Proposed collection; comment request. SUMMARY: The United States Patent and Trademark Office...- 0066 Patents for Humanity Program comment'' in the subject line of the message. Mail: Susan K....

  19. 48 CFR 970.2702-3 - Patent indemnity.

    Science.gov (United States)

    2010-10-01

    ... 48 Federal Acquisition Regulations System 5 2010-10-01 2010-10-01 false Patent indemnity. 970.2702... SUPPLEMENTARY REGULATIONS DOE MANAGEMENT AND OPERATING CONTRACTS Patents, Data, and Copyrights 970.2702-3 Patent indemnity. (a) Contracting officers must use the clause at 970.5227-6, Patent Indemnity—Subcontracts...

  20. 78 FR 19416 - Revisions to Patent Term Adjustment

    Science.gov (United States)

    2013-04-01

    ... United States Patent and Trademark Office 37 CFR Part 1 RIN 0651-AC84 Revisions to Patent Term Adjustment AGENCY: United States Patent and Trademark Office, Commerce. ACTION: Interim final rule. SUMMARY: The United States Patent and Trademark Office (Office) is revising the rules of practice to implement...

  1. 7 CFR 1250.542 - Patents, copyrights, trademarks, and information.

    Science.gov (United States)

    2010-01-01

    ... 7 Agriculture 10 2010-01-01 2010-01-01 false Patents, copyrights, trademarks, and information... AGRICULTURE EGG RESEARCH AND PROMOTION Rules and Regulations Patents, Copyrights, Trademarks, and Information § 1250.542 Patents, copyrights, trademarks, and information. Patents, copyrights, trademarks,...

  2. 77 FR 269 - Matters Related to Patent Appeals

    Science.gov (United States)

    2012-01-04

    ... United States Patent and Trademark Office Matters Related to Patent Appeals ACTION: Proposed collection; comment request. SUMMARY: The United States Patent and Trademark Office (USPTO), as part of its continuing...: Email: InformationCollection@uspto.gov . Include ``0651- 00xx Matters Related to Patent Appeals...

  3. 76 FR 34062 - Patent and Trademark Financial Transactions

    Science.gov (United States)

    2011-06-10

    ... Patent and Trademark Office Patent and Trademark Financial Transactions ACTION: Proposed collection; comment request. SUMMARY: The United States Patent and Trademark Office (USPTO), as part of its continuing... States Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. Federal Rulemaking...

  4. 48 CFR 3027.305 - Administration of Patent Rights Clauses.

    Science.gov (United States)

    2010-10-01

    ... 48 Federal Acquisition Regulations System 7 2010-10-01 2010-10-01 false Administration of Patent... SECURITY, HOMELAND SECURITY ACQUISITION REGULATION (HSAR) SOCIOECONOMIC PROGRAMS PATENTS, DATA, AND COPYRIGHTS Patent Rights under Government Contracts 3027.305 Administration of Patent Rights Clauses....

  5. 7 CFR 1220.254 - Patents, copyrights, inventions, and publications.

    Science.gov (United States)

    2010-01-01

    ... 7 Agriculture 10 2010-01-01 2010-01-01 false Patents, copyrights, inventions, and publications... Miscellaneous § 1220.254 Patents, copyrights, inventions, and publications. (a) Any patents, copyrights..., franchising, or other uses of such patents, copyrights, inventions, or publications, inure to the benefit...

  6. 7 CFR 1230.88 - Patents, copyrights, inventions, and publications.

    Science.gov (United States)

    2010-01-01

    ... 7 Agriculture 10 2010-01-01 2010-01-01 false Patents, copyrights, inventions, and publications... Information Order Miscellaneous § 1230.88 Patents, copyrights, inventions, and publications. Any patents..., leasing, franchising, or other uses of such patents, copyrights, inventions, or publications inure to...

  7. 48 CFR 1852.227-84 - Patent rights clauses.

    Science.gov (United States)

    2010-10-01

    ... 48 Federal Acquisition Regulations System 6 2010-10-01 2010-10-01 true Patent rights clauses. 1852... 1852.227-84 Patent rights clauses. The contracting officer shall insert the following provision as prescribed in 1827.303-70(e): Patent Rights Clauses (DEC 1989) This solicitation contains the patent...

  8. 14 CFR 1214.112 - Patent, data and information matters.

    Science.gov (United States)

    2010-01-01

    ... 14 Aeronautics and Space 5 2010-01-01 2010-01-01 false Patent, data and information matters. 1214... Customers § 1214.112 Patent, data and information matters. (a) Patent and data rights. NASA will not acquire rights to inventions, patents or proprietary data which may be used in, or arise from, activities...

  9. 78 FR 21787 - Changes To Implement the Patent Law Treaty

    Science.gov (United States)

    2013-04-11

    ... and 3 Changes To Implement the Patent Law Treaty; Proposed Rule #0;#0;Federal Register / Vol. 78, No... and Trademark Office 37 CFR Parts 1 and 3 RIN 0651-AC85 Changes To Implement the Patent Law Treaty.... SUMMARY: The Patent Law Treaties Implementation Act of 2012 (PLTIA) amends the patent laws to...

  10. Patent law in dentistry: An overview

    Directory of Open Access Journals (Sweden)

    Mohammed Nadeem A Bijle

    2011-01-01

    Full Text Available Dentistry in recent years has developed interest in the field of intellectual property rights (IPR and Patents due to extensive research in the fraternity and existing competition. There have been various patent applications and grants in the field of dentistry abroad due to better understanding of IPR but India still has very few patent grants and applications on the subject matter. This review article in particular deals with the understanding of IPR and Patents as a whole, especially for dental professionals involved in research and development. Hence, this would also act as an asset for dental researchers to explore and expand their scope of activities, with special privileges empowered for their work.

  11. How do Firms Use the Information in Patent Disclosures?

    DEFF Research Database (Denmark)

    Howells, John; Scholderer, Joachim

    that the patent specification should disclose sufficient information to identify the invention with respect to the prior art and therefore make the patent defensible against rival patents in court - they need not enable the making of the invention. Our research design gathers data on how firms use the information...... disclosed in patent specifications and relates this to the predictions of the different types of current theories of patent function. We intend to test and refine theory in one current patent controversy, that concerning patent information usage. [ii] [i] See Cohen, W., A. Goto, et al. (2002). "R...

  12. Intellectual Property Strategies of Multinational Companies Patenting in China

    DEFF Research Database (Denmark)

    Wolfram, Pierre; Schuster, Gerd; Brem, Alexander

    2014-01-01

    archetypes of the world’s largest patent applicants using the case of China as an empirical context. Using Questel’s professional patent search application Orbit, we build a unique data set of the world’s top patent applicants combining data from the World Intellectual Property Organization and the State......While global intellectual property trends show a stable rate of worldwide patent applications during the last five years, patent applications in emerging economies strongly increased within the same period. Unless the increasing number of applications in emerging economies, the indigenous legal...... clustering reveals the existence of five patent strategy archetypes of companies patenting in economies with weak appropriability regimes....

  13. The patent activity of the Czech R

    Directory of Open Access Journals (Sweden)

    Kučera Zdeněk

    2016-12-01

    Full Text Available An effective knowledge transfer between research institutions and industry is a significant bottleneck in the national innovation system. CR adopted in recent years a series of systemic measures aimed to stimulate the orientation of the R&D organizations towards the generation of knowledge directly applicable in the innovation process and more generally to improve the collaboration of the R&D establishment with the industry. In the majority of programs supporting the applied research patents and industrial designs and utility models are among the anticipated results. The Methodology of the evaluation of R&D organizations implemented in the second half of the last decade brought financial bonuses for the creation of the results in the category of industrial property. Despite of this stimulus CR lags behind the technologically advanced EU countries in the patent activities. The topic of this article is a comparison of the protection of the industrial property rights in the Czech higher education institutions and governmental R&D institutions with selected EU countries. We make use of a couple of quantitative indicators to assess the quality and the technological and the commercial potential of the produced industrial property. Despite a dynamic growth of the patent applications in the CR the number of patent applications relative to the country size is far below the EU-15 average. The Czech research organizations contribute to a higher extent to the number of patent applications then do the analogous institutions in EU-15 countries where the majority of patent applications come from the industrial sphere. The Czech research organizations mainly limit the patent rights to the Czech Republic whereas in the EU-15 countries the opposite is preponderant and only a small fraction of patent applications remains limited to the national environment. Thus the majority of the Czech patents created by research organizations cannot be commercialized on the

  14. Patents | NCI Technology Transfer Center | TTC

    Science.gov (United States)

    Timely reporting of discoveries is critical, because patent protection may be lost if an invention is publicly disclosed prior to filing a patent application. A public disclosure may include Talks, presentations, posters; Publications, including titles and abstracts posted on websites; Internet postings; Graduate student theses, job interviews; andDiscussions with non-NIH personnel without a Confidential Disclosure Agreement (CDA) in place. | [google6f4cd5334ac394ab.html

  15. Patents and licensing in pharmaceutical industry

    Directory of Open Access Journals (Sweden)

    Katerina Ancevska Netkovska

    2005-05-01

    Full Text Available Intellectual property rights (IPR have been defined as ideas, inventions, and creative expressions based on which there is a public willingness to bestow the status of property. IPR provide certain exclusive rights to the inventors or creators of that property, in order to enable them to reap commercial benefits from their creative efforts or reputation. There are several types of intellectual property protection like patent, copyright, trademark, etc. Patent is recognition for an invention, which satisfies the criteria of global novelty, non-obviousness, and industrial application. IPR is prerequisite for better identification, planning, commercialization, rendering, and thereby protection of invention or creativity. Each industry should evolve its own IPR policies, management style, strategies, and so on depending on its area of specialty. Pharmaceutical industry currently has an evolving IPR strategy requiring a better focus and approach in the coming era. The protection of inventions with patents in the pharmaceutical industry have a specific role in the development of society and represent one of the drivers of economic development. The license agreements are considered as one of the most common types of transfer of industrial property rights. The right holders often transfer their rights to patents by concluding licensing agreement. While the patent license may give the license a right to use the technology many license agreements have provisions for the transfer of know-how in addition to the patent.

  16. Severallssues in the Practice of Design Patent Examination

    Institute of Scientific and Technical Information of China (English)

    Zhong Hua

    2005-01-01

    @@ Subject Matter Protected by the Design Patent Right For any legal relation to be viable there must be three elements; the subject,subject matter and content. What the subject matter protected by the design patent right is one of the basic issues of the design patent system in China. However,in the design patent examination, we have found that many parties and even senior patent attorneys have many misconceptions about the issue.

  17. Empirical studies on the private value of Finnish patents

    OpenAIRE

    Grönqvist, Charlotta

    2009-01-01

    It is a commonly accepted fact that innovation is important for economic growth and that a well-designed patent system increases research and development investments. Patents are unfortunately a second best solution. While the benefits of the patent system are increased incentives to innovation, diffusion of new knowledge, and easier commercialization of patented innovations; the drawback of the patent system is the monopolies it creates. Therefore, the fundamental question that has intereste...

  18. Patent Medicine Sellers: How Can They Help Control Childhood Malaria?

    Directory of Open Access Journals (Sweden)

    Rosamund M. Akuse

    2010-01-01

    Full Text Available Roll Back Malaria Initiative encourages participation of private health providers in malaria control because mothers seek care for sick children from them. This study investigated Patent Medicine Sellers (PMS management of presumptive malaria in children in order to identify how they can assist malaria control. A cross-sectional survey of 491 PMS in Kaduna, Nigeria, was done using interviews and observation of shop activities. Most (80% customers bought drugs without prescriptions. Only 29.5% were given instructions about doses. Between 40–100% doses of recommended antimalarials were incorrect. Some (22% PMS did not ask questions about illness for which they were consulted. Most children treated in shops received injections. PMS facilitate homecare but have deficiencies in knowledge and practice. Interventions must focus on training them to accurately determine doses, give advice about drug administration, use oral medication, and ask about illness. Training should be made a prerequisite for registering and reregistering shops.

  19. Bioavailability and Bioequivalence in Drug Development

    OpenAIRE

    Chow, Shein-Chung

    2014-01-01

    Bioavailability is referred to as the extent and rate to which the active drug ingredient or active moiety from the drug product is absorbed and becomes available at the site of drug action. The relative bioavailability in terms of the rate and extent of drug absorption is considered predictive of clinical outcomes. In 1984, the United States Food and Drug Administration (FDA) was authorized to approve generic drug products under the Drug Price Competition and Patent Term Restoration Act base...

  20. A Patent Analysis on Realistic Media for R&D Projects

    Science.gov (United States)

    Hwang, Sung-Hyun; Yeon, Seung-Jun

    In this paper, we use patent statistics as the recent status of R&D in international patents. The number of patents was used to compare different countries' share in the overall number of technology patents. Using the degree of patent citations, the influence and technological prowess of patents were examined. Also, implications were drawn from an analysis of patent contents for realistic media.

  1. A Moral Economy of Patents: Case of Finnish Research Universities' Patent Policies

    Science.gov (United States)

    Kauppinen, Ilkka

    2014-01-01

    The primary objective of this paper is to demonstrate the usefulness of the concept of moral economy for higher education studies through a study of Finnish research universities' patent policies. Patent policies not only stimulate the commercialization of research, they also set norms for behavior and aim to clarify how to distribute rights and…

  2. How do public health safeguards in Indian patent law affect pharmaceutical patenting in practice?

    Science.gov (United States)

    Sampat, Bhaven N; Amin, Tahir

    2013-08-01

    The 1995 Trade Related Intellectual Property Rights (TRIPS) agreement required developing countries to grant product patents in pharmaceuticals. Developing countries have since explored various measures to ameliorate potential negative effects of the new laws on public health. A prominent example is India, whose post-TRIPS patent laws include a provision, section 3(d), that restricts patents on incremental pharmaceutical innovations. Its critics and supporters alike suggest that this provision makes Indian patent law very different from that in other jurisdictions. Yet there are concerns that given resource constraints facing the Indian patent office, this novel feature of Indian patent laws on the books may not have an effect on Indian patent prosecution in practice. We test this by examining the prosecution outcomes of 2,803 applications filed in both India and Europe, coded by whether they include claims that trigger 3(d) considerations. We find that having the 3(d) provision on the books does not translate into very different patent outcomes in practice in India, relative to Europe, a jurisdiction without this provision.

  3. Can patents prohibit research? On the social epistemology of patenting and licensing in science.

    Science.gov (United States)

    Biddle, Justin B

    2014-03-01

    A topic of growing importance within philosophy of science is the epistemic implications of the organization of research. This paper identifies a promising approach to social epistemology--nonideal systems design--and uses it to examine one important aspect of the organization of research, namely the system of patenting and licensing and its role in structuring the production and dissemination of knowledge. The primary justification of patenting in science and technology is consequentialist in nature. Patenting should incentivize research and thereby promote the development of knowledge, which in turn facilitates social progress. Some have disputed this argument, maintaining that patenting actually inhibits knowledge production. In this paper, I make a stronger argument; in some areas of research in the US--in particular, research on GM seeds--patents and patent licenses can be, and are in fact being, used to prohibit some research. I discuss three potential solutions to this problem: voluntary agreements, eliminating patents, and a research exemption. I argue against eliminating patents, and I show that while voluntary agreements and a research exemption could be helpful, they do not sufficiently address the problems of access that are discussed here. More extensive changes in the organization of research are necessary.

  4. Analysis of Patent Databases Using VxInsight

    Energy Technology Data Exchange (ETDEWEB)

    BOYACK,KEVIN W.; WYLIE,BRIAN N.; DAVIDSON,GEORGE S.; JOHNSON,DAVID K.

    2000-12-12

    We present the application of a new knowledge visualization tool, VxInsight, to the mapping and analysis of patent databases. Patent data are mined and placed in a database, relationships between the patents are identified, primarily using the citation and classification structures, then the patents are clustered using a proprietary force-directed placement algorithm. Related patents cluster together to produce a 3-D landscape view of the tens of thousands of patents. The user can navigate the landscape by zooming into or out of regions of interest. Querying the underlying database places a colored marker on each patent matching the query. Automatically generated labels, showing landscape content, update continually upon zooming. Optionally, citation links between patents may be shown on the landscape. The combination of these features enables powerful analyses of patent databases.

  5. Protecting new ideas and inventions in nanomedicine with patents.

    Science.gov (United States)

    Bawa, Raj; Bawa, S R; Maebius, Stephen B; Flynn, Ted; Wei, Chiming

    2005-06-01

    New paradigms are shrinking our world. Tiny is in and patents are essential for success in nanomedicine. In fact, patents are already shaping this nascent and rapidly evolving field. For the past decade a swarm of patent applications pertaining to nanomedicine has been arriving at the US Patent and Trademark Office (PTO). As companies develop products and processes and begin to seek commercial applications for their inventions, securing valid and defensible patent protection will be vital to their long-term survival. As we enter the "golden era" of medicine, or nanomedicine, in the next decade with the field maturing and the promised breakthroughs accruing, patents will generate licensing revenue, provide leverage in deals and mergers, and reduce the likelihood of infringement. Because development of nanobiotechnology- and nanomedicine-related products is extremely research intensive, without the market exclusivity offered by a US patent, development of these products and their commercial viability in the marketplace will be significantly hampered. In this article, we highlight critical issues relating to patenting nanomedicine products. Effects of the "nanopatent land grab" that is underway in nanomedicine by "patent prospectors" are examined as startups and corporations compete to lock up broad patents in these critical early days. Because nanomedicine is multidisciplinary, patenting presents unique opportunities and poses numerous challenges. Although patents are being sought more actively and enforced more vigorously, the entire patent system is under greater scrutiny and strain, with the PTO continuing to struggle with evaluating nanomedicine-related patent applications.

  6. A consideration of the patentability of enantiomers in the pharmaceutical industry in the United States.

    Science.gov (United States)

    Miller, Chris P; Ullrich, John W

    2008-06-01

    During the last thirty years, concern over stereoselectivity of drug action has drawn a great deal of interest within the pharmaceutical field due to an improved understanding of the pharmacology and pharmacokinetics of enantiomers. Developing single enantiomers versus racemates or introducing a single enantiomer following the development of the racemic mixture appears to be the new trend. The intellectual property status of single enantiomers from racemates may be unclear. Drug discoverers and patent attorneys must examine the examples of the past to establish an appropriate pathway towards the development and intellectual property protection of chiral drugs. The review will focus on the patenting of an enantiomer in view of the prior art disclosure for the racemic mixture.

  7. El Sistema de patentes en Colombia

    Directory of Open Access Journals (Sweden)

    Rafael Viana Barceló

    2014-01-01

    Full Text Available En este documento se realiza un análisis económico del Sistema de Patentes de Colombia. Para ello, se establece el efecto que tienen las patentes concedidas a los inventores foráneos sobre la Inversión Extranjera Directa y el Producto Interno Bruto Nacional, a través de la técnica de regresión de data panel. De igual manera, se identifican los sectores económicos que registran mayores tasas de innovación por parte de los inventores nacionales y extranjeros. Se muestra que el sistema nacional de propiedad intelectual tiene un grado de fortaleza acorde con el resto de países latinoamericanos; para ello, se construye un índice de grado de fortalecimiento de sistema de patente nacional que luego será comparado con el de otros países latinos.Palabras Clave: Sistema de Patentes; Derechos de Propiedad Intelectual; Inversión Directa extranjera; Producto Interno Bruto e innovación tecnológica. The system of patents in ColombiaAbstractIn this document an economic analysis of the System of Patents of Colombia is made. For it, the effect that has the patents granted to the foreign inventors on the Direct Foreign Investment and the Internal Product Gross National, through the technique of regression of data settles down panel. Of equal way, the economic sectors are identified that register greater rates of innovation on the part of the national and foreign inventors.Sample that the national system of intellectual property has a degree of agreed strength with the rest of Latin American countries; for it, an index of degree of fortification of system of national patent is constructed that soon will be compared with the one of other Latin countries.Keywords: System Patent; Rights of Intellectual Property; Foreign Direct Investment; Gross Domestic Product and Technology Innovation.

  8. Approved Animal Drug Products (Green Book)

    Data.gov (United States)

    U.S. Department of Health & Human Services — On November 16, 1988, the President of the United States signed into law the Generic Animal Drug and Patent Restoration Act (GADPTRA). Among its major provisions,...

  9. Gene patents, patenting life and the impact of court rulings on US stem cell patents and research.

    Science.gov (United States)

    Matthews, Kirstin R W; Cuchiara, Maude L

    2014-03-01

    In June 2013, the US Supreme Court ruled that naturally occurring genes were unpatentable in the case Association for Molecular Pathology v. Myriad Genetics. Up until this decision, Myriad Genetics was the only company in the USA that could legally conduct diagnostic testing for BRCA1 and 2, genes that are linked to familial breast and ovarian cancer. The court case and rulings garnered discussion in public about patenting biological materials. This paper will describe the progression of the Myriad Genetics case, similar US rulings and biological intellectual property policies. In addition, it will discuss the impact of the case on biological patents - specifically those for human embryonic stem cells.

  10. The Coordination of Independently-Owned Vacuum Tube Patents in the Early Radio Alleged Patent “Thicket”

    DEFF Research Database (Denmark)

    Howells, John; Ron D, Katznelson

    and entrepreneurial exploitation of patents on early vacuum tube technology where Fleming’s diode patent was alleged to have ”overlapped” with De Forest’s triode patents. We show, by means of the relevant historical record, patent claims, litigation records and other relevant law, how patent rights were resolved......It has been proposed that difficulties in negotiating cross-licenses under multiple, independently-owned and ”overlapping” patents may lead entrepreneurs to hold-up or deter development of technology covered by such patents. The literature alleges these features were present in radio development...... during 1905-1920, with numerous allegations of an impasse in bargaining the necessary patent rights for development. This paper seeks to determine with new precision how entrepreneurs and managers actually managed patent rights in this scenario. Accordingly, we re-examine the legal trajectories...

  11. Digital pathology: A systematic evaluation of the patent landscape

    Directory of Open Access Journals (Sweden)

    Ioan C. Cucoranu

    2014-01-01

    Full Text Available Introduction: Digital pathology is a relatively new field. Inventors of technology in this field typically file for patents to protect their intellectual property. An understanding of the patent landscape is crucial for companies wishing to secure patent protection and market dominance for their products. To our knowledge, there has been no prior systematic review of patents related to digital pathology. Therefore, the aim of this study was to systematically identify and evaluate United States patents and patent applications related to digital pathology. Materials and Methods: Issued patents and patent applications related to digital pathology published in the United States Patent and Trademark Office (USPTO database (www.uspto.gov (through January 2014 were searched using the Google Patents search engine (Google Inc., Mountain View, California, USA. Keywords and phrases related to digital pathology, whole-slide imaging (WSI, image analysis, and telepathology were used to query the USPTO database. Data were downloaded and analyzed using the Papers application (Mekentosj BV, Aalsmeer, Netherlands. Results: A total of 588 United States patents that pertain to digital pathology were identified. In addition, 228 patent applications were identified, including 155 that were pending, 65 abandoned, and eight rejected. Of the 588 patents granted, 348 (59.18% were specific to pathology, while 240 (40.82% included more general patents also usable outside of pathology. There were 70 (21.12% patents specific to pathology and 57 (23.75% more general patents that had expired. Over 120 unique entities (individual inventors, academic institutions, and private companies applied for pathology specific patents. Patents dealt largely with telepathology and image analysis. WSI related patents addressed image acquisition (scanning and focus, quality (z-stacks, management (storage, retrieval, and transmission of WSI files, and viewing (graphical user interface (GUI

  12. Synthetic Biology in the Biotech Patent Landscape

    Directory of Open Access Journals (Sweden)

    Viviana García-llerena

    2016-12-01

    Full Text Available Recently, the intended positive effects of the current patent system in biotechnological research have been widely questioned. As part of this review, it is discussed here one of the foundations of the model. The assumption of the indispensability of patents is examined through the analysis of their expected benefits; namely, that patents are suitable to ensure access to information, access to and use of inventions and, finally, that they should promote both creativity and research. Applied to synthetic biology, in spite of newly discovered techniques and promising products, this approach reveals that this discipline also encounters similar issues. However, it also offers a new vision of intellectual property rights and their effects on research, which is based on a different conception of the commons and its relationship with private ownership of intangible assets in the knowledge economy.

  13. Patenting humans: clones, chimeras, and biological artifacts.

    Science.gov (United States)

    Hurlbut, William B

    2005-01-01

    The momentum of advances in biology is evident in the history of patents on life forms. As we proceed forward with greater understanding and technological control of developmental biology there will be many new and challenging dilemmas related to patenting of human parts and partial trajectories of human development. These dilemmas are already evident in the current conflict over the moral status of the early human embryo. In this essay, recent evidence from embryological studies is considered and the unbroken continuity of organismal development initiated at fertilization is asserted as clear and reasonable grounds for moral standing. Within this frame of analysis, it is proposed that through a technique of Altered Nuclear Transfer, non-organismal entities might be created from which embryonic stem cells could be morally procured. Criteria for patenting of such non-organismal entities are considered.

  14. Orphan drugs

    Directory of Open Access Journals (Sweden)

    Goločorbin-Kon Svetlana

    2013-01-01

    Full Text Available Introduction. Drugs used for treatment of rare diseases are known worldwide under the term of orphan drugs because pharmaceutical companies have not been interested in ”adopting” them, that is in investing in research, developing and producing these drugs. This kind of policy has been justified by the fact that these drugs are targeted for small markets, that only a small number of patients is available for clinical trials, and that large investments are required for the development of drugs meant to treat diseases whose pathogenesis has not yet been clarified in majority of cases. The aim of this paper is to present previous and present status of orphan drugs in Serbia and other countries. The beginning of orphan drugs development. This problem was first recognized by Congress of the United States of America in January 1983, and when the ”Orphan Drug Act” was passed, it was a turning point in the development of orphan drugs. This law provides pharmaceutical companies with a series of reliefs, both financial ones that allow them to regain funds invested into the research and development and regulatory ones. Seven years of marketing exclusivity, as a type of patent monopoly, is the most important relief that enables companies to make large profits. Conclusion. There are no sufficient funds and institutions to give financial support to the patients. It is therefore necessary to make health professionals much more aware of rare diseases in order to avoid time loss in making the right diagnosis and thus to gain more time to treat rare diseases. The importance of discovery, development and production of orphan drugs lies in the number of patients whose life quality can be improved significantly by administration of these drugs as well as in the number of potential survivals resulting from the treatment with these drugs. [Projekat Ministarstva nauke Republike Srbije, br. III 41012

  15. Cross-Border Patent Disputes: Unified Patent Court or International Commercial Arbitration?

    Directory of Open Access Journals (Sweden)

    Ana Alba Betancourt

    2016-04-01

    Full Text Available Currently, the enforcement of a patent that is registered in several countries involves the risk of getting different and conflicting decisions from the national courts. In 2013, 25 European countries entered in an agreement that aims to homogenise the patent system by creating the European patent with unitary effect and a Unified Patent Court (UPC. This article focuses on the UPC, which aims to have a single court proceeding for cross-border patent conflicts. Does the UPC system represent an advantage compared to the current litigation system? The paper argues that it does and explores what it considers to be the two main advantages of a UPC over the current system of cross-border litigation of patents: the ability to drag several conflicts to a single procedure and the neutrality of the decision makers. These advantages are consequently compared to the characteristics of arbitration. Then, an explanation is provided with regards to how the UPC system is going to work in terms of jurisdiction, preliminary injunctions, the choice of law and enforcement of decisions, comparing those same procedural aspects to arbitration. The article finds that arbitration involves many of the same advantages (as compared to the UPC and that the procedural issues studied in both means are, so too, similar. Therefore, arbitration represents a viable alternative to the UPC when it comes to reducing the risks in solving cross-border patent conflicts.

  16. From flood-event to climate in an alpine context (Arve valley, France): methodological issues toward the confrontation of historical documentation and geological records

    Science.gov (United States)

    Mélo, Alain; Ployon, Estelle; Wilhelm, Bruno; Arnaud, Fabien

    2014-05-01

    Floods are complex multifactor events. As it can occur randomly on a given region, a given singular event does not clearly inform about climate variations. On the contrary, long-time series of well documented events, each one being replaced in its historical and geographical context, should bring valuable information. Such successions can be built-up using heterogeneous historical documentation taken from various social contexts. This is the case of small drainage basin of river Arve and its tributaries (Northern French Alps), on which this paper will focus. We used a plentiful and rich documentation which was elaborated quite exclusively to report damages in the aim of claiming tax abatement. As a consequence each text requires a hard critic to reach the necessary objectivity. The analysis of 18th century treasury archives led first to a geographical reconstruction of floods impacts and second to an unambiguous chronology of events. The contrasted morphology of river Arve drainage basin generates various types of floods, depending on geographical situations: summer flash-floods in the higher parts of valleys (Chamonix, Sixt) or torrential tributaries (Borne); autumn large floods in lower parts (Bonneville); some unusual events concern the whole basin (1733, 1778...). The constitution of long continuous series was thus possible. However, this does not allow evidencing any trend because most of the events are randomly-distributed flash-floods. In return, meteorological contextualization of each event replaces it in a larger climatic perception. Using this way (meteorological archives, comparisons with recently well-documented event) led us to corroborate connections between flood events and changing patterns. In order to go a step further, we led a pilot-study aiming at representing our data in space-time information system using concepts and tools of time geography. This study was limited to year 1930 AD which was rich in various meteorological events leading to

  17. Nanotechnology patents in the automotive industry (a quantitative & qualitative analysis).

    Science.gov (United States)

    Prasad, Raghavendra; Bandyopadhyay, Tapas K

    2014-01-01

    The aim of the article is to present a trend in patent filings for application of nanotechnology to the automobile sector across the world, using the keyword-based patent search. Overviews of the patents related to nano technology in the automobile industry have been provided. The current work has started from the worldwide patent search to find the patents on nanotechnology in the automobile industry and classify the patents according to the various parts of an automobile to which they are related and the solutions which they are providing. In the next step various graphs have been produced to get an insight into various trends. In next step, analysis of patents in various classifications, have been performed. The trends shown in graphs provide the quantitative analysis whereas; the qualitative analysis has been done in another section. The classifications of patents based on the solution they provide have been performed by reading the claims, titles, abstract and full texts separately. Patentability of nano technology inventions have been discussed in a view to give an idea of requirements and statutory bars to the patentability of nanotechnology inventions. Another objective of the current work is to suggest appropriate framework for the companies regarding use of nano technology in the automobile industry and a suggestive strategy for patenting of the inventions related to the same. For example, US Patent, with patent number US2008-019426A1 discusses the invention related to Lubricant composition. This patent has been studied and classified to fall under classification of automobile parts. After studying this patent, it is deduced that, the problem of friction in engine is being solved by this patent. One classification is the "automobile part" based while other is the basis of "problem being solved". Hence, two classifications, namely reduction in friction and engine were created. Similarly, after studying all the patents, a similar matrix has been created.

  18. The governance of the European patent system:

    DEFF Research Database (Denmark)

    Borras, Susana

    2006-01-01

    at the formal and informal dimensions of interactions in economic systems. This is further developed into an analytical framework which is then used in the assessment of the structural features of the current European patent system, one of the most advanced, complex, and contested economic systems in Europe....... The conclusions elaborate on the normative implications regarding the current weaknesses of the European patent system, and examine the general theoretical implications of the findings, particularly looking at the effectiveness and legitimacy of technically complex governance systems....

  19. Analyzing Patents Generated by SBIR Firms

    Science.gov (United States)

    2014-04-30

    Intervention Cumulative Knowledge  Creation   Leads to Economic Growth • Endogeneous growth theory  Romer (1990) – Investment in knowledge  creation , human capital...including patents rights to inventions funded by federal research money . To date there has been no systematic analysis of these laws on the propensity to...including patents rights to inventions funded by federal research money . To date there has been no systematic analysis of these laws on the propensity

  20. Recent patents relating to bird flu infection.

    Science.gov (United States)

    Wiwanitkit, Viroj

    2007-01-01

    Bird flu or H5N1 infection is a new emerging zoonosis. With the pandemic in avian species in Asia, it is now under surveillance for a possible new public health threat to human. There are many present researches focusing on several aspects of bird flu. There are some recent patents and patent applications published within a few years. In this article, the recent patients relating to bird flu infection covering the diagnostic and treatment aspects for both avian species and human are reviewed and discussed.

  1. Understanding Patents: The Role of R&D Funding Sources and the Patent Office

    OpenAIRE

    2005-01-01

    This paper analyzes the effects of different sources of R&D funding and patent office attributes on the patenting process. Another important contribution is modeling the effect of a random delay in the ‘pendency’ time as a stochastic process and quantifying its effect on patenting. The empirical estimation is based on four major industries – electronics, chemical and biology, transportation and aeronautics – for the time period 1976-1998. The primary results are: First, the source of R&D fund...

  2. Clinically relevant transmitted drug resistance to first line antiretroviral drugs and implications for recommendations.

    Directory of Open Access Journals (Sweden)

    Susana Monge

    Full Text Available BACKGROUND: The aim was to analyse trends in clinically relevant resistance to first-line antiretroviral drugs in Spain, applying the Stanford algorithm, and to compare these results with reported Transmitted Drug Resistance (TDR defined by the 2009 update of the WHO SDRM list. METHODS: We analysed 2781 sequences from ARV naive patients of the CoRIS cohort (Spain between 2007-2011. Using the Stanford algorithm "Low-level resistance", "Intermediate resistance" and "High-level resistance" categories were considered as "Resistant". RESULTS: 70% of the TDR found using the WHO list were relevant for first-line treatment according to the Stanford algorithm. A total of 188 patients showed clinically relevant resistance to first-line ARVs [6.8% (95%Confidence Interval: 5.8-7.7], and 221 harbored TDR using the WHO list [7.9% (6.9-9.0]. Differences were due to a lower prevalence in clinically relevant resistance for NRTIs [2.3% (1.8-2.9 vs. 3.6% (2.9-4.3 by the WHO list] and PIs [0.8% (0.4-1.1 vs. 1.7% (1.2-2.2], while it was higher for NNRTIs [4.6% (3.8-5.3 vs. 3.7% (3.0-4.7]. While TDR remained stable throughout the study period, clinically relevant resistance to first line drugs showed a significant trend to a decline (p = 0.02. CONCLUSIONS: Prevalence of clinically relevant resistance to first line ARVs in Spain is decreasing, and lower than the one expected looking at TDR using the WHO list. Resistance to first-line PIs falls below 1%, so the recommendation of screening for TDR in the protease gene should be questioned in our setting. Cost-effectiveness studies need to be carried out to inform evidence-based recommendations.

  3. 75 FR 56059 - Patent Examiner Technical Training Program

    Science.gov (United States)

    2010-09-15

    ..., Electronic Commerce, Agriculture, National Security, and License & Review: e-Commerce applications including... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF COMMERCE... States Patent and Trademark Office, Commerce. ACTION: Notice. SUMMARY: The United States Patent...

  4. The Idea of Patents vs. the Idea of University.

    Science.gov (United States)

    de Campos, Thana Cristina

    2015-01-01

    It is generally accepted that patents are a driving force for innovation through research and development. But the university's involvement in patenting is problematic as well. In particular, it is in tension with the idea of a university itself. If patents entail a restriction on the accessibility of the scientific knowledge that has been patented, and if the main purpose of universities is to produce and disseminate knowledge to the public, then, there is a tension: when universities patent their research innovations, they are making the scientific knowledge they produce less accessible to the public. The paper argues that university patenting contradicts the very idea of a university as an institution whose mission is fundamentally to disseminate the knowledge it produces to the public. The practice of university patenting involves an un-academic attitude thus: by inciting an attitude towards knowledge that is not consistent with the proper attitudes and goals of a university, university patenting hurts university's integrity.

  5. An advanced search engine for patent analytics in medicinal chemistry.

    Science.gov (United States)

    Pasche, Emilie; Gobeill, Julien; Teodoro, Douglas; Gaudinat, Arnaud; Vishnykova, Dina; Lovis, Christian; Ruch, Patrick

    2012-01-01

    Patent collections contain an important amount of medical-related knowledge, but existing tools were reported to lack of useful functionalities. We present here the development of TWINC, an advanced search engine dedicated to patent retrieval in the domain of health and life sciences. Our tool embeds two search modes: an ad hoc search to retrieve relevant patents given a short query and a related patent search to retrieve similar patents given a patent. Both search modes rely on tuning experiments performed during several patent retrieval competitions. Moreover, TWINC is enhanced with interactive modules, such as chemical query expansion, which is of prior importance to cope with various ways of naming biomedical entities. While the related patent search showed promising performances, the ad-hoc search resulted in fairly contrasted results. Nonetheless, TWINC performed well during the Chemathlon task of the PatOlympics competition and experts appreciated its usability.

  6. Evaluating patent portfolios by means of multicriteria analysis

    Directory of Open Access Journals (Sweden)

    Xiaolu Wang

    2011-01-01

    Full Text Available Valuation of intangible assets is a complex topic where traditional methodologies are not always successful. Nevertheless, intangible assets, like patents, have become of great importance to companies, as their value is considered to be relevant economic and strategic information, so it is necessary to evaluate firms’ patent portfolios. The present research introduces an extended goal programming model to calculate the relative importance of the patents of companies in a patent pool. This information may be useful for patent valuation as well as for management purposes. The proposed multicriteria methodology has been applied to the 19 companies in the MPEG2 patent pool, with a total of 770 valid patents, using 7 criteria to obtain a composite measure of the relative position of the firms in the patent pool.

  7. Patent Database : A Methodology of Information Retrieval From PDF

    Directory of Open Access Journals (Sweden)

    Pawan Sharma

    2013-10-01

    Full Text Available Patent document holds wealth of information in itself. A brief detail of Indian patent applicationinformation is published as eighteen month publication by Indian patent Office, in electronic gazetteweekly. To date, a proper database of Indian patents specifically for research determination has not beenavailable, making it complicated for researcher to use this data for measuring any kind of researchactivities in terms of patents in India. To facilitate this, we constructed a comprehensive patent databasewhich incorporates the information presented in the electronic gazette. This database includes informationsuch as technology class, applicant, inventor, country of origin etc., of the patent submitted. We present themethodology for the creation of this database, its basic features along with its accuracy and reliability inthis research paper. Patent based database has been developed and can be used for various innovationresearches and activities.

  8. DNA Dilemma: A Perspective on Current U.S. Patent and Trademarh Office Philosophy Concerning Life Patents

    Energy Technology Data Exchange (ETDEWEB)

    Franz, K.; Faletra, P.

    2002-01-01

    The lack of a solid set of criteria for determining patentability of subject matter - particularly subject matter dealing with life - has recently been of increasing public concern in the United States. Alarm for patent practices related to life systems ranges from patents being granted on biochemical processes and the knowledge of these processes to the patenting of entire organisms. One of the most volatile concerns is the patenting of human genes or parts of genes since this genetic material is the basic informational molecule for all life. Current patent law, legislated in 1952, has been interpreted by the U.S. Supreme Court to allow broad patents of DNA, biochemical processes, and what are generally considered 'inventions' of life systems. Several issues are addressed in this paper regarding the unsound reasoning underlying both the interpretation and execution of patent law. Lapses in logic provide a gateway for businesses and individuals to take patenting to an illogical and unworkable extreme. Patent Office disorder of this magnitude is unnecessary and has great potential for harming the mission that the patent office was designed to serve. Recently disclosed patent-granting guidelines suggest the United States Patent and Trademark Office is not upholding its Constitutional responsibility of promoting the progress of science.

  9. 48 CFR 1827.305 - Administration of the patent rights clauses.

    Science.gov (United States)

    2010-10-01

    ... patent rights clauses. 1827.305 Section 1827.305 Federal Acquisition Regulations System NATIONAL AERONAUTICS AND SPACE ADMINISTRATION GENERAL CONTRACTING REQUIREMENTS PATENTS, DATA, AND COPYRIGHTS Patent Rights Under Government Contracts 1827.305 Administration of the patent rights clauses....

  10. New Approaches on Leishmaniasis Treatment and Prevention: A Review of Recent Patents.

    Science.gov (United States)

    Barbosa, Juliana F; de Figueiredo, Sônia M; Monteiro, Fabricio M; Rocha-Silva, Fabiana; Gaciele-Melo, Cidiane; Coelho, Sabrina S C; Lyon, Sandra; Caligiorne, Rachel B

    2015-01-01

    Leishmaniasis is considered a neglected tropical disease having a worldwide distribution. The disease is caused by protozoa belonging to the genus Leishmania, being clinically divided into visceral leishmaniasis (VL), cutaneous leishmaniasis (CL) and mucocutaneous leishmaniasis (MCL). Domestic dogs are the main parasite reservoir and effectively participate in the protozoa transmission. The human leishmaniasis treatment is based on a selection of therapeutic compounds, but the available drugs are toxic, presenting adverse side effects. The decision to treat or not to treat seropositive dogs is under discussion in some countries, because treatment is even more toxic to animals and, also, can generate drug resistant strains. Therefore, very few treatment choices have reached the clinic for this disease and there is an urgent need of new chemotherapy for both humans and animals. This study presents a review of new patents related to treatment and prevention of Leishmania infections. Some of these patents are related to new vaccine formulations for combating leishmaniasis. Likewise, the inventions related to the cream formulations for the treatment of cutaneous leishmaniasis are very important, avoiding the side effects of drugs during the treatment. Furthermore, anti leishmaniasis products that are extracted from nature has increasingly been patented each year, demonstrating the importance of bioprospection studies to improve the armamentarium of anti leishmaniasis drugs.

  11. Patent portfolio analysis model based on legal status information

    Institute of Scientific and Technical Information of China (English)

    Xuezhao; WANG; Yajuan; ZHAO; Jing; ZHANG; Ping; ZHAO

    2014-01-01

    Purpose:This research proposes a patent portfolio analysis model based on the legal status information to chart out a competitive landscape in a particular field,enabling organizations to position themselves within the overall technology landscape.Design/methodology/approach:Three indicators were selected for the proposed model:Patent grant rate,valid patents rate and patent maintenance period.The model uses legal status information to perform a qualitative evaluation of relative values of the individual patents,countries or regions’ technological capabilities and competitiveness of patent applicants.The results are visualized by a four-quadrant bubble chart To test the effectiveness of the model,it is used to present a competitive landscape in the lithium ion battery field.Findings:The model can be used to evaluate the values of the individual patents,highlight countries or regions’ positions in the field,and rank the competitiveness of patent applicants in the field.Research limitations:The model currently takes into consideration only three legal status indicators.It is actually feasible to introduce more indicators such as the reason for invalid patents and the distribution of patent maintenance time and associate them with those in the proposed model.Practical implications:Analysis of legal status information in combination of patent application information can help an organization to spot gaps in its patent claim coverage,as well as evaluate patent quality and maintenance situation of its granted patents.The study results can be used to support technology assessment,technology innovation and intellectual property management.Originality/value:Prior studies attempted to assess patent quality or competitiveness by using either single patent legal status indicator or comparative analysis of the impacts of each indicator.However,they are insufficient in presenting the combined effects of the evaluation indicators.Using our model,it appears possible to get a

  12. Patent Disclosure and R&D Competition in Pharmaceuticals

    OpenAIRE

    Fpammolli, F.Pammolli; Lmagazzini, L.Magazzini.; Mriccaboni, M.Riccaboni; Marossi, M.A.Rossi

    2009-01-01

    The prominent role played by patents within the pharmaceutical domain is unquestionable. In this paper we take an unusual perspective and focus on a relatively neglected implication of patents: the effect of patent-induced information disclosure (of both successes and failures) on the dynamics of R&D and market competition. The study builds upon the combination of two large datasets, linking the information about patents to firm level data on R&D projects and their outcome. Two case studies i...

  13. Digital pathology: A systematic evaluation of the patent landscape

    OpenAIRE

    Cucoranu, Ioan C.; Anil V. Parwani; Suryanarayana Vepa; Weinstein, Ronald S.; Liron Pantanowitz

    2014-01-01

    Introduction: Digital pathology is a relatively new field. Inventors of technology in this field typically file for patents to protect their intellectual property. An understanding of the patent landscape is crucial for companies wishing to secure patent protection and market dominance for their products. To our knowledge, there has been no prior systematic review of patents related to digital pathology. Therefore, the aim of this study was to systematically identify and evaluate United State...

  14. Contribution of rainfall, snow and ice melt to the hydrological regime of the Arve upper catchment and to severe flood events

    Science.gov (United States)

    Lecourt, Grégoire; Revuelto, Jesús; Morin, Samuel; Zin, Isabella; Lafaysse, Matthieu; Condom, Thomas; Six, Delphine; Vionnet, Vincent; Charrois, Luc; Dumont, Marie; Gottardi, Frédéric; Laarman, Olivier; Coulaud, Catherine; Esteves, Michel; Lebel, Thierry; Vincent, Christian

    2016-04-01

    In Alpine catchments, the hydrological response to meteorological events is highly influenced by the precipitation phase (liquid or solid) and by snow and ice melt. It is thus necessary to simulate accurately the snowpack evolution and its spatial distribution to perform relevant hydrological simulations. This work is focused on the upper Arve Valley (Western Alps). This 205 km2 catchment has large glaciated areas (roughly 32% of the study area) and covers a large range of elevations (1000-4500 m a.s.l.). Snow presence is significant year-round. The area is also characterized by steep terrain and strong vegetation heterogeneity. Modelling hydrological processes in such a complex catchment is therefore challenging. The detailed ISBA land surface model (including the Crocus snowpack scheme) has been applied to the study area using a topography based discretization (classifying terrain by aspect, elevation, slope and presence of glacier). The meteorological forcing used to run the simulations is the reanalysis issued from the SAFRAN model which assimilates meteorological observations from the Meteo-France networks. Conceptual reservoirs with calibrated values of emptying parameters are used to represent the underground water storage. This approach has been tested to simulate the discharge on the Arve catchment and three sub-catchments over 1990-2015. The simulations were evaluated with respect to observed water discharges for several headwaters with varying glaciated areas. They allow to quantify the relative contribution of rainfall, snow and ice melt to the hydrological regime of the basin. Additionally, we present a detailed analysis of several particular flood events. For these events, the ability of the model to correctly represent the catchment behaviour is investigated, looking particularly to the relevance of the simulated snowpack. Particularly, its spatial distribution is evaluated using MODIS snow cover maps, punctual snowpack observations and summer

  15. 78 FR 60256 - Initial Patent Applications

    Science.gov (United States)

    2013-10-01

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF COMMERCE... USPTO's system for electronic filing of patent correspondence. EFS-Web is accessible via the Internet on....41, 1.48, and 1.53(c)(2) can be filed electronically as well as in paper. The electronic options...

  16. Patent, Nanotechnology, and the Role of University

    Directory of Open Access Journals (Sweden)

    Agus Sardjono

    2011-01-01

    Full Text Available University has significant contribution tot the development of nanotechnology, The role of university can be implemented through the TTLO, particulary in an effort to build a bridge for bottom-up nanotechnology for commercial purposes. There will be an increasingly significant link betweent the patent system on the university role in the development of nanotechnology.

  17. Two new patents of Baoxiniao suit

    Institute of Scientific and Technical Information of China (English)

    2012-01-01

    Recently,Baoxiniao released two patents of suit--cool suit,zero grams of weight suits. "Cool suit" is fashion design,with leisure craft production.Natural fibre blended fabric to retain cool sense of the natural fibre fabric

  18. 14 CFR 1274.911 - Patent rights.

    Science.gov (United States)

    2010-01-01

    ...) Definitions. (1) Administrator means the Administrator or Deputy Administrator of NASA. (2) Invention means any invention or discovery which is or may be patentable or otherwise protectable under Title 35 of the United States Code. (3) Made when used in relation to any invention means the conception or...

  19. The Applicability of Patented Technologies to Sonobuoys

    Science.gov (United States)

    1989-06-30

    to Navy suppliers. F. Contact: Darryl Mexic, Esquire Patent Counsel Sughrue, Mion, Zinn , Macpeak & Seas 2100 Pennsylvania Avenue, NW Washington, DC...Bovernack Auoney, Agent. or Firm- Howard P. Terry; Seymour (75) Inventor: D d H. MeMa , Carlisle, Mass. Levine [73] Assignee: Sperry Corporatloin, New York

  20. Plant biotechnological patents from the legal perspective

    Directory of Open Access Journals (Sweden)

    Farhah Abdullah

    2009-08-01

    Full Text Available The purpose of this article is to examine the extent to which plant biotechnological patent in terms of natural product which has human intervention, different from other product and the entitlement of such a patent whether it is the inventor or biological donor s patent? In addition, the article discusses how would one determine the value added” by the company s researchers as opposed to the value contributed by the original genetic material. Meanwhile, the poor farmers and indigenous people who are the pioneers in terms of the knowledge of the plant, they are left unprivileged and deprived of their contribution and benefits. Thus, this article would highlight the significance of the contribution made by the original donor especially, in a poor developing country whose natural heritage has been taken away without any consideration, acknowledgment and how to strike a balance between the rights of an inventor and biological donor? Keywords: Plant Biotechnology, Patents, Inventor, Biological Donor, Developing countries Received: 7 July 2009 / Received in revised form: 28 August 2009, Accepted: 28 August 2009, Published online: 22 September 2009

  1. On Sharks, Trolls, and Other Patent Animals

    DEFF Research Database (Denmark)

    Reitzig, Markus; Henkel, Joachim; Heath, Christopher

    2007-01-01

    so, we map international indemnification rules with strategic rationales of small patent-holding firms within a game-theoretical model. Our central finding is that the courts’ unrealistic consideration of the trade-offs faced by inadvertent infringers is a central condition for sharks to operate...

  2. Savannah River Site Patented Technologies Summaries

    Energy Technology Data Exchange (ETDEWEB)

    Rabold, D.E.

    1995-07-18

    This information represents SRS`s contribution of the DOE technology information network, an internet service coordinated out of Los Alamos. The information provided is strictly DOE-SR-titled and-issued patented technologies including environmental remediation, robotics, sensors, materials science, biomedical applications, hydrogen, and consumer products.

  3. Patenting Marketing Methods: A Missing Topic in the Classroom

    Science.gov (United States)

    Christ, Paul

    2005-01-01

    Since the 1998 landmark case that validated the patenting of business methods as intellectual property, a plethora of patents has emerged. Patents for marketing-related processes have been particularly abundant, especially when new marketing processes are tied to a technology component. A review of the marketing literature and textbooks shows an…

  4. Patent Blocking and Infringement and their Effects on Firms?

    DEFF Research Database (Denmark)

    Grimpe, Christoph; Hussinger, Katrin

    In recent years, firms have increasingly contributed to and been confronted with a patent landscape characterized by numerous but marginal inventions, overlapping claims and patent fences. As a result, firms risk to be blocked in their patent applications or to be infringed upon by rivals. While...

  5. 45 CFR 650.4 - Standard patent rights clause.

    Science.gov (United States)

    2010-10-01

    ... special patent clause has been negotiated (see § 650.5). Patent Rights (August, 2005) (a) Definitions—(1) Invention means any invention or discovery which is or may be patentable or otherwise protectable under... Plant Variety Protection Act (7 U.S.C. 2321 et seq.). (2) Subject invention means any invention of...

  6. Use of Patent Information : Empirical Evidence from Innovative SMEs

    NARCIS (Netherlands)

    Masurel, Enno

    2005-01-01

    This paper discusses the use of patent information by innovative SMEs. The standard literature tends to focus on obtaining patents; studies of using patent information for different purposes are underrepresented in the innovation literature. Studying the case of SMEs is especially interesting, becau

  7. 78 FR 70294 - Intent To Grant an Exclusive Patent License

    Science.gov (United States)

    2013-11-25

    ... Department of the Air Force Intent To Grant an Exclusive Patent License Pursuant to the provisions of Part.... Provisional Patent Application No. 61/354,522, filed on June 14, 2010, entitled ``SUPERHYDROPHILIC AND...-provisional Patent Application No. 13/159,950, filed on June 14, 2011, entitled ``SUPERHYDROPHILIC...

  8. 14 CFR 1214.204 - Patent and data rights.

    Science.gov (United States)

    2010-01-01

    ... 14 Aeronautics and Space 5 2010-01-01 2010-01-01 false Patent and data rights. 1214.204 Section... Substantial Investment in the STS Program § 1214.204 Patent and data rights. (a) When accommodating missions... purposes rights to inventions, patents and data resulting from such missions, subject to the...

  9. 25 CFR 152.4 - Application for patent in fee.

    Science.gov (United States)

    2010-04-01

    ... 25 Indians 1 2010-04-01 2010-04-01 false Application for patent in fee. 152.4 Section 152.4 Indians BUREAU OF INDIAN AFFAIRS, DEPARTMENT OF THE INTERIOR LAND AND WATER ISSUANCE OF PATENTS IN FEE, CERTIFICATES OF COMPETENCY, REMOVAL OF RESTRICTIONS, AND SALE OF CERTAIN INDIAN LANDS Issuing Patents in...

  10. 48 CFR 52.227-3 - Patent Indemnity.

    Science.gov (United States)

    2010-10-01

    ... 48 Federal Acquisition Regulations System 2 2010-10-01 2010-10-01 false Patent Indemnity. 52.227-3... AND FORMS SOLICITATION PROVISIONS AND CONTRACT CLAUSES Text of Provisions and Clauses 52.227-3 Patent Indemnity. As prescribed in 27.201-2(c)(1), insert the following clause: Patent Indemnity (APR 1984) (a)...

  11. 77 FR 64315 - Prospective Grant of Exclusive Patent License

    Science.gov (United States)

    2012-10-19

    ... National Institute of Standards and Technology Prospective Grant of Exclusive Patent License AGENCY... patent license. SUMMARY: This is a notice in accordance with 35 U.S.C. 209(e) and 37 CFR 404.7(a)(1)(i... and commonwealths, to NIST's interest in the invention embodied in U.S. Provisional Patent...

  12. 48 CFR 970.5227-6 - Patent indemnity-subcontracts.

    Science.gov (United States)

    2010-10-01

    ... 48 Federal Acquisition Regulations System 5 2010-10-01 2010-10-01 false Patent indemnity... for Management and Operating Contracts 970.5227-6 Patent indemnity—subcontracts. Insert the following clause in solicitations and contracts in accordance with 970.2702-3: Patent Indemnity—Subcontracts...

  13. 77 FR 22298 - Intent To Grant an Exclusive Patent License

    Science.gov (United States)

    2012-04-13

    ... Department of the Air Force Intent To Grant an Exclusive Patent License Summary: Pursuant to the provisions....S. Patent No. 7,391,877, issued 24 June 2008, entitled ``Spatial Processor for Enhanced Performance... for the patent unless a written objection is received within fifteen (15) days from the date...

  14. 45 CFR 650.5 - Special patent provisions.

    Science.gov (United States)

    2010-10-01

    ... 45 Public Welfare 3 2010-10-01 2010-10-01 false Special patent provisions. 650.5 Section 650.5 Public Welfare Regulations Relating to Public Welfare (Continued) NATIONAL SCIENCE FOUNDATION PATENTS § 650.5 Special patent provisions. At the request of the prospective awardee or on recommendation...

  15. 36 CFR 9.18 - Surface use and patent restrictions.

    Science.gov (United States)

    2010-07-01

    ... 36 Parks, Forests, and Public Property 1 2010-07-01 2010-07-01 false Surface use and patent... INTERIOR MINERALS MANAGEMENT Mining and Mining Claims § 9.18 Surface use and patent restrictions. (a) The... to any claimant who wishes to take his claim to patent in Olympic National Park, Glacier Bay...

  16. 77 FR 55465 - US Air Force Exclusive Patent License

    Science.gov (United States)

    2012-09-10

    ... Department of the Air Force US Air Force Exclusive Patent License AGENCY: Air Force Research Laboratory... an Exclusive Patent License. SUMMARY: Pursuant to the provisions of part 404 of Title 37, Code of... interest the United States Air Force has in: U.S. Patent No. 8,051,475, filed on March 27, 2007 and...

  17. 77 FR 65673 - Prospective Grant of Exclusive Patent License

    Science.gov (United States)

    2012-10-30

    ... National Institute of Standards and Technology Prospective Grant of Exclusive Patent License AGENCY... patent license. SUMMARY: This is a notice in accordance with 35 U.S.C. 209(e) and 37 CFR 404.7(a)(1)(i... and commonwealths, to NIST's interest in the invention embodied in U.S. Patent Application No....

  18. 76 FR 57720 - Intent To Grant an Exclusive Patent License

    Science.gov (United States)

    2011-09-16

    ... Department of the Air Force Intent To Grant an Exclusive Patent License SUMMARY: Pursuant to the provisions... exclusive license in any right, title and interest the United States Air Force has in: U.S. Patent... license for the invention described in this patent application will be granted unless a written...

  19. 43 CFR 6.7 - Domestic patent protection.

    Science.gov (United States)

    2010-10-01

    ... 43 Public Lands: Interior 1 2010-10-01 2010-10-01 false Domestic patent protection. 6.7 Section 6.7 Public Lands: Interior Office of the Secretary of the Interior PATENT REGULATIONS Inventions by Employees § 6.7 Domestic patent protection. (a) The Solicitor, upon determining that an invention...

  20. 7 CFR 1160.505 - Patents, copyrights, inventions and publications.

    Science.gov (United States)

    2010-01-01

    ... 7 Agriculture 9 2010-01-01 2009-01-01 true Patents, copyrights, inventions and publications. 1160... PROGRAM Fluid Milk Promotion Order Miscellaneous § 1160.505 Patents, copyrights, inventions and publications. (a) Any patents, copyrights, trademarks, inventions or publications developed through the use...

  1. 25 CFR 152.5 - Issuance of patent in fee.

    Science.gov (United States)

    2010-04-01

    ... 25 Indians 1 2010-04-01 2010-04-01 false Issuance of patent in fee. 152.5 Section 152.5 Indians BUREAU OF INDIAN AFFAIRS, DEPARTMENT OF THE INTERIOR LAND AND WATER ISSUANCE OF PATENTS IN FEE, CERTIFICATES OF COMPETENCY, REMOVAL OF RESTRICTIONS, AND SALE OF CERTAIN INDIAN LANDS Issuing Patents in...

  2. 48 CFR 2527.7002 - NSF patent policy.

    Science.gov (United States)

    2010-10-01

    ... 48 Federal Acquisition Regulations System 6 2010-10-01 2010-10-01 true NSF patent policy. 2527... CONTRACTING REQUIREMENTS PATENTS, DATA, AND COPYRIGHTS Disposition of Rights in Inventions 2527.7002 NSF patent policy. As authorized by the National Science Board at its 230th meeting, October 15-16, 1981,...

  3. 50 CFR 82.19 - Patents and inventions.

    Science.gov (United States)

    2010-10-01

    ... 50 Wildlife and Fisheries 6 2010-10-01 2010-10-01 false Patents and inventions. 82.19 Section 82...-IN-AID (MARINE MAMMAL PROTECTION ACT OF 1972) Administration § 82.19 Patents and inventions. Determination of the patent rights in any inventions or discoveries resulting from work under...

  4. 7 CFR 1150.184 - Patents, copyrights, inventions and publications.

    Science.gov (United States)

    2010-01-01

    ... 7 Agriculture 9 2010-01-01 2009-01-01 true Patents, copyrights, inventions and publications. 1150... Dairy Promotion and Research Order Miscellaneous § 1150.184 Patents, copyrights, inventions and publications. Any patents, copyrights, trademarks, inventions or publications developed through the use...

  5. 7 CFR 1260.215 - Patents, copyrights, inventions and publications.

    Science.gov (United States)

    2010-01-01

    ... 7 Agriculture 10 2010-01-01 2010-01-01 false Patents, copyrights, inventions and publications... AGRICULTURE BEEF PROMOTION AND RESEARCH Beef Promotion and Research Order Miscellaneous § 1260.215 Patents, copyrights, inventions and publications. (a) Any patents, copyrights, inventions or publications...

  6. 77 FR 71004 - Patents and Inventions; Delegation of Authority

    Science.gov (United States)

    2012-11-28

    ... HUMAN SERVICES Centers for Disease Control and Prevention Patents and Inventions; Delegation of... administer and make decisions regarding the invention and patent program of CDC and the authority to make determinations of rights in inventions and patents in which CDC and the Department have an interest....

  7. 10 CFR 603.840 - Negotiating data and patent rights.

    Science.gov (United States)

    2010-01-01

    ... 10 Energy 4 2010-01-01 2010-01-01 false Negotiating data and patent rights. 603.840 Section 603... patent rights. (a) The contracting officer must confer with program officials and assigned intellectual... that would support modification of standard patent and data terms, and should include...

  8. 48 CFR 28.105-2 - Patent infringement bonds.

    Science.gov (United States)

    2010-10-01

    ... 48 Federal Acquisition Regulations System 1 2010-10-01 2010-10-01 false Patent infringement bonds... GENERAL CONTRACTING REQUIREMENTS BONDS AND INSURANCE Bonds and Other Financial Protections 28.105-2 Patent infringement bonds. (a) Contracts providing for patent indemnity may require these bonds only if— (1)...

  9. 9 CFR 124.20 - Patent term extension calculation.

    Science.gov (United States)

    2010-01-01

    ... 9 Animals and Animal Products 1 2010-01-01 2010-01-01 false Patent term extension calculation. 124... OF AGRICULTURE VIRUSES, SERUMS, TOXINS, AND ANALOGOUS PRODUCTS; ORGANISMS AND VECTORS PATENT TERM RESTORATION Regulatory Review Period § 124.20 Patent term extension calculation. (a) As provided in 37 CFR...

  10. Mapping (USPTO) patent data using overlays to Google Maps

    NARCIS (Netherlands)

    Leydesdorff, L.; Bornmann, L.

    2012-01-01

    A technique is developed using patent information available online (at the U.S. Patent and Trademark Office) for the generation of Google Maps. The overlays indicate both the quantity and the quality of patents at the city level. This information is relevant for research questions in technology anal

  11. The Coordination of Independently-Owned Vacuum Tube Patents in the Early Radio Alleged Patent ‘Thicket’

    DEFF Research Database (Denmark)

    Howells, John; Katznelson, RD

    present in radio development, 1905-1920, with numerous allegations of an impasse in bargaining the necessary patent rights for legal development. This paper seeks to determine with new precision how entrepreneurs and managers actually managed patent rights in this scenario. Accordingly, this paper re......-examines the legal trajectories and entrepreneurial exploitation of these patents with a focus on vacuum tube technology where Fleming’s diode patent ‘overlapped’ with earlier prior art and, dependent on court decisions, with later commercial implementations of De Forest’s triode patents. We show, by means...... of the relevant historical record, patent claims, litigation records and other relevant law, how the ‘overlapping’ patent rights were resolved by the courts and by the immunity of suppliers to the Government from patent infringement liability. We trace the cross-licensing agreements between the different radio...

  12. MOUTH DISSOLVING FILM AND THEIR PATENT: AN OVERVIEW

    Directory of Open Access Journals (Sweden)

    Udhan Ravindra Radhakisan

    2012-09-01

    Full Text Available Now days the researchers are focusing on the fast dissolving dosage form (FDDF’s.The fast dissolving dosage forms includes the mouth dissolving tablets, mouth dissolving thin films .The alternative words used for these dosage forms are fast disintegrating, orodispersible, fast dissolving. The oral thin film technology (OTF’s is a dissolvable film technology have evolved from a purely confectionery novelty from a drug delivery platform. The OTH dosage form dissolves in the moth without need of water and within 10-15 seconds is the novelty of this dosage form. On the basis of this novelty many patents are available in the US country. Intraoral delivery is particularly beneficial to patients with special needs that are unable to tolerate traditional oral (entral/through GI track administration due to nausea, vomiting or dysphasia. Many pharmaceutical companies focusing on this Oral thin film technology. Today, this film technology is approved by is approved by FDA.

  13. Taiwan's Information Security Policy Enhancement: an Analysis of Patent Indicators and Patent Documents

    Science.gov (United States)

    Hsu, Nai-Wen; Liang-Shiuan, Jr.; Chen, Yi-Chang

    2007-12-01

    Information security policy in Taiwan stems the gap between expectation and reality. For this, the paper presents an analysis of patent indicators and patent document attempt to conclude the overview of the information security technology development. The paper also identifies the leading countries and cutting-edge areas with potential trends. Finally, several practicable and valuable strategies after this work are generalized to achieve the goals of Taiwan information security policy.

  14. A Patent Analysis for Sustainable Technology Management

    Directory of Open Access Journals (Sweden)

    Junhyeog Choi

    2016-07-01

    Full Text Available Technology analysis (TA is an important issue in the management of technology. Most R&D (Research & Development policies have depended on diverse TA results. Traditional TA results have been obtained through qualitative approaches such as the Delphi expert survey, scenario analysis, or technology road mapping. Although they are representative methods for TA, they are not stable because their results are dependent on the experts’ knowledge and subjective experience. To solve this problem, recently many studies on TA have been focused on quantitative approaches, such as patent analysis. A patent document has diverse information of developed technologies, and thus, patent is one form of objective data for TA. In addition, sustainable technology has been a big issue in the TA fields, because most companies have their technological competitiveness through the sustainable technology. Sustainable technology is a technology keeping the technological superiority of a company. So a country as well as a company should consider sustainable technology for technological competition and continuous economic growth. Also it is important to manage sustainable technology in a given technology domain. In this paper, we propose a new patent analysis approach based on statistical analysis for the management of sustainable technology (MOST. Our proposed methodology for the MOST is to extract a technological structure and relationship for knowing the sustainable technology. To do this, we develop a hierarchical diagram of technology for finding the causal relationships among technological keywords of a given domain. The aim of the paper is to select the sustainable technology and to create the hierarchical technology paths to sustainable technology for the MOST. This contributes to planning R&D strategy for the sustainability of a company. To show how the methodology can be applied to real problem, we perform a case study using retrieved patent documents related to

  15. Ethical limitations in patenting biotechnological inventions.

    Science.gov (United States)

    Lugagnani, V

    1999-01-01

    In order to connect ethical considerations with practical limits to patentability, the moral judgement should possibly move from the exploitation of the invention to the nature and/or objectives of Research and Development (R&D) projects which have produced it: in other words, it appears quite reasonable and logical that Society is not rewarding unethical R&D activities by granting intellectual property rights. As far as biotechnology R&D is concerned, ethical guidance can be derived from the 1996 Council of EuropeOs OConvention for the protection of human rights and dignity of the human being with regard to the application of biology and medicineO, whose Chapter V - Scientific research - provides guidelines on: i. protection of persons undergoing research (e.g. informed consent); ii. protection of persons not able to consent to research; iii. research on embryos in vitro. As far as the specific point of patenting biotechnology inventions is concerned, the four exclusions prescribed by Directive 98/44/EC (i.e. human cloning, human germ-line gene therapy, use of human embryos for commercial purposes, unjustified animal suffering for medical purposes) are all we have in Europe in terms of ethical guidance to patentability. In Italy, in particular, we certainly need far more comprehensive legislation, expressing SocietyOs demand to provide ethical control of modern biotechnology. However it is quite difficult to claim that ethical concerns are being raised by currently awarded biotechnology patents related to living organisms and material thereof; they largely deal with the results of genomic R&D, purposely and usefully oriented toward improving health-care and agri-food processes, products and services. ONo patents on lifeOO can be an appealing slogan of militants against modern biotechnology, but it is far too much of an over-simplified abstraction to become the Eleventh Commandment our Society.

  16. A patent strategy for genomic and research tool patents: are there any differences between the USA, Europe and Japan?

    Science.gov (United States)

    L Ihnen J

    2000-12-01

    The patenting of genomics and research tools, and its effects on the development of therapeutics are attracting considerable attention. Regardless of whether one is in favor of patents for this technology, it is not specifically excluded from patenting in most countries. Accordingly, it is imperative that a suitable global patent strategy be developed and followed to maximize both intellectual property rights and returns on R&D investment.

  17. The pharmaceutical sector, patents and access to medicines in the South

    Directory of Open Access Journals (Sweden)

    Xabier Barrutia Etxebarría

    2003-12-01

    Full Text Available This article deals with the lack of access to drug treatments experienced by the poor in the economic South. First, it studies the extraordinarily profitable pharmaceutical industry, whose research forgets about the illnesses typical of the South, given its greatbusiness and market concentration in the countries of the North, where marketing is decisive. Then, it deals with the relationship between the high prices of medicines and a patent system which is greatly strengthened by the rules of the WTO and which clasheswith people’s right to health, as revealed by the case of HIV-AIDS treatment in the countries of the South. The paper concludes by underscoring the need for an active intervention by the public sector, both at a national and international level, which wouldlimit the patents on drugs and promote research on the forgotten diseases.

  18. Innovation Effect on Patent Pool Formation:Empirical Case of Philips’ Patents in Digital Versatile Disc 3C

    Directory of Open Access Journals (Sweden)

    Yu-Hui Wang

    2013-08-01

    Full Text Available The aim of this paper is to understand the evolution of a patent pool over time, focusing on an individual firm. The legitimacy of patent pools requires a careful balance between innovation incentives, anti-competitive possibilities and consumer surpluses. Thus, it is an empirically important issue whether a patent pool continues to maintain this carefully struck balance even as the mix of its patent assets continues to evolve. The particular focus of this study is to examine the quality and quantity of Phillips’ patent holdings within the DVD 3C patent pool in order to understand the extent of the firm’s innovation within that patent pool over its lifetime, measured by four indicators that previous scholars have linked to the notion of patent quality. The result shows that, while the four indicators of patent quality varied, they together reveal that the breadth of exclusivity expanded significantly during the life of the patent pool, but that this expansion represented little innovative activity. Most of the patents issued post-formation are extensions of patents granted before pool-formation.

  19. Evaluating patent portfolios by means of multicriteria analysis

    Directory of Open Access Journals (Sweden)

    Xiaolu Wang

    2011-06-01

    Full Text Available Valuation of intangible assets is a complex topic where traditional methodologies are not always successful. Nevertheless, intangible assets, like patents, have become of great importance to companies, as their value is considered to be relevant economic and strategic information, so it is necessary to evaluate firms’ patent portfolios. The present research introduces an extended goal programming model to calculate the relative importance of the patents of companies in a patent pool. This information may be useful for patent valuation as well as for management purposes. The proposed multicriteria methodology has been applied to the 19 companies in the MPEG2 patent pool, with a total of 770 valid patents, using 7 criteria to obtain a composite measure of the relative position of the firms in the patent pool.RESUMENLa valoración de activos intangibles constituye un área compleja donde los métodos tradicionales no siempre obtienen buenos resultados. Sin embargo, los activos intangibles, entre ellos las patentes, han ganado importancia en las empresas, de forma que el cálculo de su valor se ha convertido en una cuestión estratégica en muchos casos. Este hecho requiere que las empresas valoren la cartera de patentes en su conjunto. La presente investigación presenta un modelo extendido de programación por metas y su aplicación para el cálculo de la importancia relativa de las patentes. Este modelo puede resultar importante tanto para la valoración de las patentes como para la gestión empresarial. La metodología multicriterio propuesta ha sido aplicado a 19 empresas en el sector de las patentes del formato MPEG2, con un total de 770 patentes válidas, y utilizando 7 criterios con el objetivo de obtener una medida compuesta de la posición relativa de las empresas en el conjunto de patentes.

  20. Pharmaceutical Patents and Prices : A Preliminary Empirical Assessment Using Data from India

    OpenAIRE

    Duggan, Mark; Goyal, Aparajita

    2012-01-01

    The enforcement of stringent intellectual property rights in the pharmaceutical sector of developing countries generates considerable controversy, due to both the extensive research investment and the public policy importance of this sector. This paper explores the likely effects of enforcing product patents on prices and utilization of drugs in the Central Nervous System market in India. The Central Nervous System segment is the second largest therapeutic category in terms of retail sales in...

  1. Patent analysis for competitive technical intelligence and innovative thinking

    Directory of Open Access Journals (Sweden)

    H Dou

    2006-01-01

    Full Text Available Patents are a very useful source of technical information. The public availability of patents over the Internet, with for some databases (eg. Espacenet the assurance of a constant format, allows the development of high value added products using this information source and provides an easy way to analyze patent information. This simple and powerful tool facilitates the use of patents in academic research, in SMEs and in developing countries providing a way to use patents as a ideas resource thus improving technological innovation.

  2. Inventing around Edison’s Incandescent Lamp Patent

    DEFF Research Database (Denmark)

    Katznelson, RD; Howells, John

    ’s ‘898 patent. Third, by analysis of forward citation to these patents we show that regardless of these inventions’ commercial viability in the incandescent lamp market, some became important prior art for new technological fields and some laid the groundwork for the later successful substitute...... for Edison’s carbon filament. Fourthly, we show that the recent view that Edison’s patent gave the patent holder General Electric (GE) a dominant position in the incandescent lamp market is incorrect: we show that besides commercially-successful invention around the claims of this patent, data for GE...

  3. Chemical named entity recognition in patents by domain knowledge and unsupervised feature learning.

    Science.gov (United States)

    Zhang, Yaoyun; Xu, Jun; Chen, Hui; Wang, Jingqi; Wu, Yonghui; Prakasam, Manu; Xu, Hua

    2016-01-01

    Medicinal chemistry patents contain rich information about chemical compounds. Although much effort has been devoted to extracting chemical entities from scientific literature, limited numbers of patent mining systems are publically available, probably due to the lack of large manually annotated corpora. To accelerate the development of information extraction systems for medicinal chemistry patents, the 2015 BioCreative V challenge organized a track on Chemical and Drug Named Entity Recognition from patent text (CHEMDNER patents). This track included three individual subtasks: (i) Chemical Entity Mention Recognition in Patents (CEMP), (ii) Chemical Passage Detection (CPD) and (iii) Gene and Protein Related Object task (GPRO). We participated in the two subtasks of CEMP and CPD using machine learning-based systems. Our machine learning-based systems employed the algorithms of conditional random fields (CRF) and structured support vector machines (SSVMs), respectively. To improve the performance of the NER systems, two strategies were proposed for feature engineering: (i) domain knowledge features of dictionaries, chemical structural patterns and semantic type information present in the context of the candidate chemical and (ii) unsupervised feature learning algorithms to generate word representation features by Brown clustering and a novel binarized Word embedding to enhance the generalizability of the system. Further, the system output for the CPD task was yielded based on the patent titles and abstracts with chemicals recognized in the CEMP task.The effects of the proposed feature strategies on both the machine learning-based systems were investigated. Our best system achieved the second best performance among 21 participating teams in CEMP with a precision of 87.18%, a recall of 90.78% and aF-measure of 88.94% and was the top performing system among nine participating teams in CPD with a sensitivity of 98.60%, a specificity of 87.21%, an accuracy of 94.75%, a

  4. Chemical named entity recognition in patents by domain knowledge and unsupervised feature learning

    Science.gov (United States)

    Zhang, Yaoyun; Xu, Jun; Chen, Hui; Wang, Jingqi; Wu, Yonghui; Prakasam, Manu; Xu, Hua

    2016-01-01

    Medicinal chemistry patents contain rich information about chemical compounds. Although much effort has been devoted to extracting chemical entities from scientific literature, limited numbers of patent mining systems are publically available, probably due to the lack of large manually annotated corpora. To accelerate the development of information extraction systems for medicinal chemistry patents, the 2015 BioCreative V challenge organized a track on Chemical and Drug Named Entity Recognition from patent text (CHEMDNER patents). This track included three individual subtasks: (i) Chemical Entity Mention Recognition in Patents (CEMP), (ii) Chemical Passage Detection (CPD) and (iii) Gene and Protein Related Object task (GPRO). We participated in the two subtasks of CEMP and CPD using machine learning-based systems. Our machine learning-based systems employed the algorithms of conditional random fields (CRF) and structured support vector machines (SSVMs), respectively. To improve the performance of the NER systems, two strategies were proposed for feature engineering: (i) domain knowledge features of dictionaries, chemical structural patterns and semantic type information present in the context of the candidate chemical and (ii) unsupervised feature learning algorithms to generate word representation features by Brown clustering and a novel binarized Word embedding to enhance the generalizability of the system. Further, the system output for the CPD task was yielded based on the patent titles and abstracts with chemicals recognized in the CEMP task. The effects of the proposed feature strategies on both the machine learning-based systems were investigated. Our best system achieved the second best performance among 21 participating teams in CEMP with a precision of 87.18%, a recall of 90.78% and a F-measure of 88.94% and was the top performing system among nine participating teams in CPD with a sensitivity of 98.60%, a specificity of 87.21%, an accuracy of 94.75%, a

  5. Review of patents and application of spray drying in pharmaceutical, food and flavor industry.

    Science.gov (United States)

    Patel, Bhavesh B; Patel, Jayvadan K; Chakraborty, Subhashis

    2014-04-01

    Spray drying has always remained an energetic field of innovation in pharmaceutical, food and flavor industry since last couple of decades. The current communication embodies an in-depth application of spray drying in pulmonary drug delivery for production of uniform and respirable size particles suitable for nebulizers, dry powder inhalers (DPI) and pressurized metered dose inhalers (pMDI). The review also highlights spray drying application in the manufacturing of mucoadhesive formulation suitable for nasal cavities to improve the drug absorption and bioavailability. Recent research works and patents filed by various researchers on spray drying technology for solubility enhancement have also been accentuated. Benefits of spray drying in production of dry flavorings to meet a product with maximum yield and least flavor loss are also discussed. The use of spray drying in production of various food products like milk or soymilk powder, tomato pulp, dry fruit juice etc, and in encapsulation of vegetable oil or fish oil and dry creamer has been discussed. Current review also highlights the application of spray drying in the biotechnology field like production of dry influenza or measles vaccine as well as application in ceramic industry. Spray drying based patents issued by the U.S. Patent and Trademark Office in the area of drug delivery have also been included in the current review to emphasize importance of spray drying in the recent research scenario.

  6. Patent Value: A Business Perspective for Technology Startups

    Directory of Open Access Journals (Sweden)

    Angela de Wilton

    2011-12-01

    Full Text Available In the last year, news headlines have highlighted record patent infringement settlements, multibillion dollar auctions of large corporate patent portfolios, and ongoing patent battles between key technology industry players. Despite this acknowledgment of the significant value of patents for large corporations, many small technology companies are understandably more focused on the near-term costs of obtaining a patent rather than future value. Costs may seem prohibitive to an early stage technology startup. Some software startups question whether patents are relevant to their business. In practice, effective intellectual property (IP strategy and management is dependent on many factors, such as technology or industry sector, size and maturity of the business, technology lifecycle, and the business and market environment. IP strategy must be aligned to business strategy from the outset. By considering IP in the broader context of the overall business plan and the competitive environment, opportunities for generating increased return on R&D investment and added business value through patents or other forms of IP can be recognized early on. This approach ensures that a decision about whether or not to patent is driven by business reasons rather than budget constraints. This article examines the costs and benefits of patents from the perspective of early-stage technology startups and growing businesses, and it provides some general guidance on best practices for developing an IP and patent activity plan and for building a patent portfolio that appropriately supports business objectives.

  7. Inventing around Edison’s Incandescent Lamp Patent

    DEFF Research Database (Denmark)

    Howells, John; Katznelson, Ron D.

    We provide an anatomy of the influence of Edison’s incandescent lamp patent U.S. 223,898 on downstream development and show how subsequent inventor activity adjusts to the improved certainty provided by court decisions as to the boundaries of a patent’s claims. First, we show that court decisions...... upholding Edison’s patent generated a surge of patent filings in the incandescent lamp classes at the U.S. Patent Office. Second, by inspection of the specifications of these later patents we are able to categorize certain design-around efforts by their evasion of specific elements of the claims of Edison......’s ‘898 patent. Third, by analysis of forward citation to these patents we show that regardless of these inventions’ commercial viability in the incandescent lamp market, some became important prior art for new technological fields and some laid the groundwork for the later successful substitute...

  8. An Analysis of the Patents concerning Hevea brasiliensis

    Institute of Scientific and Technical Information of China (English)

    Xijuan; LI; Qing; CHEN; Bingjiang; XU; Xinxin; REN; Huasun; HUANG; Qiong; LI

    2015-01-01

    This paper mainly analyzes the application data of patents concerning Hevea brasiliensis in the world and China from the perspectives of time,research field,and the geographical distribution of applicants. It also interprets the patents for invention in China from time,research field,and types of applicants. Based on the study,it shows that although the patent applications fluctuate,the general trend is rising. And the patents are mostly concentrated in plant protection,and agricultural biotechnology. The Chinese applicants of patents for invention largely work in the research institutes,and most of these patents focus on the field of plant protection,agricultural biotechnology,and agro-processing.However,the foreign applicants mainly work in companies,and most of these patents only focus on plant protection. These findings will provide a reference for formulating development policies about natural rubber industry in China.

  9. The Unified Patent Court (UPC) in Action

    DEFF Research Database (Denmark)

    Petersen, Clement Salung; Schovsbo, Jens Hemmingsen; Riis, Thomas

    2015-01-01

    The new common judiciary for European patents (UPC) will play a crucial role in the future European patent system. The UPC will be a very specialised court that i.a. recruits judges from specialists’ circles and has as part of its mission to develop a coherent and autonomous body of case law....... The article points out that the UPC because of this design will be biased towards technology based values and uniformity at the expense of other values and interests e.g. non-economic public interests, and values associated with diversity. The practical effects of these biases are analysed regarding cases...... involving ordre public and morality and scope of protection. The article shows that the biases will affect the law in all the areas discussed and that if unchecked they will reduce some of the “wriggling room” which the current system has provided. To maintain that room a focused effort by the UPC...

  10. Patent ductus arteriosus with Eisenmenger syndrome.

    Science.gov (United States)

    Moustafa, Sherif; Patton, David J; Balon, Yvonne; Connelly, Michael S; Alvarez, Nanette

    2013-11-01

    Herein we report a 21 year-old woman with a previously documented patent ductus arteriosus and Eisenmenger physiology. She presented with increasing cyanosis and exercise intolerance which could be explained by a new finding of right to left shunting through an interatrial communication. She was started on Bosentan therapy aiming to reduce the pulmonary pressure with consideration for heart-lung transplantation should any further deterioration occur.

  11. A rare association with patent ductus arteriosus

    Directory of Open Access Journals (Sweden)

    Dhanya Warrier

    2012-01-01

    Full Text Available Persistent fifth aortic arch (PFAA, also known as congenital double-lumen aortic arch, is a rare developmental anomaly of the aortic arch. A 5-month-old baby who presented with congestive cardiac failure was diagnosed to have a large patent ductus arteriosus with PFAA. Although this arch anomaly had no hemodynamic relevance in this case, preoperative diagnosis prevented surprises "on table."

  12. Bioethics commission to review gene patenting

    Energy Technology Data Exchange (ETDEWEB)

    Rothenburg, L.

    1995-12-01

    In October, in an unexpected development, U.S. President Bill Clinton created a national ethics advisory board, the National Bioethics Advisory Commission (NBAC, Washington, DC), to study both research ethics and the management and use of genetic information. Of particular interest to biotechnology companies and researchers is the fact that the commission`s brief encompasses issues about human gene patenting, a subject not contained in earlier proposals for the commission.

  13. Transparency in the pharmaceutical industry - A cost accounting approach to the prices of drugs

    NARCIS (Netherlands)

    Broekhof, Martijn

    2002-01-01

    The WTO TRIPS agreement grants pharmaceutical companies patent rights on new innovative drugs. Patents give these companies the opportunity to charge higher prices for their drugs in order to recover their R&D expenses. For developing countries this is one of the reasons why people in developing cou

  14. On Management Crisis, Innovation and Patent

    Institute of Scientific and Technical Information of China (English)

    陈荣莲

    2005-01-01

    There are lots of management crisises in chinese enterprises with development of china' s economy. There exists a bottle neck in the transition from middle-level to international level group for Chinese companies. While the general principles behind wise competition policy are well understood, their application in particular industries and particular cases calls for careful analytical thinking. That thinking often includes economics. Innovation competition policy can be analyzed using the same general principles as other parts of competition policy. It is important to understand innovation competition policy, because several kinds of innovation are important in the modern economy. How could such industries as software, semiconductors, and computers have been so innovative despite historically weak patent protection? We argue that if innovation is both sequential and complementary- as it certainly has been in those industries-competition can increase firms' future profits thus offsetting short-term dissipation of rents. A simple model also shows that in such a dynamic industry, patent protection may reduce overall innovation and social welfare. Standard arguments would predict that R&D intensity and productivity should have increased among patenting firms.

  15. Why Is Hard To Patent An Invention?

    Directory of Open Access Journals (Sweden)

    2007-01-01

    Full Text Available When employed by a company, in almost all the cases a new employee has to sign an agreement giving the company exclusive rights to any intellectual property developed as part of their work assignments. This agreement could extend beyond a change of jobs and cause conflict of interests in new employment situations. A patent is a government-granted monopoly given to an inventor as both a reward for the intellectual and financial investment, and a stimulus to innovate. As a monopoly, the patent has legal power to exclude others from exploiting the invention in any way for a period of 20 years from the time the patent application has been filed. A trademark provides instant recognition of a product or company; a service mark provides instant recognition of a service. They both have unlimited lifetime. But the owner must renew or confirm continuous use at the end of five years, and every 10 years thereafter. A trade secret is information keep secret by the owner to give him advantage over competitors. Since it is secret, a trade secret protection has unlimited lifetime.

  16. Patents Assessed through Sectoral Operational Programs

    Directory of Open Access Journals (Sweden)

    Paula – Angela VIDRAȘCU

    2014-06-01

    Full Text Available According to the International Accounting Standards – IAS 38 „Intangible assets”; these assets are identifiable non-monetary assets under construction were considered without physical substance. Lack actual physical form must not be understood that an intangible asset would have no material support, because the presence of any intangible asset can be demonstrated only by a support material form. Exmple: frequently encounter compact-disc (in case a software, legal documentation (in the case of licences, trade marks and patents of invention, contracts, permits and licences, technical documentation or films. Nowadays we are constantly subjected to the changing flow of information that is found in a perpetual technological change which started the emergence of a new stage in the society development that which carries the name of knowledge. The object of my research is the patent for the structural funds reimbursable project submitted in the "Operational Program, Economic Competitiveness" Operation 2.3.1. "Support for start-ups and innovative spin-offs. Patent is an official document certifying the inventor, the exclusive right to produce a certain good or product or use a particular process. Remember that evaluation of intangible assets is the most complex and systematic procedure.

  17. Evaluation of Brazilian biotechnology patent activity from 1975 to 2010.

    Science.gov (United States)

    Dias, F; Delfim, F; Drummond, I; Carmo, A O; Barroca, T M; Horta, C C; Kalapothakis, E

    2012-08-01

    The analysis of patent activity is one methodology used for technological monitoring. In this paper, the activity of biotechnology-related patents in Brazil were analyzed through 30 International Patent Classification (IPC) codes published by the Organization for Economic Cooperation and Development (OECD). We developed a program to analyse the dynamics of the major patent applicants, countries and IPC codes extracted from the Brazilian Patent Office (INPI) database. We also identified Brazilian patent applicants who tried to expand protection abroad via the Patent Cooperation Treaty (PCT). We had access to all patents published online at the INPI from 1975 to July 2010, including 9,791 biotechnology patent applications in Brazil, and 163 PCTs published online at World Intellectual Property Organization (WIPO) from 1997 to December 2010. To our knowledge, there are no other online reports of biotechnology patents previous to the years analyzed here. Most of the biotechnology patents filed in the INPI (10.9%) concerned measuring or testing processes involving nucleic acids. The second and third places belonged to patents involving agro-technologies (recombinant DNA technology for plant cells and new flowering plants, i.e. angiosperms, or processes for obtaining them, and reproduction of flowering plants by tissue culture techniques). The majority of patents (87.2%) were filed by nonresidents, with USA being responsible for 51.7% of all biotechnology patents deposited in Brazil. Analyzing the resident applicants per region, we found a hub in the southeast region of Brazil. Among the resident applicants for biotechnology patents filed in the INPI, 43.5% were from São Paulo, 18.3% were from Rio de Janeiro, and 9.7% were from Minas Gerais. Pfizer, Novartis, and Sanofi were the largest applicants in Brazil, with 339, 288, and 245 biotechnology patents filed, respectively. For residents, the largest applicant was the governmental institution FIOCRUZ (Oswaldo Cruz

  18. Longitudinal Detection and Persistence of Minority Drug-Resistant Populations and Their Effect on Salvage Therapy.

    Directory of Open Access Journals (Sweden)

    Masako Nishizawa

    Full Text Available Drug-resistant HIV are more prevalent and persist longer than previously demonstrated by bulk sequencing due to the ability to detect low-frequency variants. To clarify a clinical benefit to monitoring minority-level drug resistance populations as a guide to select active drugs for salvage therapy, we retrospectively analyzed the dynamics of low-frequency drug-resistant population in antiretroviral (ARV-exposed drug resistant individuals.Six HIV-infected individuals treated with ARV for more than five years were analyzed. These individuals had difficulty in controlling viremia, and treatment regimens were switched multiple times guided by standard drug resistance testing using bulk sequencing. To detect minority variant populations with drug resistance, we used a highly sensitive allele-specific PCR (AS-PCR with detection thresholds of 0.3-2%. According to ARV used in these individuals, we focused on the following seven reverse transcriptase inhibitor-resistant mutations: M41L, K65R, K70R, K103N, Y181C, M184V, and T215F/Y. Results of AS-PCR were compared with bulk sequencing data for concordance and presence of additional mutations. To clarify the genetic relationship between low-frequency and high-frequency populations, AS-PCR amplicon sequences were compared with bulk sequences in phylogenetic analysis.The use of AS-PCR enabled detection of the drug-resistant mutations, M41L, K103N, Y181C, M184V and T215Y, present as low-frequency populations in five of the six individuals. These drug resistant variants persisted for several years without ARV pressure. Phylogenetic analysis indicated that pre-existing K103N and T215I variants had close genetic relationships with high-frequency K103N and T215I observed during treatment.Our results demonstrate the long-term persistence of drug-resistant viruses in the absence of drug pressure. The rapid virologic failures with pre-existing mutant viruses detectable by AS-PCR highlight the clinical importance of

  19. Androgen receptor splice variant 7 (AR-V7) and drug efficacy in castration-resistant prostate cancer: Biomarker for treatment selection exclusion or inclusion?

    Science.gov (United States)

    Leibrand, Crystal R; Price, Douglas K; Figg, William D

    2016-05-01

    Currently there are no molecular biomarkers used to help guide treatment selection for those patients with castration-resistant prostate cancer. A recent study published in JAMA Oncology (Antonarakis et al.) presents evidence supporting the potential use of androgen receptor splice variant 7 as a biomarker for optimal treatment selection in this population.

  20. Patent Foramen Ovale: Is Stroke Due to Paradoxical Embolism?

    Science.gov (United States)

    Ranoux, D.; Cohen, A.; Cabanes, L.; Amarenco, P.; Bousser, M. G.; Mas, J. L.

    1993-01-01

    Background and Purpose: A patent foramen ovale has been reported to be significantly more frequent in young stroke patients than in matched control subjects, and paradoxical embolism has been suggested as the main mechanism of stroke in-this situation. The present study was designed to test this hypothesis. Methods: Sixty-eight consecutive patients under 55 years of age presenting with an ischemic stroke had an extensive workup, including transesophageal echocardiography with contrast. We compared the prevalence of criteria for the diagnosis of paradoxical embolism in patients with and without a patent foramen ovale. Results: A patent foramen ovale was found in 32 patients (47%). A Valsalva-provoking activity was present at stroke onset in six patients with a patent foramen ovale and in eight patients with no patent foramen ovale (X(sup 2)=0.1, nonsignificant). Clinical/radiological features suggestive of an embolic mechanism were not more frequent in patients with a patent foramen ovale. Clinical evidence of deep vein thrombosis was present in one patient with a patent foramen ovale and in none of the others. No occult venous thrombosis was found in a subgroup of patients with a patent foramen ovale and no definite cause for stroke who underwent venography (n=13). Conclusions. Our results do not support the hypothesis that paradoxical embolism is the primary mechanism of stroke in patients with a patent foramen ovale. (Stroke 1993;24:31-34) KEY WORDS e cerebral ischemia e embolism foramen ovale, patent

  1. International collaboration in patenting : a case study of contributions of Indian inventors

    OpenAIRE

    Dutt, Bharvi

    2006-01-01

    This paper investigates international collaboration of Indian inventors in patenting, using United States Patent and Trademark Office (USPTO) database from 1976-2004. The result indicates that Indian inventors had 911 patents with the inventors of 28 countries. It examines these patent documents in terms of patent assignees and their countries, type of assignees, areas of patenting, joint ownerships and key players holding these patents. It is observed that Indian inventors have contributed m...

  2. Impact of Global Patent and Regulatory Reform on Patent Strategies for Biotechnology

    Directory of Open Access Journals (Sweden)

    Vincent J. Napoleon

    2009-04-01

    Full Text Available  I come to you this morning not as an intellectual property lawyer but as a former general counsel of biotechnology and pharmaceutical related companies, as an attorney with significant exposure to intellectual property issues and as one who has seen first-hand the importance of intellectual property in shaping commercial strategies in biotechnology. With that as a backdrop, I would like to thank you for allowing me the opportunity to share with you today thoughts that I have regarding patents and the impact of patent reform on biotechnology. It has been said that the best way to predict the future is to invent it. However, I believe that the best way to control the future is to patent it.

  3. Confidential patent application with an example of preparation

    Directory of Open Access Journals (Sweden)

    Obrad T. Čabarkapa

    2013-12-01

    Full Text Available In order that the invention solving a technical problem receives a patent protection, it is necessary to file a patent application. For the protection of confidential inventions which are important for defense and national security, a confidential patent application[1] must be filed. A confidential patent application is an important and complex document, the parts of which are,  in principle, exposed in an established order. For the preparation of patent applications, it is necessary to engage experts with higher education, primarily in the technical field the invention relates to. The contents of the patent application is a basis for examining whether the application meets the requirements for patentability and whether the right to patent protection is achieved. Besides theoretical discussions on patent application, the paper gives a short version of an example of an application regarding a protected confidential invention. Introduction The basic condition for the exercise of patent protection is filing a patent application, the test procedure and, eventually, depending on the test results - the recognition or rejection of the patent. The paper gives a description of all parts of the patent application on an example of a confidential invention already patented. The content of the confidential patent application The confidential patent application for confidential invention protection consists of the following parts: The application for a patent; description of the invention; the claims (indication of what is new and what is required to be protected by patenting; abstract (short summary of the invention  and a draft of the invention (to which the description and the claims are referred. The application for a patent The application for patent is filed on Form P-1 and a request for the petty patent on Form MP-1. The data entered in the file is, for example: the applicant; the lawyer; the name of the invention in Serbian and English; the inventor

  4. Commentary on patents: Don`t dismiss Rifkin`s damning of gene patents

    Energy Technology Data Exchange (ETDEWEB)

    Hoyle, R.

    1995-07-01

    Biotech may have less to fear from Rifkin than from its own inclination to dismiss the fact that the evolution of ethics and patent laws applying to patenting genes has been haphazard. Perhaps it is time for the biotechnology industry to get behind the establishment of an effective forum for opening much-needed dialogue. Perhaps a Senate proposal to establish a bioethics commission, which reportedly has bogged down in partisan politics, is just such a venue for the government and private sector to begin to hash out the ethical and legal dilemmas that are indisputably at the heart of the biotechnology industry, and its future success.

  5. ["Holtos," a Patented Medicine of the Late Edo Era--Wrapping Style, Statement of Medicine Efficacy, and Tablet Form].

    Science.gov (United States)

    Nojiri, Kayoko

    2015-01-01

    Holtos is a medicine that was patented by Kan-sei-do, a pharmacy in Osaka, and sold as a Western medicine from the late Edo era to the Meiji era. It is similar to the patented medicine Uluus, which sold well using the katakana brand name. This article introduces HOLTOS products marketed beginning in the late Edo era and makes a comparative study with Uluus products. The features of Holtos include more indications of what the drug can be used to treat in order to emphasize its versatility. There was also a slight increase in size of the tablet sold at the same price as Uluus, and other improvements such as embossing the name "Holtos" on the surface of the tablet. These reasons lead to the conclusion that Holtos was a patented medicine that imitated Uluus. Furthermore, it has been confirmed that strategic measures were taken by Holtos to outlast competition in the market.

  6. Languages, Fees and the International Scope of Patenting

    DEFF Research Database (Denmark)

    Harhoff, Dietmar; Hoisl, Karin; Van Pottelsberghe de la Potterie, Bruno;

    2016-01-01

    Recent developments in patenting activity are the subject of a growing literature. Existing research contributes to a better understanding of the incentives that drive economic agents to rely on the patent system (e.g. Cohen et al., 2000; Arundel, 2001; Blind et al., 2006; Peeters and van...... Pottelsberghe, 2006; von Graevenitz et al., 2013) and on potential implications of their behaviour for the effectiveness of the patent system. Lately, a number of researchers have started to explore the design of the patent system itself, i.e. the role of fees and costs of patenting (Archontopoulos et al., 2007......; Harhoff et al., 2009; de Rassenfosse and van Pottelsberghe, 2013), the duration of examination (Thomas, 2010; Harhoff, 2011), as well as patent office governance and management (Friebel et al., 2006)....

  7. Making Patent Scopes Exceed the Technological Scopes of Scientific Inventions

    DEFF Research Database (Denmark)

    Beukel, Karin

    This paper presents the results of a grounded theory study of the transformation of scientific discoveries into patented inventions. Using an algebraic interpretive approach, the narratives collected during interviews are analyzed as Bayesian inferences and the developed theory is tested....... The findings recast the relationship between science and patents as a process in which the way the transformation of the scientific invention is handled has an effect on the breadth of the patent scope. Unleashing patent scope surplus is dependent on processes related to abstraction and cognitive variety......, which can be mobilized by patent experts with both an in-depth understanding of the scientific discovery, due to their educational background in the life sciences, and capabilities within the legal framework for patenting. More specifically, the findings reveal previously unreported aspects...

  8. 我院中成药应用分析%Application analysis of Chinese patent medicine in our hospital

    Institute of Scientific and Technical Information of China (English)

    庞国丽

    2015-01-01

    目的:评价本院中成药应用的现状和发展中存在的问题。方法对本院门诊所使用的中成药的金额、数量、种类进行统计分析。结果本院门诊应用的中成药占药品使用的比例很大,以清热类药居多(48.9%),其次为活血化瘀类(24.5%)和止血类(11.0%)。总体使用规范,但仍存在一些不合理现象。结论提高中成药疗效,规范合理使用中成药需全院全社会共同努力。%Objective To evaluate the problems in current condition and development of Chinese patent medicine application in our hospital.Methods The statistical analysis was made on the consumption sum, quantity, and category of Chinese patent medicine in outpatient service of our hospital.Results Chinese patent medicine accounted for a large proportion in outpatient drug use in our hospital, with a majority of heat-clearing drugs (48.9%) following by promoting circulation and removing stasis drugs (24.5%) and hemostasis drugs (11.0%). The application was basically standard with a few of irrational phenomena.Conclusion Improving the curative effect of Chinese patent medicine and standardizing the rational use of Chinese patent medicine require the concerted efforts in the hospital and society.

  9. Patent Reform: Issues in the Biomedical and Software Industries

    Science.gov (United States)

    2006-04-07

    Patents, Innovation, and Access to New Pharmaceuticals , p. 852. 34 The Economics of Human Gene Patents, p. 1352. 35 For more information see CRS...Federal Reserve Bank of Boston, March 2003, available at [http://www.findarticles.com]. 28 Henry G. Grabowski, “Patents, Innovation, and Access to New ... Pharmaceuticals ,” Journal of International Economic Law, 2002, p. 851. 29 Iain Cockburn, “The Changing Structure of the Pharmaceutical Industry,” Health

  10. Intellectual Property Rights in India: Significance of Patents

    OpenAIRE

    Y, Srinivasa Rao

    2014-01-01

    This paper highlights an overview of Intellectual Property Rights (IPRs) in India and their trends. Importantly, patents have played a key role in changing national and global innovation landscape.The IPR trends during 2003-13, the approved rate of designs (87.38%) and trademarks registrations (65.54%) were significantly higher than the granted patents (22.06%) in India. Though, the patents (63.26%) have generated huge revenues than the designs, trademarks and GIs over last dec...

  11. Patents on computer-related inventions in India

    OpenAIRE

    Noto La Diega, Guido

    2016-01-01

    In India, sec. 3(k) of the Patents Act 1970 clearly excludes the patentability of computer programmes per se. For many years, the regime of computer-implemented inventions has been unclear, until the Controller General of Patents, Designs and Trade Marks (the Indian homologous of the Intellectual Property Office) issued its Guidelines on the examination of computer-related inventions. Notably, this gave rise the civil society’s protests; indeed, there was the fear that the government was surr...

  12. 77 FR 40345 - Intent to Grant an Exclusive Patent License

    Science.gov (United States)

    2012-07-09

    ... Department of the Air Force Intent to Grant an Exclusive Patent License AGENCY: United States Air Force, DoD..., Jonathan A. Green, and David L. McGlasson; U.S. Patent Number 7,927,828, Serial No. 11/550,130, issued on... William V. Stoecker, Hernan F. Gomez, Jonathan A. Green, and David L. McGlasson; U.S. Patent...

  13. Compulsory licensing, price controls, and access to patented foreign products

    OpenAIRE

    Eric Bond; Kamal Saggi

    2012-01-01

    Motivated by existing multilateral rules regarding intellectual property, we develop a North-South model to highlight the dual roles price controls and compulsory licensing play in determining Southern access to a patented Northern product. The Northern patent-holder chooses whether and how to work its patent in the South (either via entry or voluntarily licensing) while the South determines the price control and whether to issue a compulsory license. The threat of compulsory licensing benefi...

  14. Mapping (USPTO) Patent Data using Overlays to Google Maps

    OpenAIRE

    Leydesdorff, Loet; Bornmann, Lutz

    2011-01-01

    A technique is developed using patent information available online (at the US Patent and Trademark Office) for the generation of Google Maps. The overlays indicate both the quantity and quality of patents at the city level. This information is relevant for research questions in technology analysis, innovation studies and evolutionary economics, as well as economic geography. The resulting maps can also be relevant for technological innovation policies and R&D management, because the US market...

  15. Needle-like instruments for steering through solid organs: A review of the scientific and patent literature.

    Science.gov (United States)

    Scali, Marta; Pusch, Tim P; Breedveld, Paul; Dodou, Dimitra

    2016-12-01

    High accuracy and precision in reaching target locations inside the human body is necessary for the success of percutaneous procedures, such as tissue sample removal (biopsy), brachytherapy, and localized drug delivery. Flexible steerable needles may allow the surgeon to reach targets deep inside solid organs while avoiding sensitive structures (e.g. blood vessels). This article provides a systematic classification of possible mechanical solutions for three-dimensional steering through solid organs. A scientific and patent literature search of steerable instrument designs was conducted using Scopus and Web of Science Derwent Innovations Index patent database, respectively. First, we distinguished between mechanisms in which deflection is induced by the pre-defined shape of the instrument versus mechanisms in which an actuator changes the deflection angle of the instrument on demand. Second, we distinguished between mechanisms deflecting in one versus two planes. The combination of deflection method and number of deflection planes led to eight logically derived mechanical solutions for three-dimensional steering, of which one was dismissed because it was considered meaningless. Next, we classified the instrument designs retrieved from the scientific and patent literature into the identified solutions. We found papers and patents describing instrument designs for six of the seven solutions. We did not find papers or patents describing instruments that steer in one-plane on-demand via an actuator and in a perpendicular plane with a pre-defined deflection angle via a bevel tip or a pre-curved configuration.

  16. Preliminary study into query translation for patent retrieval

    DEFF Research Database (Denmark)

    Jochim, C.; Lioma, Christina; Schütze, H.

    2010-01-01

    boundaries do not hinder their accessibility. This multilingual-ity of patent collections offers opportunities for improving patent retrieval. In this work we exploit these opportunities by applying query translation to patent retrieval. We expand monolingual patent queries with their translations, using......, but not always, and without great improvement compared to standard statistical monolingual query expansion (Rocchio). The improvement is greater when the source language is English, as opposed to French or German, a finding partly due to the effect of the complex French and German morphology upon translation...

  17. Patented Biologically-inspired Technological Innovations: A Twenty Year View

    Institute of Scientific and Technical Information of China (English)

    Richard H. C. Bonser

    2006-01-01

    Publication rate of patents can be a useful measure of innovation and productivity in fields of science and technology. To assess the growth in industrially-important research, I conducted an appraisal of patents published between 1985 and 2005 on online databases using keywords chosen to select technologies arising as a result of biological inspiration. Whilst the total number of patents increased over the period examined, those with biomimetic content had increased faster as a proportion of total patent publications. Logistic regression analysis reveals that we may be a little over half way through an initial innovation cycle inspired by biological systems.

  18. Nano/micro-electro mechanical systems: a patent view

    Energy Technology Data Exchange (ETDEWEB)

    Hu, Guangyuan, E-mail: hu.guangyuan@mail.shufe.edu.cn, E-mail: hu.guangyuan@shufe.edu.cn [Shanghai University of Finance and Economics, School of Public Economics and Administration (China); Liu, Weishu [Shanghai Jiao Tong University, Antai College of Economics and Management (China)

    2015-12-15

    Combining both bibliometrics and citation network analysis, this research evaluates the global development of micro-electro mechanical systems (MEMS) research based on the Derwent Innovations Index database. We found that worldwide, the growth trajectory of MEMS patents demonstrates an approximate S shape, with United States, Japan, China, and Korea leading the global MEMS race. Evidenced by Derwent class codes, the technology structure of global MEMS patents remains steady over time. Yet there does exist a national competitiveness component among the top country players. The latecomer China has become the second most prolific country filing MEMS patents, but its patent quality still lags behind the global average.

  19. The Scope of Gene Patent Protection and the TRIPS Agreement

    DEFF Research Database (Denmark)

    Sommer, Tine

    2007-01-01

    The Scope of Gene Patent Protection and the TRIPS Agreement - An Exclusively Nondiscriminatory Approach?   Gene patenting in Europe has provoked much debate both before and since the adoption of Directive 98/44/EC on the legal protection of biotechnological inventions. Some of the major points...... of discussion have been focused on the scope of protection (e.g. purpose-bound protection) and gene patents being subject to a specific DNA regime on patent rights. The Directive can be interpreted as favouring such a solution, but so far the European Commission has decided neither to support nor reject...

  20. Prevailing impact trends in patenting

    DEFF Research Database (Denmark)

    Elsmore, Matthew J.

    2009-01-01

      Patents are at the heart of science and public policy. Getting European patent policy right is a daunting task and involves listening to numerous voices. Part of this process must entail a full understanding of emerging trends that challenge the present system. The challenges are fluid and vary...... from sector to sector. This paper identifies and evaluates key recent developments in patenting which impact upon the European patent system, whichever way it looks. An analysis of these and the underlying causes means we are in a much better position to build an effective policy rearguard.    ...

  1. Must an inventor "possess" an invention to patent it?

    Science.gov (United States)

    Woessner, Warren D; Chadwick, Robin A

    2014-09-18

    The requirements for patenting inventions relating to biotechnology have become increasingly strict and complicated in recent years. Despite early patent rulings that there is no need for an inventor to "reduce to practice" an invention, the courts are now ruling that an inventor must "possess" his or her invention before filing for patent. This review discusses what such "possession" may mean and describes decisions in which courts have found that an inventor has met or failed the possession test before filing for patent protection.

  2. AUTOMATIC PATENT DOCUMFNT SUMMARIZATION FOR COLLABORATIVE KNOWLEDGE SYSTEMS AND SERVICES

    Institute of Scientific and Technical Information of China (English)

    Amy J.C.TRAPPEY; Charles V.TRAPPEY; Chun-Yi WU

    2009-01-01

    Engineering and research teams often develop new products and technologies by referring to inventions described in patent databases. Efficient patent analysis builds R&D knowledge, reduces new product development time, increases market success, and reduces potential patent infringement. Thus, it is beneficial to automatically and systematically extract information from patent documents in order to improve knowledge sharing and collaboration among R&D team members. In this research, patents are summarized using a combined ontology based and TF-IDF concept clustering approach. The ontology captures the general knowledge and core meaning of patents in a given domain. Then, the proposed methodology extracts, clusters, and integrates the content of a patent to derive a summary and a cluster tree diagram of key terms. Patents from the International Patent Classification (IPC) codes B25C, B25D, B25F (categories for power hand tools) and B24B, C09G and H011 (categories for chemical mechanical polishing) are used as case studies to evaluate the compression ratio, retention ratio, and classification accuracy of the summarization results. The evaluation uses statistics to represent the summary generation and its compression ratio, the ontology based keyword extraction retention ratio, and the summary classification accuracy. The results show that the ontology based approach yields about the same compression ratio as previous non-ontology based research but yields on average an 11% improvement for the retention ratio and a 14% improvement for classification accuracy.

  3. 14 CFR 1274.913 - Patent rights-retention by the recipient (small business).

    Science.gov (United States)

    2010-01-01

    ... Patent rights—retention by the recipient (small business). Patent Rights—Retention by the Recipient..., or research work the patent rights clause (Patent Rights—Retention by the Recipient (Large Business... 14 Aeronautics and Space 5 2010-01-01 2010-01-01 false Patent rights-retention by the...

  4. 37 CFR 1.17 - Patent application and reexamination processing fees.

    Science.gov (United States)

    2010-07-01

    ... 37 Patents, Trademarks, and Copyrights 1 2010-07-01 2010-07-01 false Patent application and reexamination processing fees. 1.17 Section 1.17 Patents, Trademarks, and Copyrights UNITED STATES PATENT AND TRADEMARK OFFICE, DEPARTMENT OF COMMERCE GENERAL RULES OF PRACTICE IN PATENT CASES General Provisions...

  5. 37 CFR 1.18 - Patent post allowance (including issue) fees.

    Science.gov (United States)

    2010-07-01

    ... 37 Patents, Trademarks, and Copyrights 1 2010-07-01 2010-07-01 false Patent post allowance (including issue) fees. 1.18 Section 1.18 Patents, Trademarks, and Copyrights UNITED STATES PATENT AND TRADEMARK OFFICE, DEPARTMENT OF COMMERCE GENERAL RULES OF PRACTICE IN PATENT CASES General Provisions...

  6. 37 CFR 1.501 - Citation of prior art in patent files.

    Science.gov (United States)

    2010-07-01

    ... 37 Patents, Trademarks, and Copyrights 1 2010-07-01 2010-07-01 false Citation of prior art in patent files. 1.501 Section 1.501 Patents, Trademarks, and Copyrights UNITED STATES PATENT AND TRADEMARK OFFICE, DEPARTMENT OF COMMERCE GENERAL RULES OF PRACTICE IN PATENT CASES Ex Parte Reexamination...

  7. 37 CFR 11.10 - Restrictions on practice in patent matters.

    Science.gov (United States)

    2010-07-01

    ... 37 Patents, Trademarks, and Copyrights 1 2010-07-01 2010-07-01 false Restrictions on practice in patent matters. 11.10 Section 11.10 Patents, Trademarks, and Copyrights UNITED STATES PATENT AND TRADEMARK OFFICE, DEPARTMENT OF COMMERCE REPRESENTATION OF OTHERS BEFORE THE UNITED STATES PATENT...

  8. 75 FR 71072 - Extension of the Patent Application Backlog Reduction Stimulus Plan

    Science.gov (United States)

    2010-11-22

    ... United States Patent and Trademark Office Extension of the Patent Application Backlog Reduction Stimulus Plan AGENCY: United States Patent and Trademark Office, Commerce. ACTION: Notice. SUMMARY: The United States Patent and Trademark Office (USPTO) provides a basis (the Patent Application Backlog...

  9. 78 FR 2960 - Request for Comments on Preparation of Patent Applications

    Science.gov (United States)

    2013-01-15

    ... United States Patent and Trademark Office Request for Comments on Preparation of Patent Applications AGENCY: United States Patent and Trademark Office, Commerce. ACTION: Request for comments. SUMMARY: The United States Patent and Trademark Office (USPTO) is seeking to improve the quality of issued patents....

  10. 37 CFR 1.178 - Original patent; continuing duty of applicant.

    Science.gov (United States)

    2010-07-01

    ... 37 Patents, Trademarks, and Copyrights 1 2010-07-01 2010-07-01 false Original patent; continuing duty of applicant. 1.178 Section 1.178 Patents, Trademarks, and Copyrights UNITED STATES PATENT AND TRADEMARK OFFICE, DEPARTMENT OF COMMERCE GENERAL RULES OF PRACTICE IN PATENT CASES National...

  11. The Doha declaration in action: An examination of patent law flexibilities in the South African acquired immunodeficiency syndrome epidemic

    Directory of Open Access Journals (Sweden)

    Sophie Huddart

    2017-01-01

    Full Text Available Patent law flexibilities outlined in the Trade-related Aspects of Intellectual Property Rights agreement make it possible for low-income nations to provide affordable essential medicine during health crises. During the rise of the human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS epidemic in South Africa, multinational pharmaceutical companies challenged the implementation of these flexibilities. In response to this lawsuit, the World Trade Organization enacted the Doha Declaration, an affirmation of the right of low-income nations to import and produce generic versions of patented essential medicines. This case study assesses the Doha Declaration's impact on access to HIV/AIDS treatment in South Africa by examining drug pricing, antiretroviral treatment coverage and drug licensing fees. The declaration ultimately contributed to the decrease in HIV/AIDS treatment costs and the subsequent increase in availability and affordability of life-saving drug regimens.

  12. Especificidades do patenteamento no setor farmacêutico: modalidades e aspectos da proteção intelectual Specificities of patent protection in the pharmaceutical industry: modalities and traits of intellectual property

    Directory of Open Access Journals (Sweden)

    Anna Haydée Lanzillotti Jannuzzi

    2008-06-01

    Full Text Available As formas de proteção das invenções no setor farmacêutico apontam para estratégias de perpetuação da proteção patentária. Com base em uma revisão bibliográfica mostrou-se as especificidades do patenteamento no setor, perpassando por um breve histórico sobre a concessão de patentes farmacêuticas no Brasil, uma abordagem sobre invenções patenteáveis e não-patenteáveis, e pelas modalidades e aspectos da proteção patentária que visam à extensão do monopólio temporário conferido pela patente. Dentre essas estratégias estão as patentes direcionadas a polimorfos e isômeros ópticos de fármacos; combinações de fármacos e segundo uso médico, cada vez mais presentes nas reivindicações dos pedidos de privilégio de invenção das indústrias farmacêuticas. O objetivo do trabalho é mostrar algumas especificidades dos pedidos de patente farmacêuticas, de modo a contribuir para a formação de expertise na área e para a discussão sobre o impacto da ampliação dos escopos de proteção das patentes. Conclui-se que se por um lado a tendência de escopos de proteção mais permissivos pode desvelar oportunidades para os inventores nacionais, por outro, pode ser danosa para uma política de acesso a medicamentos.Different forms of protection for inventions in the pharmaceutical industry point to strategies for the perpetuation of patent protection. Based on a literature review showing the specificities of patenting in the industry, the article provides a brief history of drug patents in Brazil, a discussion of patentable and non-patentable inventions, and the modalities and traits of patent protection that aim to extend the temporary monopoly granted under the patent. Such strategies include patents targeting polimorphs and optical isomers of drugs and drug combinations and specific clinical preparations, increasingly present in the drug patent claims filed by pharmaceutical companies. The study's objective is to

  13. Tracking 20 Years of Compound-to-Target Output from Literature and Patents

    Science.gov (United States)

    Southan, Christopher; Varkonyi, Peter; Boppana, Kiran; Jagarlapudi, Sarma A.R.P.; Muresan, Sorel

    2013-01-01

    The statistics of drug development output and declining yield of approved medicines has been the subject of many recent reviews. However, assessing research productivity that feeds development is more difficult. Here we utilise an extensive database of structure-activity relationships extracted from papers and patents. We have used this database to analyse published compounds cumulatively linked to nearly 4000 protein target identifiers from multiple species over the last 20 years. The compound output increases up to 2005 followed by a decline that parallels a fall in pharmaceutical patenting. Counts of protein targets have plateaued but not fallen. We extended these results by exploring compounds and targets for one large pharmaceutical company. In addition, we examined collective time course data for six individual protease targets, including average molecular weight of the compounds. We also tracked the PubMed profile of these targets to detect signals related to changes in compound output. Our results show that research compound output had decreased 35% by 2012. The major causative factor is likely to be a contraction in the global research base due to mergers and acquisitions across the pharmaceutical industry. However, this does not rule out an increasing stringency of compound quality filtration and/or patenting cost control. The number of proteins mapped to compounds on a yearly basis shows less decline, indicating the cumulative published target capacity of global research is being sustained in the region of 300 proteins for large companies. The tracking of six individual targets shows uniquely detailed patterns not discernible from cumulative snapshots. These are interpretable in terms of events related to validation and de-risking of targets that produce detectable follow-on surges in patenting. Further analysis of the type we present here can provide unique insights into the process of drug discovery based on the data it actually generates. PMID

  14. Tracking 20 years of compound-to-target output from literature and patents.

    Science.gov (United States)

    Southan, Christopher; Varkonyi, Peter; Boppana, Kiran; Jagarlapudi, Sarma A R P; Muresan, Sorel

    2013-01-01

    The statistics of drug development output and declining yield of approved medicines has been the subject of many recent reviews. However, assessing research productivity that feeds development is more difficult. Here we utilise an extensive database of structure-activity relationships extracted from papers and patents. We have used this database to analyse published compounds cumulatively linked to nearly 4000 protein target identifiers from multiple species over the last 20 years. The compound output increases up to 2005 followed by a decline that parallels a fall in pharmaceutical patenting. Counts of protein targets have plateaued but not fallen. We extended these results by exploring compounds and targets for one large pharmaceutical company. In addition, we examined collective time course data for six individual protease targets, including average molecular weight of the compounds. We also tracked the PubMed profile of these targets to detect signals related to changes in compound output. Our results show that research compound output had decreased 35% by 2012. The major causative factor is likely to be a contraction in the global research base due to mergers and acquisitions across the pharmaceutical industry. However, this does not rule out an increasing stringency of compound quality filtration and/or patenting cost control. The number of proteins mapped to compounds on a yearly basis shows less decline, indicating the cumulative published target capacity of global research is being sustained in the region of 300 proteins for large companies. The tracking of six individual targets shows uniquely detailed patterns not discernible from cumulative snapshots. These are interpretable in terms of events related to validation and de-risking of targets that produce detectable follow-on surges in patenting. Further analysis of the type we present here can provide unique insights into the process of drug discovery based on the data it actually generates.

  15. Tracking 20 years of compound-to-target output from literature and patents.

    Directory of Open Access Journals (Sweden)

    Christopher Southan

    Full Text Available The statistics of drug development output and declining yield of approved medicines has been the subject of many recent reviews. However, assessing research productivity that feeds development is more difficult. Here we utilise an extensive database of structure-activity relationships extracted from papers and patents. We have used this database to analyse published compounds cumulatively linked to nearly 4000 protein target identifiers from multiple species over the last 20 years. The compound output increases up to 2005 followed by a decline that parallels a fall in pharmaceutical patenting. Counts of protein targets have plateaued but not fallen. We extended these results by exploring compounds and targets for one large pharmaceutical company. In addition, we examined collective time course data for six individual protease targets, including average molecular weight of the compounds. We also tracked the PubMed profile of these targets to detect signals related to changes in compound output. Our results show that research compound output had decreased 35% by 2012. The major causative factor is likely to be a contraction in the global research base due to mergers and acquisitions across the pharmaceutical industry. However, this does not rule out an increasing stringency of compound quality filtration and/or patenting cost control. The number of proteins mapped to compounds on a yearly basis shows less decline, indicating the cumulative published target capacity of global research is being sustained in the region of 300 proteins for large companies. The tracking of six individual targets shows uniquely detailed patterns not discernible from cumulative snapshots. These are interpretable in terms of events related to validation and de-risking of targets that produce detectable follow-on surges in patenting. Further analysis of the type we present here can provide unique insights into the process of drug discovery based on the data it actually

  16. Academic patenting and the professor's privilege

    DEFF Research Database (Denmark)

    Lissoni, Francesco; Lotz, Peter; Schovsbo, Jens Hemmingsen;

    2009-01-01

    Siden 2000 har danske universiteter m.v. som følge af en særlig lov haft retten til de ansattes opfindelser. I artiklen undersøges på baggrund af en statistisk analyse af universitetsansattes bidrag som opfindere konsekvenserne af loven. Det påviser bl.a., at antallet af universitetsgenerede pate...... patenter ikke er forøget særligt som følge af loven, og at tredjemands ejerskab fortsat er særdeles vigtigt. Dette harmonerer med tendensen i øvrige europæiske lande....

  17. Compulsory licensing of patents in India.

    Science.gov (United States)

    Chaudhry, Rahul

    2016-09-01

    This article deals with compulsory licensing scenarios in India, provides a background of relevant provisions in the Patents Act and examines how these provisions are Trade-Related Aspects of Intellectual Property Rights compliant. This article further discusses the procedure followed by India in granting a compulsory license, provides an overview of compulsory license applications filed in India to date and judicial precedence regarding the same. This article also highlights how compulsory licensing is a great safeguard that balances the interests of the innovators and the public at large.

  18. 78 FR 51177 - Notice of Intent To Grant Partially Exclusive Patent License; ICAP Patent Brokerage, LLC

    Science.gov (United States)

    2013-08-20

    ... No. 6,384,953: Micro-Dynamic Optical Device.//U.S. Patent No. 6,433,465: Energy- Harvesting Device... September 4, 2013. ADDRESSES: Written objections are to be filed with the Office of Research and Technology... Technology Applications, Space and Naval Warfare Systems Center Pacific, Code 72120, 53560 Hull St, Bldg...

  19. PatentMatrix: an automated tool to survey patents related to large sets of genes or proteins

    Directory of Open Access Journals (Sweden)

    de Rinaldis Emanuele

    2007-09-01

    Full Text Available Abstract Background The number of patents associated with genes and proteins and the amount of information contained in each patent often present a real obstacle to the rapid evaluation of the novelty of findings associated to genes from an intellectual property (IP perspective. This assessment, normally carried out by expert patent professionals, can therefore become cumbersome and time consuming. Here we present PatentMatrix, a novel software tool for the automated analysis of patent sequence text entries. Methods and Results PatentMatrix is written in the Awk language and requires installation of the Derwent GENESEQ™ patent sequence database under the sequence retrieval system SRS. The software works by taking as input two files: i a list of genes or proteins with the associated GENESEQ™ patent sequence accession numbers ii a list of keywords describing the research context of interest (e.g. 'lung', 'cancer', 'therapeutics', 'diagnostics'. The GENESEQ™ database is interrogated through the SRS system and each patent entry of interest is screened for the occurrence of user-defined keywords. Moreover, the software extracts the basic information useful for a preliminary assessment of the IP coverage of each patent from the GENESEQ™ database. As output, two tab-delimited files are generated which provide the user with a detailed and an aggregated view of the results. An example is given where the IP position of five genes is evaluated in the context of 'development of antibodies for cancer treatment' Conclusion PatentMatrix allows a rapid survey of patents associated with genes or proteins in a particular area of interest as defined by keywords. It can be efficiently used to evaluate the IP-related novelty of scientific findings and to rank genes or proteins according to their IP position.

  20. Getting patent policy right: a conclusion to a special issue on the European patent system

    DEFF Research Database (Denmark)

    Elsmore, Matthew J.

    2009-01-01

    Good or bad, the patent system really is important. Its ever-increasing use, for a variety of reasons, means there is a danger of collapse under its own weight. Those charged with steering the European patent system past the challenges it faces have a huge task. Because unchecked, challenges...... in the contributions made and continues the perennial quest for getting patent policy right in Europe; and in so doing, proposes specific sets of solutions....

  1. A Comparative Study of Linkage Indexes: Co-assignee, Reciprocal Citation, Patent Coupling and Co-patent

    Directory of Open Access Journals (Sweden)

    Szu-chia Scarlett Lo

    2010-06-01

    Full Text Available Four indexes including co-assignees, reciprocal citation, patent coupling and co-patent were examined in this study to reveal the meanings of the correlations generated via different citation linkages. This study includes 6,274 genetic engineering patents, and 16 primary assignees identified by Bradford model analysis as the base for correlation analysis. The results show that there are four cluster types, including technological affiliated, technological competitor correlated, commercial collaborated and technological isolated.

  2. Prevalence and type of drug–drug interactions involving ART in patients attending a specialist HIV outpatient clinic in Kampala, Uganda

    Science.gov (United States)

    Seden, K.; Merry, C.; Hewson, R.; Siccardi, M.; Lamorde, M.; Byakika-Kibwika, P.; Laker, E.; Parkes-Ratanshi, R.; Back, D. J.; Khoo, S. H.

    2015-01-01

    Objectives Scale-up of HIV services in sub-Saharan Africa has rapidly increased, necessitating evaluation of medication safety in these settings. Drug–drug interactions (DDIs) involving antiretrovirals (ARVs) in sub-Saharan Africa are poorly characterized. We evaluated the prevalence and type of ARV DDIs in Ugandan outpatients and identified the patients most at risk. Methods A total of 2000 consecutive patients receiving ARVs at the Infectious Diseases Institute, Kampala were studied. The most recent prescription for each patient was screened for clinically significant DDIs using www.hiv-druginteractions.org. Univariable and multivariable logistic regression were used to identify risk factors for DDIs. A screening tool was developed using significant risk factors and tested in a further 500 patients. Results Clinically significant DDIs were observed in 374 (18.7%) patients, with a total of 514 DDIs observed. Only 0.2% of DDIs involved a contraindicated combination. Comedications commonly associated with DDIs were antibiotics (4.8% of 2000 patients), anthelmintics (2.2%) and antifungals (3.5%). Patient age, gender, CD4 count and weight did not affect risk of DDIs. In multivariable analysis, the patient factors that independently increased risk of DDIs were two or more comedications (P < 0.0001), a PI-containing ARV regimen (P < 0.0001), use of an anti-infective (P < 0.0001) and WHO clinical stage 3–4 (P = 0.04). A scoring system based on having at least two of these risk factors identified between 75% and 90% of DDIs in a validation cohort. Conclusions Significant ARV DDIs occur at similar rates in resource-limited settings and developed countries; however, the comedications frequently causing DDIs differ. Development of tools that are relevant to particular settings should be a priority to assist with prevention and management of DDIs. PMID:26286575

  3. Cooperation Treat Patent, present and future; El tratado de cooperacion en materia de patentes. Presente y futuro

    Energy Technology Data Exchange (ETDEWEB)

    Gurry, F.

    2011-07-01

    In its 32 years of operation, the Patent Cooperation Treaty (PCT), a powerful tool used by innovators to protect their developments by multi-national patent, has been a huge success. The PCT has many users, a remarkable and sustained growth for over 30 years and become the cornerstone of the international patent system. Today, the PCT provides many benefits and useful features for their users. However, even taking into account the many benefits it currently offers, this treaty is able to offer more. To achieve this goal, the patent offices of PCT Contracting States should use the Treaty as provided by its founders. (Author)

  4. The practical Einstein experiments, patents, inventions

    CERN Document Server

    Illy, József

    2012-01-01

    Albert Einstein may be best known as the wire-haired whacky physicist who gave us the theory of relativity, but that's just one facet of this genius' contribution to human knowledge and modern science. As Jozsef Illy expertly shows in this book, Einstein had an eminently practical side as well. As a youth, Einstein was an inveterate tinkerer in the electrical supply factory his father and uncle owned and operated. His first paid job was as a patent examiner. Later in life, Einstein contributed to many inventions, including refrigerators, microphones, and instruments for aviation. In published papers, Einstein often provided ways to test his theories and fundamental problems of the scientific community of his times. He delved deeply into a variety of technological innovations, most notably the gyrocompass, and consulted for industry in patent cases and on other legal matters. Einstein also provided explanations for common and mundane phenomena, such as the meandering of rivers. In these and other hands-on exam...

  5. 77 FR 43082 - Federal Acquisition Regulation; Information Collection; Commerce Patent Regulations

    Science.gov (United States)

    2012-07-23

    ... Regulation; Information Collection; Commerce Patent Regulations AGENCIES: Department of Defense (DOD... approved information collection requirement concerning Department of Commerce patent regulations. Public...: Submit comments identified by Information Collection 9000- 0095, Commerce Patent Regulations, by any...

  6. 78 FR 31551 - Federal Acquisition Regulation; Submission for OMB Review; Commerce Patent Regulations

    Science.gov (United States)

    2013-05-24

    ... Regulation; Submission for OMB Review; Commerce Patent Regulations AGENCIES: Department of Defense (DOD... approved information collection requirement concerning Department of Commerce patent regulations. A notice... Collection 9000- 0095, Commerce Patent Regulations, by any of the following methods: Regulations.gov :...

  7. 7 CFR 1209.75 - Patents, copyrights, inventions, publications, and product formulations.

    Science.gov (United States)

    2010-01-01

    ... 7 Agriculture 10 2010-01-01 2010-01-01 false Patents, copyrights, inventions, publications, and..., Research, and Consumer Information Order Miscellaneous § 1209.75 Patents, copyrights, inventions, publications, and product formulations. Any patents, copyrights, inventions, publications, or...

  8. 7 CFR 1215.75 - Patents, copyrights, inventions, publications, and product formulations.

    Science.gov (United States)

    2010-01-01

    ... 7 Agriculture 10 2010-01-01 2010-01-01 false Patents, copyrights, inventions, publications, and..., and Consumer Information Order Miscellaneous § 1215.75 Patents, copyrights, inventions, publications, and product formulations. Any patents, copyrights, inventions, publications, or product...

  9. 78 FR 66740 - Federal Acquisition Regulation; Submission for OMB Review; Patents

    Science.gov (United States)

    2013-11-06

    ... Regulation; Submission for OMB Review; Patents AGENCIES: Department of Defense (DOD), General Services... requirement concerning patents. DATES: Submit comments on or before December 6, 2013. ADDRESSES: Submit comments identified by Information Collection 9000- 0096, Patents, by any of the following...

  10. Annotated chemical patent corpus: A gold standard for text mining

    NARCIS (Netherlands)

    S.A. Akhondi (Saber); A.G. Klenner (Alexander G.); C. Tyrchan (Christian); A.K. Manchala (Anil K.); K. Boppana (Kiran); D. Lowe (Daniel); M. Zimmermann (Marc); S.A.R.P. Jagarlapudi (Sarma A. R. P.); R. Sayle (Roger); J.A. Kors (Jan); C. Muresan (Cornelia)

    2014-01-01

    textabstractExploring the chemical and biological space covered by patent applications is crucial in early-stage medicinal chemistry activities. Patent analysis can provide understanding of compound prior art, novelty checking, validation of biological assays, and identification of new starting poin

  11. The Battle for Patent Rights in Plant Biotechnology

    DEFF Research Database (Denmark)

    Schneider, Cédric

    2011-01-01

    ”. In contrast to previous findings, however, the results show that large-volume applicants are more likely to be opposed. Because the boundaries of plant biotech patents are ill-defined, large patent portfolios do not promote cooperative behavior such as licensing or settlements. The analysis rejects...

  12. Software and patents: the law and its (ab)uses

    CERN Document Server

    CERN. Geneva

    2015-01-01

    Patents and software live on a tense footing: on the one hand, the law doesn't draw a clear line, and on the other hand, patents on computer-implemented inventions are frequently used in ways which hamper innovation. Are there any legitimate uses? How can abuses be addressed?

  13. Increasing Access to Patented Inventions by Post-grant Measures

    DEFF Research Database (Denmark)

    Schovsbo, Jens Hemmingsen

    2009-01-01

    " and the so called "tragedy of the anticommons". Next the paper discusses the use of (some) post grant measure to increase access to patented inventions. Traditionally patent law has not paid much attention to such measures. The paper argues that developments suggest that there is good reason to reconsider...

  14. Ex-post Liability Rules in Modern Patent Law

    NARCIS (Netherlands)

    R.J.F.M. Castro Bernieri (Rosa)

    2010-01-01

    textabstractThis book examines alternative ways of protecting patent rights using the law and economics framework of property and liability rules. Traditional compulsory licenses are compared with the most recent discussions on the choice between granting or denying injunctive relief for patents (ex

  15. Patent Strategy at the Age of High Technology

    Science.gov (United States)

    Aoyama, Hirokazu

    This paper is a summary of the lecture which the author presented at the 5th Hokuriku Workshop for Study of Scientific and Technological Information Activities on the 17th of January in 1986. The author analyzed the present situation and made some suggestions on them ; (1) the role of patent system has shifted from introduction of foreign technologies to independent technological development at the age of high technology, (2) circumstances of rapidly increasing international patent war, particularly patent conflict between U.S. and Japan concerning U.S. ITC, (3) as the service of soft aspects of economy has been closed up, the new business has come to the fore front, and the move to consider technology as a good has been activated, (4) how patent specification should be written, the way of obtaining and protecting patent successfully, (5) basic pattern of patent strategy and what the strategy should be to respond to the enterprises level, (6) present situation of patent information service, effective use of patent maps and information strategy.

  16. About "trivial" software patents: The IsNot case

    NARCIS (Netherlands)

    Bergstra, J.A.; Klint, P.

    2007-01-01

    So-called "trivial" software patents undermine the patenting system and are detrimental for innovation. In this paper we use a case-based approach to get a better understanding of this phenomenon. First, we establish a baseline for studying the relation between software development and intellectual

  17. Domestic Enterprise Awarded Overseas Patents On Fiber Optical Technologies

    Institute of Scientific and Technical Information of China (English)

    2009-01-01

    Beijing Aerospace Times Optical-Electronic Technology Corp. Ltd was granted a patent for a fiber optical gyroscope using a low-polarization and polarization-maintaining hybrid light path in Ukraine. After filling an ordinary patent application for the technology domestically in 2006, the company filed a Paris Convention application in Ukraine to collaborate with a Ukrainian technical center in 2007.

  18. 76 FR 55364 - Rules for Patent Maintenance Fees

    Science.gov (United States)

    2011-09-07

    ... United States Patent and Trademark Office Rules for Patent Maintenance Fees ACTION: Proposed collection... or after December 12, 1980. Payment of these maintenance fees is due at 3\\1/2\\, 7\\1/2\\, and 11\\1/2... maintenance fee and any applicable surcharge within a grace period of six months following each of the...

  19. 77 FR 55027 - Setting and Adjusting Patent Fees

    Science.gov (United States)

    2012-09-06

    .... Also, despite increases in some fees, applicants who meet the new micro entity definition will pay less... right to the invention sooner, which would increase the private value of that patent. Because the..., faster dissemination of information, and certainty in patented inventions; and (3) help recover...

  20. 78 FR 4211 - Setting and Adjusting Patent Fees

    Science.gov (United States)

    2013-01-18

    ..., applicants who meet the new micro entity definition will pay less than the amount paid for small entity fees... right to the invention sooner, which increases the private value of that patent. Because the outcomes of... regarding the claimed invention and scope of patent rights for patentees, competitors, and new...